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 Pref ace 
     
 This book is the fi nal product of the InfoGest FA1005 COST Action. InfoGest is an 
international network that aims at “Improving Health Properties of Food by Sharing 
our Knowledge on the Digestive Process”. The specifi c objectives of the network 
are to:
 –  Compare the existing digestion models, harmonise the methodologies and pro-
pose guidelines for performing new experiments 
 –  Validate in vitro models towards in vivo data (animal and/or human) 
 –  Identify the benefi cial/deleterious components that are released in the gut during 
food digestion 
 –  Demonstrate the effect of these compounds on human health 
 –  Determine the effect of the matrix structure on the bioavailability of food nutri-
ents and bioactive molecules 
 InfoGest is supported for 4 years (June 2011–May 2015) by European COST 
funds and gathers more than 320 scientists from 34 countries (primarily within 
Europe but also Canada, Australia, Argentina and New Zealand). Connections 
between academic partners and industry are also strengthened through the partici-
pation of more than 40 food companies (large groups as well as SMEs). InfoGest 
has released several reviews and opinion papers on the topic of food digestion and 
related topics (e.g. health effects, bioavailability) and has proposed a consensus 
in vitro digestion model to the scientifi c community (Minekus et al. 2014). A stan-
dardised static in vitro digestion method suitable for food—an international con-
sensus. Food & Function 5:1113–1124). It has also created the International 
vi
Conference on Food Digestion that every year gathers around 200 scientists from 
all over the world. 
 In this book, which was coordinated by Kitty Verhoeckx, we describe the in vitro 
and ex vivo models that can be used to investigate benefi cial or detrimental effects 
of digested food products and highlight the advantages and limitations of each one 
of them. It is hoped that the details provided, and the citations included, will allow 
you to identify the model(s) that best suit your needs. 
 We hope that you will enjoy reading this book and will learn a bit more about the 
complexity of the digestive process. 
  
 Rennes, France  Didier  Dupont 
 Zeist, The Netherlands   Kitty  Verhoeckx 
Preface
vii
 General In troduction 
 This book is a product of the InfoGest COST Action FA 1005. This Action was 
granted by COST in the domain of Food and Agriculture and coordinated by the 
French National Institute for Agricultural Research (INRA). 
 Every day our gastrointestinal tract (GIT) is exposed to many different food 
components. These food components can be processed, digested and eventually 
transported across the intestinal tract and can have a variety of direct and indirect 
effects, both positive and negative, on our health. In vivo assessments of the impacts 
of food components (or food bioactives) on health are not trivial and are not practi-
cal when examining more than just a few components. Thus, in many instances it is 
necessary to employ in vitro and ex vivo models as part of a funnelled approach to 
identify the components that merit particular attention. 
 In this book, we describe the in vitro and ex vivo models which can be used to 
investigate benefi cial or detrimental effects of digested food products. The models 
that we describe in this book include those used to study digestion and fermentation 
in the small and large intestine (Parts I and VI), models used to investigate absorp-
tion (e.g. Ussing chamber, epithelial cell systems) in Part II and Part V and the 
immune and enteroendocrine responses (e.g. macrophages, dendritic cells, co- 
cultures) in Parts III and IV . For each model, we provide you with background 
information, a general protocol with tips and tricks concerning their proper use, 
readouts provided by the systems, the applicability of the model with respect to 
food research and pros and cons of the model. Indeed, this book has been prepared 
for the particular benefi t of students/researchers who are not experienced in the use 
of these models but are considering their use. It is hoped that the details provided, 
and the citations included, will allow you to identify the model(s) that best suit(s) 
your needs. 
viii
 Digestion and Absorption 
 The GIT represents the largest interface between our body and the environment and, 
when functioning correctly, absorbs nutrients while providing protection from 
harmful components . By the broadest defi nition, the GIT extends from the mouth to 
the anus and can be divided into the upper and the lower tracts. The upper tract 
consists of the oral cavity, oesophagus, stomach, duodenum, jejunum and the ileum. 
The latter three together represent the small intestine. The lower tract comprises the 
large intestine consisting of the cecum, colon, rectum and anal canal (see Fig. 1). 




 Every part of the GIT has its own function in food processing. The mouth is 
responsible for mastication and mixing of the food with saliva, which contains a 
complex array of components including amylase, an enzyme that catalyses the 
hydrolysis of starch into sugars. After the formation of a food bolus, the food is 
transported through the oesophagus to the stomach where it is further processed. 
The food bolus is mixed with enzymes like protease and lipase, which break down 
proteins and lipids, respectively. Acid is also secreted into the stomach and this will 
gradually lower the pH of the content and aid in hydrolysis. The food bolus is bro-
ken down into chyme, which is gradually transported to the small intestine. In the 
duodenum, the low pH of the stomach is neutralised by bicarbonate and digestive 
juices from the pancreas (digestive enzymes like trypsin and chymotrypsin) and the 
gall bladder (bile acids) are introduced. The digestive enzymes further break down 
the proteins, lipids and starch, while the bile acids help emulsify the products of 
lipid hydrolysis into micelles (Withney 2008; Wickham et al. 2009). More informa-
tion on digestion and digestion models can be found in Part I. The fi nal stage in the 
digestion of dietary carbohydrates and proteins occurs right on the surface of small 
intestinal enterocytes by brush boarder enzymes (Shimizu 2004). These enzymes, 
including maltase, sucrose-isomaltase, lactase and peptidases, are integral mem-
brane proteins that are present in enterocytes. The nutrients produced are mainly 
absorbed by the enterocytes of the jejunum and to a lesser extent in the ileum 
(Withney 2008). One of the main functions of the large intestine is the absorption of 
water. In addition, while it is known that the GIT contains a large microbial popula-
tion, the concentration of this population is greatest in the large intestine. Many of 
these microorganisms contribute to the digestion of food components, including 
prebiotics such as complex polysaccharides which cannot be digested by human 
enzymes (Flint 2012). 
 After absorption of nutrients by enterocytes, the compounds especially peptides 
can be further degraded by intracellular proteases before they enter the bloodstream 
or the lymphatic system. Water-soluble nutrients are mostly released into the blood-
stream and end up in the liver via the hepatic portal vein. Fat-soluble nutrients are 
transported into the lymph after assembly into chylomicrons. After reprocessing, 
these compounds also end up in the blood (Withney 2008). Further details on trans-
port mechanisms can be found in Chap.  24 . 
 Cells Present in the Intestine 
 As already mentioned, the GIT is the largest interface between the body and the 
environment, and, for this reason, it also serves as a point of communication between 
the environment and the host immune system (Brandtzaeg 2011; Faria et al. 2013). 
This interface consists of a single epithelial layer folded into crypts and villi to 
increase the surface area of the gut (Cummins and Thompson 2002; Ismail and 
Hooper 2005). The colon does not contain villi. The intestinal epithelial layer is 
composed of several distinct cell types, originating from multipotent stem cells 
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present in the crypts (see Fig. 2). The most abundant are the enterocytes that have 
an absorptive function. Interlaced between the enterocytes are mucin-secreting gob-
let cells and peptide hormone exporting enteroendocrine cells (see also Part IV) 
(Ismail and Hooper 2005; Snoeck et al. 2005). During their migration to the top of 
the villi, enterocytes, goblet cells and enteroendocrine cells differentiate and even-
tually die (apoptosis) when they reach the top of the villi. A fourth cell type, the 
Paneth cells, migrates downwards to the crypt base. The Paneth cells secrete diges-
tive enzymes, growth factors and antimicrobial peptides (AMPs) such as cryptdins 
or defensins (Snoeck et al. 2005). For more information on epithelial cells and 
ex vivo cell systems, see Part II and Part IV. 
 Given its large surface area and the number of antigens and microorganisms to 
which the GIT is exposed, it is not surprising that it contains the highest number of 
lymphoid (immune) cells in the entire body (Faria et al. 2013). The gut immune 
system consists of inductive sites where antigen recognition and primary adaptive 
immune responses take place and effector sites that harbour, amongst other cells, 
activated T- and B-cells and memory cells. The main inductive sites are gut- 
associated lymphoid tissues (GALT) such as Peyer’s patches (PP), isolated lym-
phoid follicles (ILF) and the mesenteric lymph nodes (mLNs). The lamina propria 
(LP) and the epithelium constitute the main effector sites (Pabst and Mowat 2012). 
In the GALT and at the effector sites, a wide range of immune cells are present 
(Faria et al. 2013). Dendritic cells (DCs), which are recognised as an important link 
between innate and adaptive immunity, take up, process and present antigens to 
T-cells (Willart et al. 2013). DCs are found in all organised intestinal lymphoid tis-
sues. In the sub-epithelial dome (SED) of Peyer’s patches, they capture antigens 
that are transported into the SED by specialised epithelial cells called microfold 
cells (M-cells) (Shreedhar et al. 2003). Next to DCs a mixture of T and B lympho-
cytes, plasma cells and macrophages, a second type of antigen-presenting cells, are 
present in the SED (Pabst 1987). In the lamina propria (LP), a range of different 
immune cells can be found, typically DCs, macrophages, plasma cells, memory B- 
and T-cells, mast cells, eosinophils and cytotoxic natural killer cells (NK cells) 
(Macdonald and Monteleone 2005; Peterson and Artis 2014). Also, LP contains 
additional innate immune cell populations not found in peripheral blood. These 
cells, called innate lymphoid cells (ILC), are potent cytokine producers, much like 
the classical T helper cell subsets. Recent evidence suggests important functions of 
ILCs in the maintenance of barrier integrity and mucosal homeostasis. The only 
immune cells that are virtually absent in the healthy intestine are neutrophils and 
basophils. Both cell types, however, will infi ltrate intestinal tissues in case of 
infl ammation (Stone et al. 2010; Ismail and Hooper 2005). Generally, the small 
intestine contains more immune cells than the colon. More details on the different 
immune cell types present in the intestine can be found in Part III. 
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 Role of Microbiota 
 As noted above, the investigation of the impact of foods and food components on 
host health cannot be said to be complete without considering the role of the host 
microbiota. Our understanding of the interplay between the human GIT microbiota 
and digestion as well as health has increased dramatically in recent years as a con-
sequence of the development of culture-independent, DNA-sequencing-based 
approaches to study these populations. It is now clear that diet has a considerable 
infl uence on the composition and function of the gut microbiota (Yatsunenko et al. 
2012; Claesson et al. 2012). These microbial populations in turn impact on the 
extraction of energy from food, including the fermentation of complex carbohy-
drates and proteins to produce short-chain fatty acids and other metabolites (Russell 
et al. 2013). The relationship between gut microbes and diet can also have a 
 Fig. 2  Intestinal cells and structures in the small intestine.  Note : Normally you will not fi nd the 
mesenteric lymph node in the submucosa, but in humans they are situated close to the serosa on the 





signifi cant impact on mucosal and systemic immune responses (Hooper et al. 2002). 
It is thus notable that, among the model gut systems that are described in this book 
(see Part VI), several can be populated with human GIT microbial populations to 
 facilitate investigations into the impact gut microbes in food digestion. 
 In conclusion, while, in many instances, in vivo human or animal data represent 
the “gold standard” with respect to carrying out studies on food and health, fre-
quently, due to fi nancial, ethical or practical (e.g. high-throughput screens) reasons, 
in vitro and/or ex vivo models are more appropriate. For this reason, in this book, 
we focus on in vitro and ex vivo models, with the requirement that the models 
should be closely related to human physiology and should be readily available to the 
scientifi c community. We hope that this book will be your fi rst port of call with 
respect to determining which in vitro and ex vivo assays best serve your needs when 
studying the health effects of food bioactives in the gut.
 Zeist, The Netherlands  Kitty  Verhoeckx 
Cork, Ireland  Paul  D.  Cotter 
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 General Introduction 
 This book is a product of the Infogest COST Action chaired by Didier Dupont, 
which had as one of its main aims to harmonise in vitro approaches to digestion. 
Thus, as vice-chair of the action I have become aware of the wide range of models 
and applications that are being used by the scientifi c community. These range from 
simple enzyme reactions such as hydrolysis of proteins by pepsin under rather 
 non- physiological conditions in a beaker to the complex sophistication of the 
TIM-1 and other similar dynamic models. Their application has been equally wide 
ranging. The pharmaceutical industry typically use these models as dissolution 
tests for new formulations; resistance to proteolysis has been used by food allergy 
researchers as a risk factor for a protein being an allergen (Astwood et al.  1996 ); 
others have used in vitro digestion to assess the bioaccessibility of soil contami-
nants (Oomen et al.  2002 ) and there are many other examples. Despite this diver-
sity in both methods and applications, one can draw a few general conclusions 
about the design of gastrointestinal (GI) models. Firstly, the model should be as 
simple as possible but not so simple that the results do not provide information 
relevant to the “real life” situation. Secondly, what has been done previously is not 
always the best or indeed most relevant approach. Finally, digestion is not a goal in 
itself and the way that samples of digesta are collected is very dependent on the 
type of measurement to be made. 
 The digestive tract in humans and indeed other mammals is highly complex 
because of the need to effi ciently extract the optimum amount of nutrients and bio-
actives from the food consumed, whilst at the same time keeping out pathogens and 
toxic compounds. This requirement has led to the evolution of a complex multi- 
layered system of control involving a number of distinct compartments. These are 
the oral compartment (mouth) where the initial sensory input from the food is 
acquired; the gastric compartment (stomach) where food is stored, partially digested 
and partially sterilised; the duodenum, jejunum and ileum (small intestine) which is 
the primary site of digestion and absorption and fi nally the cecum and colon 
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(large intestine) where fermentation breaks down some dietary fi bre into an absorbable 
form and other bioactive compounds are metabolised by the gut fl ora and absorbed. 
 There are clearly a number of aspects of digestion that are not readily reproduced 
by any of the currently available digestion models. For example, at the macroscopic 
scale some foods may separate out in the stomach leading to different retention 
times caused by various parameters such as the viscosity of the gastric contents the 
size of the particles remaining in the stomach and the sensing on nutrients in the 
small intestine. These parameters are diffi cult to measure in vivo and so a number 
of simplifi cations are generally used. For example a good approximation that can be 
used in a dynamic model of the gastric phase is that 1–2 kcal/min are generally 
emptied from the gastric compartment when under energy-control (van Aken  2010 ). 
This is of course diffi cult to follow in vitro if there is any phase separation of the 
food. At the other end of the scale, transport from the intestinal lumen to the epithe-
lium through the mucus layer and then absorption are also complex processes that 
are diffi cult to mimic in vitro (Mackie et al.  2012 ). 
 When conducting experiments aimed at understanding the digestion of food or 
the bioaccessibility of specifi c compounds we need to understand what aspects of 
the GI tract are important, where they are digested and absorbed and what environ-
ment they may be exposed to. In the models outlined in the rest of this chapter the 
reader will be presented with a range of models of differing complexity with the aim 
of guiding those new to the fi eld. The aim is to provide suffi cient information so that 
the correct decision can be made about the level of complexity needed to answer a 
specifi c digestion related problem and what facilities are available in different leading 
groups around the world. 
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 Chapter 1 
 Static Digestion Models: General Introduction 
 Amparo  Alegría ,  Guadalupe  Garcia-Llatas , and  Antonio  Cilla 
 Abstract  Several in vitro methods have been developed to simulate the physiological 
conditions of the human gastrointestinal digestion, the simplest being the static 
methods. The following chapter clarifi es the concepts of bioaccessibility and dialyz-
ability, and describes the conditions (pH, enzymes, agitation, etc.) to be applied in 
oral, gastric and intestinal phases when assessing a food component (nutrient, bio-
active or toxin) or a food product, in a single or multi-phase model. The advantages 
and disadvantages of the static models vs. dynamic and in vivo models are dis-
cussed, and a review of specifi c conditions applied on nutrients (minerals, vitamins, 
proteins, fatty acids, etc.) and bioactive compounds (carotenoids, plant sterols, etc.) 
from recent studies is provided. Currently, it must be considered that, although the 
static digestion conditions must be adapted according to the component or food 
sample to be studied, a harmonization and standardization of the models are needed 
in order to establish suitable correlations among in vitro and in vivo assays, as it has 
been defi ned for some food components (carotenoids, proteins and minerals). 
 Keywords  Static models •  Bioaccessibility •  Dialyzability •  Gastrointestinal •  In vitro 
digestion 
1.1  Defi nition of Concepts: Bioavailability, Bioaccessibility 
and Bioactivity 
 The term bioavailability can be defi ned as the fraction of ingested component 
 available at the site of action for utilization in normal physiological functions, and 
is determined through in vivo assays (Guerra et al.  2012 ). Bioavailability is the 
result of three main steps: digestibility and solubility of the element in the gastroin-
testinal tract; absorption of the element by the intestinal cells and transport into the 
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circulation; and incorporation from the circulation to the functional entity or target 
(Wienk et al.  1999 ; Etcheverry et al.  2012 ). 
 Bioavailability furthermore includes two additional terms: bioaccessibility and 
bioactivity. Bioaccessibility has been defi ned as the fraction of a compound that is 
released from its food matrix within the gastrointestinal tract and thus becomes 
available for intestinal absorption (typically established from in vitro procedures). 
It includes the sequence of events that take place during food digestion for transfor-
mation into potentially bioaccessible material but excludes absorption/assimilation 
through epithelial tissue and pre-systemic metabolism (both intestinal and hepatic). 
Bioactivity in turn includes events linked to how the nutrient or bioactive compound 
is transported and reaches the target tissue, how it interacts with biomolecules, the 
metabolism or biotransformation it may experience, and the generation of biomarkers 
and the physiological responses induced. Although bioavailability and bioaccessi-
bility are often used indistinctly, it must be clarifi ed that bioavailability includes 
bioactivity (Etcheverry et al.  2012 ). 
1.2  Static Methods 
1.2.1  Solubility/Dialyzability 
 In the past two to three decades, several in vitro methods have been developed to 
simulate the physiological conditions (temperature, agitation, pH, enzyme and 
chemical composition) and the sequence of events that occur during digestion in 
the human gastrointestinal tract. Static methods (also called biochemical methods) 
are the simplest techniques in this respect and include two or three digestion steps 
(oral, gastric, and intestinal) whose products remain largely immobile in a single 
static bioreactor. These methods simulate a limited number of parameters of physi-
ological digestion (to be described below), and do not mimic physical processes 
such as shearing, mixing, hydration, changes in conditions over time, or peristalsis 
(Fernández-García et al.  2009 ; Wickham et al.  2009 ). 
 In a fi rst step, simulated gastrointestinal digestion is applied to homogenized 
foods or isolated compounds in a closed system, followed by determination of the 
amount of soluble compound present in the supernatant obtained by centrifugation or 
fi ltration (solubility methods). The amount of solubilized component can be used as 
a measure of the bioaccessibility of a nutrient or bioactive component. An  important 
alternative methodological approach compared with previous systems is the intro-
duction of a dialysis bag containing sodium bicarbonate, after gastric digestion of the 
food sample, and dialysis of soluble components across a semi-permeable membrane 
without removal of the dialyzed compounds. The use of a dialysis bag of a specifi c 
pore size also permits discrimination between high and low molecular weight 
 components (Ekmekcioglu  2002 ; Etcheverry et al.  2012 ). 
A. Alegría et al.
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1.2.2  Digestion Conditions 
 It is necessary to take into account in vivo conditions when applying in vitro digestion 
methods, in order to maximally reproduce them. In this sense, Ekmekcioglu ( 2002 ) 
summarized relevant aspects for bioavailability studies using in vitro models like 
peptic and pancreatic digestion (chemical and enzymatic composition of saliva, 
gastric juice, duodenal and bile juice, incubation time, temperature), adjustment of 
pH, peristaltic frequency (shaking or agitation), osmolality, serosal composition, 
and permeability characteristics of the enterocyte monolayer, based on the physio-
logical conditions. 
 The entire process in the mouth lasts from a few seconds to minutes, and since the 
salivary pH value is close to neutral, signifi cant compound dissolution from food 
samples is not expected in this stage. This is why most methods only include the 
gastric and intestinal phases of digestion, and oral processing is perhaps the most 
diffi cult to simulate for solid foods. In place of such processing, use is normally 
made of a homogenization step, though this does not create a bolus. In the case of 
liquid foods or isolated food components, the homogenization and bolus formation 
phase is not performed, though salivary amylase may be added (Moreda- Piñeiro 
et al.  2011 ). For example, in studies on the hydrolysis of proteins there is no signifi -
cant enzyme action in the mouth (Wickham et al.  2009 ), although an oral phase has 
been applied for other components (carotenoids, plant sterols and minerals). Some 
examples are shown in Table  1.1 .
 The gastric phase is performed with HCl or HCl-pepsin under fi xed pH and 
 temperature conditions, for a set period of time. Food is homogenized in aqueous 
solution and typically pepsin is added following adjustment to pH 1–2. The sample 
is then incubated at 37 °C during 1–3 h, holding the pH constant. In the case of 
infant food the samples are acidifi ed to pH 4. A recent review has published a com-
pilation of infant digestive conditions of gastric and duodenal phases with the aim 
of defi ning them for in vitro methods (Bourlieu et al.  2014 ). 
 Regarding the gastric enzymes, a minimum amount of 4,000–5,000 IU of pepsin 
seems to be necessary for optimal protein digestion (Ekmekcioglu  2002 ; Etcheverry 
et al.  2012 ). Wickham et al. ( 2009 ) reported that the pepsin digestion protocols that 
have been employed involve pepsin activities in the range of 8–12 units per mg of 
test protein, which may be considered far in excess of values likely to be found in 
the stomach. The protein dietary intake for an adult (around 75 g in 24 h) would 
yield a ratio of ~3 mg protein/unit pepsin secreted, compared to ~3 μg protein/unit 
pepsin during digestion assays. Some authors add mucin in the gastric step in order 
to better simulate the physiological secretions. Gastric emptying times depend on 
meal composition, and in this regard meals with high fi bre and fat contents can 
delay gastric emptying. Table  1.1 shows the conditions such as enzymes, pH and 
gastric emptying times recently used in some studies on different foods. 
 Intestinal digestion needs subsequent neutralization (usually with NaOH or 
NaHCO 3 ), and incubation with pancreatic enzymes such as lipase, amylase, 
1 Static Digestion Models: General Introduction
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ribonuclease and protease with or without bile salts as emulsifi ers (see Table  1.1 ). 
Since the majority of nutrients are absorbed in the jejunum (pH 6.7–8.8) and ileum 
(6.8–7.7), most intestinal digestion studies adjust the pH to 6.5–7.5 at 37 °C for 
1–5 h (Ekmekcioglu  2002 ). Lipophilic compounds (carotenoids, plant sterols, etc.) 
partition into liposomes and micellar phases during intestinal digestion. 
Consequently, human pancreatic lipase and other specifi c enzymes (cholesterol 
esterase, phospholipase A2, co-lipase, etc.) are added to achieve more physiological 
conditions (Table  1.1 ). Other components such as phospholipids and calcium are 
also used in various in vitro models (Hur et al.  2011 ). Wickham et al. ( 2009 ) indi-
cated that the colloidal phases should be included within the design of static diges-
tion models used to assess the digestibility of protein allergens, because the 
multi-phase nature of the gastric and duodenal environments could play an impor-
tant role in terms of allergenic protein potential, and thus in the conduction of risk 
assessments. These authors reviewed the studies on the role of physiological surfac-
tants found in the gastric and the duodenal compartments in relation to potential 
allergens. 
 In studies that have used static methods, the choice of enzymes and incubation 
conditions is conditioned by the study objective. Thus, the application of such 
methods to a single nutrient has conditioned the use of a single enzyme, e.g., 
protein- pepsin, starch-amylase or lipid-lipase. Using a single purifi ed enzyme 
offers the advantage of making standardization of the in vitro model easier; 
thereby allowing results to be obtained that are more reproducible among differ-
ent laboratories. However, the digestion of a nutrient is infl uenced by other food 
components, and consequently the use of complex mixtures of enzymes affords 
results that more closely refl ect the actual in vivo situation than the utilization of 
single purifi ed enzymes. As an example, if protein digestion is carried out with 
three enzymes (trypsin, chymotrypsin and peptidase) in a single-step digestion 
process, greater protein digestibility (39–66 %) is obtained than in the case of a 
two-step digestion process with several enzymes (pepsin and pancreatic enzymes) 
(Abdel-Aal  2008 ; Hur et al.  2011 ). The enzymes are collected from human sub-
jects, though a number of studies consider that it is possible to replace human 
pepsin, pancreatic lipase and co-lipase with porcine enzymes (Hur et al.  2011 ). 
Aarak et al.  2013 compared in vitro models using human and porcine intestinal 
enzymes applied to eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA) release from salmon, using only a duodenal digestion step. Results show 
that the human lipolytic enzyme system produces a comparatively higher release 
of EPA and DHA. 
 During peptic and pancreatic digestion, food samples are often incubated in a 
continuously shaking water-bath, although not all studies indicate the conditions 
used. A recently developed static device (Chen et al.  2011 ) allows agitation with a 
spherical probe, applying vertical movement within the vessel to create a fl ow pattern 
similar to that of the contraction waves of the stomach wall. 
A. Alegría et al.
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1.3  Applications: Advantages and Disadvantages 
 Static models are particularly useful where there is limited digestion (e.g., gastric 
and/or intestinal steps), but are less applicable in total digestion studies, including 
colonic fermentation. These methods can be used to evaluate the infl uence of diges-
tion conditions, and to carry out studies on the positive or negative effect of food 
structure (particle size, addition of emulsifi ers, etc.), food composition (food fortifi -
cation, etc.), dietetic factors (interactions between food components such as fi bre, 
minerals, etc.) and food processing (thermal and non-thermal treatment, fermentation, 
etc.) upon nutrient and bioactive compound bioaccessibility, in order to establish the 
nutritional value of foods and improve food formulation/design. In conclusion, 
static models are predominantly used for digestion studies on simple foods and 
isolated or purifi ed food components. Such studies not only contribute to improve 
food properties (nutritional or sensory) but also constitute preliminary trials produc-
ing evidence referred to possible nutrition and health claims, since it must be shown 
that the substance is digested and available to be used by the body (Fernández-
García et al.  2009 ). An overview on different characteristics and conditions of the 
static models is represented in Fig.  1.1 . A recent review assesses the importance of 
in vitro methods in nutritional, toxicological, pharmaceutical, and microbiological 
studies (Guerra et al.  2012 ). 
 Data from human intervention studies (in vivo assays) constitute the reference 
methods, whereas bioaccessibility studies (based on in vitro methods) are used as 
surrogates for predictive purposes. A number of disadvantages, such as limitations 
in experimental design, diffi culties in data interpretation, high cost of equipment 
and labour, ethical constraints, inter-individual variations, and the lack of certifi ed 
reference standards to compare data among studies limit the utility of in vivo meth-
ods (Fernández-García et al.  2009 ). In contrast, in vitro models are reproducible, 
since they allow better control of the experimental variables than animal or human 
studies, provided they are adequately validated and standardized, with the use of 
reference material if needed. In general, they are rapid and simple methods, since 
they only need materials that are routinely available in the laboratory, and are there-
fore relatively inexpensive and cost-effective. Furthermore, in vitro models allow a 
reduction of the sample size when this is a limiting factor. Static systems evaluate 
the aforementioned term “bioaccessibility”, and can be used to establish trends in 
relative bioaccessibility, comparing the solubility of a component in different foods 
as a screening or categorizing tool. However, it is generally recognized that not all 
soluble or dialyzable compounds are absorbable. 
 Nevertheless, despite their potential and broad applicability, none of the static 
models reproduce the dynamic environment of the intestine. They cannot assess 
uptake or absorption, or transport kinetics, or measure nutrient or food component 
competition at the site of absorption as occurs in vivo. They are models lacking the 
complex mucosal barrier with all its regulatory processes, particularly hormonal 
and nervous control, feedback mechanisms, mucosal cell activity, complexity of 
peristaltic movements, gastric emptying or continuous changes in pH and secretion 
1 Static Digestion Models: General Introduction
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fl ow rates, involvement of the local immune system, effects of the intestinal micro-
fl ora and liver metabolism. Furthermore, factors that infl uence the bioavailability of 
a nutrient or bioactive compound, such as nutritional status, age, genotype, physio-
logical state (e.g., pregnancy, lactation and obesity), or chronic and acute infections 
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 Fig. 1.1  Overview on static model conditions 
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1.4  Static Versus In Vivo Digestion: Conclusions 
 Few studies have evaluated the in vivo–in vitro correlation of results obtained in 
foods, and it is therefore diffi cult to properly assess the accuracy of the current 
in vitro assays. Some reviews, such as that published by Fernández-García et al. 
( 2009 ), consider that a correlation effectively exists in the case of carotenoids, and 
that a measure of bioaccessibility might be suffi cient as an estimation of how bio-
available a carotenoid is from the food in question (Etcheverry et al.  2012 ). Likewise, 
Butts et al. ( 2012 ), in reference to amino acid and protein digestibility, affi rm that 
simple in vitro digestion methods have the potential to give useful measures of the 
in vivo behaviour. Van Campen and Glahn ( 1999 ) reviewed static solubility and 
dialyzability methods for estimating the availability of essential mineral elements, 
and found these methods to be in reasonable agreement with human absorption 
data, especially for iron. The authors also indicated that there has been much less 
development of in vitro methods for other trace minerals (zinc, copper, manganese, 
selenium) than for iron. A recent review (Etcheverry et al.  2012 ) compiles in vitro 
bioaccessibility and bioavailability methods applied to different nutrients, and rec-
ommends concrete methods for each nutrient. The need for more validation studies 
of in vivo–in vitro results is also discussed. 
 In conclusion, investigators who use static methods must consider how to adapt 
the static digestion conditions according to the composition of the sample and/or to 
food components under study—seeking a balance between technical simplifi cation 
and accuracy, and always retaining the in vivo situation as reference with a view 
to maximally reproducing the physiological situation through the static model. 
In addition, it is necessary to know and assess the advantages and disadvantages of 
static in vitro digestion models for different food samples. Thus, there is urgent need 
for harmonization and standardization of the in vitro techniques, particularly the 
static methods. Furthermore, these methods must be validated with proper assess-
ments of gastrointestinal human physiology, in order to afford improved study 
designs. In this context, although such methods are unable to reproduce all the con-
ditions found in the in vivo setting, their validation at least will allow the compari-
son of preliminary results among laboratories, prior to the conduction of more 
advanced studies (dynamic in vitro studies, the use of cell cultures, or in vivo 
experimentation). 
 Open Access This chapter is distributed under the terms of the Creative Commons Attribution 
Noncommercial License, which permits any noncommercial use, distribution, and reproduction in 
any medium, provided the original author(s) and source are credited. 
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 Chapter 2 
 InfoGest Consensus Method 
 Alan  Mackie and  Neil  Rigby 
 Abstract  This section describes the consensus static digestion method developed 
within the COST Action InfoGest. Simulated gastro-intestinal digestion is widely 
employed in many fi elds of food and nutritional research. Various different diges-
tion models have been proposed, which often impedes the possibility of comparing 
results across research teams. For example, a large variety of enzymes from differ-
ent sources such as porcine, rabbit or human have been used and these differ in their 
activity and characterization. Differences in pH, mineral composition and digestion 
time that alter enzyme activity and other phenomena may also signifi cantly alter 
results. Other parameters such as the presence of phospholipids, specifi c enzymes 
such as gastric lipase and digestive emulsifi ers, etc. have also been discussed at 
length. In this section, a general standardised and practical static digestion method 
is given, based on physiologically relevant conditions that can be applied for various 
endpoints. A framework of parameters for the oral, gastric and small intestinal 
digestion is outlined and their relevance discussed in relation to available in vivo 
data and enzymes. Detailed, line-by-line guidance recommendations and justifi ca-
tions are given but also limitations of the proposed model. This harmonised static, 
in vitro digestion method for food should aid the production of more comparable 
data in the future. 
 Keywords  In vitro •  Digestion •  Oral •  Gastric •  Small intestinal 
2.1  Introduction 
 The static protocol for simulating digestion in the upper GI tract published by 
InfoGest and led by Andre Brodkorb was the result of more than 2 years’ work 
involving extensive discussion among scientists from a wide range of relevant dis-
ciplines (Minekus et al.  2014 ). The fi nal consensus recommendation is relatively 
simple, based on physiological parameters that have been cited and is widely 
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supported by those undertaking in vitro digestions, especially in food research. 
In keeping with the requirement for simplicity but not oversimplifi cation discussed 
in the general introduction to this chapter, this is a static model using values of pH, 
ionic composition endogenous surfactants and enzyme activity that are fi xed at the 
start of the experiment. All aspects of digestion in the upper GI tract were consid-
ered in the development of the method and the reasons for the inclusion or exclusion 
of specifi c features will be discussed below. The method comprises up to three 
stages that mimic the oral, gastric and small intestinal phases of digestion in vivo. 
At each stage the duration and physical and biochemical environment are described 
and the reasons for their selection given. The enzymes recommended for inclusion 
are described using their IUBMB Enzyme Nomenclature and the method has been 
written in such a way as to allow the sourcing of material from any suitable supplier. 
The method is outlined in the fl ow diagram given in Fig.  2.1 . All enzyme activities 
and other concentrations are given per mL of digesta as they will fi nally be used. 
2.2  The Oral Phase 
 The oral phase of digestion is where solid foods are physically broken down through 
the process of chewing. Residence time is short, especially for liquid or semi-solid 
foods, and solids are mixed with saliva to form a bolus with a paste-like consistency 
before swallowing. In addition to processing there is a great deal of sensing, including 
taste, texture, aroma, etc. However, most of these functions do not affect digestion in 
any tangible way and so for the purposes of the method they have been ignored. The 
exception to this is the texture, which in vivo is continually assessed and generally 
only when particles of food have been reduced to 2 mm or smaller will the bolus be 
swallowed (Peyron et al.  2004 ). Before the oral phase is started a decision needs to be 
made about what kind of processing is to be included as shown in Fig.  2.1 . On the face 
of it this seems simple as liquid samples don’t need to be chewed and so can simply 
be mixed with simulated salivary or gastric fl uid and passed to the gastric phase while 
solid samples go through the full oral phase as outlined below. However, the user 
needs to decide where the boundary between solid and liquid lies and whether the 
addition of salivary amylase is important for their sample. 
 In addition to chewing the other important factor for solid food is the addition of 
saliva, which contains a broad range of ions, proteins and peptides, only some of 
which are directly relevant to digestion (Humphrey and Williamson  2001 ). Saliva 
also contains the enzyme α-amylase (EC 3.2.1.1) but not lingual lipase as is often 
quoted. There is general interest in the importance of mucin in saliva (Sarkar et al. 
 2009 ) and much debate about whether it is important to add it or not. There are two 
types of mucin secreted into saliva MUC5B and MUC7 although there is none in 
parotid saliva. Mucin represents less than 20 % of the total protein in whole saliva, 
which is normally around 0.7 mg/mL (Lee et al.  2007 ). At such low levels as 
0.15 mg/mL, other surface active proteins are more likely to be important than 
mucin for the behaviour of saliva. Also the availability of reliable sources of such 
A. Mackie and N. Rigby
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salivary mucin would make inclusion diffi cult under normal circumstances. Thus the 
method uses a simulated salivary fl uid (SSF) containing the ion composition given 
in Table  2.1 at pH 7.0 and α-amylase at 150 units per mL of SSF (Bornhorst et al. 
 2014 ; Hoebler et al.  1998 ) but no mucin or other proteins. Here, 1 unit is defi ned as 
liberating 1.0 mg of maltose from starch in 3 min at pH 6.9 at 20 °C and the activity 
 Fig. 2.1  A fl ow diagram describing the InfoGest digestion method involving simulated salivary 
fl uid ( SSF ), simulated gastric fl uid ( SGF ) and simulated intestinal fl uid ( SIF ) 
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should be determined using the method of Bernfeld ( 1955 ). We now have our saliva 
but how do we simulate mixing and chewing of the food in a standardised way? 
After much discussion it was decided to recommend the use of what is known in the 
UK as a mincer, which is commonly used in kitchens to mince raw or cooked meat. 
Having chewed the food, how much saliva do we need to add? On average, unstimu-
lated fl ow rate is 0.3 mL/min but stimulated fl ow rate is, at maximum, 7 mL/min 
(Humphrey and Williamson  2001 ). Stimulated saliva is reported to contribute as 
much as 80–90 % of the average daily salivary production. Thus based on stimu-
lated fl ow, the amount of saliva to add is a 1:1 v/w ratio with the food i.e. 5 g of 
food + 5 mL SSF. The only remaining question is how long should we expose the 
food to the SSF? Although a value of 0.5 min might be close to the situation in vivo, 
the practicalities of handling suggest that in order to be confi dent of reproducing the 
oral phase in a consistent manner, including mixing of saliva, 2 min would be more 
appropriate. The temperature at which the amylase containing SSF is mixed with 
the “chewed” food should of course be 37 °C and the 2 min is the contact time 
between the food and SSF.
 In a typical example: 5 g of solid or 5 mL of liquid food is mixed with 3.5 mL 
of SSF electrolyte stock solution, either during or after mincing, if necessary. Next, 
0.5 mL salivary α-amylase solution of 1,500 U/mL made up in SSF electrolyte 
stock solution (α-amylase from human saliva Type IX-A, 1,000–3,000 U/mg 
protein, Sigma) is added followed by 25 μL of 0.3 M CaCl 2 and 975 μL of water 
and thoroughly mixed. 
2.3  The Gastric Phase 
 Following whatever oral processing has been undertaken there needs to be a gastric 
phase of digestion. Commonly held beliefs about the stomach are that the pH is very 
low (1–2) and that there is a lot of mixing. Neither of these is a useful idea as the pH 
is generally only very acidic in the fasted state and there is only mixing in the small 
region close to the exit of the stomach known as the antrum. The pH in the gastric 
compartment is rather dynamic and is highly dependent of the buffering capacity of 
 Table 2.1  The ionic composition of simulated digestion fl uids 
 Constituent  SSF (pH 7) (mmol/L)  SGF (pH 3) (mmol/L)  SIF (pH 7) (mmol/L) 
 K +  18.8  7.8  7.6 
 Na +  13.6  72.2  123.4 
 Cl −  19.5  70.2  55.5 
 H 2 PO 4 −  3.7  0.9  0.8 
 HCO 3 − , CO 3 2−  13.7  25.5  85 
 Mg 2+  0.15  0.1  0.33 
 NH 4 +  0.12  1.0  – 
 Ca 2+  1.5  0.15  0.6 
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the food (Carrière et al.  1991 ; Dressman et al.  1990 ; Kalantzi et al.  2006 ). However, 
as this is a static method a specifi c value needs to be recommended and this was 
chosen in conjunction with a decision about the duration of the gastric phase. Given 
that the method needs to be broadly applicable, the method recommends 2 h. This 
time represents the half emptying of a moderately nutritious and semi-solid meal 
(Dressman et al.  1990 ) and in order to match the 2 h recommendation for the dura-
tion of the gastric phase the pH we recommend must represent a mean value for a 
general meal over that time. Thus we recommend the use of a static value of pH 3 
combined with the ionic composition outlined in Table  2.1 . In this static model 
the physical environment of the gastric compartment will not be reproduced but 
some mixing is required and this can be supplied either by shaking or stirring the 
sample at 37 °C. 
 The only proteolytic enzyme present in the stomach is pepsin, which is secreted 
in the form of the precursor pepsinogen. Large variations in pepsin activities are 
reported in the literature due to the use of different assays and calculations (Ulleberg 
et al.  2011 ; Armand et al.  1995 ). Based on the literature the recommended activity 
of porcine pepsin (EC 3.4.23.1) is 2,000 U/mL of gastric contents where one unit 
will produce a ΔA 280 of 0.001 per minute at pH 2.0 and 37 °C, measured as TCA- 
soluble products using haemoglobin as a substrate, adapted from Anson ( 1938 ) and 
Anson and Mirsky ( 1932 ). The use of lipolytic enzymes is always more diffi cult and 
whilst the potential importance of human gastric lipase (HGL) is acknowledged it 
has not been included for the following reasons. Firstly, because of the relatively 
low pH, lipid interfaces tend to become saturated and thus gastric lipolysis is gener-
ally limited. Secondly, there is no lipase currently widely available, affordable and 
that has the correct pH and site specifi city. The fi nal recommended option is to 
include phosphatidylcholine (PC) at 0.17 mM in vesicular form (Macierzanka et al. 
 2009 ; Mandalari et al.  2009 ). 
 In a typical example: 10 mL of liquid sample or oral bolus is mixed with 7.5 mL 
of SGF electrolyte stock solution, 2.0 mL porcine pepsin solution of 20,000 U/mL 
made up in SGF electrolyte stock solution (pepsin from porcine gastric mucosa 
3,200–4,500 U/mg protein, Sigma), 5 μL of 0.3 M CaCl 2 , 0.2 mL of 1 M HCl to 
reach pH 3.0 and 0.295 mL of water. 
2.4  The Small Intestinal Phase 
 The fi nal and most complex phase is the small intestinal phase in which the pH is 
again raised to 7 and the gastric effl uent is exposed to a broader range of enzymes 
and surfactants (Kalantzi et al.  2006 ; Kopf-Bolanz et al.  2012 ; Versantvoort et al. 
 2005 ). As with the gastric compartment the intestinal phase duration is 2 h. This is 
again a compromise but is based on normal transit times in the human gut but also 
on the fact that because there is no product removal, inhibition may become a prob-
lem at extended times, especially if there is a signifi cant amount of lipid present. 
The suggested ionic composition for the SIF is again given in Table  2.1 . There are 
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two possible approaches that can be used with regard to the enzymes used. Firstly, 
for reasons of simplicity and cost one can use a pancreatic extract (pancreatin) 
containing all the relevant enzymes but in a fi xed ratio or secondly if preferred one 
can use the individual enzymes (proteases, lipases and amylase). If pancreatin is 
used then the amount to add must be based on a specifi c enzyme activity and we 
suggest that it is based on the trypsin activity and should be added in suffi cient 
quantity to provide 100 U/mL of intestinal phase content. The activity should be 
based on the TAME assay. The pancreatin should also be assayed for its chymo-
trypsin, lipase and amylase activities. Where individual enzymes are to be used the 
following activities should be added per mL of intestinal content. Bovine trypsin 
(EC 3.4.21.4) at 100 U/mL where one unit hydrolyses 1 μmole of  p -toluene-sulfo-
nyl- L -arginine methyl ester (TAME) per minute at 25 °C, pH 8.1, in the presence 
of 10 mM calcium ions (Walsh and Wilcox  1970 ); bovine chymotrypsin (EC 
3.4.21.1) at 25 U/mL  N -Benzoyl- L -Tyrosine Ethyl Ester (BTEE) units where one 
unit will hydrolyse 1.0 μmole of BTEE per minute at pH 7.8 at 25 °C (Bergmeyer 
et al.  1974 ); porcine pancreatic amylase (EC 3.2.1.1) at 200 U/mL where one unit 
will liberate 1.0 mg of maltose from corn starch in 3 min at pH 6.9 at 20 °C 
(Bernfeld  1955 ); porcine pancreatic lipase (EC 3.1.1.3) at 2,000 U/mL where 1 
unit will release 1 μmole of free fatty acid per minute from a substrate of tributyrin 
at 37 °C, pH 8.0, in the presence of 2 mM calcium ions and 4 mM sodium taurode-
oxycholate and excess colipase at a 2:1 molar excess, which is approximately a 
mass ratio of 1:2 colipase/lipase. 
 In addition to the enzymes there are also a range of endogenous surfactants 
including bile salts and phospholipids. These are important in the digestion of both 
protein and lipid and in the case of the latter they are involved in product removal 
to the gut epithelium. They can conveniently be added as a bile extract or as frozen 
porcine or bovine bile. Suffi cient should be added to provide 10 mM bile in the 
fi nal intestinal content (Kalantzi et al.  2006 ). This can be assayed using a number 
of different kits such as the bile assay kit 1 2212 99 90 313 from Diagnostic Systems 
GmbH in Germany (Collins et al.  1984 ). Of course none of the animal bile will be 
a really close match for human bile and it is currently unclear what impact that is 
likely to have on the digestion process. For information, the typical composition of 
human, bovine and porcine bile are given in Table  2.2 . Surprisingly, the bovine bile 
is a closer match to human than porcine bile, at least in terms of tauro- and glyco- 
cholate. The bile will also contain phospholipids and cholesterol in suffi cient 
 quantity for the digestion.
 In a typical example of intestinal simulation, 20 mL of gastric chyme is mixed 
with 11 mL of SIF electrolyte stock solution, 5.0 mL of a pancreatin solution 
800 U/mL made up in SIF electrolyte stock solution based on trypsin activity, 
2.5 mL fresh bile (based on 160 mM fresh bile), 40 μL of 0.3 M CaCl 2 , 0.15 mL of 
1 M NaOH to reach pH 7.0 and 1.31 mL of water. Verifi cation of the pH is recom-
mended to determine the amount of NaOH/HCl required in a test experiment prior 
to digestion. In this way base/acid can be added more rapidly and followed by fi nal 
verifi cation of the pH. 
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2.5  Practicalities 
 The outline method given above gives the general approach that should be used in 
terms of enzymes, their activities, ionic composition and endogenous surfactants. 
However, there are some practicalities that need to be taken into account when exe-
cuting the method. For example the simulated digestion fl uids (SSF, SGF and SIF) 
are made up using the electrolyte stock solutions given in Table  2.3 , enzymes, bile, 
CaCl 2 and water. The volumes are calculated for a fi nal volume of 500 mL for each 
simulated fl uid. However, we recommend making up the stock solution with dis-
tilled water to 400 mL, i.e. 1.25 times concentrated, for storage at −20 °C. The addition 
of enzymes, bile, Ca 2+ solution etc. and water will result in the correct electrolyte 
 Table 2.2  The approximate bile acid composition of human, bovine and porcine bile 
 Bile acid  Human bile (%)  Bovine bile (%)  Porcine bile (%) 
 Taurohyodeoxycholate  0  0  37 
 Glycohyodeoxycholate  0  0  34 
 Taurocholate  11  31  0 
 Glycocholate  26  46  0 
 Taurochenodeoxycholate  13  2  2 
 Glycochenodeoxycholate  25  3  26 
 Taurodeoxycholate  5  8  0 
 Glycodeoxycholate  11  10  0 
 Other  9  0  0 
 Table 2.3  Preparation of stock solutions of simulated digestion fl uids 
 Salt 
 Stock conc. 
 SSF  pH 7  SGF  pH 3  SIF  pH 7 
 Vol of 
stock 
 Conc. in 
SSF 
 Vol of 
stock  Conc. in SSF 
 Vol of 
stock 
 Conc. in 
SSF 
 g/L  mol/L  mL  mmol/L  mL  mmol/L  mL  mmol/L 
 KCl  37.3  0.5  15.1  15.1  6.9  6.9  6.8  6.8 
 KH 2 PO 4  68  0.5  3.7  3.7  0.9  0.9  0.8  0.8 
 NaHCO 3  84  1  6.8  13.6  12.5  25  42.5  85 
 NaCl  117  2  –  –  11.8  47.2  9.6  38.4 
 MgCl 2 (H 2 O) 6  30.5  0.15  0.5  0.15  0.4  0.12  1.1  0.33 
 (NH 4 ) 2 CO 3  48  0.5  0.06  0.06  0.5  0.5  –  – 
 For pH adjustment 
 NaOH  1  –  –  –  –  –  – 
 HCl  6  0.09  1.1  1.3  15.6  0.7  8.4 
 CaCl 2 (H 2 O) 2 is not added to the simulated digestion fl uids, see legend 
 CaCl 2 (H 2 O) 2  44.1  0.3  1.5 (0.75) a  0.15 (0.075) a  0.6 (0.3) a 
 a In brackets is the corresponding Ca 2+ concentration in the fi nal digestion mix 
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concentration in the fi nal digestion mixture. CaCl 2 is not added to the electrolyte 
stock solutions as precipitation may occur. Instead, it is added to the fi nal mixture 
of simulated digestion fl uid and food.
2.6  Sampling 
 The way that sampling should be done depends on the nature of the study and should 
be carefully considered for each study. For example, it may be advisable to have indi-
vidual sample tubes for each time point rather than withdrawing samples from the 
reaction vessel. Also, it may be important to sample at multiple time points through 
both gastric and intestinal phases or it may only be necessary at the end of digestion. 
Regardless of such questions, the way in which the reactions are stopped will depend 
on what the samples will be subsequently required for. The following are some 
recommendations to inhibit further enzyme action in the digesta samples:
•  Snap freezing of samples is recommended in liquid nitrogen immediately after 
the reaction for further analysis. It should be born in mind that enzymes will 
continue to act, even in frozen samples albeit slowly. Therefore the colder the 
sample is stored the better. 
•  If samples are sent to other labs, i.e. by courier or by post, the digestion should 
be stopped completely and for this, the following procedures are recommended:
 –  Neutralize the pH in the gastric phase by adding 0.5 M sodium bicarbonate. 
This will inactivate the pepsin before snap-freezing in liquid nitrogen and 
subsequent storage and/or freeze drying. 
 –  Addition of protease inhibitor (e.g. 1 mM 4-(2-aminoethyl) benzenesulfonyl 
fl uoride hydrochloride [AEBSF], Roche or similar), snap freezing in liquid 
nitrogen and subsequent freeze drying of samples. 
2.7  Conclusions 
 The InfoGest harmonised static digestion simulation method has been endorsed by 
a wide range of international experts. We have endeavoured to make it as physiolog-
ically relevant as a static model can be but readers should bear in mind that it is still 
only a simplifi ed model. The main limitations of such a simplifi ed model are the 
fi xed pH and duration of the various phases. However, this can also be seen as an 
advantage in terms of consistency and comparability. The other potentially prob-
lematic issue is the lack of an adsorption step but there are now a number of cellular 
systems where this aspect can be investigated. It is hoped that this simple model will 
be widely adopted, allowing faster progress when developing healthier foods and 
more effective bioactives. 
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 Chapter 3 
 Approaches to Static Digestion Models 
 Alan  Mackie ,  Neil  Rigby ,  Adam  Macierzanka , and  Balazs  Bajka 
 Abstract  It is not possible to look in detail at the wide range of static digestion 
methods that have been used to date. However, this section looks at some of the 
general approaches that have been used to look at the digestion of various nutrients 
and bioactives. I have focussed on the two main nutrients that undergo digestion in 
the upper GI tract, namely protein and lipid. In the case of protein, the research has 
largely been driven by the need to assess allergenic potential and the parameters 
used in such an assessment are given along with the justifi cation provided by the 
authors for their choice. For the lipid digestion, we have drawn heavily upon the 
work of Julian McClemments and colleagues who have been prolifi c in generating 
data in this area. The information provided highlights the fact that a wide range of 
methods are in use leading to a need for a single method, a role that can be fi lled by 
the Infogest method. 
 Keywords  Infogest •  Protein •  Lipid •  Allergy •  Bioactive •  Delivery 
3.1  Introduction 
 Since the increase in interest in the health implications of specifi c foods or diets, 
there has also been an interest in how foods are digested and this has led to the 
development of a wide range of digestion methods and upper GI tract simulations. 
Of course the methods have been developed to address specifi c questions such as 
the allergenic potential of a protein or the delivery of fat soluble bioactives. Whilst 
many would argue that specifi c nutrients should not be considered in isolation, a 
reductionist approach can sometimes prove helpful. However, this does beg the 
question of how relevant some of the model digestion systems that have been used 
are to what happens in vivo after consumption of real foods. The macronutrients 
that are digested in the upper GI tract are protein, lipid and starch. For many reasons 
the digestion of both proteins and lipids have often been considered independent of 
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one another and the sections below will outline some of the approaches that have been 
used when considering the digestion of the micronutrients in isolation. In general, 
we would recommend that people using static simulations of digestion should use 
the Infogest model as described in Chap.  2 of this book. However, it is not always 
possible and so some of the circumstances under which other approaches may be 
appropriate are given below. 
3.2  Static Models for Protein Hydrolysis 
 The ability of proteins to interact with the immune system in the gut causing intolerance 
such as coeliac disease and food allergy has led to a signifi cant number of studies. 
One of the most highly cited articles using in vitro digestion is in the fi eld of allergy. 
In the article by Astwood et al. ( 1996 ) a method is given for determining protein 
stability. In the article they used a single (gastric) phase of digestion involving simu-
lated gastric fl uid (SGF) containing pepsin at 3.2 mg/mL with an activity of 20,100 
units in 30 mM NaCl at pH 1.2. The reason given for using these values was that 
they were “in line with recommendations from the US pharmacopeia”. When com-
pared to the value of 2,000 U/mL at pH 3 that is recommended in the Infogest pro-
tocol, this seems very high, even if the units are not identical. Surprisingly perhaps, 
the Astwood article shows that proteins that were food allergens were generally not 
digested under these conditions. Indeed, this idea led to the use of pepsin resistance 
as a measure of the allergenic potential of a food protein (Eisenbrand et al.  2002 ). 
Under these circumstances it is argued that the method is merely an indicator of 
structural robustness rather than a precise simulation of how the protein would 
behave when it is consumed in vivo. It should perhaps be highlighted at this point 
that the allergenic proteins that were pepsin resistant tended to be those that were 
thought to sensitise via the oral route. There are a great many allergenic proteins, 
such as Ara h 1 (Vicillin-type 7S globulin from peanut) or Bos d 8 (casein from 
cows’ milk) that are very susceptible to hydrolysis by pepsin. 
 In studies undertaken to look at the digestion of allergenic proteins, it is common 
practice to add protease in a specifi c proportion relative to the amount of protein 
being digested. Certainly from the perspective of comparison it is useful to use a 
consistent activity of enzyme such as the 2,000 U/mL given above and a consistent 
protein concentration. For example in a ring trial comparing the digestion of milk 
proteins β-lactoglobulin and β-casein in different laboratories (Mandalari et al. 
 2009a ), two regimes were used, a high and a low protease activity. The high prote-
ase used a pepsin activity of 10,560 U/mL based on haemoglobin as a substrate and 
a substrate concentration of 0.25 mg/mL, equivalent to a pepsin activity of 42,240 U/
mg substrate. The low protease part used 165 U/mg of substrate. The pH used in the 
high protease phase was 1.2 whereas that used in the low protease phase was 2.5. 
The data from this study are very revealing in terms of comparison of data from 
different groups. As already stated elsewhere, if a comparison is to be made then 
the in vitro digestion methods employed must be standardised or at least comparable. 
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In this study, the methods used were nominally the same in all groups. However, the 
results varied signifi cantly. For example, under the lower protease condition, 
β-casein was persistent for 10 min in 62 % of cases but 20 min in 26 % of cases and 
the remainder showed the protein persistent until either 5 or 40 min. After the simu-
lated gastric phase the study also used a “duodenal” phase lasting 1 h at pH 7.5 or 
6.5 for the high and low protease conditions respectively. For the high protease 
condition pancreatin was used at 12.8 mg per mg substrate and for the low protease 
condition, trypsin and chymotrypsin were used at 35.4 BAEE U/mg of substrate and 
0.4 U/mg of substrate respectively. This is in comparison to the Infogest recommen-
dations of 100 TAME U/mL and 25 U/mL for trypsin and chymotrypsin respec-
tively. There is about a 100-fold difference between TAME and BAEE as a substrate 
with BAEE giving the higher values. The pancreatin concentration used is likely to 
have yielded trypsin activities around 8,000 BAEE units per mg of substrate. 
 In addition to different protease conditions, the study also looked at the effect of 
3 mM phospholipid addition to the gastric stage of digestion. The results showed 
that the addition increased the resistance of β-lactoglobulin to simulated duodenal 
hydrolysis over 60 min. The mechanism by which this occurs was investigated in 
more detail in a related paper (Mandalari et al.  2009b ). The authors also showed that 
thermal processing signifi cantly decreased the effect. Such interactions highlight 
the importance of considering both the protein of interest and other components that 
may be present during and post consumption in vivo. 
 The safety assessment of genetically modifi ed products requires consideration of 
various parameters including assessment of homology with known allergens using 
various in silico databases, IgE binding studies and resistance of the protein to 
digestion with simulated gastric fl uid (Foster et al.  2013 ). In all such studies the 
standard approach has become the use of pepsin at 3.2 mg/mL in 0.03 M NaCl and 
pH 1.2 (Selgrade et al.  2009 ). Such amounts of pepsin will typically yield an activity 
of 10,560 U/mL, as indicated above. In a recent study investigating the safety of the 
protein osmotin, expressed in transgenic crops to enhance abiotic stress tolerance, 
the protein was shown to be resistant to pepsin digestion under standard conditions 
(Sharma et al.  2011 ). As result, osmotin was regarded as being a potential allergen. 
In addition to studying proteins for their potential detrimental effects, there has been 
signifi cant study with regard to the release of bioactive peptides. For example, the 
group at the Institute of Food Research (CIAL) in Madrid have studied this exten-
sively and in a recent publication they have shown the resistance of casein derived 
bioactive peptides. The method that they use to simulate adult digestion comprises 
two phases, gastric and duodenal. The gastric phase uses pepsin at 114 U/mL 
(11.4 U/mg of substrate) at pH 2.0 for 90 min. The small intestinal phase used 
Corolase (a pancreatic extract similar to pancreatin) at an enzyme to substrate ratio 
of 1:25. Given the pepsin activity recommended by Infogest of 2,000 U/mL this 
seem a little on the low side but it should be born in mind that the pH is also lower 
(2 rather than 3) and thus the activity of the pepsin in the actual experiment will be 
slightly higher (Okoniewska et al.  2000 ). 
 There has been a signifi cant amount of study of the digestion of protein using the 
simulated adult gut. However, there have also been many studies of the breakdown 
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of milk proteins in the infant gut. For a good review of the conditions pertaining to 
the infant gut there is a recent article by the Bourlieu et al. ( 2014 ). This review gives 
a good idea of the physiological environment of the infant gut, both of premature 
and term infants. In a study where the digestion of protein was compared using 
infant and adult simulations (Dupont et al.  2010 ). The adult model used was similar 
to those given above with a gastric phase at pH 2.5, phospholipid and 182 U/mL 
pepsin followed by a duodenal phase at pH 6.5, containing 8 mM bile and chymo-
trypsin and trypsin at 0.4 and 34.5 U/mg of substrate respectively. For the infant 
model the following changes were made: The pH of the gastric digestion mix was 
adjusted at 3.0 instead of 2.5; the pepsin concentration in the gastric digestion mix 
was decreased by a factor of 8 and the duodenal digestion mix was altered by reduc-
ing the bile salt concentration by a factor of 4, while the PC, trypsin and chymotryp-
sin concentrations were reduced by a factor of 10. The proteins used for this 
comparison were β-lactoglobulin, β-casein and ovalbumin. One might expect that 
the lower concentrations of proteases used in the infant model would result in less 
extensive degradation of the three proteins used. Although this was found to be the 
case for β-casein and ovalbumin, the β-lactoglobulin was more extensively degraded 
by the infant than the adult digestion simulations. This was thought to be a result of 
the reduction in the protective effect that gastric phospholipid has on native 
β-lactoglobulin retarding digestion by trypsin and chymotrypsin. Surprisingly, no 
information is provided about the justifi cation of the values chosen for the infant 
model. In a similar, more recent study of simulated gastric digestion of β-lactoglobulin 
and lactoferrin by a group in Israel, (Shani-Levi et al.  2013 ) the comparison between 
adult and infant used gastric pepsin activity of 240 and 210 U/mg of substrate 
respectively. The main difference between the two models was the way that the pH 
was lowered going from 6.5 to 3.5 over 4 h in the infant model as opposed to 4.5 to 
1.5 over 2 h in the adult model. Needless to say there was little difference in the 
digestion of β-lactoglobulin but very signifi cant differences in the persistence of 
lactoferrin, which is a much more labile protein. 
 Enzyme activity should be measured under the standard conditions recom-
mended by the assay in order to be comparable with other measurements in the lit-
erature. However, it should be kept in mind that the activity of the enzyme on the 
substrate used in the simulation and under the conditions of the simulation is likely 
to be rather different. For this reason, the simulation should NOT aim to deliver a 
specifi c protease activity but rather to deliver a specifi ed amount of active enzyme. 
This may be a subtle distinction but it has important consequences. 
3.3  Static Models for Lipid Hydrolysis 
 In a similar way that in vitro digestion has been used in some cases to investigate 
protein digestion in isolation, a number of studies have concentrated on lipid diges-
tion. For a review of this topic, there is an excellent article by Julian McClemments 
(McClements and Li  2010 ) in which a large number of different study conditions 
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are given. Perhaps the main message for us from this review is that there is no 
 consistency of approach and everyone uses their own model based on various differ-
ent requirements and assumptions. Indeed, this very issue was the reason that 
Infogest was set up. The fi rst stage of digestion may be considered the mouth but 
whilst there have been a number of studies looking at the behaviour of fat in the 
mouth (van Aken et al.  2007 ), as there is no lingual lipase produced in man there is no 
digestion of fat by endogenous enzymes in the oral cavity. Essentially all the work 
undertaken on lingual lipase has been done in rodents (Hamosh and Scow  1973 ) and 
this has led to the misconception that the same physiology applies to humans. Many 
studies do not include an oral phase for liquid systems containing fat (Borel et al. 
 1994 ; Fernandez et al.  2009 ; Hedren et al.  2002 ) or they include an oral phase that 
merely represents a resting phase after sample preparation (Beysseriat et al.  2006 ). 
 The next phase of digestion is the gastric phase containing human gastric lipase 
(HGL). However, this step is also often excluded from a static digestion focussed on 
lipolysis for a combination of reasons (Mun et al.  2007 ; Bonnaire et al.  2008 ). The 
most obvious reason is the pH that is being used in simulating the gastric phase is 
often too low for the HGL to be active as the activity drops rapidly below pH 2 
(Ville et al.  2002 ). There is also the issue of what type of lipase to use as a substitute 
that has the same pH sensitivity and site specifi city as HGL. Also lipolysis under 
gastric conditions may be considered diffi cult to follow as the fatty acids (FA) 
released are not fully dissociated and so not amenable to titration using the normal 
pH-stat methods. This can be corrected for at the end of the simulation by raising 
the pH to 9.0, assuring full dissociation of the fatty acids (Helbig et al.  2012 ). Those 
that do include a substitute HGL in their gastric simulations often opt for a fungal 
lipase such as that from  Rhizopus oryzae (Day et al.  2014 ; Wooster et al.  2014 ). This 
lipase has been well characterised (Hiol et al.  2000 ), exhibits similar site-specifi c 
hydrolysis of triglycerides to that of HGL and is acid stable. However the ‘optimal’ 
pH of hydrolysis by  R. oryzae lipase is 7.5 and the enzyme is only stable in the 
range pH 4.5–7.5. These values are different from the sensitivity of HGL which is 
said to have an apparent optimum at pH 4.5 and is still stable at pH 2 (Aloulou and 
Carriere  2008 ). 
 Regardless of the debate as to whether HGL or a substitute should be included in 
a gastric simulation, there is still the consideration of how much should be added. 
Recent work has used 0.2 mg/mL fungal lipase at pH 1.9 (Wooster et al.  2014 ), 
which given the activity determined by Hiol et al. ( 2000 ) of 8,800 U/mg is equivalent 
to 1,760 U/mL of SGF. As always the method used for the assay is important, and in 
this case it was against long-chain triacylglycerol plant oils and was determined with 
20 mL of substrate emulsion prepared from 40 mL of oil in 400 mL of a 2 % solution 
of gum acacia prepared in distilled water. One lipase unit corresponded to the release 
one millimole of fatty acid per minute under assay conditions. This type of assay is 
diffi cult to repeat and is thus not comparable with the preferred standard method 
using tributyrin as a substrate (Carriere et al.  1993 ). The tributyrin method is pre-
ferred because the hydrolysis takes place mainly in solution and is thus not dependant 
on the surface area of substrate available in an emulsion. This makes it much more 
reproducible, at least in principle. The activity of HGL has been measured in humans 
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using the tributyrin assay and is around 1,000 U/mg with the activity in gastric fl uid 
of about 100 U/mL in the fed state (Carriere et al.  1993 ). 
 In another recent study (van Aken et al.  2011 ), HGL was substituted by Amano 
Lipase A, a fungal lipase from  Aspergillus niger that is quoted by Sigma as having 
an activity of 120 U/mg but the assay used is not quoted. In the article describing the 
study the authors go into some detail about the reason for their choice of this 
enzyme. The main reason for the choice was the broad pH stability meaning that the 
enzyme remains active at the low gastric pH. However such attention to detail is rare 
as the small intestine is quite correctly seen as the main site of fat digestion. Despite 
the lack of importance given to gastric lipolysis, it has been shown that in infants, 
HGL plays an important role in lipid digestion (Hamosh  1996 ). This is because in 
the neonate the production of pancreatic lipases is not fully developed. In a recent 
study of emulsion digestion using an infant simulation (Lueamsaisuk et al.  2014 ), 
fungal ( R. oryzae ) lipase was added at 16 U/mL and a range of pH was assessed (2, 
3.5, 4.5 and 5.5). Despite the interesting results confi rming the need for a full spec-
trum of enzymes, one of the main conclusions was the recommendation that out-
comes based on in vitro digestion with fungal lipases should always be validated 
with at least one mammalian gastric lipase. As a fi nal comment, we want to high-
light the problems of pH sensitivity in the case of HGL substitutes. If suffi cient 
lipase is added to a gastric simulation to give the relevant activity at the low gastric 
pH then when the pH is raised for the small intestinal simulation the lipase activity 
is likely to increase dramatically perhaps dominating the pancreatic lipases. This 
situation should be avoided. 
 As already stated the main site of fat digestion is the upper small intestine, 
 duodenum and jejunum. This has led to simulation of this phase of digestion being 
the focus of most studies. There are three main factors that have been taken into 
account, enzymes (pancreatic lipase, colipase, etc.), bile (extract or specifi c compo-
sition) and pH. Starting with the simplest parameter, pH, the range of different val-
ues used is relatively narrow falling between 6.5 and 7.5 with the occasional study 
using values as low as pH 5.3 (Beysseriat et al.  2006 ), which is clearly of no physi-
ological relevance. With this exception, values are generally physiologically rele-
vant to the small intestine as a whole and allow the production of free fatty acids to 
be reasonably accurately followed by the pH-stat method (Helbig et al.  2012 ). In the 
pH-stat method the pH is monitored and any decrease caused by the formation of 
fatty acids is countered by addition of hydroxide. By monitoring the amount of 
hydroxide added, the amount of free fatty acid produced can be calculated. If the 
fatty acid is fully dissociated then the amount of hydroxide added is the same as the 
amount of fatty acid produced. Endogenous surfactants such as phospholipids and 
bile acids play a vital role in the hydrolysis and transport of lipids. Bile salts can 
adsorb onto fat droplets and can remove other materials such as proteins, emulsifi ers 
and lipolysis products from the lipid surface (Maldonado-Valderrama et al.  2011 ). 
As a result they should be used in intestinal simulations. The question then arises as 
to what bile to use and the answer is not clear cut as can be seen from the recom-
mendations in the Infogest method (Chap.  2 ). Table  2.2 in Chap.  2 shows an analy-
sis of bovine, porcine and human bile using the method of Rossi et al. ( 1987 ). It is 
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clear from the table that whilst neither is a perfect match, the bovine bile is closer to 
human in composition. 
3.4  Other Static Models 
 In addition to studying the digestion of proteins and lipids, static models of gastro-
intestinal digestion have been used for a range of other things. In particular, starch 
resistance has been studied using such models for many years (Ring et al.  1988 ; 
Wolf et al.  1999 ). However, the key to the functionality of resistant starch is its lack 
of digestion in the upper GI tract, thus the models have tended to focus on colonic 
fermentation. Despite this focus there have been some more recent articles that look 
at the digestion of starch in the upper GI tract. In an article by Wooster et al. ( 2014 ), 
an emulsion was combined with a range of different polymers including starch and 
the in vitro digestion simulated the small intestine with the use of pancreatin at 
125 mg/mL but the activity was not assayed. 
 In addition to the three groups of macronutrients (protein, lipid and carbohy-
drate) food provides a wide range of other bioactive molecules and many of these 
have been studied using static simulations of the upper GI tract. For example the 
release of polyphenols from orange juice was assed using a static digestion model 
(Gil-Izquierdo et al.  2001 ) in which the gastric phase was simulated for 2 h at pH 2 
with 315 U of pepsin per mL of juice. The small intestinal phase was incubated for 
~2.5 h at pH ~5 with 1 g pancreatin in 250 mL digesta and 6.25 g of bile extract. 
The conclusion was that although orange juice is a very rich source of fl avanones, 
the concentration of compounds that are in a soluble bioaccessible form under the 
conditions of the small intestine, is probably much smaller but again the conditions 
were not those recommended. 
 Our fi nal example looks at a GI simulation used to assess the iron availability 
from meals (Miller et al.  1981 ). The conditions used in this simulation are essen-
tially identical to those used in the above simulation used to follow polyphenol 
release. It includes an interesting way of raising the pH between the gastric and 
small intestinal phases. Segments of dialysis tubing containing 25 mL water and an 
amount of NaHCO 3 equivalent to the titratable acidity measured previously were 
placed in the gastric sample. This was then sealed incubated in a 37 °C shaking 
water bath until the pH reached about 5 (approximately 30 min). This method pro-
vides the gentle rise in pH necessary for working with minerals. However the fi nal 
pH is rather low compared to what might be expected in vivo. This method also 
highlights approaches that tend to be used out of context and one could argue that 
this might not be the most appropriate simulation for following the release of poly-
phenols from orange juice. When using a static model of digestion the parameters 
used should be appropriate to the question and physiologically relevant. 
 Open Access This chapter is distributed under the terms of the Creative Commons Attribution 
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 Chapter 4 
 Dynamic Digestion Models: General 
Introduction 
 Eva  C.  Thuenemann 
 Abstract  The fi rst section of this chapter has focused on static digestion models 
and their specifi c applications. Whilst these static models have many advantages, 
they mainly function to mimic the biochemical processes in the gastrointestinal (GI) 
tract and usually use a single set of initial conditions (pH, concentration of enzymes, 
bile salts, etc.) for each part of the GI tract. However, this simplistic approach is 
often not a realistic simulation of the more complex in vivo conditions, where the 
biochemical environment encountered is constantly changing and physical param-
eters such as shear and grinding forces can have a large impact on the breakdown of 
larger food particles and the release of nutrients. Several dynamic digestion models 
have been developed in recent years to address these complex aspects of digestions, 
and four of these dynamic models will be presented in more detail in the following 
subchapters. This introduction will provide a brief overview of how the aspects of 
geometry, biochemistry and physical forces have been addressed in these and other 
dynamic digestion models. 
 Keywords  Dynamic model •  Digestion •  GI tract •  In vitro 
4.1  Geometry 
 The human gastrointestinal tract consists of distinct compartments of differing 
shapes, sizes and orientations. These need to be considered when designing a real-
istic dynamic model. The stomach has a shape of an expanded J, with food entering 
from the esophageal sphincter at the top and eventually being released through the 
pylorus at the bottom. During digestion, body position may have an infl uence on 
some aspects of gastric digestion, especially gastric sieving of larger particles and 
pharmaceuticals. Three main approaches have been followed in the design of the 
models’ gastric compartments, each with their own advantages and disadvantages: 
vertical alignment, horizontal alignment and beaker. Vertical alignment of the 
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gastric model allows phase separation to occur during digestion, as in vivo, but has 
the disadvantage of gravity infl uencing the sedimentation of larger particles towards 
the bottom opening (examples include the Dynamic Gastric Model  [DGM, Chap.  6 ] 
and the Human Gastric Simulator [HGS; Chap.  7 ]). Horizontal alignment may be 
more suitable for the simulation of gastric sieving, but it does not provide a realistic 
representation of the low mixing environment of the gastric fundus (for example: 
TNO Intestinal Model [TIM-1, Chap.  5 ]). A stirred beaker is used in some models 
and is reminiscent of most static models (e.g. the DIDGI system [Chap.  8 ], and the 
in vitro Digestion System [IViDiS; Tompkins et al.  2011 ]). In a newer version of the 
IViDiS, Campbell et al. ( 2011 ) report the use of a molded, elastic stomach construct 
which more closely resembles the shape and size of the human stomach and is 
designed to mimic gastric peristalsis through the use of external rollers. 
 In contrast to the stomach, the peristaltic movements and tube-like structure of 
the small intestine may reduce the impact of body position on its function. Several 
dynamic digestion models use a horizontal, tube-like alignment to represent the 
small intestine. In these models, the peristaltic movements of the small intestine are 
simulated either by alternating pressure on the fl exible wall of the compartment 
(TIM-1) or constrictions within the wall of the compartment (IViDiS). Other models 
use one or more thermostated beakers to simulate the small intestine (e.g. DIDGI-
system; SHIME model, Chap.  27 ). 
 The design of the stomach and intestinal parts of digestion models has a direct 
impact on the physical forces exerted on the chyme, and how realistically the model 
simulates in vivo shear forces. 
4.2  Physical Forces 
 Whilst passing through the stomach and small intestine, food particles and drugs are 
subjected to physical shear and grinding forces as well as pressure exerted by peri-
staltic movements. This is particularly true in the fed state within the stomach: 
During a meal, a complex mixture of masticated food bolus enters the fundus of the 
stomach where it may reside for several hours, depending on meal volume and calo-
rifi c content. Within the fundus only gentle mixing occurs, whereas closer to the 
antrum peristaltic waves strengthen and the bolus is subjected to strong mixing and 
shear. The complex physical forces exerted by the GI tract are not well simulated by 
a stirred beaker approach; therefore the geometry of some dynamic models 
(see above) has been designed in such a way as to simulate these physical forces. 
Three notable examples are the HGS, the DGM and the TIM-agc (TNO’s advanced 
gastric compartment), each of which has undergone validation of the physical forces 
exerted on the food bolus. 
 The Human Gastric Simulator’s (Chap.  7 ) vertically aligned, cylindrical gastric 
compartment is periodically squeezed by the action of Tefl on rollers on its fl exible 
wall. These rollers impinge the compartment successively more towards the bottom, 
thereby simulating stronger forces nearer the antrum of the stomach. Kong and 
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Singh ( 2010 ) validated the model by measuring the pressure exerted on a rubber 
bulb within the compartment, and these pressures were found to fall within the rage 
of mechanical stresses reported in literature for the human stomach. 
 The Dynamic Gastric Model (Chap.  6 ) consists of two connected compartments, 
simulating the fundus/main body and the antrum. Within the antral part, the food 
bolus is repeatedly passed through a fl exible disc (annulus) to simulate the mixing 
and shear stresses encountered during antral contraction waves (ACWs) in vivo. 
Vardakou et al. ( 2011 ) validated these forces by comparing the mean breaking times 
of agar beads in high- and low-viscosity meals within the DGM, to the mean breaking 
times of beads in an equivalent in vivo study (Marciani et al.  2001a ). 
 The TIM advanced gastric model (Chap.  5 ) simulates ACWs by modulating the 
pressure within a water jacket surrounding the antral compartment. Pressure profi les 
within this compartment were measured using a pressure-measuring capsule and 
compared to in vivo gastric pressure profi les (see Sect.  5.5 ). 
4.3  Biochemistry 
 Dynamic digestion models, like static models, are built to mimic the biochemical 
environment of the compartments of the GI tract. Many of the considerations high-
lighted in the earlier sections of this chapter therefore apply to dynamic models as 
well: What concentrations of which enzymes, bile salts and phospholipids should be 
used? Can porcine, bovine or fungal versions of enzymes be used? Is it better to use 
complex mixtures (e.g. pancreatin) or individual, purifi ed enzymes? At what pH 
should digestion take place? How long should a given meal reside in the stomach? 
 In contrast to static models, however, the exact conditions within the different com-
partments of a dynamic model will change over time to simulate the in vivo digestion 
processes. Dynamic digestion models generally have a number of different digestive 
secretions which are added to the compartments of the model over time. This addition 
can either follow a steady secretion rate (e.g. the simulated gastric juice of HGS is 
added at a rate of 2.5 mL/min), or it can follow a pre- programmed pattern allowing the 
rate to change over time (e.g. in the TIM-1 model), or it can be programmed to change 
in response to other parameters, such as the fi ll volume of the model (e.g. gastric 
secretion in the DGM). The pH is often monitored in real- time within dynamic mod-
els and is used to control the rate of addition of hydrochloric acid, allowing the acidi-
fi cation of the meal within the gastric compartment to follow a pre-determined curve. 
In dynamic models which incorporate a duodenal step, at this stage the pH of the 
chyme is neutralized by controlled addition of sodium bicarbonate solution, and 
secretions of bile and pancreatic enzymes (or pancreatin) are added. 
 Whilst the concentrations of enzymes, bile, electrolytes and phospholipids are 
set for the various secretions used in dynamic models, the concentrations of these 
components within the digesta cannot be readily determined. This is in part due to 
the dynamic nature of the models, allowing secretion rates to change throughout the 
digestion process. However, it is also due to the inhomogeneity of the bolus within 
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the models. In vivo, a solid meal will be ingested over a period of time as small balls 
of chewed food. Within the fundus of the stomach, the bolus is only subjected to 
gentle contractions and therefore is not well mixed. Whilst the outside of the bolus 
is acted upon by gastric secretions, it can take over 1 h for these secretions to 
penetrate to the center of the bolus (Marciani et al.  2001b ). In the antral part of the 
stomach, strong peristaltic waves mix the bolus more readily, producing a more 
homogeneous chyme. 
 Some of the more advanced dynamic digestion models have a geometry designed 
to represent the fundus and antrum of the stomach, and/or the duodenum. These 
designs allow for the simulation of the physical forces exerted on the digesta during 
transit through the GI tract, which in turn allows for simulation of the inhomogeneous 
nature of digesta and localized biochemical environments, as in vivo. 
 Open Access This chapter is distributed under the terms of the Creative Commons Attribution 
Noncommercial License, which permits any noncommercial use, distribution, and reproduction in 
any medium, provided the original author(s) and source are credited. 
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 Chapter 5 
 The TNO Gastro-Intestinal Model (TIM) 
 Mans  Minekus 
 Abstract  The TNO Gastro-Intestinal Model (TIM) is a multi-compartmental 
model, designed to realistically simulate conditions in the lumen of the gastro- 
intestinal tract. TIM is successfully used to study the gastro-intestinal behavior of a 
wide variety of feed, food and pharmaceutical products. Experiments in TIM are 
based on a computer simulation of the digestive conditions in the lumen of the gut 
during transit and digestion of a meal in vivo. These conditions include controlled 
parameters such as gastric and small intestinal transit, fl ow rates and composition of 
digestive fl uids, pH values, and removal of water and metabolites. Simulation pro-
tocols have been developed for young, adult and elderly humans, dogs, pigs and 
calves after ingestion of various meals. The typical end point from results obtained 
with TIM is the availability of a compound for absorption through the gut wall 
 (bio-accessibility). Results from TIM—with or without additional intestinal cell 
assays and in silico modeling—show a high predictability as compared to in vivo 
data (Marteau et al., J Dairy Sci 80:1031–1037, 1997; Verwei et al., J Nutr 136:3074–
2078, 2006; Bellmann et al., TIM-carbo: a rapid, cost-effi cient and reliable in vitro 
method for glycaemic response after carbohydrate ingestion. In: van der Kamp J-W, 
Jones JM, McCleary BV (eds) Dietary fi bre: new frontiers for food and health. 
Wageningen Academic Publishers, Wageningen, p 467–473, 2010; Van Loo- 
Bouwman et al., J Agric Food Chem 62(4):950–955, 2014). 
 Keywords  Multi-compartmental dynamic gastric intestinal model •  Physiological 
•  Gastric •  In vitro •  Digestion •  Bio-accessibility •  Nutrient •  Digestion 
5.1  Introduction 
 The TNO Gastro-Intestinal Model (TIM) is a multi-compartmental dynamic model 
that was developed in the early 1990s in response to industrial demand to study 
food products under more physiologically relevant conditions as compared to con-
temporary digestion models (Minekus et al.  1995 ). During the past years TIM has 
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developed from an experimental lab setup—controlled by an 8 MHz PC—into a 
platform of cabinet systems that are successfully used for a broad range of studies, 
serving the feed, food and pharmaceutical industries. This chapter describes the 
concept of TIM, the TIM gastro-intestinal systems and some examples of methods 
to study the digestion of nutrients. 
5.2  Concept of TIM 
 The gastro-intestinal tract is a tube like organ with different compartments (stomach, 
small intestine, large intestine) for each step of digestion. During the gradual transit of 
the meal through the compartments different fractions of the meal are exposed to 
changing conditions due to gradual secretion of digestive fl uids and absorption of 
water and nutrients. TIM intends to simulate the dynamic conditions in the lumen of 
the gastrointestinal tract. It is designed to combine the controllability and reproduc-
ibility of a model system with physiological parameters such as mixing, meal transit, 
variable pH values in place and time, realistic secretion and composition of digestive 
fl uids, and removal of digested compounds and water. These parameters are combined in 
a protocol as an input for a computer simulation of a specifi c digestive setting. Such 
settings includes species (human, dog, pig, calve), age (infant, adult, elderly), pathology 
and meal-related parameters, obtained from in vivo data (Marteau et al.  1997 ; Minekus 
 1998 ; Smeets-Peeters  2000 ; Havenaar et al.  2013 ). Based on the computer simulation, 
the physical model is controlled to reproduce the underlying in vivo settings. 
5.3  TIM-1 
 TIM-1 (Fig.  5.1 ) is the most frequently used confi guration of the TIM platform. It 
comprises four compartments, representing the stomach, duodenum, jejunum and 
ileum. Compartments are connected by peristaltic valve pumps (PVP) that allow the 
transfer of controlled amounts of chyme. The PVPs are designed to have low dead 
volume in the closed position. They are not blocked by particles and able to handle 
complete meals. Mixing for each compartment is achieved by alternating the pres-
sure on fl exible walls. Temperature is maintained by controlling the temperature of 
the water circulating outside the fl exible walls. Prior to introduction into the gastric 
compartment, the meal is masticated with a food processor (Solostar II, Tribest) and 
mixed with artifi cial saliva containing electrolytes and α-amylase. Gastric secretion 
contains electrolytes, pepsin and a fungal lipase (F-AP 15, Amano) as an alternative 
to gastric lipase. The pH is measured and controlled with hydrochloric acid, to follow 
a predetermined curve or at a variable rate in time. Duodenal secretion consists of, 
electrolytes, bile and pancreatin. The pH is controlled at pre-set values for each com-
partment with sodium bicarbonate. All fl ows of secretion are programmable in time. 
Digestion products are removed by two different systems. Water soluble products are 
removed by dialysis through membranes with a molecular weight cutoff of app. 
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10 kDa, connected to the jejunal and ileal compartments. Lipophilic products cannot 
be removed effi ciently by these membranes since they are incorporated in micelles 
that are too big to pass the membrane. Lipophilic products are removed through a 
50 nm fi lter that passes micelles but retains fat droplets. Meal transit is controlled by 
dictating the gastric- and ileal-emptying according to the formula (Fig.  5.2 ) described 
by Elashoff et al. ( 1982 ). A typical protocol for the simulation of the digestion of a 
high fat meal in a human adult is presented in Table  5.1 . An overview of the composi-
tion of physiological relevant secreted fl uids for a human adult is given in  Chap.  2 on 
the Infogest consensus method for static digestion. 
5.4  TinyTIM 
 TinyTIM (Fig.  5.3 ) is a simplifi ed version of the TIM-1, designed to increase the 
throughput as compared to TIM-1, with focus on studies that do not need separate 
intestinal steps. The TinyTIM is used with the same gastric compartment as TIM-1 
 Fig. 5.1  Schematic presentation of TIM-1, equipped with fi lters to study the bio-accessibility of 
lipids. A. gastric compartment; B. pyloric sphincter; C. duodenal compartment; D. peristaltic 
valve; E. jejunal compartment; F. peristaltic valve; G. ileal compartment; H. ileal-cecal valve; I. 
gastric secretion; J. duodenal secretion; K. bicarbonate secretion; L. pre-fi lter; M. fi ltration system; 
N. fi ltrate with bio-accessible fraction; O. hollow fi ber system (cross section); P. pH electrodes; Q. 
level sensors; R. temperature sensors; S. pressure sensor 
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 Fig. 5.2  Gastric emptying 
( circles , t 1/2 = 80 min, β = 2) 
and ileal emptying curve 
( squares , t 1/2 = 220 min, 
β = 2.2) to control transit of a 
solid meal in TIM-1 
 Table 5.1  Typical parameter settings for digestion of a high fat meal in TIM-1 with fi lters 
 Volume (ml)  Stomach: 300, duodenum: 55, jejunum: 130, ileum: 130 
 Meal size (g)  300 
 Gastric secretion (ml/min)  1 
 Gastric emptying curve  t 1/2 = 80 min, β = 2 
 Gastric pH curve (time, pH)  (0, 5.2) (30, 3.2) (60, 2.2) (120, 1.7) 
 Bile secretion (ml/min)  0.5 
 Pancreatin/electrolytes (ml/min)  0.5 
 Ileal emptying curve  t 1/2 = 220 min, β = 2.2 
 Small intestinal pH  Duodenum: 6.2, jejunum: 6.5, ileum: 7.4 
 Filtration rate (ml/min)  Jejunum: 4.5, ileum: 4.5 
 Fig. 5.3  Schematic presentation of TinyTIM, equipped with a dialysis membrane to study the bio-
accessibility of water soluble compounds. A. gastric compartment; B. pyloric sphincter; C. duode-
nal compartment; D. gastric secretion; E. duodenal secretion; F. pre-fi lter; G. pH electrodes; 





when the ratio between amount of food and ingested material, such as pharmaceutical 
formulations, is important. For other experiments, a half size gastric compartment 
is used. All functions of the gastric compartment are similar to the gastric compart-
ment of TIM-1. TinyTIM has a single small intestinal compartment instead of three 
and no ileal effl ux. All fl uids entering the small intestinal compartment are removed 
through the fi ltration- or dialysis-membrane. This implies that small intestinal transit 
is simulated by assuming a plug of chyme traveling through the small intestine, 
instead of a “fl ow through” compartment such as in TIM-1. 
5.5  Advanced Gastric Compartment (TIM-agc) 
 In the standard gastric compartment, the meal is mixed to obtain a homogenized 
gastric content and a consequent predictable gastric emptying of compounds. This 
is particularly important to compare the digestion of compounds under exactly con-
trolled conditions. In order to include the effect of gastric motility on the gastric 
behavior of food components and pharmaceuticals, a gastric compartment is 
designed that mimics the shape and motility of the stomach in a more realistic man-
ner (Fig.  5.4 ). The system consists of a body part with a fl exible wall that gradually 
contracts to simulate gastric tone and consequent reduction of gastric volume during 
emptying. Two antral units can be moved to simulate mixing by an antral wave. 
A valve is synchronized with an antral wave to simulate the opening of the pyloric 
sphincter during gastric emptying. Similar to other TIM models, the contractions 
are achieved by modulating the pressure on water that is circulated in the space 
between a glass jacket and a fl exible membrane. All contractile movements and the 
resulting mixing and pressure profi les are accurately controlled and synchronized. 
Motility patterns as well as gastric emptying and secretion of digestive fl uids are 
dictated by a predetermined protocol that describes a specifi c condition (e.g. fed or 
fasting) in time. A study has been performed in both the TIM-agc and human volun-
teers to compare gastric pressure profi les, using a smartpill ® (Given Imaging GmbH, 
Hamburg, Germany) (Fig.  5.5 , Minekus et al.  2013 ). 
 Fig. 5.4  Schematic 
presentation of the TIM 
advanced gastric 
compartment (TIM-agc). The 
 left and  right pictures show a 
fi lled and completely empty 
gastric compartment, 
respectively. A. body; B. 
proximal antrum; C. distal 
antrum; D. pyloric sphincter 
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5.6  The Use of TIM to Study the Bio-accessibility 
of Nutrients 
 The TIM has been successfully used to study the bio-accessibility of macro nutrients, 
minerals, fat- and water soluble vitamins, and bioactive compounds (Larsson et al. 
 1999 ;  Verwei et al.  2006 ; Mateo Anson et al.  2009 ). Bio-accessibility is defi ned as 
the fraction of a compound that is available for absorption through the gut wall. In 
TIM, this is determined by measuring the fraction of a compound that has passed 
the dialysis or fi ltration membrane. When validating TIM with in vivo data, it is 
important to realize that a valid correlation between bio-accessibility and bio- 
availability can only be achieved when transport through the gut wall (mucus layer 
and enterocytes) is not a limiting step. This gap can be bridged by using TIM data 
in combination with transport data obtained with intestinal cells and/or in silico 
modeling. The digestion of a nutrient is determined by the characteristics of the 
nutrient, the composition and structure of the meal matrix and the individual’s 
 physical response to the digesting nutrient and meal while travelling through the 
gastro- intestinal tract. As is the case in all digestive models, TIM does not include 
feedback on the characteristics of the meal. Therefore, the approach is taken to 
assume a set of conditions that is based on in vivo data and normal for the type of 
meal and target group. The effect of variability of a specifi c condition on digestion 
within a population can be tested by changing only this condition in the digestive 
protocol. The reproducible conditions allow comparison of different compounds 
under the same conditions and do not need as many replicates as are necessary to 
obtain suffi cient statistical power for in vivo studies. 
5.7  Protein Quality 
 The basic method to study protein digestion in TIM is to determine the bio- 
accessibility by expressing the amount of protein nitrogen dialyzed as a percentage 
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 Fig. 5.5  Gastric pressure profi le measured with a smartpill ® in the TIM-agc ( left ) as compared to 




corrected with the bio-accessibility of protein nitrogen from the secreted protein, 
thus presenting the true digestibility of the protein. 
 To optimize the nutritional quality of food and feed, it is important for the food 
and feed industries to have insight in the nutritional quality of the protein in their 
ingredients. The nutritional quality of proteins depends on the amino acid composi-
tion profi le and the bio-accessibility of essential amino acids, while digestion of 
proteins may be affected by processing steps during manufacturing. Essential amino 
acids cannot be produced by the body and need to be supplied in suffi cient quanti-
ties in the diet. A protein of high biological value contains all essential amino acid 
in proportion to the need. The amino acid that is in shortest supply in relation to the 
need is referred to as the limiting amino acid. Traditionally protein quality is evalu-
ated by determination of the Protein Effi ciency Ratio (PER). The PER method 
refl ects the amino acid requirements of young animals such as broiler chickens and 
rats, as determined with growth experiments on protein sources (Skinner et al. 
 1991 ). However, these experiments are relatively slow and do not give insight into 
the availability of the relevant amino acids. Also, this method determines the 
requirements of rats and broilers, not humans. Moreover, such experiments can 
result in strong growth retardation due to amino acid defi ciencies and have therefore 
ethical drawbacks. A method was developed with TinyTIM as an alternative to the 
time consuming PER test that uses young animals. In this method the bio-accessible 
amount of the limiting amount of amino acid is determined after digesting the feed 
in TinyTIM (Minekus and Van der Klis  2001 ; Minekus et al.  2006 ). The FAO/WHO 
adopted the Protein Digestibility Corrected Amino Acid Score (PDCAAS) and later 
the Digestible Indispensable Amino Acid Score (DIAAS) as best method to deter-
mine the protein quality (Schaafsma  2005 ; FAO  2013 ). The method with TinyTIM 
to determine the true digestibility of protein and (limiting) amino acids offers an 
alternative to the use of rats for the determination of the PDCAAS and DIAAS, 
respectively. 
5.8  Prediction of Glycemic Response 
 Studies on the digestion of carbohydrates and consequent glucose plasma levels are 
important for diabetic patients, obesity control and designing sport foods. As an 
alternative to expensive and time consuming human trials, a rapid in vitro method 
has been developed to predict the glycemic response after intake of carbohydrates 
(Bellmann et al.  2010 ). In this method the carbohydrates are digested in TinyTIM 
and a successive step with brush border enzymes. The released glucose and fructose 
are analyzed as a function of time and processed with in silico modeling based on 
the homeostatic model assessment (HOMA; Matthews et al.  1985 ) to predict the 
glycemic response. The method was validated against in vivo plasma glucose curves 
of 21 different food products (R = 0.91). 
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5.9  Lipids 
 The uptake of fat soluble compounds needs a realistic simulation of the digestion of 
the compound and the food matrix, and the formation of mixed micelles. In TIM, 
fresh porcine bile is used to supply adequate quantities of bile salts, phospholipids 
and cholesterol for mixed micelle formation. Filters with a pore size of 50 nm are 
used to differentiate between undigested fat and micelles, and to remove lipolytic 
products to avoid product inhibition. It is assumed that the products in micelles are 
available for absorption through the gut wall. Figure  5.6 shows the cumulative 
appearance of total fatty acids in the jejunal and ileal fi ltrates during digestion of 
intra lipid in TIM-1. This method has been used to study the bio-accessibility of 
carotenoids (Southon  2001 ; Van Loo-Bouwman et al.  2014 ), the study of Partially 
Hydrolysed Guar Gum (PHGG) on lipid digestion (Minekus et al.  2005 ) and the 
bio-accessibility of blueberry anthocyanins (Ribnicky et al.  2014 ). 
5.10  Conclusions 
 TIM is designed to reproduce the conditions in the lumen of the gastro-intestinal 
tract by realistic mixing, transit of the meal, rate and composition of secretions and 
removal of digested products and water. It is designed to predict the bio- accessibility 
of a wide variety of ingested compounds present in a broad range of foods and phar-
maceutical matrices. Accurate simulation and control of the multi-compartmental 
 Fig. 5.6  Bio-accessibility profi les of fatty acids from the jejunal compartment ( circles ), ileal 





processes in the lumen of the GIT allows the testing of compounds under exactly the 
same conditions or specifi cally modifi ed conditions for “what if” studies. Bio- 
accessibility profi les directly from TIM or after a separate transport assay with intes-
tinal cells can be processed further with in silico modeling to predict the bio- availability 
of compounds. In contrast with static methods, that are only useful for specifi c stud-
ies within a narrow range of products (Minekus et al.  2014 ), TIM is intended to simu-
late the dynamic conditions in the lumen of the GIT to predict the bio-accessibility 
of a variety of nutrients in a wide range of meals. The more complex system with a 
lower throughput and higher costs is well compensated by the high predictability and 
broad applicability. As a high-end digestion model system, it may offer a faster and 
a more ethical alternative to studies in animals and humans. 
 Contract research on gastro-intestinal behavior of nutrients and pharmaceuticals, 
as well as sales and lease of TIM equipment is located at TNO-Triskelion, Zeist, 
The Netherlands ( http://www.tnotriskelion.com/ ). 
 Open Access This chapter is distributed under the terms of the Creative Commons Attribution 
Noncommercial License, which permits any noncommercial use, distribution, and reproduction in 
any medium, provided the original author(s) and source are credited. 
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 Chapter 6 
 Dynamic Gastric Model (DGM) 
 Eva  C.  Thuenemann ,  Giuseppina  Mandalari , 
 Gillian  T.  Rich , and  Richard  M.  Faulks 
 Abstract  The Dynamic Gastric Model (DGM) was developed at the Institute of 
Food Research (Norwich, UK) to address the need for an in vitro model which 
could simulate both the biochemical and mechanical aspects of gastric digestion in 
a realistic time-dependent manner. As in the human stomach, masticated material is 
processed in functionally distinct zones: Within the fundus/main body of the DGM, 
gastric acid and enzyme secretions are introduced around the outside of the food 
bolus which is subjected to gentle, rhythmic massaging. Secretion rates adapt 
dynamically to the changing conditions within this compartment (acidifi cation, fi ll 
state). Portions of gastric contents are then moved into the DGM antrum where they 
are subjected to physiological shear and grinding forces before ejection from the 
machine (and subsequent separate duodenal processing). 
 The DGM has been used extensively for both food and pharmaceutical applications, 
to study, for example, release and bioaccessiblity of nutrients and drugs. The system 
allows the use of complex food matrices (as used in in vivo studies) and processes 
these under physiological conditions in real-time, thereby providing a realistic tool 
for the simulation of human gastric digestion. 
 Keywords  Dynamic gastric model •  Physiological •  Gastric •  In vitro •  Digestion • 
 Bioaccessiblity •  Nutrient •  Dissolution •  Pharmaceutical •  Real-time 
6.1  Origins and Design of the DGM 
 The Dynamic Gastric Model was developed at the Institute of Food Research 
(Norwich, UK) to address the need for an in vitro model which could simulate both 
the biochemical and mechanical aspects of human gastric digestion in a realistic 
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time-dependent manner. This was initially done in the interest of food-based 
research to enable the study of parameters such as nutrient bioaccessibility, effect of 
food structure on nutrient delivery, nutrient interactions, survival and delivery of 
functional foods. Over the years, the DGM has also increasingly been used by 
 pharmaceutical industry as an in vitro tool to study the effect of food matrices on the 
disintegration and dissolution of drug formulations and delivery profi le to the 
 duodenum. This is in part due to its ability to realistically process any complex food 
matrix for direct comparison with the results of in vivo/clinical studies. 
 The design of the DGM is based on extensive research into the process of diges-
tion and the physiology of the human stomach, both biochemical and mechanical 
(reviewed by Wickham et al.  2012 ). It builds on these fi ndings as well as literature 
data to closely mimic the conditions encountered by food particles and drug formu-
lations as they move through the upper gastrointestinal tract. To this end, digestions 
using the DGM are performed in real-time, and the length of each experiment is 
designed around the estimated gastric residence time of the particular meal used. 
Experiments typically last between 25 min (glass of water) and 4.5 h (high-fat FDA 
breakfast) depending on meal size, composition and calorifi c content. 
 The following paragraphs provide an introduction to the parts of the DGM and 
how these are used to simulate the natural physiology of the healthy adult human 
stomach (from ingestion to release into the duodenum).  Schematic drawings and 
further descriptions are provided in Fig.  6.1 and Table  6.1 respectively. 
 Masticated food, a complex inhomogeneous mixture of accessible and inacces-
sible protein, carbohydrate and fat (in particles of varying sizes) as well as water and 
saliva, enters the stomach in portions from the esophagus. It initially encounters an 
acidic environment of resting gastric fl uid (24±5 ml, Dubois et al.  1977 ), whose pH 
is subsequently altered by the buffering capacity of the meal. In the DGM, masti-
cated food can be introduced in real-time or as a bulk from the top into the fundus 
and main body (Fig.  6.1 ), where it encounters a previously added 20 ml volume of 
gastric priming acid (Table  6.2 ).
 Initiation of gastric digestion of a food bolus in the stomach is via secretions 
from the mucosal gastric surface and a change from resting to rhythmic phase 2 
contractions. The secretion rates of acid and enzyme are dependent on, amongst 
others, the composition of the food bolus and fi ll volume of the stomach, and are 
therefore not constant throughout the digestion process but change in response to 
factors such as the acidifi cation of the bolus and emptying of the stomach contents 
into the duodenum (Konturek et al.  1974 ; Schubert and Peura  2008 ). Within the 
DGM, gastric acid and enzyme solutions (Table  6.2 ) are added through a perforated 
hoop situated around the wall of the fundus (Fig.  6.1 and Table  6.1 ). The fl ow rates 
of these secretions is controlled dynamically: The rate of gastric acid addition slows 
gradually in response to the acidifi cation of the meal as detected by the pH electrode 
inserted within the fundus; The rate of gastric enzyme addition slows in response to 
the gradual decrease in food bolus volume as recorded in response to ejection of 
samples from the antrum. 
 The human stomach has distinct zones which differ markedly in the physical 
forces applied to the meal bolus: the fundus/main body (proximal) and the antrum 
E.C. Thuenemann et al.
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 Fig. 6.1  The dynamic gastric model (DGM). ( a ) Schematic representation of the main components 
of the DGM ( side view ) ( b ) Photographic image of the DGM ( front view ) 
(distal) (Bornhorst and Singh  2014 ). Within the fundus, the meal is subjected to low 
physical forces exerted by gentle rhythmic peristaltic contractions. Upon ingestion, 
the bulk of the meal resides within this part of the stomach and it was found that the 
penetration of this bolus by acidic gastric secretions occurs very slowly (Marciani 
et al.  2001b ). Additionally, it has been shown that gastric secretions can form an 
acidic pool on top of a dense meal (Holloway and Sifrim  2008 ). This not only infl u-
ences conditions such as gastric refl ux disease, but also has a bearing on the micro-
environment encountered by drug formulations when they are taken after a meal. 
The DGM also models the two distinct regions of the stomach. Within the fundus/
main body, the food bolus is subjected to rhythmic squeezing brought about by 
cyclical pressurization of the 37 °C water jacket surrounding the main body. 
Depending on the meal viscosity, the gastric secretions applied to the outside sur-
face of the fundus can take a considerable amount of time to fully acidify the meal 
bolus. Also, a pool of gastric secretions forms on the surface, mimicking the phase 
separation of the meal within the stomach. 
 Within the antral part of the human stomach, the food bolus is subjected to 
higher shear forces and turbulence, resulting in greater mixing as well as gradual 
size reduction of particles. Peristaltic contractions push the food towards the 
pyloric sphincter which provides resistance resulting in retrograde movement of 
the chyme which is pushed forwards again by the next contraction (Ferrua and 
Singh  2010 ). Within a meal of high viscosity, the shear and grinding forces are 
higher than in a meal of low viscosity, as shown in an in vivo study of the gastric 
residence time of agar beads of different strengths within the two meal types 
(Marciani et al.  2001a ). A similar study using the same agar beads and meal types 
was conducted in the DGM to calibrate the physical forces within the DGM antrum 
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 Table 6.1  Functional parts of the DGM 




 Records pH within DGM main 
body, enabling automatic 
adjustments to gastric acid fl ow 
rate (within physiological 
production rates) in response to 
acidifi cation of meal. Can be 
forced outside of “normal” range 
if necessary 
 Gastric acid production is 








 Distribution of gastric secretions 
around outside of DGM main 
body, fed by computer-controlled 
pumps. Secretion rates respond 
dynamically to pH and volume 
changes of food bolus 
 Acid and enzymes are 
secreted from the walls of 
the stomach and can form 





 Maintains DGM main body at 
37 °C allowing heat transfer to 
food bolus. Enables gentle 
mixing within DGM main body 
by cyclical pressurization 
 Normal body temperature 






 Holds up to 800 ml of masticated 
real food and drink. Gentle mixing 
due to cyclical pressurization of 
water jacket. Heat transfer rates 
from 37 °C water jacket similar to 
those in vivo 
 Typical meal sizes are less 
than 1 l 
 Main body of stomach is 
characterized by gentle 





 Inlet valve allows movement of 
portions of food bolus from main 
body into antral part of 
DGM. Inlet valve allows 
retrograde movement from antral 
part to main body during 
processing outlet valve allows 
ejection of samples from DGM 
 Phase II contractions 
periodically empty digesta 
from antrum through 






 Maintains antral temperature at 
37 °C 
 Normal body temperature 
is ca. 37 °C 
  
 Barrel and 
fl exible 
membrane 
 Barrel moves fl exible membrane 
rhythmically through food bolus 
contained within antral part of 
DGM, creating an environment 
of high shear and mixing 
 Contractions of the 
proximal stomach 
strengthen towards the 
antrum, creating 
potentially high shear 
forces dependent on meal 
viscosity and particle sizes 
  
 Piston  Allows food bolus to move from 
main body through valves into 
antral part of DGM 
 Compensates volume changes 
within antrum due to barrel 
movement to modulate refl ux 
 Maintains a dead volume within 
barrel to simulate gastric sieving 
 Large, dense food 
particles and/or 
pharmaceuticals can sink 
to the greater curvature of 
the stomach, thereby 
delaying their emptying 
from the stomach (gastric 
sieving) 
 The main functions of each part along with their relevance to the human stomach are given 
 a Schematic representations and names of parts refer to Fig.  6.1 
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(Vardakou et al.  2011a ). The two studies show a good correlation between the 
physical forces of the human stomach and the DGM antrum, using both low vis-
cosity and high viscosity meals. 
 The DGM antrum consists of a barrel and a piston, which move within a 37 °C 
water jacket (Fig.  6.1 ). While the piston draws portions of food bolus through an inlet 
valve from the fundus into the antrum, it is the upward and downward movement of 
the barrel during processing which exerts shear stresses on the antral contents. This 
is due to a fl exible annulus mounted within the top part of the barrel through which 
food (and formulations) passes during every stroke, thereby simulating the rhythmic 
peristaltic contractions of the human stomach. While the speed of movements has 
been calibrated to provide physiological shear forces (Vardakou et al.  2011a ), the 
actual volume of food bolus processed within the antrum at any one time, as well as 
duration of processing are tailored to the specifi c meal used (volume, composition, 
 Table 6.2  Composition of solutions used in the DGM 
 Solution  Component  Source  Concentration a 
 Artifi cial saliva (pH 6.9)  Salt (NaCl)  Sigma b  150 mM 
 Urea  Sigma b  3 mM 
 Salivary amylase (human)  Sigma b  36 U/ml 
 Gastric priming acid  Salts (NaCl, KCl, CaCl 2 , NaH 2 PO 4 )  Sigma b  89 mM (total) 
 HCl  Sigma b  10 mM 
 Gastric acid  Salts (NaCl, KCl, CaCl 2 , NaH 2 PO 4 )  Sigma b  89 mM (total) 
 HCl  Sigma b  200 mM 
 Gastric enzyme  Salts (NaCl, KCl, CaCl 2 , NaH 2 PO 4 )  Sigma b  89 mM (total) 
 Egg lecithin  Lipid P. c  0.38 mM 
 Lipase (fungal, DF15)  Amano d  60 U/ml 
 Gastric pepsin (porcine)  Sigma b  8.9 kU/ml 
 Duodenal hepatic  Salts (NaCl, KCl, CaCl 2 )  Sigma b  154 mM (total) 
 Egg lecithin  Lipid P. c  6.5 mM 
 Cholesterol  Sigma b  3 mM 
 Bile salts (Na-taurocholate, 
Na-glycodeoxycholate) 
 Sigma b  25 mM (total) 
 Duodenal pancreatic  Salts (NaCl, KCl, CaCl 2 , MgCl 2 , ZnSO 4 )  Sigma b  154 mM (total) 
 Pancreatic lipase (porcine, Type VI-S)  Sigma b  590 U/ml 
 Colipase (porcine)  Roche e  0.2 mg/ml 
 Trypsin (porcine, Type IX-S)  Sigma b  11 U/ml 
 α-Chymotrypsin (bovine, Type II)  Sigma b  24 U/ml 
 α-Amylase (porcine, Type VI-B)  Sigma b  300 U/ml 
 a Stated concentrations are within the stock solutions used. Final concentrations within gastric/
duodenal compartment will be signifi cantly lower due to dilution with food bolus and other solu-
tions, bringing them within physiological ranges presented in literature 
 b Sigma Aldrich, Gillingham, Dorset, UK 
 c Lipid Products Ltd, Redhill, UK 
 d Amano Enzyme Inc., Nagoya, Japan 
 e Roche Diagnostics GmbH, Mannheim, Germany 
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calorifi c content). At pre-defi ned intervals, the inlet valve closes and the outlet valve 
opens, allowing the processed chyme to be ejected from the DGM. 
 A phenomenon observed in the human stomach is that of gastric sieving, whereby 
larger, denser particles/formulations can be retained within the greater curvature of 
the stomach longer than smaller particles, therefore subjecting them to extended 
processing (Meyer  1980 ). Gastric sieving is simulated within the DGM by defi nition 
of a “dead volume,” i.e. a defi ned space between barrel and piston whose volume is 
maintained during ejection thereby allowing large, dense particles to remain in the 
antrum and undergo repeated processing cycles. At the end of a simulated digestion, 
any material remaining in this dead volume is ejected to simulate the phase III 
contraction (housekeeper wave) which fully empties the human stomach at the end 
of gastric digestion (Meyer  1987 ). 
 Following ejection from the DGM, samples can be subjected to further digestion 
using a static duodenal model. To this end, the pH of the samples is elevated and a 
physiological mix of bile salts with lecithin and cholesterol and pancreatic enzymes, 
is added to simulate conditions found within the duodenum. 
6.2  General Protocol for DGM Experiments 
 Planning  First, the following information about the test meal (and/or drink) is 
gathered: mass, energy content, composition (carbohydrate, fat, protein content). 
This information is used to estimate total gastric residence time of the meal as well 
as maximum rate of gastric secretion. 
 Using parameters such as the volume and frequency of ejection from the antrum, a 
program is designed to allow the DGM to empty the test meal fully within the calculated 
gastric residence time. The chosen sample volume and frequency are dictated by the 
gastric residence time and volume of the meal, as well as any downstream processing 
and analysis of the samples which may require certain minimum volumes to be ejected. 
 Preparation  Any enzyme solutions needed during the experiment (salivary, gas-
tric, duodenal) are prepared immediately prior to the experiment. The components 
of solutions and enzymes used in the experiments are detailed in Table  6.2 . Solutions 
have been designed to provide biochemical conditions (e.g. concentrations of salts, 
enzymes, etc., and/or secretion rates) within the “normal” physiological range of 
healthy subjects (Lentner  1981 ). For example, the contents of the DGM at any one 
time will be a complex inhomogeneous mixture of food matrix and the components 
of gastric priming acid, gastric acid and gastric enzyme solutions. 
 Mastication  Depending on the requirements of the project and food type, several 
methods of mastication can be used.
•  No mastication (e.g. for liquid meals, drinks and meals where mastication is not 
required) 
•  Simulated mastication using a food processor, mincer or grinder, with or without 
addition of artifi cial or human saliva 
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•  Human chew, whereby the test meal is chewed to the naturally perceived point of 
swallowing and collected in a beaker before addition to the DGM 
•  Real-time human chew, similar to the above but with real-time transfer of each 
mouthful to the DGM 
 Dynamic Gastric Processing  Before the start of gastric processing, the DGM pH 
electrode is allowed to equilibrate in the test meal/drink. This sets the range of pH 
during processing of this specifi c meal (from start reading to pH 2) and allows the 
DGM to dynamically adjust gastric acid addition as the pH drops. The DGM is 
primed with 20 ml priming acid to simulate the residual gastric fl uid normally found 
in the resting human stomach. 
 Upon start of the program, the meal is added to the fundus of the DGM. Fluid 
portions of the meal are poured slow over a spoon and allowed to trickle down the 
outside edge of the fundus and main body. This simulates how fl uid would enter the 
stomach from the esophagus and minimizes any artifi cial turbulence and mixing of 
the gastric contents. Masticated foods are usually added slowly over the course of 
several minutes to mimic the swallowing of food. 
 Any food/drink added at the start of a run is immediately in contact with the walls 
of the main body, allowing heat transfer to occur. The contents are also  subjected to 
gentle squeezing in the main body (three contractions per minute). Gastric acid and 
enzyme secretions are added through the perforated ring at physiological rates depen-
dent on meal size and buffering capacity. These rates slow down progressively during 
the experiment in response to reducing bolus volume and change in pH. Shortly after 
start of the run, the lower part of the DGM is activated and pulls a portion of the food 
bolus into the antrum for processing (high shear, mixing). 
 At programmed intervals, the inlet valve of the DGM closes, the outlet valve 
opens and the defi ned proportion of bolus from the antrum is ejected by an upward 
movement of the barrel and piston. Any pre-defi ned dead volumes between piston, 
barrel and valves are maintained to allow for large dense particles to remain in the 
machine for further processing (gastric sieving). The outlet valve then closes, the 
inlet valve opens and the next portion of partially digested food enters the antrum 
from the main body. 
 At the end of the DGM run, the fi nal sample is ejected by complete upward 
movement of barrel and piston, thereby ejecting any remaining dead volumes that 
were present in the antrum region and simulating the housekeeper wave. The DGM 
is disassembled to recover any residues. 
 Static Duodenal Processing  Where required, samples from the DGM can be sub-
jected to further static digestion in a duodenal model. First, the pH of the sample is 
adjusted to pH 6.8 to reduce further activity of gastric enzymes and to simulate the 
change of pH in the duodenum. One of two main methods is then employed:
•  From each DGM gastric sample, a subsample is transferred to a separate vessel, 
and pancreatic enzymes as well as bile salts, lecithin and cholesterol are added at 
physiological levels depending on food. These separate duodenal incubations 
(3–4 h each in an orbital shaker, 170 rpm, at 37 °C) can then be sampled at 
defi ned intervals to establish separate duodenal nutrient/pharmaceutical release 
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profi les for each gastric ejection. This approach is often followed for nutrient 
bioaccessibility studies and pharmaceutical studies using formulations that 
disperse in the stomach. 
•  Subsamples of each DGM gastric sample are neutralized and pooled in a single 
vessel and kept on ice until the end of the gastric phase. Pancreatic enzymes and 
bile salts, lecithin and cholesterol are added at physiological levels depending on 
food, and the vessel is incubated in an orbital shaker for 3–4 h at 170 rpm, 
37 °C. Samples are taken at defi ned intervals to establish a single duodenal 
release profi le. This method is often used for gastro-resistant pharmaceutical 
formulations which are recovered from the DGM intact and transferred to this 
duodenal pool to monitor dispersal and dissolution in the duodenal phase. 
 Controls  Control experiments are designed for any project involving DGM runs. 
In the case of food applications such as bioavailability studies, these control runs 
essentially follow the same protocol as the actual experiments, but do not include 
any digestive enzymes. The starting material before gastric digestion is also anal-
ysed. This enables a distinction to be made between the effects of mechanical 
 processing in the DGM alone, and full mechanical and biochemical digestion. 
For pharmaceutical applications, control experiments generally follow the full 
experimental protocol including enzymes but without the drug. 
 DGM experiments are generally carried out in triplicate in the fi rst instance. 
6.3  Uses of the DGM 
 The DGM has a wide variety of applications and has so far been used to study nutri-
ent bioaccessibility and structural changes of food matrices during digestion, as 
well as the disintegration and dissolution of various drug formulations. Normal 
experimental readouts include a photographic/video record of digesta appearance, 
acidifi cation profi le and temperature profi le. Some previously studied parameters 
are summarized Table  6.3 .
6.3.1  Food-Based Research 
 The DGM has extensively been used to evaluate the rate and extent of nutrient and 
phytochemical release from plant foods and the effect of food matrix on their release 
in the upper GI tract (Mandalari et al.  2010 ,  2013 ). The effect of mastication and 
processing on the lipid release from almond seeds in the upper GI tract has recently 
been investigated (Mandalari et al.  2014a ). 
 The bioaccessibility of pistachio polyphenols, xanthophylls and carotenoids dur-
ing simulated human digestion was recently assessed using the DGM followed by 
duodenal incubation: results demonstrated that the presence of a food matrix, such 
as muffi n, decreased the bioaccessibility of certain polyphenols in the upper GI tract 
(Mandalari et al.  2013 ). 
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 Ongoing research aims to establish the key parameters involved in starch digestion 
from cereal (Ballance et al.  2013 ) and  Durum wheat (IFR, unpublished data). The data 
obtained using the DGM compared well with in vivo data of glycaemic response, 
indicating that the DGM was predictive of the kinetics of digestible starch hydrolysis 
(Ballance et al.  2013 ).The effect of particle size on starch degradation from  Durum 
wheat is currently being investigated using the DGM coupled with the static duodenal 
model and compared with an in vivo ileostomy study (IFR, unpublished data). 
 The DGM has recently been used to assess digestibility of almond protein in the 
upper GI tract, evaluate the effects of food matrix on protein release and assess the 
persistence of immunoreactive polypeptides generated during simulated digestion 
(Mandalari et al.  2014b ). The results obtained are useful to investigate the relation-
ship between food matrix and almond allergy. 
 The persistence of allergens present in cow’s milk and peanut fl our as measured 
by gastric and duodenal aspirates from human volunteers has been compared with 
data sets obtained from similar meals processed by the DGM. The comparison 
suggests that the DGM was predictive, not only of the persistence of the original 
allergens, but also of the profi le of peptide fragments generated during digestion 
(IFR, unpublished data). 
 Table 6.3  Applications of DGM samples (this list is not exhaustive) 
 Parameter  Method of analysis  Output  References 
 Viscosity  Rheological analysis  Plot of changes in viscosity 
 Cellular 
structure 
 Microscopy  Changes in cell/surface 
integrity 
 Mandalari et al. 
( 2014b ) 
 Phytochemicals 
bioaccessibility 
 GC, HPLC  Effect of food matrix on the 
bioaccessibility of bioactives 
from pistachios during 
simulated digestion 
 Mandalari et al. 
( 2013 ) 
 Starch 
digestion 
 Starch analysis  Changes in ratio of 
glucose:starch, total starch 
 Effect of particle size on 
starch degradation from 
 Durum wheat 
 Ballance et al. 
( 2013 ) 





 Total lipid release and 
fatty acid analysis 
 Effect of mastication and 
processing on lipid release 
from almond seeds 
 Mandalari et al. 
( 2014a ) 
 Protein 
digestion 
 1D and 2D SDS-PAGE, 
RP-HPLC, MALDI- 
ToF, immunoblotting 
 Effect of food matrix on 
protein digestion from almond 
seeds 
 Mandalari et al. 
( 2014b ) 
 Peptide 
production 
 1D and 2D SDS-PAGE, 
RP-HPLC, MALDI- 
ToF, immunoblotting 
 Persistence of allergens from 
cow’s milk and peanut fl our 




 Culturing on selective 
media 
 Effect of food matrix on 
probiotic survival in the upper 
GI tract 
 Lo Curto et al. 
( 2011 ) and Pitino 
et al. ( 2010 ,  2012 ) 
 Prebiotic 
delivery 
 Culturing on selective 
media, genetic analysis 
 Delivery of potential 
prebiotics in the distal GI tract 
 Mandalari et al. 
( 2010 ) 
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 Probiotic strains of  Lactobacillus spp. were investigated for their ability to survive 
in the upper GI tract using a number of vehicles and different growth phases: the 
results obtained showed that probiotic survival using dynamic models was affected by 
the buffering capacity of the matrix in relation to the pH decrease in the stomach (Lo 
Curto et al.  2011 ; Pitino et al.  2010 ). Cheese was also found to be a good vehicle for 
passage of probiotic bacteria in the upper GI tract and scanning electron microscopy 
indicated production of extracellular polysaccharides by  Lactobacillus rhamnosus 
strains as a response to acid stress in the gastric compartment (Pitino et al.  2012 ). 
 A full model of the gastrointestinal tract, including in vitro gastric and duodenal 
digestion, followed by colonic fermentation using mixed faecal bacterial cultures, 
was used to investigate the prebiotic potential of natural (NS) and blanched (BS) 
almond skins, which are rich in dietary fi ber (Mandalari et al.  2010 ). Both NS and 
BS signifi cantly increased the population of bifi dobacteria and  Clostridium 
coccoides / Eubacterium rectale group, which are known for their benefi cial effect in 
relation to health. 
6.3.2  Pharmaceutical-Based Research 
 In recent years, the DGM group has seen a marked increase in projects from pharma-
ceutical industry. Current in vitro methods used in the study of disintegration and 
dissolution of oral solid dosage forms do not provide a physiological representation of 
the dynamic biochemical and physical environment of the human stomach (Vardakou 
et al.  2011a ) and are therefore sometimes not predictive of the in vivo behaviour of 
dosage forms, particularly in the case of dosing with or after a typical meal. The DGM 
is well placed to bridge the gap between these simpler dissolution tests and in vivo 
studies (animal or human) and can be used in either to explain unexpected in vivo 
results, or as a predictive tool (Mann and Pygall  2012 ; Wickham et al.  2009 ). 
 Past studies in the DGM have involved a wide variety of dosage forms (capsule, 
tablet, powder, liquid) and types e.g. immediate release, modifi ed release, gastro- 
retentive, self-emulsifying drug delivery system (Vardakou et al.  2011b ; Mercuri 
et al.  2009 ,  2011 ). Particularly in the case of gastro-retentives, the ability to introduce 
sequential meal cycles (e.g. breakfast, lunch, dinner) within the same experiment 
allows for the real-time, realistic simulation of the range of conditions (pH, viscosity, 
shear forces) that these formulations are likely to encounter in vivo. The DGM may 
also fi nd future use in the assessment of alcohol-drug interactions (dose- dumping) as 
well as the modelling of pediatric and/or geriatric physiology, all of which provide 
challenges (ethical and otherwise) in the justifi cation of in vivo tests.
6.4  Advantages, Disadvantages and Limitations 
 Some advantages and limitations of the DGM are provided in (Table  6.4 ). 
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6.5  Availability of the System 
 At the time of writing, two DGM machines are in operations (Mark I and Mark II), 
with a third machine in development. The machines can be used for food- and 
pharmaceutical- based research, by both industry and academia. The Dynamic 
Gastric Model is protected by granted patents and pending patent applications 
owned by Plant Bioscience Limited (PBL). Enquiries about purchasing a DGM unit 
for academic or commercial use should be directed to PBL (Plant Bioscience 
Limited, Norwich, UK; martin@pbltechnology.com;  http://pbltechnology.com ). 
Access to the DGM as an outsourced contract research facility is available exclu-
sively through Bioneer:FARMA (Bioneer:FARMA, Copenhagen, Denmark; 
bioneer@bioneer.dk;  http://www.bioneer.dk/DGM/ ). 
 Open Access This chapter is distributed under the terms of the Creative Commons Attribution 
Noncommercial License, which permits any noncommercial use, distribution, and reproduction in 
any medium, provided the original author(s) and source are credited. 
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 Chapter 7 
 Human Gastric Simulator (Riddet Model) 
 Maria  J.  Ferrua and  R.  Paul  Singh 
 Abstract  An in vitro ‘dynamic’ model for food digestion diagnosis, the Human 
Gastric Simulator (HGS), has been designed to reproduce the fl uid mechanical con-
ditions driving the disintegration and mixing of gastric contents during digestion. 
The HGS simulates the stomach as a fl exible compartment, and mimics its contractive 
motility by a series of rollers that continuously impinge and compress the compart-
ment wall with increasing amplitude. Operated at 37 °C, the HGS facilitates a precise 
control of the mechanical forces to which foods are exposed during the process, as 
well as of the rate of simulated gastric secretions and emptying patterns. 
 Applications of the HGS have illustrated the need to better understand, and mimic, 
the fl uid mechanic conditions that develop during digestion to improve the perfor-
mance and reliability of novel in vitro models. To date, the HGS has been used to 
analyse the digestion behaviour of different foods, and the role of their materials prop-
erties on the physicochemical changes that they experience during the process. While 
the ability of the HGS to reproduce the gastric forces that develop in vivo has been 
proved, further studies are needed to achieve a thorough validation of its digestive 
capabilities. 
 Keywords  Human gastric simulator •  In vitro model •  Digestion •  Gastric motility 
•  Digesta fl uid mechanics 
7.1  Origins of the HGS 
 Central to the delivery of optimal nutrition, the stomach is, after the mouth, the main 
site for food disintegration during digestion (Wickham et al.  2012 ). Once in the 
stomach, products are stored, digested and progressively emptied into the 
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duodenum by a synergy of physicochemical processes triggered and regulated by 
the motor and secretory activities of the gastric wall (Barrett and Raybould  2010a ; 
Mayer  1994 ). 
 From a functional point of view, the stomach is divided into two main regions. 
Within the proximal region (upper half), changes in the compliance and secretory 
activity of the gastric wall allow the stomach to accommodate the ingested meal and 
provide the biochemical environment needed for its conditioning (Schwizer et al. 
 2002 ; Wickham et al.  2012 ). The distal region, on the other hand, is expected to play 
a major role in the structural disintegration of the meal. It is within this region where 
a series of peristaltic antral contraction waves (ACWs) continuously mix, compress 
and shear gastric contents during the process (Schwizer et al.  2006 ; Schulze  2006 ). 
As a result, food is converted into a semi-liquid mass of partially digested food, whose 
emptying from the stomach is feedback-regulated by a series at physicochemical 
receptors within the intestine (Barrett and Raybould  2010b ). 
 Despite the complexities of gastric processes, increasing evidence indicates that 
the hydrodynamic conditions that develop during digestion have a central role on 
the material response and subsequent bioavailability of nutrients and bioactive com-
pounds (Dikeman et al.  2006 ; Lentle and Janssen  2010 ). In particular, the poor 
in vitro–in vivo performance of many of the in vitro models currently used for 
digestion diagnosis has been largely attributed to their inability to reproduce the 
in vivo mechanics of the gastrointestinal (GI) tract (Yoo and Chen  2006 ). 
 Signifi cant efforts have been made during the last decade to better understand the 
overall functioning of the human stomach and to develop a new generation of 
in vitro models of enhanced biochemical and mechanical relevance (Boulby et al. 
 1999 ; Faas et al.  2002 ; Kunz et al.  2005 ; Goetze et al.  2007 ,  2009 ; Kwiatek et al. 
 2006 ; Marciani et al.  2001a ,  2007 ,  2012 ; Marciani  2011 ; Schwizer et al.  2002 , 
 2006 ; Steingoetter et al.  2005 ; Treier et al.  2006 ; Mackie et al.  2013 ). More notably 
among those models are the TNO and DGM systems discussed in the previous 
sections. However, it is noteworthy that there is still no consensus agreement on the 
way in which these models reproduce the hydrodynamic conditions that develop 
in vivo, with none of them being able to replicate the actual motility of the gastric 
wall during digestion. 
 The Human Gastric Simulator (HGS) was specifi cally designed and developed 
by Kong and Singh ( 2010 ) to mimic the peristaltic activity of ACWs as reported 
in vivo (Kwiatek et al.  2006 ; Schwizer et al.  2006 ). Aimed at reproducing one of the 
main features driving the dynamics of gastric contents, this model is expected to 
better simulate the fl uid mechanical forces driving food disintegration during diges-
tion. Since its development, the HGS has been used to investigate not only the phys-
icochemical changes experienced by different food products during digestion, but 
also the role of gastric motility on the outcomes of the process. 
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7.2  Model Description 
 The HGS consists of a cylindrical latex chamber that simulates the stomach com-
partment, and four conveyor belts that periodically impinge a series of Tefl on rollers 
upon its wall to mimic the antral contraction wave activity of the stomach wall 
(Fig.  7.1 ). The system operates inside an insulated chamber maintained at 37 °C, 
while facilitating the delivery of gastric juices and emptying of simulated digesta in 
a continuous and controlled manner. 
7.2.1  Gastric Compartment 
 The stomach is represented by a 5.7 L cylindrical vessel (20 cm high and 10.2 cm 
diameter) that ends in the form of a conic frustum (13 cm height and 2.5 cm fi nal 
diameter). 
 Made of latex rubber, the gastric compartment sits straight up, wrapped onto a 
stainless steel ring (10.2 cm high and 15.2 cm diameter) that is supported by four 
 Fig. 7.1  Human gastric simulator. (1) Motor (2) Gastric compartment (3) Mesh bag (4) Simulating 
secretion tubes (5) Tefl on roller set (6) Conveying belt (7) Insulated chamber. From Kong and 
Singh ( 2010 ) 
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diametrically opposed legs welded to the base. The open end of the container 
provides a simple way for loading food materials into the unit and for sampling of 
the simulated digesta during the process. 
7.2.2  Gastric Motility 
 With the primary goal of mimicking the physical processes driving food disintegration, 
the HGS was designed to reproduce the motor activity of the antral contraction 
waves (ACWs) along the distal region of the stomach. 
 The dynamics of the ACWs along the lower part of the cylindrical vessel is 
mimicked by a mechanical drive system. Four conveyor rubber belts move along the 
height of the gastric compartment at 90° from each other. 
 Each belt is supported by four 0.95 cm pulleys, which attached to a low-carbon steel 
plate are moved by a drive shaft (1.27 cm diameter brass rod) connected to a 115 V 
Stir-Pak Heavy-Duty Mixer head (model R-50002-10, Cole-Parmer) motor. A Stir-
Pak controller (model R-50002-02, Cole- Parmer) is used to allow for speed adjust-
ments within the range of 2–180 rpm. Power is transmitted from one drive shaft to 
another via two bevel gears coupled at a 90° angle. 
 Each timing belt (0.95 cm wide) carries three sets of equally spaced Tefl on rollers 
located every 20 cm of each other. Each set of rollers consists of two wide Tefl on 
wheels (1.27 cm diameter, 0.9 mm long) placed together through an aluminium rod, 
that is secured to the belt by a male threaded screw (0.2 cm diameter, 1.5 cm long). 
As the belt moves, rollers start impinging the compartment wall (at about two-thirds of 
its total height). As the rollers propagate down, they replicate the increasing compres-
sion pattern of the ACWs by getting successively closer to the rollers on the opposite 
belt. The closer the rollers, the higher the compression forces. 
 To avoid possible interference between neighbouring rollers as they get further 
down the bottom of the gastric compartment, the lower pulleys closer to the com-
partment are placed at two different levels, with one pair of opposite pulleys located 
3.0 cm higher than the other pair. 
 In order to simulate the motility pattern of the ACWs, the drive system is set to 
impose three propagating contractions per minute (with one fi nishing while another 
commences). If desired, this propagation speed can be changed by simply adjusting 
the rpm of the driving shaft. The force imposed by the rollers on the simulated 
digesta can be controlled by adjusting the distance between opposite rollers through 
the screw engagement depth inside the aluminium rod. 
7.2.3  Gastric Emptying 
 To simulate the sieving effect of the pylorus, a polyester mesh bag (pore size of 
1.5 mm) is used to line the inner surface of the gastric compartment and prevent 
larger particles from emptying the compartment. At the end of the trial, the mesh 
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can be easily taken out through the open top section of the compartment, facilitating 
the removal and analysis of the remaining digesta. 
 The rate of gastric emptying is controlled by means of a peristaltic pump 
(Masterfl ex Pump Controller 7553-50/7090-42 Pump, Cole-Parmer, Chicago, Ill., 
U.S.A.) connected to the bottom of the gastric compartment through a 0.32 cm 
plastic tube. 
7.2.4  Gastric Secretions 
 Simulated gastric juices are delivered at about 10–15 cm from the bottom of the 
compartment through fi ve polyethylene tubes (I.D. 0.86 mm) uniformly distrib-
uted between the mesh bag and the latex wall. 
 The delivery rate of the simulated gastric juice into the compartment is controlled 
by a mini peristaltic pump (Model 3385, VWR, Scientifi c, Rochester, N.Y., U.S.A.) 
and a control valve placed on a 6.4 mm plastic tube that later on divides into fi ve 
tubes going into the compartment. The fl ow rate of the simulated secretion can be 
adjusted between 0.03 and 8.2 mL/min. 
 It is noteworthy that while it is possible to control the release of gastric juices 
during the simulated processes, there are no mechanisms in place to automatically 
adjust this gastric response to the specifi c composition and volume of simulated 
digesta. 
7.2.5  Temperature Control 
 The system is placed inside an insulated plastic foam chamber, where two 60 W 
light bulbs and a mini-fan are installed to maintain the system operating at uniform 
and constant temperature of 37 °C. The operation of the bulbs is automatically 
controlled by a thermostat (Model T675A 1516, Honeywell, Honeywell Inc., 
Minneapolis, Minn., U.S.A.). 
7.3  Analysis of HGS Biomechanical Relevance 
 The ability of the HGS to replicate the biomechanics of the human stomach was 
confi rmed by analysing its ability to simulate the mechanical forces that develop 
in vivo (Kong and Singh,  2010 ). Based on the signifi cant variation that exists on the 
levels of gastric forces and contractive activity of the stomach wall during digestion, 
the mechanical forces within the HGS were investigated for two different compres-
sions levels: 50 % and 70 % (as determined by a minimum distance between oppo-
site rollers of 1.2 cm and 0.6 cm, respectively). The HGS was fi lled with water and 
the forces that develop at the bottom of the compartment were determined by 
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measuring the pressure to which a rubber bulb is exposed due to the contractive 
activity of the rollers. Details of the experimental methodology and force computa-
tions can be found in Kong and Singh ( 2010 ). Normalized by the cross-sectional 
area of the bulb, the maximum stresses recorded within the HGS were 6.7 ± 1.2 kPa 
and 8.9 ± 2.5 kPa, for a 50 % and a 70 % of compression, respectively. As stated by 
the authors, these results, as well as the periodic changes in the pressure values 
inside the HGS, were in reasonably good agreement with in vivo data, that com-
monly report mechanical stresses varying from 5.1 to 67 kPa (Marciani et al.  2001b ; 
Kamba et al.  2000 ). 
7.4  Operating Protocol 
 To provide a reference frame for the operation of the HGS, a brief description of the 
methodologies applied during the use of the HGS is presented in the following. 
7.4.1  Preparation of a Food Bolus 
 Different methods can be used to prepare the simulated bolus. In particular, during 
current applications of the HGS, food samples are either cut or ground to emulate 
the particle size distribution observed in human boluses. The particulate sample is 
then mixed with simulated saliva (100 g food: 20 mL saliva) for 30 s and allowed to 
stand at 37 °C for 2 min. The exact composition of the artifi cial saliva can be varied 
depending on the type of food and scope of the study (Kong and Singh  2010 ; Guo 
et al.  2014 ). 
7.4.2  Gastric Processing 
 Simulated gastric juice is prepared by dissolving pepsin (1 g), gastric mucin (1.5 g), 
and NaCl (8.775 g) in 1 L distilled water with pH of 1.3 adjusted using 6 N HCl. To 
simulate the fasting conditions of the stomach, 50–70 mL of simulated gastric juice 
is fi rst loaded into the HGS and equilibrated at 37 °C. The release of gastric juice 
within the gastric compartment starts immediately after the bolus is loaded, and 
continues at a rate of 2.5 mL/min during the entire processes (Hoebler et al.  2002 ). 
Gastric digesta is removed at a rate of 3 mL/min and subject to different chemical 
and physical analysis. Depending on study, after 3–5 h of simulated process the 
digesta remaining inside the HGS is removed for further analysis. 
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7.5  Uses of the HGS 
 The HGS has been used to investigate the role that ACW dynamics and food material 
properties have on the structural changes and disintegration profi le of different 
foods during digestion. 
7.5.1  Role of ACW Activity on Food Digestion 
 To investigate the relevance of ACW motility on the digestion behaviour of foods, 
Kong and Singh ( 2010 ) compared the performance of the HGS against the more 
traditional shaking bath method. 
 Apple cubes and extra-long white rice kernels were mixed with simulated saliva 
and exposed to 2 h of digestion in both, the HGS and a shaking bath. It is noteworthy 
that a batch approach was employed in both cases, with gastric juices being added to 
the systems only at the beginning of the process. The results clearly illustrated the 
signifi cant effect that the crushing and squeezing forces generated within the HGS 
have on the breakdown of both food models during the process. In the case of the 
apples, 61 % of the total dry matter from the shaking bath was still in particles larger 
than 6.3 mm, and only 20 % in particles smaller than 2.8 mm. In comparison, only 
16 % of the total dry matter from the HGS remained in particles larger than 6.3 mm, 
with a 69 % of it distributed in particles smaller than 2.8 mm. A similar result was 
found in the case of rice. Most kernels were intact after digestion in the shaking bath, 
while 52 % of the dry matter from the HGS was associated with particles smaller 
0.8 mm. 
 Considering that the structural breakdown of the diet will have a signifi cant 
impact on the rate of nutrient release during digestion, this study confi rmed the need 
to better emulate the fl uid mechanical conditions that develop during digestion. To 
further investigate the role of gastric motility on the disintegration kinetics of foods, 
Kong and Singh ( 2010 ) investigated the disintegration profi le of white rice when 
exposed to two different levels of compression. Unlike the previous study, the HGS 
was operated under dynamic conditions, where a continuous release of 2.5 mL/min 
of gastric juice was imposed. In agreement with in vivo data, an exponential decay 
of the digesta’s pH from an initial value of 4.27 to a fi nal constant value of 1.35 was 
observed within the fi rst 2 h of process. Simulated digesta was continuously removed 
from the HGS at a rate of 3 mL/min, leading to a 60 % of the total dry mass being 
emptied after 3 h of process. The HGS was operated under two levels of compres-
sion (50 % and 70 %). The higher the compression, the higher the disintegration of 
the food particles. In particular, a 75 % compression was able to break down 75 % 
of the rice kernels into particles much smaller than 1.2 mm in size. This study 
showed once again the need to better understand and mimic the biomechanical 
functions of the human stomach in order to improve the performance and reliability 
of in vitro digestive systems. 
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7.5.2  Role of Food Material Properties 
 Kong et al. ( 2011 ) used the HGS to investigate the physical changes that white and 
brown rice experience during digestion. The authors cooked the rice, mixed it with 
simulated saliva, and placed it in the HGS (previously loaded with 50 mL of simu-
lated gastric juice). During the 3 h of process, gastric juice was added to the system 
at a rate of 2.5 mL/min. The simulated digesta was emptied at a rate of 3 mL/min 
and exposed to a maximum compression level of 50 %. The solid composition of the 
emptied digesta clearly illustrated the greater level of disintegration and dissolution 
experienced by white rice. After 3 h of digestion, 55 % of the white rice solids were 
emptied from the HGS, as compared with 45 % for the brown rice. Sieving of the 
digesta allowed the authors to associate the slower emptying rate of brown kernels 
to its slower rate of disintegration. By the end of the process, 80 % of the particles 
within the white rice digesta were smaller than 10 mm 2 compared to only 40 % for 
the brown rice. The differences observed in the physical changes of both types of 
rice were largely associated with the bran layer surrounding the brown kernels. 
As illustrated by the authors, this bran layer not only delayed the diffusion of gastric 
juice into the kernels, but also protected them from the mechanical forces that 
develop during the process. In addition, while both digesta samples behave as weak- 
gels, the brown rice digesta was found to have an enhanced elastic component, 
which could further slow down its mechanical disintegration. 
 Guo et al. ( 2014 ) used the HGS to investigate the effect of different emulsion 
gels’ structures on their disintegration profi le during digestion. Homogeneous ‘soft’ 
gels and heterogeneous ‘hard’ gels were mechanically grounded and mixed with 
artifi cial saliva to specifi cally simulate in vivo masticated gel boluses. The simu-
lated boluses were loaded into the HGS already containing 70 mL of simulated 
gastric juice and exposed to 5 h of digestion process. Gastric juice was delivered at 
2.5 mL/min and digesta samples removed at a rate of 3 mL/min (starting after 
30 min). Rollers were set to impose a maximum compression level of 60 %. Despite 
the differences in the initial strength and size of the gel particles, similar amounts of 
solids were emptied from the HGS (≈74 %) at the end of the process, and a similar 
distribution of particles sizes was found in the digesta remaining inside the 
HGS. Despite this similarities, the authors did fi nd signifi cant differences in the 
emptying profi le and size distribution of the digesta leaving the HGS during the pro-
cess. Initially, the amount of solids leaving the HGS was higher in the case of the 
‘hard’ gel, but this trend reversed after 3 h of process. This initial trend was explained 
by the smaller size of hard gel particles in the simulated masticated bolus. In addi-
tion, they also found that while the diameter (d4,3) of oil droplets in the empited 
digesta of the ‘hard’ gel did not change during the process, in the case of the soft gel 
it remained unchanged only for the fi rst hour. After that time, the d4,3 of emptied oil 
droplets from the ‘soft’ gel increased to reach a maximum at about 2.5 hours of 
process. These differences in the emptying profi le of solids and size distribution of 
oil droplets at later stages of the process were related to the way in which the struc-
ture of gels ingluences their chemical digestion by pepsin. Within the fi rst hour of 
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process, a combination of chemical and mechanical effects gradually broke down 
both gels to particles of about 10 μm. During this process, the microstructure of the 
gels was largely maintained and only very small quantities of oil were released. As 
time evolves, the fi ne-stranded structure of the ‘soft’ gel allowed pepsin to further 
disintegrate the gel particles down to a size of 0.45 μm (a process not observed in 
the case of the ‘hard’ gel). This further disintegration of the ‘soft’ gel enhanced its 
rate of emptying from the HGS and the release of oil droplets from the matrix. The 
transitional increase in the size of the liberated oil droplets after 1 h of process was 
associated with their fl occulation, as the digesta passes through the isoelectric point 
of the denatured whey proteins. 
7.6  Advantages and Limitations 
 Specifi cally designed to mimic the motor activity of the antral contractions waves 
during digestion, the HGS has been proved to reproduce the fl uid mechanical forces 
that develop in vivo. Preliminary applications of the HGS have demonstrated the 
need to better understand and mimic the physical processes underlying digestion. 
The possibility to control the motor activity of the ACW offer new opportunities to 
investigate the impact gastric motility dysfunctions on food digestion. Further 
efforts needs to be done to automate the secretory and emptying patterns of the 
HGS in response to digesta properties during the process, and to pursue a thorough 
validation of its digestive capabilities. 
7.7  Availability of the System 
 Two HGS models are in operation. One in the Department of Biological and 
Agricultural engineering at the University of California (Davis), where it was fi rst 
created. A second replicate was made and currently used at the Riddet Institute, 
Massey University (New Zealand). 
 Open Access This chapter is distributed under the terms of the Creative Commons Attribution 
Noncommercial License, which permits any noncommercial use, distribution, and reproduction in 
any medium, provided the original author(s) and source are credited. 
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Olivia Ménard, Daniel Picque, and Didier Dupont
Abstract A simple two-compartment in vitro dynamic gastrointestinal digestion 
system allowing the study of the disintegration of food during digestion has been 
recently developed at INRA. As a first application, it has been used for understand-
ing the mechanisms of infant formula disintegration in the infant gastrointestinal 
tract. The developed system was validated by comparing the kinetics of proteolysis 
obtained in vitro towards in vivo data collected on piglets. Results showed a good 
correlation between in vitro and in vivo data and prove the physiological relevance 
of the newly developed system.
Keywords Two-compartment in vitro dynamic gastrointestinal digestion system •
Disintegration of food • In vitro • Digestion • Infant gastrointestinal tract
8.1  Origins and Design of the DIDGI® System
At the French National Institute for Agricultural Research (INRA), several groups 
are trying to improve our understanding of the fate of different foods (dairy, egg, 
meat, bakery products, etc.) in the gastrointestinal tract. Our first objective is to 
unravel the mechanisms of food disintegration in the gastrointestinal tract and 
identify the molecules (nutrients, bioactive compounds, contaminants etc.) that are 
released during digestion (Barbé et al. 2013). A second objective is to determine 
how the structure of food matrices affects food digestion and nutrient bioaccessi-
bility and bioavailability (Barbé et al. 2014). Finally, we model digestion and 
translate this cascade of events into mathematical models (Le Feunteun et al. 2014) 
in order to design new foods through a reverse engineering approach i.e. starting 
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from the bioactivity we want to deliver to the body and going back to the most 
adapted structure.
Since dynamic digestion devices are not very available on the market or quite 
expensive, we decided to build our own system. The system developed had to be 
cheap, simple, robust and applicable to all kind of foods INRA is working on. This 
model was built in order to monitor the disintegration and the kinetics of hydrolysis 
of the food occurring during a simulated digestion. It focuses on the upper parts of 
the digestive tract, i.e. the stomach and the small intestine. To be physiologically 
realistic, the computer-controlled system reproduces the gastric and intestinal 
transit times, the kinetics of gastric and intestinal pH, the sequential addition of 
digestive secretions and the stirring of the stomach and small intestine contents.
The gastrointestinal digestion system (Fig. 8.1) consists of two consecutive com-
partments simulating the stomach and the small intestine. Each compartment is sur-
rounded by a glass jacket filled with water pumped using a temperature-controlled 
water bath. The system is equipped with temperature, pH and redox sensors and 
variable speed pumps to control the flow of meal, HCl, Na2CO3, bile, enzymes and 
the emptying of each compartment. Flow rates are regulated by specific computer- 
controlled peristaltic pumps. Anaerobic conditions can be simulated by purging air 
with nitrogen. A Teflon membrane with 2 mm holes is placed before the transfer 
pump between the gastric and the intestinal compartment to mimic the sieving effect 
of the pylorus in human, as described previously (Kong and Singh 2008).
The computer program was designed to accept parameters and data obtained from 
in vivo studies in animals or human volunteers, such as the quantity and duration of a 
meal, the pH curves for the stomach and small intestine, the secretion rates into the 
different compartments and the gastric and small intestine emptying rates. The system 
is controlled by software named StoRM for Stomach regulation and monitoring 
(Guillemin et al. 2010). To control the transit time of the chyme in each compartment, 
a power exponential equation for gastric and intestinal delivery is used f t= -( )2 1 2t / / b  
where f represents the fraction of the chyme remaining in the stomach, t is the time of 
delivery, t½ is the half time of delivery and β is the coefficient describing the shape of the 
curve, as described previously (Elashoff et al. 1982).
Fig. 8.1 Presentation of the gastro-intestinal dynamic digestion system
O. Ménard et al.
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8.2  Validation of DIDGI® for the Digestion  
of Infant Formula
The DIDGI® system is a very recent one. Although several matrices (dairy, meat, 
fruits and vegetables, emulsions) have been submitted to digestion using the 
DIDGI® system, only data obtained on the digestion of infant formulas have been 
published so far (Ménard et al. 2014). In order to demonstrate that this system was 
physiologically- relevant, a comparison of the in vitro and in vivo digestion of an 
infant formula was performed. The in vivo trial was conducted on 18 piglets that 
were fed the infant formula for which the concentration in lipids and proteins was 
increased compared to a standard one, but the ratio lipids/proteins was kept con-
stant. In parallel, in vitro gastro-intestinal digestion was performed on this enriched 
infant formula using the newly developed system and the extent of milk proteolysis 
was monitored and compared to the one obtained in vivo.
8.2.1  Protocol for the In Vitro Dynamic Digestion  
of Infant Formula Using the DIDGI® System
Infant formula (150 ml) was introduced into the gastric compartment within a pre- set 
period of time, i.e. 10 min. The pH values were controlled via the computer by 
secreting either 0.5 M HCl to decrease the pH in the stomach or 0.1 M Na2CO3 to 
neutralize the pH in the small intestine.
The dynamic digestive system was set up using parameters taken from the 
literature that are listed in Table 8.1. The pH curve in the stomach was obtained by 
combining data from different in vivo experiments on piglets (Moughan et al. 
1991; Chiang et al. 2008; Bouzerzour et al. 2012) whereas intestinal pH was kept 
constant at 6.5. Other parameters like the transit time of the formula in the stomach 
(determination of t1/2 and β) was obtained from an exhaustive review on human 
infant gastrointestinal physiological conditions (Bourlieu et al. 2014) and fixed at 
t1/2 = 70 min or 200 min and β = 1.23 or 2.2 for gastric or intestinal transit time, 
respectively. Volumes, flow rates of secretions, nature and quantity of enzymes in 
the different stages of the gastro-intestinal model have been described previously 
(Minekus et al. 1995; Blanquet et al. 2004; Bouzerzour et al. 2012) based on results 
of in vivo experiments. Digestive enzymes and bile were diluted in 150 mM NaCl, 
pH 6.5. After rehydration, all the digestive enzymes were kept on ice throughout 
the experiment in order to avoid autolysis. Digestion experiments were performed 
in  triplicates. Samples were collected during the digestion in each compartment at 
30, 60, 90, 120 and 210 min after ingestion. Before being frozen at −20 °C, phenyl-
methanesulfonyl fluoride was added at 0.37 g/kg of digested sample in order to 
inhibit proteolysis.
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8.2.2  In Vivo Digestion of Infant Formula on Piglets
An in vivo study on piglets was conducted in parallel in accordance with the guide-
lines formulated by the European Community for the use of experimental animals 
(EU Directive 2010/63/EU). Eighteen piglets [Pietrain × (Large White × Landrace)] 
were separated from their mothers after 2 days and fed for 26 days with the formula 
using an automatic milk feeder, as described previously (Bouzerzour et al. 2012). 
The experimental design was a complete block design with 1 × 3 factorial arrange-
ment of 1 diet and 3 slaughter times after the last meal (30 min, 90 min and 
210 min). The daily net energy ration of 1,450 kJ/body weight (BW)0.75 was parti-
tioned into ten meals automatically distributed during the day. Body weights were 
recorded weekly, and feeding schedules were adjusted accordingly. At the age of 
28 days, piglets were allotted in three groups according to their slaughter times 
after the last meal: 30 min, 90 min and 210 min. They were slaughtered by electro-
narcosis immediately followed by exsanguination. Immediately afterwards, the 
digestive tract was removed, dissected and samples were collected from the stomach 
to the ileum.
Table 8.1 Parameters of in vitro gastro-intestinal conditions
Gastric conditions
Volume ingested (ml) 150
Fasted volume (ml) 30
Pepsin 625 U/mL diluted in NaCl 150 mM pH = 3
pH (acidification curve) Y = −0.011*t + 5.4 [t: time after ingestion(min)]
Secretions
Pepsin flow 1,250 U/mL
0.25 ml/min
Lipase flow 60 U/mL
0.25 mL/min
Transit time t1/2(min) 70 min
β 1.23
Intestinal conditions
Fasted volume 5 ml of bile solution (1 %)
+5 ml of pancreatin solution (10 %)
pH Maintained at 6.5
Secretions
Bile flow 1 %
0.5 mL/min
Pancreatin flow 10 %
0.25 mL/min
Transit time t1/2(min) 200
β 2.2
O. Ménard et al.
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The total content of each segment was collected, dispersed and pH was measured. 
Sodium benzoate and phenylmethanesulfonyl fluoride (10 and 0.37 g/kg of content, 
respectively) were added to each digested sample in order to avoid further protein 
breakdown. All effluents were stored at −20 °C until further analyses.
8.2.3  Comparison In Vitro/In Vivo Data
The evolution of the volume emptied from the stomach into the small intestine, 
the volume remaining in the stomach and the total volume of gastric content 
(emptied + remaining) monitored during three independent digestion experiments is 
represented on Fig. 8.2. The rapid increase in the total volume during the first 
10 min of digestion corresponds to the ingestion of the infant formula. Subsequently, 
its increase is due to the injection of gastric secretions.
The emptied volume follows the gastric transit described by the Elashoff’s equa-
tion (Elashoff et al. 1982). Figure 8.2 also shows an excellent reproducibility 
between experiments since the curves of the replicates are similar in the gastric 
compartment. In the intestinal compartment, the reproducibility was also excellent 
(data not shown). Measuring all the volumes coming in and out of the two compart-
ments allowed an assessment of the reliability of the system by comparing the values 
obtained by the system with those predicted by the software. The initial pH of 
the formula was 6.5. The pH regulation started only 5 min after the beginning of the 
experiment. Indeed, a minimum volume of c.a. 15 ml is needed for the pH electrode 


























Fig. 8.2 Evolution of the volume emptied from the stomach into the small intestine, the volume 
remaining in the stomach and the total volume of gastric content (emptied + remaining) monitored 
during three independent in vitro digestion experiments
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acidification curve. The decrease in pH throughout the experiment is due to the 
addition of hydrochloric acid to the gastric compartment. After 210 min of diges-
tion, gastric pH reached 3.10; at this stage, only 40 mL were present in the stomach 
mainly consisting of simulated gastric fluid.
Volumes of the stomach content observed in vitro with the dynamic digestion 
system were compared to the ones observed in vivo in piglets (Fig. 8.3). No signifi-
cant differences were observed 30, 90 and 210 min after ingestion confirming that 
the parameters chosen for mimicking the gastric transit of infant formula in vitro 
were physiologically relevant.
Evolution of caseins (Fig. 8.4a) and β-lactoglobulin (Fig. 8.4b) throughout 
in vitro and in vivo digestion, as determined by ELISA, was compared. Results 
showed that the kinetics of hydrolysis of both proteins during in vitro and in vivo 
digestion were similar. The proportion of immunoreactive caseins appeared not to 
be significantly different between both experiments for samples collected in the 
stomach as well as in the small intestine after 30, 90 and 210 min of digestion 
(Fig. 8.4a). Similarly, the percentage of immunoreactive β-lactoglobulin showed no 
significant differences for samples collected in vivo and in vitro in the stomach after 
30, 90 and 210 min. However, the percentage of immunoreactive β-lactoglobulin in 
the small intestine was significantly higher in vitro than in vivo. The correlation 
coefficient, between in vitro and in vivo ELISA determination for caseins and 
β-lactoglobulin was 0.987 (p < 0.001), proving a good agreement between in vitro 
and in vivo proteolysis during digestion.
8.3  Advantages, Disadvantages and Limitations
Some advantages and limitations of the DIDGI® are provided in Table 8.2.
Fig. 8.3 Comparison of the volumes remaining in the gastric compartment between in vivo (filled 
square) and in vitro (open square) experiments
O. Ménard et al.
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8.4  Conclusion and Prospects
We present here the development of a simple and new dynamic digestion system, 
DIDGI® that has been validated against in vivo (porcine) data for the digestion of 
infant formula. The system is currently being applied to study (1) the digestion of 
Fig. 8.4 Casein (a) and β-lactoglobulin (b) concentrations determined by ELISA
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human milk, dairy gels and emulsions, cheese, and (2) the survival of food microor-
ganisms in the gastro-intestinal tract. The results obtained so far are quite promis-
ing. Some improvements have recently been applied to the system: it now has three 
compartments (stomach, duodenum and jejunum + ileum) instead of two; dialysis 
membranes will soon be added to the system to mimic absorption; the pump allow-
ing the bolus to enter the stomach has been modified to allow the introduction of 
solid matrices (meat, bread, fruits and vegetables).
Open Access This chapter is distributed under the terms of the Creative Commons Attribution 
Noncommercial License, which permits any noncommercial use, distribution, and reproduction in 
any medium, provided the original author(s) and source are credited.
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 Part II 
 General Introduction to Cells, Cell Lines 
and Cell Culture 
 Introduction 
 Cell and tissue culture technology holds a central position in modern biomedical 
research. Cells in culture are useful model systems for studying normal physiological 
and biochemical processes in cells and can even be used for diagnostic purposes. The 
main advantage of using cell culture systems is the consistency and reproducibility 
obtained. 
 In most situations cells or tissues have to be cultivated for longer periods to obtain 
suffi cient numbers of cells for analysis. Alternatively, the same cells can be continu-
ously propagated in the laboratory for use in repeated experiments. Normal cells 
(primary cells) usually divide only a limited number of times before entering into 
senescence. However, cells can be immortalized through transformation, a process 
that can occur spontaneously or by treating the cells with chemicals or viruses. Long-
term culture of cells requires well established aseptic techniques to avoid contamina-
tion with bacteria, yeasts, molds or viruses. Contamination may cause erroneous 
results and eventually the loss of valuable cell material. 
 Usually, there are two different ways of growing cells in culture, either as cells 
attaching to the surface of the culture vessel, adherent cells, or as cells growing in 
suspension. Most cells from vertebrates, either in the form of primary cells or cell 
lines, adhere to the plastic surface of the culture vessel. Some cells adhere rather 
loosely and may require that the plastic of the culture tray is coated with a 1 % solu-
tion of gelatin, collagen or fi bronectin before use. Most cells and cell lines of hemo-
poietic origin, typically lymphocytes, grow free-fl oating in the culture medium. 
 Salt Solutions 
 In vitro, tissue and cells should only be exposed to isotonic solutions at physiologi-
cal pH, either in the form of  balanced salt solutions or  culture media . The simplest 
salt solutions are saline (0.9 % NaCl) or phosphate-buffered saline (PBS, 10–15 mM 
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phosphate buffer in saline). Many balanced salt solutions (typically Earle’s balanced 
salt solution (EBSS), Hank’s balanced salt solution (HBSS), Dulbecco’s phosphate-
buffered saline (D-PBS) or similar) have been developed to provide optimal short 
term support for different cell types in vitro and for different culturing conditions. 
 Culture Media 
 Most culture media are based on balanced salt solutions with a variable number of 
additions in the form of amino acids, vitamins, trace minerals, a pH indicator, and 
eventually antibiotics. Such media are called  basal media . Typical examples are 
RPMI 1640 (Roswell Park Memorial Institute 1640) and DMEM (Dulbecco’s 
Modifi ed Eagle Medium), eventually with the Ham’s F12 nutrient mixture (DMEM/
F12). In addition to the basal media special medium formulations that require less 
serum addition, so called Reduced Serum Media, alternatively Serum-Free Media 
(SFM), are available for special cell types and special applications. 
 The culture medium is absolutely crucial for successful cell culture experiments. 
In general, recommendations are available for each particular cell line or cell type. 
However, different media may satisfy the required conditions for a particular cell 
type. Thus, personal experience could be valuable when choosing medium. Such 
personal experience may also include observed benefi cial effects due to the addition 
of non-essential amino acids, pyruvate, reducing agents etc. It is extremely impor-
tant to know that any addition to ready-made media requires components that have 
been tested and certifi ed for cell culture work. Even chemicals of  pro analysi quality 
may contain traces of toxic compounds that can be detrimental to cells in culture. 
 Medium Quality 
 More important than medium type is perhaps the overall “quality” of the medium. 
Most researchers today prefer the simplicity of using sterile, ready-to-use media. 
However, many media contain storage-sensitive components. Glutamine for example 
tends to decompose upon storage creating pyrrolidone carboxylic acid and ammo-
nia. At 4 °C approximately 10 % of the glutamine will decompose in 9 days. Thus, 
to be on the safe side many researchers add fresh glutamine to their medium before 
use. If glutamine addition is repeatedly carried out, the build-up of ammonia may 
become toxic to the cells affecting protein glycosylation patterns and even cell via-
bility (Heeneman et al.  1993 ). As an alternative to glutamine, GlutaMAX ™ -based 
media may be used. GlutaMAX ™ is a stable dipeptide of alanyl-glutamine serving 
the same functions as glutamine in the culture medium (Roth et al.  1988 ). Generally, 
media should be as fresh as possible. Storage in a cold room for more than a few 
months may provide suboptimal culture conditions. This will, however, depend 
on the cell type or cell line under study. If working with demanding cells, one can 
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benefi t from preparing fresh medium from powder. In this situation water quality is 
absolutely essential. Distilled or deionized water is usually not of high enough qual-
ity for medium preparation. Double or triple glass-distilled water or similar should 
be used. 
 pH and CO 2 
 The optimum pH for most mammalian cells is pH 7.2–7.4, and there is very little 
variability. This is usually obtained with a sodium bicarbonate buffer that requires 
a delicate balance of dissolved carbon dioxide (CO 2 ) and bicarbonate (HCO 3 − ). 
Changes in atmospheric CO 2 may affect the pH of the medium. Therefore, a supply 
of exogenous CO 2 (5–7 % CO 2 in air) is necessary when using media based on 
CO 2 /bicarbonate as buffering system. Alternatively, the synthetic buffer HEPES 
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) can be used. HEPES allows 
experiments to be carried out when a CO 2 incubator is not available. However, 
HEPES is expensive, and toxic effects of HEPES on some cell lines have been 
reported. 
 Serum Addition 
 Although chemically defi ned, serum-free media are available, most cell culture 
media require the addition of serum to provide essential transport proteins, fatty 
acids, growth factors and hormones. However, serum from different animal species, 
and even different batches of serum from the same species, may have very different 
properties in supporting cell growth in vitro. Depending on the cells in question, 
serum from horse, swine, cattle, newborn calves, calf fetuses and humans can be 
used. Usually, fetal bovine serum/fetal calf serum (FBS/FCS) is preferred. 
 The properties of FBS may vary from vendor to vendor and from batch to batch. 
Large cell culture laboratories often test a number of different batches and screen 
for select properties depending on the type of cells under study. One particular batch 
may provide good growth support, while another batch from the same supplier may 
be inferior in comparison. Thus, to be able to work reproducibly with cell cultures 
over time will require access to larger volumes of the same serum batch, and selec-
tion of new serum batches must be based on experiences with the prior or reference 
batch used in the laboratory. Serum is usually added to the medium in concentra-
tions between 5 and 20 %. People tend to believe that medium quality improves 
with increasing serum concentrations. However, 20–25 % of a low quality serum 
may be inferior in performance to 5–10 % of a good quality serum. 
 One of the main reasons for choosing fetal serum is the low content of antibodies 
present. Antibodies together with serum complement could have negative effects on 
cell viability. Thus, routinely FBS is still inactivated, i.e. incubated at 56 °C for 
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30 min to destroy heat-labile complement proteins. However, the usefulness of this 
procedure can be questioned. First, complement protein levels in FBS are only a 
few percent of the levels found in adult serum. Secondly, heat inactivation may 
destroy other valuable serum components, as well. Today, it can be considered 
unnecessary to heat-inactivate FBS from established suppliers. 
 Most cell culture work today is carried out with continuously growing, 
 transformed cell lines. Primary cells have limited life span. Based on experience 
with primary cells with proliferating potential, like multipotent stromal cells (MSC) 
from bone marrow or adipose tissue, it is possible to cultivate primary cells for in 
excess of 40 population doublings before they reach senescence and die. Among 
immune cells, T lymphocytes can also be expanded in vitro by stimulation and 
 periodic restimulation with antigen or antibodies against the T-cell receptor/CD3 
complex in the presence of recombinant cytokines like interleukin 2 (IL-2). This is 
currently not possible for B lymphocytes since activated B lymphocytes differenti-
ate into short-lived antibody-producing plasma cells that do not express antigen 
receptors, and cannot be restimulated. Monocytes, macrophages and dendritic cells 
do not proliferate in vitro. Epithelial cells have also been very diffi cult to establish 
in culture as primary cells. So, for most purposes, we depend on using transformed 
cell lines that have been established from tumors of different tissues. This means 
that such cell lines are not necessarily clonal in their origin. Transformed cell lines 
can be very heterogeneous containing cells with different properties. During propa-
gation, culture conditions can be expected to infl uence and select for cells with 
special properties. Thus, during long-term cultivation a particular cell line changes 
in composition and properties. It is absolutely recommended that when a cell line 
arrives in a laboratory, its passage number should be known. Then the cells should 
be expanded and frozen to create a stock cell bank so that new cells can be thawed 
and brought into culture to preserve the properties of the original cell line. This is 
also one of the reasons why comparison of results with the “same” cell line from 
different laboratories often turns out to be very diffi cult. Cells or cell lines subject 
to different cultivation conditions, e.g. different media, different serum source, dif-
ferences in passage number, differences in density before subcultivation, will even-
tually acquire and express different properties and respond differently to the same 
stimuli in in vitro experiments. 
 The Cell Culture Hood 
 Aseptic working conditions are absolutely essential for a cell culture laboratory. 
A separate cell culture room is preferred. However, a designated area for cell culture 
work as part of a large laboratory can also be used. A cell culture hood represents 
an aseptic work area allowing protection of both cells and laboratory personnel. 
Class II cell culture hoods will provide the necessary conditions for long term cell 
culture work. Today’s class II biosafety cabinets effi ciently protect the working 
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environment from dust and microbial contaminants by means of a HEPA-fi ltered 
vertical laminar air fl ow. All remedies like medium bottles, trays, culture fl asks, 
tube racks, pipettor etc. should be kept in the back or at the side of the cabinet leav-
ing a free working space. Remember that all equipment found inside the cabinet is 
potentially contaminated, and it is of utmost importance to avoid disturbing the 
laminated airfl ow above the open media bottles and culture trays with any contami-
nated material. As a rule of thumb, never work with more than one cell line at the 
time inside the cell culture hood. Likewise, never use the same medium bottle to 
feed different cell lines! 
 Cell Culture Terminology (Fig.  1 ) 
 Most cells and cell lines cultivated in vitro adheres to the tissue culture plastic, and 
this adherence is often essential for maintaining the cells in a healthy, viable state. 
A culture of primary cells can be grown to confl uence, e.g. in a continuous mono-
layer, in any tissue culture vessel like a petri dish, a tissue culture fl ask or plates with 
6-, 12- or 24 wells. When reaching confl uence they have to be  subcultured or 
 passaged . If not, continued culture of confl uent cells may result in reduced mitotic 
activity, selection of variant cells and even cell death. Subcultivation of cells 
requires detachment of the cells from the surface of the tissue culture tray, usually 
by  trypsinization or scraping with a mechanical device like  a rubber policeman 
(see Fig.  2 ). 
 The cell suspension is then subdivided and seeded into fresh medium. Such sec-
ondary cultures are fed at regular intervals, and may eventually be subcultured in 
the same way to produce tertiary cultures. The time between feeding and subcultur-
ing of the cells may vary from cell type to cell type depending on growth rate. 
 General Cell Culture Protocols 
 Trypsinisation and Subculturing of Cells 
 Remove gently all medium from the culture to be passaged with a sterile Pasteur 
pipette or by suction from a vacuum pump. The adherent cell layer should then be 
rinsed one to two times with HBSS without Ca 2+ /Mg 2+ to get rid of any FBS that 
may interfere with the trypsinization process. Add just enough trypsin/EDTA solu-
tion to cover the culture plate/tray. Keep at 37 °C for 1–2 min. Tap the culture tray 
against the working plate of the laminated air fl ow cabinet, and inspect the cells in 
an inverted microscope to ascertain that the cells are rounded up and detached from 
the surface. It may be necessary to increase trypsinization up to 15 min. However, 
prolonged incubation with trypsin may reduce cell viability. 
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 Add a suffi cient volume of complete medium with FBS and draw the cell 
 suspension into a Pasteur pipet. Rinse the plate carefully with the cell suspension to 
dislodge any residual cells. When all cells are detached, add more complete medium 
with FBS to inhibit residual trypsin activity that may damage the cells. 
 Count the cells in a haemocytometer, alternatively in a Coulter counter or similar 
device. Dilute the cells in complete medium and seed them at a suitable density in 
the tissue culture tray of choice. 
 If necessary, feed subconfl uent cell layers after 3–4 days by removing most of 
the spent medium and replacing it with fresh new medium at 37 °C. Follow the 
same protocol for subsequent subcultivations. Notify the number of passages for 
each culture. 
 Passaging of Cells in Suspension Culture 
 Although most primary cells and cell lines are plastic adherent, some cell types are 
non-adherent. Typically, primary immune cells like B and T lymphocytes and trans-
formed lymphoid cells, NK cells and granulocytes grow in suspension. It is easier 
to passage cells growing in suspension than adherent cells since no trypsinization or 
detachment from the tissue culture plastic is necessary. Cells in suspension culture 
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 Fig. 1  The fi gure describes the relationship and differences between primary cells, transformed 
and immortalized cell lines and clones 
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do not grow to confl uence, and different cells may tolerate growing at different 
densities. Thus, optimal cell concentration has to be determined in each instance. 
Also, seeding densities may vary. Some cells are able to grow at very low densities 
while others need support from accompanying cells and have to be reseeded at 
higher densities. As a rule of thumb, when the cells reach a density of around 2 × 10 6 /ml, 
they should be split back to 2–3 × 10 5 cells/ml. An optimal cell concentration will 
usually be around 10 6 /ml. 
 If you are going to expand the cells to obtain large cell numbers, remove the fl ask 
from the incubator, swirl the fl ask gently to resuspend the cells and remove a small 
sample to measure cell density by counting in a hemocytometer or a Coulter coun-
ter. Depending on cell concentration aseptically distribute the contents into new 
fl asks allowing a new cell concentration of 2–3 × 10 5 cells/ml. 
 Add fresh medium and ascertain that the height of the medium never exceeds 
2 cm above the bottom of the fl ask or tray. This is important to allow proper buffer-
ing of the medium and physiological pH for the cells sedimenting to the bottom of 
the fl ask. 
 If cells are growing slowly, they might be fed by aseptically removing 1/3 of the 
old medium to be replenished by fresh medium. 
 Freezing Cells 
 Both adherent and suspension culture cells can be frozen and stored in liquid nitro-
gen for extended periods of time. In general, the same protocol can be used for both 
cell types. 
 Harvest the cells and spin them down in a table top centrifuge. Resuspend the 
cells carefully with a Pasteur pipette in cold medium containing 10 % FBS to a 
concentration of around 5 × 10 6 cells/ml. Keep tube or bottle with cells on ice in the 
sterile hood. Add a similar volume of cold freezing medium dropwise to the tube 
with cells while gently swirling the tube. 
 Fig. 2  The drawing shows a rubber policeman ( left ) and a typical cell scraper to collect adherent 
cells from the surface of the tissue culture plastic ware 
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 Distribute the cell suspension in 1 ml aliquots in 2 ml cryovials. Tighten caps 
properly. Place vials in a styrofoam box and place in a −80 °C freezer overnight 
before transfer to liquid nitrogen storage tank. 
 The Thawing and Recovery of Cells 
 Cells can be stored in liquid N 2 , or in the gas phase over the liquid N 2 for long 
 periods of time. However, valuable cells should be thawed and brought back into 
culture once a year to ascertain viability and function. Thawing is as important as 
the freezing process to maintain cell viability, and thawing should be carried out 
according to a rigorous protocol. 
 Frozen vials with cells are placed on ice directly from the liquid N 2 storage tank. 
 The vials should be immersed in a water bath at 37 °C and thawed leaving a 
small lump of ice in the vial before transfer of the vial to melting ice again. When 
fully thawed, transfer the contents of the vial into a tube and add slowly cold 
medium to dilute the DMSO in the freezing medium. It is very important that the 
cell suspension is kept cold during this procedure. 
 Spin the cells carefully down in a table top centrifuge, remove the DMSO con-
taining medium and add a small volume of complete medium to resuspend the cells. 
 Take  a small sample to monitor cell viability by trypan blue exclusion and light 
microscopy, or similar viability test (see Sect.  9.5 ). If cell viability is below 70 % it 
may turn out diffi cult to obtain proper cell growth. Reduced cell viability is most 
likely due to improper handling of cells either before freezing, during freezing or 
thawing of the cells. 
 Dilute with complete medium to the desired cell concentration, and add the cell 
suspension to a suitable culture vessel. Place in incubator. Monitor cell morphology 
and cell growth during the following days. 
 Cell Viability Testing 
 Assessment of cell viability is fundamental in all cell culture work. Cell viability 
will provide information about culture conditions, in general, and may also repre-
sent the fi nal read-out system for a cytotoxicity experiment. A large number of via-
bility assays are reported in the literature, ranging from the simple trypan blue 
exclusion test to complex analysis of individual cells with Raman spectroscopy. 
 Cell viability assays will often overlap with cell proliferation assays. They are 
divided into assays that monitors viability at the single cell level and those that 
analyses viability at the population level. The simplest and cheapest viability test 
exploits the vital stain trypan blue. Trypan blue is excluded from cells and tissues 
with intact membranes, and the staining of dead cells is easy to detect in a standard 
light microscope. 
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 Prepare a 0.8 mM trypan blue solution in phosphate-buffered saline (PBS). Mix 
cells and trypan blue solution in a 1:1 ratio. Inspect and count dead and alive cells 
under a light microscope in a haemocytometer. Dead cells will stain blue due to 
trypan blue uptake, while live cells appear transparent. Cells should not be exposed 
to trypan blue solution for more than 20 min. Prolonged incubation will increase 
cell death and reduce viability. 
 A variety of fl uorescent dyes can also be used to monitor cell viability, typical in 
the combination with fl ow cytometry. Propidium iodide and 7-actinomycin D are 
commonly used for this purpose. 
 Assessing cell viability at the population level has become very popular. These 
assays are typically carried out by using different tetrazolium compounds. Among 
the most popular are MTT ((3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide), MTS, XTT and WST-1. Among these MTT is positively charged and 
readily penetrates viable cells, while the others are negatively charged and are 
excluded from viable cells. The MTT assay is perhaps the most popular to assess 
cell viability and proliferation in a population of cells. It was the fi rst assay to be 
developed for high trough put screening in a 96-well format. Viable cells convert 
MTT into a purple colored formazan product. When cells die, they lose ability to 
convert MTT into formazan. The mechanism behind this process is not well under-
stood, although many publications suggest that the MTT assay refl ects changes in 
mitochondrial activity. Commercial kits containing MTT and a solubilization 
reagent can be obtained from several vendors like Sigma Aldrich, Promega and 
Millipore, among others. 
 Contamination of Cell Cultures 
 Cell cultures may become contaminated by bacteria, molds, viruses and mycoplas-
mas. In general, contamination by bacteria and molds are easy to detect by visual 
inspection. Mycoplasmas, however, are perhaps the most severe and diffi cult cell 
culture contaminant to observe and handle. Since its discovery in 1956 (Armstrong 
et al.  2010 ), the presence of mycoplasmas in cell cultures has been a great chal-
lenge, both in research as well as in industrial laboratories and production facilities 
for cell-derived biological and pharmaceutical products. Although the risks and 
consequences of mycoplasma infection have been known for decades, recent stud-
ies (Drexler and Uphoff  2002 ) indicate that there has been no decline in infection 
rates. Mycoplasmas are small (0.1–0.6 μm) bacteria that lack cell wall. Thus, they 
are diffi cult to observe by conventional light microscopy. Furthermore, they are 
unaffected by antibiotics that target cell wall biosynthesis like penicillin and 
β-lactams, so they will continue to grow in infected cell cultures despite the pres-
ence of standard antibiotics and antimycotics. Mycoplasma species have been found 
associated with a range of hosts, including humans and other mammals, birds, rep-
tiles, insects and plants. Despite the fact that more than 100 mycoplasma species 
have been described, most mycoplasmas that contaminate cell culture laboratories 
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belong to only six species of bovine, swine and human origin. Bovine and swine 
mycoplasmas typically derive from contaminated sera or other animal-derived 
products used in the cell culture laboratory. Currently, many infections are trans-
fered from already infected cultures within the same laboratory due to inadequate 
aseptic and cell culture techniques or from equipment that has been contaminated 
through prior handling of infected cells. However, laboratory personnel also repre-
sent an important source of mycoplasma infections, and mycoplasma species from 
humans, mainly of oral origin, are responsible for 40–80 % of mycoplasma infec-
tions in cell cultures. In total it is estimated that 15–35 % of all cultures based on 
continuous cell lines are mycoplasma infected (Barile et al.  1973 ), while contami-
nated cultures based on primary cells are seldom found. 
 Their fl exibility in shape due to the lack of cell wall, allows most mycoplasmas 
to pass through 0.2 μm fi lters traditionally used for sterilization of media and 
medium ingredients. For the same reason they are diffi cult to observe in cell 
 cultures. Moreover, despite the richness of standard culture media, mycoplasmas 
grow slowly, a fact that contributes to the problems with detecting them, visually or 
by change in turbidity. Although we tend to consider mycoplasmas mainly as a 
problem in cell culture work, it should be remembered that the mycoplasma family 
also includes a number of human pathogens. 
 How will mycoplasma infection affect the cultivated cells? Different mycoplasma 
species will introduce different problems, but in general, mycoplasma infections 
tend to infl uence a number of cellular processes leading to decreased growth rate due 
to inhibition of protein-, DNA- and RNA synthesis. Additionally, they introduce 
changes in gene expression that can be measured as down-regulation of cytokine and 
growth factor secretion, expression of receptors, intracellular signaling molecules, 
ion channels etc. 
 How to avoid contamination by mycoplasmas? A few major guidelines should 
be followed: (1) Strict aseptic techniques are an absolute requirement. Minimize 
talking, and do not practice mouth pipetting when working with cell cultures. Never 
pour medium between bottles and fl asks, and avoid crowding in the laminar fl ow 
hood. Unnecessary equipment in the hood will contribute to turbulence in the lami-
nar airfl ow thus increasing the risk of contaminating fl asks and culture plates. Avoid 
unnecessary traffi c in the vicinity of the sterile hood. (2) All surfaces in laminar fl ow 
hoods, incubators and water baths should be regularly cleaned and disinfected 
(70 % ethanol or isopropanol). (3) Try to avoid unnecessary and excessive use of 
antibiotics. Routine work may preferably be carried out without addition of antibi-
otics to the medium. Use of antibiotics will camoufl age poor aseptic techniques, and 
will contribute to worsen the problem. (4) When new cell lines arrive in the labora-
tory, they should be cultivated separated from other cell cultures, rigorously tested 
and found to be mycoplasma free before being admitted to the cell culture labora-
tory. (5) Establish a routine for frequent testing of the cultures. This is an absolute 
requirement for a responsible scientist. If a culture or cell line is found to be infected, 
cells, culture trays, medium bottles and any other equipment that has been in contact 
with the contaminated culture should be destroyed by autoclaving. 
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 There are several ways to detect mycoplasma infection in cell cultures, but today, 
most people rely on PCR technique which is fast and sensitive. Results can be 
obtained in hours. Several vendors provide kits with specially designed primers that 
allow selective amplifi cation of mycoplasma DNA for PCR-detection with a sensi-
tivity that is close to the direct culture approach. Thus, for routine purposes PCR 
represents the method of choice. 
 Mycoplasma infection of cell lines and particularly clones of valuable primary 
cells can be a disaster. It may be possible to “cure” the cells with antibiotics. 
Typically, antibiotics like ciprofl oxacin, minocyclin or a combination of tiamulin 
and minocyclin, have been demonstrated to be effective. However, toxic effects 
causing cell death is not uncommon. In general, cleaning up a contaminated culture 
should only be considered as an alternative for absolutely irreplaceable cultures 
provided that the source of the contamination has been identifi ed and removed from 
the laboratory. 
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Epithelial Cell Models; General Introduction
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Abstract An extremely important feature of the intestinal epithelium is its function 
as a physical barrier between the environment and our bodies’ internal milieu. At the 
same time it has to allow for uptake of important nutrients. At least four different 
transport mechanisms exist that allow selective uptake and transport of macromole-
cules across the epithelial cell layer, i.e. paracellular transport, passive diffusion of 
molecules from the apical to the basolateral side, vesicle-mediated transcytosis and 
carrier-mediated uptake and diffusion through the epithelial cell layer. Each of these 
transport mechanisms depends on the physicochemical  properties of the compound, 
its ability to interact with the plasma membrane, its molecular weight and size, stabil-
ity and charge distribution. In vivo, parameters not directly associated with the mol-
ecule in question will influence uptake and transepithelial transport. Intestinal 
motility, interactions with other molecules from the diet and the digestive process 
like bile salts and enzymes, and solubility in the mucus layer will affect the absorp-
tion process. Thus, in vitro models for studying absorption through the intestinal 
epithelium have several limitations. Still, they are considered useful model systems 
for such purposes. Similarly, effects of bioactive molecules on the epithelium can be 
studied by measuring barrier function and effects on transport processes.
Keywords Polarized epithelium • barrier function • tight junctions • transepithelial 
transport • paracellular transport • transepithelial electrical resistance (TEER) •
permeability coefficient
The one cell-layer thick intestinal epithelium has two challenging and opposing 
missions. The first is to represent a physical barrier between the contents of the gut 
lumen and the rest of our body. The second is to ascertain efficient absorption of 
essential nutrients from the gut lumen and produce mucus with protective proper-
ties, anti-microbial peptides that affect microbiota composition, and cytokines with 
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both protective and immune-regulatory properties. The small and large intestine are 
differently organized, have different functional properties and exhibit differences 
regarding resistance to injury and disease susceptibility.
The small intestinal epithelium is organized into numerous units of crypts and 
villi. The villi project into the lumen to maximize nutrient breakdown and absorp-
tion. It has been estimated that each crypt domain comprises approximately 250 
cells, and an equivalent number of cells are generated every day. The epithelial cell 
layer includes four major cell types that all derive from adult stem cells located at 
the crypt bottoms: (1) absorptive enterocytes, (2) goblet cells responsible for mucus 
secretion, (3) enteroendocrine cells that secrete important hormones, and (4) Paneth 
cells that secrete antimicrobial peptides. In addition, rare and characteristic M-cells 
(microfold cells) are found in the epithelium overlaying the organized lymphoid 
tissue, and Peyers patches, in the small intestine. For various purposes, the intestinal 
epithelium has a very high turnover rate. In the small intestine, apoptotic absorptive 
enterocytes are continuously sloughed off into the lumen completely renewing the 
epithelium every 5–7 days.
An extremely important feature of the intestinal epithelium is its function as an 
efficient barrier between the environment and our bodies’ internal milieu. Firstly, the 
single layer of columnar epithelial cells acts as a mechanical barrier, and, in addition, 
throughout the whole digestive tract, the epithelium is covered with a highly viscous 
mucus layer that both trap antimicrobial peptides and neutralizing secretory IgA 
antibodies. In addition, the mucus layer reduces the direct contact between the 
luminal microbiota and the epithelial cell layer. The mucus is made up of mucins, 
i.e. proteoglycans, among which MUC2 dominates in the intestine. There are two 
types of mucus organization in the intestine. The small intestine has a single mucus 
layer, while the colon has a two-layered system with an outer and an inner layer 
(reviewed by Johansson et al. 2013). Despite the high load of microbiota in the colon, 
the inner mucus layer is more or less impermeable to the lumenal bacteria.
The epithelial cell layer is selectively permeable to bacterial metabolites and 
digested nutrients allowing regulated transport of soluble molecules through the 
paracellular space between the epithelial cells. Paracellular transport is controlled 
by intercellular tight junction (TJ) structures. Disruption of the intestinal TJ barrier, 
followed by permeation of lumenal noxious molecules, induces a perturbation of 
the mucosal immune system and inflammation, and can act as a trigger for the 
development of intestinal and systemic diseases. Over the past decade, there has 
been increasing recognition of an association between disrupted intestinal barrier 
function and the development of autoimmune and inflammatory diseases. Recently, 
although experiments were carried out in Drosophila, barrier function turned out to 
be a better predictor for life expectancy than nominal age and any other clinical 
parameter tested for Rera et al. (2012).
The protein networks connecting epithelial cells form three adhesive complexes: 
desmosomes, adherens junctions, and tight junctions (see Fig. 9.1). These complexes 
consist of transmembrane proteins that interact extracellularly with adjacent cells and 
intracellularly with adaptor proteins that link to the cytoskeleton. TJ barrier disruption 
and increased paracellular permeability, followed by permeation of lumenal proin-
flammatory molecules, can induce activation of the mucosal immune system, resulting 
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in inflammation and tissue damage. Thus reduced barrier function may have far reach-
ing consequences, not only for gut health but also systemic health.
As mentioned above, the intestinal epithelium is not only a mechanical barrier 
that prevents entry of molecules into circulation. At least four different transport 
mechanisms exist that allow selective uptake and transport of macromolecules 
across the epithelial cell layer (Fig. 9.2). Transport of molecules through the 
 epithelium by paracellular transport is regulated by complex intracellular processes 
finely tuning the permeability of the tight junction complex (1 in Fig. 9.2). Some 
nutrients or microbial metabolites have properties allowing them to diffuse passively 
through the enterocyte plasma membrane and through the cell to be released at the 
basolateral side (2 in Fig. 9.2). Endocytosis (eventually via membrane receptors) 
allows vesicle-mediated uptake, transport and release at the basolateral side in a pro-
cess called transcytosis (3 and 4 in Fig. 9.2). Various membrane associated carrier 
systems may contribute in internalizing luminal molecules allowing further diffusion 
through the cell cytoplasm and release at the basolateral side.
Each of these transport mechanisms depends on the physicochemical properties 
of the compound, its ability to interact with and pass the plasma membrane, its 
molecular weight and size, stability and charge distribution. In vivo parameters not 
directly associated with the molecule in question will influence uptake and transepi-
thelial transport. Typically, intestinal motility, interactions with other molecules 
from the diet and the digestive process like bile salts and enzymes, solubility in the 





Fig. 9.1 The figure shows a 
schematic drawing of 
polarized epithelial cells with 
different types of intercellular 
contacts being essential for 
maintenance of barrier 
function and communication 
between neighboring cells
Paracellular transport Transcellular transport
1 2 3  4Fig. 9.2 The figure 
illustrates the different modes 
of absorption and transport 
through the intestinal 
epithelium: (1) paracellular 
transport, (2) passive 
diffusion of molecules from 
the apical to the basolateral 
side, (3) vesicle-mediated 
transcytosis and (4) 
carrier-mediated uptake and 
diffusion through the 
epithelial cell layer
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small intestine, will affect the absorption process. Thus, in vitro models for studying 
absorption through the intestinal epithelium have many limitations. Still, they are 
considered as useful model systems for such purposes. Similarly, effects of bioac-
tive molecules on the epithelium can be studied by measuring barrier function and 
influences on transport processes.
Epithelial cells from the intestine have been very difficult to cultivate in vitro as 
primary cells. Recent technological developments have allowed the growth of intes-
tinal organoids in 3D culture. This approach is described in Chap. 22 of this book. 
However, 3D organoids are difficult to use for screening purposes. During the last 
four decades the preferred model of the intestinal epithelium has been transformed, 
continuously growing epithelial cell lines like Caco-2, and HT29. Both are described 
in the following chapters. Caco-2 demonstrates many of the properties associated 
with the enterocytes of the small intestine. When grown on filter supports, after 
reaching confluence the Caco-2 cells will spontaneously start to differentiate into a 
polarized cell layer with apical microvilli and intercellular tight junction complexes. 
Caco-2 cells also express many of the enzyme markers and transport systems of 
primary epithelial cells. However, Caco-2 cells do not produce mucins, a property 
present in the HT29 cell line. When HT29 cells were treated with the antimetabolite 
methotrexate, they differentiated into mature goblet cells (Lesuffleur et al. 1990). 
Mucus-secreting HT29-MTX cells have been characterized with regard to tight junc-
tion formation, development of confluent monolayers and production of the mucus 
layer. Confluent HT29-MTX cells develop functional tight junction complexes, but 
not to the same degree as Caco-2 cells. Thus, Caco-2 cells have been more often used 
to study epithelial barrier function and transepithelial transport than HT29. To com-
pensate for lacking mucus production a co-culture system has been developed based 
on Caco-2 and the HT29-MTX cell line. This co-culture system is described in detail 
in Chap. 13. Irrespective of the cell model chosen, e.g. Caco-2, HT29 or Caco-2/
HT29 co-cultures, the main readout parameters are effects on the epithelial barrier 
function, absorption or transepithelial transport of the test compound. The reliability 
of such studies depends on the uniformity and integrity of the confluent and polar-
ized cell monolayer. Monolayer integrity can be verified in different ways, e.g. by 
measuring transepithelial electrical resistance or by measuring the passage of the 
fluorescent dye Lucifer Yellow. Both methods are described below.
9.1  Measurement of Transepithelial Electrical  
Resistance (TEER)
Determination of transepithelial electrical resistance is a simple and convenient 
technique that provides information about the uniformity of the Caco-2 cell layer on 
the filter support, and the integrity of the tight junctions formed between the polar-
ized cells. Thus, TEER measurements are often used to study epithelial barrier 
function. The electrode is placed in the medium in the upper chamber, and resis-
tance is directly measured by a portable voltmeter like the Millicell-ERS Voltmeter 
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(Millipore) or the EVOM2, Epithelial Voltohmmeter for TEER (World Precision 
Instruments Inc., Sarasota, FL) (see Figs. 9.3 and 9.4, respectively).
If the culture is to be continued, the electrode should be sterilized with 70 % 
ethanol. Before use rinse the electrode in electrolyte solution similar to the culture 
medium.
9.1.1  Basic Protocol
Measure the resistance of a blank culture cup with no cells that has been thoroughly 
soaked with an electrolyte solution similar to the culture medium. Move the culture 
tray from the incubator into the laminar air hood and place it on the heating plate 
a b
Fig. 9.3 The figure shows The Millicell ERS-2 unit with an STX chopstick electrode. To the left, 
a drawing of the electrode placed in a tissue culture insert. Note that the shorter tip of the electrode 




Fig. 9.4 The figure shows different variants of the Endohm chambers with culture inserts for 6, 12 
and 24 well plate inserts. To the left is a schematic drawing of the chamber with culture insert. 
The gap between the upper electrode and the cell layer should be adjusted to 1–2 mm
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maintained at 37 °C. Change medium in the culture inserts. Depending on the voltmeter 
and electrode in use, different protocols have to be followed:
 A. With a chopstick probe like the Millicell STX probe, the shorter electrode is 
placed into the upper compartment (apical side) containing the complete culture 
medium, and the other electrode in the lower compartment (basolateral side, 
see Fig. 9.3) containing the same medium. The shorter electrode should not be in 
contact with the cell layer. Ascertain that the electrode is held steady and at a 90° 
angle to the plate insert.
This is perhaps the most common way of measuring TEER. However, the 
readings with the STX electrodes may vary across the cell layer. An alternative 
is to use the Endohm electrode system developed for the EVOM2 Epithelial 
Voltohmmeter (Fig. 9.4) which measures resistance or voltage over the whole 
area covered by the cells. However, this alternative necessitates transfer of the 
inserts from their culture wells to the Endohm chamber for measurement rather 
than using the hand-held STX electrodes. The Endohm chamber and the cap 
each contain a pair of concentric electrodes, a voltage-sensing silver/silver 
chloride pellet in the center plus an annular current electrode. The height of the 
top electrode can be adjusted to fit cell culture inserts from different manufac-
turers. The circular disc electrodes, situated above and beneath the membrane, 
allow a more uniform current density to flow across the membrane than with 
STX electrodes.
 B. Sterilize the Endohm chamber and electrode with 70 % ethanol for 15 min and 
let air dry. Measure the resistance of a blank culture cup with no cells that has 
been thoroughly soaked with an electrolyte solution similar to the culture 
medium. Add culture medium to the chamber and transfer the insert to the 
Endohm chamber and mount the upper electrode. The height of the culture 
medium outside and inside the insert should be at the same level. Measure 
resistance in ohms (Ω).
9.1.2  Calculating Transepithelial Resistance
If using a chopstick electrode like the Millicell STX electrode, resistance should be 
measured several times at different places of a monolayer due to variability in the 
uniformity of the cell layer, and an average value calculated. The average value of 
the blank, or preferably blanks, should then be subtracted from the resistance read-
ing of the sample (Rsample − Rblank = Rcell layer). In a typical example the values can be 
like: 450 Ω − 160 Ω = 290 Ω, meaning that the resistance of the monolayer is 290 Ω. 
Then a correction has to be made for the area covered by the monolayer. Different 
culture inserts may have different shapes, and the filter covers different areas. Also, 
data from experiments carried out in different plate formats, i.e. 6-, 12- or 24-well 
plates must be normalized for comparison. Typically, the area covered by a filter 
insert for a 24-well plate will be 0.4 cm2. Multiply the area covered by the cell 
monolayer with the resistance found in the experiments: 290 Ω × 0.4 cm2 = 116 Ω cm2. 
This value is independent of the area of the membrane used.
T. Lea
101
9.2  Verification of Monolayer Integrity by Lucifer 
Yellow Flux
The permeability of the cell monolayer can also be studied by measuring the passive 
transport of small hydrophilic molecules across the monolayer. Such molecules 
mainly pass the monolayer via the paracellular route, i.e. through the tight junctions 
(TJ), and can be used to get information about the leakiness of the TJs. Lucifer 
Yellow (LY) is an easily detectable marker. It is particularly useful in studies of 
transepithelial transport of a test compound where it can be used to determine the 
highest concentration of the sample that does not disturb the integrity of the cell 
monolayer. The protocol is based on the exposure of the apical side of monolayer to 
a 4.5 μM solution of LY, eventually together with the test substance, prior to collecting 
samples from the basolateral side at different time intervals.
9.2.1  Basic Protocol
Prepare the LY (and test compound) solutions immediately prior to each experiment 
by diluting stocks in buffered Hanks Balanced Salt Solution (HBSS) assay buffer, 
for example HEPES- or MES-buffered HBSS. LY should be used in a final concen-
tration of 4.5 μM. Prepare a working solution of the test compound containing 
4.5 μM LY. Change the medium on the culture inserts 24 h before the experiment. 
Wash the inserts with buffered HBSS solution to remove medium components. Add 
0.5 ml buffered HBSS to the insert compartment (apical) and 1.2 ml to the outside 
compartment (this is for inserts in a 24-well plate). Keep inserts at 37 °C on a heat-
ing plate (temperature is a critical parameter in this type of experiments. Carefully 
add an extra 0.5 ml LY working solution with or without the test substance to the 
apical side of the monolayer and 1.2 ml buffered HBSS in the outside compartment 
(basolateral side). Place the culture trays with inserts on a rotary plate shaker (200–
300 rpm at 37 °C). At different time points, for example 30, 60, 90, 120 min, remove 
a 0.5 ml sample from the basolateral side and replace with 0.5 ml prewarmed buff-
ered HBSS solution. Based on fluorimetric readings (excitation wavelength 428 nm 
and emission wavelength 536 nm), measure the concentration of LY in the test 
samples and make a standard curve. Calculate the apparent permeability coefficient 
(Papp) values of the LY flux through the monolayer. Papp, (unit: cm s−1) is determined 
from the amount of compound transported per time by the equation:
 
P d dapp =( ) ( )Q t AC/ ( /1 0  
where dQ/dt is the steady-state flux (μmol s−1), A is the surface area of the filter (cm2) 
and C0 is the initial concentration in the donor chamber (μM). If the value deviates 
from the normal values obtained, the cell monolayer integrity is disrupted.
In the same way, the effects of a given compound on epithelial LY permeability 
can be tested by including the test compound with the LY solution in the donor com-
partment. Then the calculated permeability coefficient to the test compound (Pappt) 
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can be compared with the apparent permeability value of the control cells, e.g. 
 without added compound (Pappc). Values of Pappt ≤ Pappc suggest that the test compound 
can be regarded as non-toxic and that it can be used to perform studies of effects on 
epithelial barrier function or absorption experiments.
9.3  Summary
The single layer of epithelial cells in the intestine represents the rate-limiting barrier 
for transport and uptake of compounds between the lumen and the body interior. 
Thus, in vitro-differentiated human epithelial cell monolayers allows for testing of 
absorption and active and passive transport processes through the intestinal epithelium. 
Among available epithelial cell lines Caco-2 has been found particularly suitable. In 
food science, problems of interest are not only related to absorption and transport 
issues, but also to biological effects of dietary compounds that may influence other 
aspects of epithelial function, typically tight junction structure, pattern recognition 
receptor activation and intracellular signaling processes that may affect cytokine 
production and subsequently both innate and adaptive immune responses. In 
such situations the lack of mucus production by Caco-2 cells may be considered a 
disadvantage. The HT29-MTX cell line may then represent an alternative, or a co-
culture of Caco-2 and HT29-MTX cells, that also may provide information about 
effects on mucus production, an essential part of the intestinal barrier function. All 
these culture systems are described in the following chapters.
Open Access This chapter is distributed under the terms of the Creative Commons Attribution 
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 Chapter 10 
 Caco-2 Cell Line 
 Tor  Lea 
 Abstract  The human epithelial cell line Caco-2 has been widely used as a model of 
the intestinal epithelial barrier. The Caco-2 cell line is originally derived from a 
colon carcinoma. However, one of its most advantageous properties is its ability to 
spontaneously differentiate into a monolayer of cells with many properties typical 
of absorptive enterocytes with brush border layer as found in the small intestine. 
The Caco-2 cell line is heterogeneous and contains cells with slightly different 
properties. Thus, cultivation conditions can be expected to select for the growth of 
subpopulations of cells resulting in a cellular model system with properties that may 
differ from the original cell line. Accordingly, results obtained under similar experi-
mental conditions in different laboratories may not be directly comparable. Due to 
this, a variety of cloned Caco-2 cell lines has been established, and described in the 
literature. This chapter will however, focus on describing how to handle and culti-
vate the original Caco-2 cell line as obtained from cell culture collections like 
American Type Culture Collection and the European Collection of Cell Cultures. 
Detailed protocols for handling the Caco-2 cells in the laboratory are provided. 
Furthermore, in Chap.  9 general protocols for measuring barrier function by tran-
sepithelial resistance (TEER), and monolayer integrity by Lucifer Yellow fl ux are 
described. Proper testing of the cell monolayer is absolutely critical in exploiting 
Caco-2 cells to measure interaction, uptake and cellular transport of drugs and food 
components. 
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10.1  Origin 
 Back in the 1970s several epithelial cell lines were established from gastrointestinal 
tumors. The purpose was to study mechanisms in cancer development and effects of 
cytotherapy. Partly due to the heterogeneity of primary intestinal epithelial cells 
both in morphology and function, i.e. small bowel enterocytes, goblet cells, entero-
endocrine cells, Paneth cells and M-cells, there was a need for differentiating the 
tumor cells into more specialized cell types. Several of the cell lines could be partly 
differentiated by addition of synthetic or biological factors to the medium. However, 
one of them, Caco-2, was rather unique as it was able to differentiate spontaneously 
when reaching confl uence. Caco-2 ( Ca ncer  co li-2) was established from a human 
colorectal adenocarcinoma by Jorgen Fogh at the Sloan-Kettering Cancer Research 
Institute (Fogh et al.  1977 ). 
10.2  Features and Mechanisms 
 Early studies revealed that differentiated Caco-2 cells expressed several morpho-
logical and functional properties characteristic of small bowel enterocytes. Towards 
confl uence they start to polarize acquiring a characteristic apical brush border with 
microvilli. Tight junctions form between adjacent cells, and they express enzyme 
activities typical of enterocytes, i.e. lactase, aminopeptidase N, sucrase-isomaltase 
and dipeptidylpeptidase IV. However, markers of colonocytes are also present in 
Caco-2 cells (Engle et al.  1998 ) (Table  10.1 ).
 Table 10.1  Properties of Caco-2 cells 
 Growth  Grows in culture as an adherent monolayer of epithelial cells 
 Differentiation  Takes 14–21 days after confl uence under standard culture conditions 
 Cell morphology  Polarized cells with tight junctions and brush border at the apical side 
 Electrical parameters  High electrical resistance 
 Digestive enzymes  Expresses typical digestive enzymes, membrane peptidases and 
disaccharidases of the small intestine (lactase, aminopeptidase N, 
sucrase-isomaltase and dipeptidylpeptidase IV) 
 Active transport  Amino acids, sugars, vitamins, hormones 
 Membrane ionic 
transport 
 Na + /K + ATPase, H + /K + ATPase, Na + /H + exchange, Na + /K + /Cl − 
cotransport, apical Cl − channels 
 Membrane non-ionic 
transporters 
 Permeability glycoprotein (P-gp, multidrug resistance protein), 
multidrug resistance-associated protein, lung cancer-associated 
resistance protein 
 Receptors  Vitamin B12, vitamin D3, EGFR (epidermal growth factor receptor), 
sugar transporters (GLUT1, GLUT2, GLUT3, GLUT5, SGLT1) 
 Cytokine production  IL-6, IL-8, TNFα, TGF-β1, thymic stromal lymphopoietin (TSLP), IL-15 
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10.3  Stability, Consistency and Reproducibility 
 During the 35 years that have passed since its establishment, Caco-2 cells have been 
propagated in a number of laboratories worldwide. Due to different culture condi-
tions and different numbers of passages, Caco-2 cells have often acquired different 
properties. Thus, the expression of differentiation markers typical of enterocytes, 
change with increasing numbers of passages (Artursson et al.  2001 ). Also, param-
eters like transepithelial electric resistance (TEER) and proliferation rate have been 
reported to increase with passage number (Briske Andersson et al.  1997 ). It has also 
been documented that late passage cells may start growing in multilayers, a phe-
nomenon that will affect TEER measurements, and make comparisons with results 
based on early passage cells diffi cult. 
10.4  Relevance to Human In Vivo Situation 
 To closer mimic the steric conditions in the intestine in vivo, Caco-2 cells are 
 cultured on permeable fi lter inserts that can be obtained from a number of vendors 
like Becton Dickenson, Corning, Costar, etc. Cultivation of Caco-2 cells on fi lter 
supports improves their morphological and functional differentiation. It has been 
well documented that polarized Caco-2 monolayers represent a reliable correlate for 
studies on the absorption of drugs and other compounds after oral intake in humans. 
Several studies have compared Caco-2 permeability coeffi cients with absorption 
data in humans and found high correlation, particularly if the compounds are trans-
ported by passive paracellular transport mechanisms (Artursson and Karlsson  1991 ; 
Cheng et al.  2008 ; Sun et al.  2008 ). 
 Although Caco-2 cells have been found to express a large number of enzymes 
and transporter proteins present in normal human intestinal epithelium, recent stud-
ies suggest that there are variations between gene expression profi les of transformed 
epithelial cell lines like Caco-2, HT29 and normal human intestinal epithelium 
(Bourgine et al.  2011 ). Furthermore, differences are not only found between the cell 
lines and normal epithelium, principle component analysis of gene expression pro-
fi les reveals clear differences between the Caco-2 and HT29 cell lines, also 
(Bourgine et al.  2011 ). This is not unexpected. Normal intestinal epithelium is made 
up of several different cell types, and differences in gene expression profi les are not 
only observed in the mucosal epithelium along the whole gastrointestinal tract, but 
also along the crypt-villus axis (Anderle et al.  2005 ). Obviously, data analysis of 
experiments in the Caco-2 cell model cannot be directly compared with the in vivo 
situation. Still, intestinal epithelial cell models like the Caco-2 model, holds many 
advantages due to its simplicity and reproducibility allowing inter-laboratory com-
parison of results. Furthermore, pursuing an effect of a food bioactive in a cell line 
model opens for studies of molecular mechanisms which may be more diffi cult to 
address in vivo. 
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10.5  General Protocols for Caco-2 Cells 
10.5.1  General Maintenance 
 Caco-2 cells are routinely maintained in RPMI 1640 (alternatively Dulbecco’s 
Modifi ed Eagle Medium, DMEM) with 10 % fetal bovine serum and the following 
additions: 1 % non-essential amino acids (NEAA), 50 μM thioglycerol, 25 mg/ml 
gentamycin (complete medium). The cells should be kept at 37 °C in a humidifi ed 
atmosphere containing 5 % CO 2 . For propagation in culture fl asks, Caco-2 cells are 
seeded in a concentration of 10 5 cells/cm 2 . Medium should be changed every 3 days. 
At 80 % confl uence, typically after 4–5 days, the cells are split 1:10 before further 
cultivation. Trypsinize Caco-2 cells by fi rst rinsing with PBS (15 ml pr. 75 cm 2 fl ask). 
Add 5 ml trypsin/EDTA solution, rinse the cells and pour off most of the trypsin/
EDTA. Only 1 ml trypsin/EDTA solution is necessary to wet the whole cell layer in 
a 75 cm 2 fl ask. Incubate the fl ask at 37 °C for 6–15 min. The incubation with trypsin 
should be as short as possible as this process will affect cell viability. As soon as the 
cells are detached, stop trypsinization by adding complete medium containing fetal 
calf serum. Transfer the cells to a test tube and let cell aggregates and debris 
 sediment. Transfer the supernatant to a new test tube, and take an aliquot to count the 
cells. Check cell viability. The content of dead cells should not exceed 5 %. 
10.5.2  Protocol for Polarizing Caco-2 Cells 
in Tissue Culture Inserts 
 Caco-2 cells can be cultured on a fi lter support (Fig.  10.1 ). The fi lter support can 
be made from polycarbonate, polyester or polyethylene terephthalate. Particularly 
the latter is claimed to be inert with low non-specifi c protein-binding properties. 
The fi lter supports can be transparent or translucent. If you want to follow the 
differentiation process in the inverted microscope and prepare the differentiated 
cells for scanning electron microscopy, transparent fi lters are preferred. Furthermore, 
 Fig. 10.1  The fi gure is a drawing of the differentiation of Caco-2 cells on a tissue culture insert. 
After the Caco-2 cells reach confl uence ( middle ) they start to differentiate spontaneously, and after 
a total culture period of around 21 days they will appear with dense microvilli on the apical side 




the fi lters can come with different pore sizes ranging from 0.4 to 8 μm. To study 
parameters like transcellular transport and permeability, 0.4 μm fi lters are recom-
mended. Insert with larger pore sizes can be exploited if direct cell–cell interactions 
are being scrutinized, i.e. in co-cultures of Caco-2 cells with stromal cells or adherent 
immune cells. 
 Depending on inherent properties of the particular Caco-2 cells available, it may be 
necessary to coat the fi lters with protein to prevent the cells from detaching in the fi nal 
stages of the differentiation process. Some vendors offer ready-coated fi lters. However, 
effi cient coating of the fi lters can be carried out by covering them with collagen solu-
tion Type I from Sigma (1/100 in water). Incubate at room temperature for 3–4 h. 
Remove the collagen solution and leave the fi lter inserts to dry overnight. 
 Place the necessary number of fi lter inserts in a 12 well plate. Dilute the cell 
suspension to a concentration of 1 × 10 6 /ml. Seed 0.5 ml of the cell suspension to 
each insert corresponding to seeding density of 500,000 cells pr. 12 mm fi lter insert. 
 This seeding density corresponds to 4 × 10 5 cells/cm 2 . Add 1.5 ml medium to the 
basolateral compartment in a 12 well plate, and 0.5 ml to the apical compartment. 
Depending on experience it is recommended to start with setting up fi lters in quadru-
plicate, that is later reduced to triplicate or even duplicate. Medium should be 
changed on days 4, 8, 12, 16 and 18. Cells will be fully polarized by day 21. See SEM 
picture in Fig.  10.2 . 
 The differentiation of Caco-2 cells seem to follow a time schedule in the  expression 
of morphological and biochemical properties of the absorptive enterocytes. Due to 
the cellular heterogeneity of the cell line the differentiation process occurs in a 
mosaic pattern, with some areas expressing fully differentiated cells with microvilli 
after 12–14 days while other areas contain less differentiated cells. According to the 
protocol above, the Caco-2 monolayer will be homogenously differentiated after 
18–21 days. When polarized and confl uent, the cell layer forms a continuous barrier 
between the upper and lower compartments (apical/mucosal and  basolateral/serosal). 
The compound of interest, suspended in a physiological fluid, typically PBS, 
 Fig. 10.2  SEM picture of 
polarized Caco-2 cells after 
21 days of culture 
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is added to the upper compartment, and the increase in concentration in the lower 
compartment is measured. In this way the permeability, absorption and transepithe-
lial transport of any nutritional compound can be studied. Special emphasis should be 
paid to compounds or drugs that are poorly soluble in physiological buffers. If stock 
solutions of the compound of interest has to be made in organic solvents like ethanol 
or dimethylsulfoxide (DMSO), be aware that organic solvents may affect the cell 
layer in various ways. Always include a fi lter/fi lters for solvent control. In general, 
avoid using higher solvent concentrations than 1 % (v/v) or else. 
10.5.3  Troubleshooting Guide for Transport Experiments 
Across Caco-2 Monolayers 
 Problem  Possible explanation  Try the following 
 Very high P app  Leaky cell monolayers.  Validate integrity of monolayers (see protocol 
with Lucifer Yellow fl ux in Chap.  9 ). 
 High expression level of 
transporter protein for 
active transport process 
 Protein expression levels may vary with passage 
number and culturing conditions. Use the same 
batch of cells with similar passage number for 
consistent results. 
 Very low P app  Test compound degradation  Check stability of test compound under 
experimental conditions 
 Poor solubility  Verify that the test compound is fully dissolved. 
 Membrane transporter may 
have become saturated 
 Verify the concentration of the test substance. 
Titrate and use lower concentration. 
 Poor mass 
balance 
 High degradation  Stability of test compound (see above) 
 High cellular uptake  Analyze amount of compound in the cell 
monolayer by lysing the cells and extracting the 
compound for quantifi cation. 
 Adsorption of compound to 
the fi lter insert or culture 
vessel 
 Monitor compound concentration before and 
after transfer to the fi lter insert system. 
 High standard 
deviation 
 Damaged cell monolayers  It is vitally important to avoid damaging the 
monolayers during sampling 
10.6  Applications 
 Cell culture assays has offered exciting new possibilities in many scientifi c disciplines. 
If properly used the Caco-2 cell line can provide information about the biological and 
biochemical basis of barrier properties of the intestinal mucosa, but may also unravel 
valuable information about the absorption of drugs and dietary components relevant 
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for both the pharmaceutical and the food industry. Thus, the Caco-2 cell line has 
been exploited for a range of applications, among them the following:
 To study mechanisms and effects of microbiota, microbiota metabolites, food 
digesta and bioactive food components on the barrier function of the intestinal 
epithelium (Shimizu  2010 ). 
 To elucidate pathways for the transport of drugs or food components (e.g. paracel-
lular versus transcellular or passive versus carrier-mediated mechanisms) across 
the intestinal epithelium (Knipp et al.  1997 ). 
 In studying potential toxic effects of drug candidates or food metabolites in the 
intestinal mucosa (Chang et al.  1993 ). 
 To determine how components of a formulation (e.g. adjuvants or food matrices) 
may infl uence intestinal epithelial transport of bioactive molecules (Nerurkar 
et al.  1996 ). 
 In the characterization of the optimal physiochemical properties of a bioactive mol-
ecule for passive diffusion via the paracellular or transcellular pathways across 
the intestinal epithelium (Burton et al.  1996 ). 
 To study molecular details and signifi cance of effl ux systems (e.g. multi-drug 
resistance proteins like the P-glycoprotein) in the intestinal epithelium (Burton 
et al.  1997 ). 
 To study and determine interactions between bioactive molecules during transport 
across the intestinal epithelium (Wacher et al.  1996 ). 
10.7  Advantages and Disadvantages 
 The Caco-2 cells spontaneously differentiate to express morphological (polarized 
columnar epithelium) and functional characteristics of mature small intestinal 
enterocytes. The polarized Caco-2 cell layer shows 4 times higher TEER values 
compared to HT29 monolayers, i.e. more similar to the in vivo situation. Caco-2 
cells express most receptors, transporters and drug metabolizing enzymes like ami-
nopeptidase, esterase and sulfatase found in normal epithelium. However, no P-450 
metabolizing enzyme activity has been reported. 
 In comparison with normal intestinal epithelium the Caco-2 cell model have 
 several limitations. First of all that the normal epithelium contains more than one 
cell type, not only enterocytes. Secondly, when using the Caco-2 cell model, no 
mucus and unstirred water layer is present. Furthermore, a number of non-cellular 
parameters will affect the absorption of a certain compound in cells. Thus, transport 
of lipophilic molecules is strongly infl uenced by the presence of bile acids and 
phospholipids, and also compound solubility in the mucus layer as well as the 
unstirred water layer close to the epithelium, will strongly infl uence uptake in vivo. 
Although Caco-2 cells in general provide a powerful tool for studying properties of 
the intestinal epithelium, one has to be cautious in extrapolating data from such 
in vitro models to the in vivo situation. 
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10.8  Conclusion 
 For Caco-2 cell monolayer systems to provide reliable information several critical 
parameters have to be controlled. First of all, it is imperative that the integrity of the 
monolayers is validated prior to transport studies. The protocol based on TEER 
measurements of Lucifer Yellow fl ux (Chap.  9 ) are crucial for confi rming the quality 
and integrity of the polarized epithelial cell monolayer. Also, if the compound being 
tested is a candidate substrate for a specifi c transporter, the monolayer must be 
checked to verify the expression and activity of that particular transporter. The pres-
ence of the transporter at the mRNA level can be verifi ed by PCR, at the protein 
level by immunoblotting and functionally by employing inhibitors to and known 
ligands to demonstrate the presence of a functional transporter. It is important to 
recognize that protein expression may be infl uenced by a variety of parameters, 
the most important being culture conditions, passage number or age of the cells in 
culture. Thus, a positive control should always be included demonstrating the pres-
ence of a functional transporter protein or protein complex. It is also important that 
the effect of contamination of the cell culture is eliminated. Although short time 
protocols for obtaining a polarized Caco-2 cell monolayer has been published, 
the standard and most reliable procedure requires 21 days of culture to obtain a 
polarized monolayer with full expression of tight junctions and other intercellular 
contacts. During a 3 weeks culture period and with antibiotics in the medium, a 
subclinical infection not identifi able even by light microscopy, may bias or obscure 
results completely. Thus, it is of imperative importance.
Open Access This chapter is distributed under the terms of the Creative Commons Attribution 
Noncommercial License, which permits any noncommercial use, distribution, and reproduction in 
any medium, provided the original author(s) and source are credited. 
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 Chapter 11 
 HT29 Cell Line 
 Daniel  Martínez-Maqueda ,  Beatriz  Miralles , and  Isidra  Recio 
 Abstract  The human colon adenocarcinoma cell line HT29, is not only used to 
study the biology of human colon cancers, but it is receiving special interest in 
 studies focused on food digestion and bioavailability due to the ability to express 
characteristics of mature intestinal cells. In the differentiated phenotype, they are 
able to form a monolayer with tight junctions between cells and a typical apical 
brush border. In addition, these differentiated cells express brush-border- associated 
hydrolases typical of the small intestine although the enzymatic activity is lower 
than that found in vivo. Although they represent a valuable model due to their simi-
larities with enterocytes of the small intestine, their limitations and the relevance to 
the in vivo situation are also considered in this chapter. The application of this cell 
line to transport studies of drugs and food compounds is illustrated, especially 
when the effect of the mucus layer is considered or used as co-culture in combina-
tion with Caco-2 cells. They have also been frequently used to study the intestinal 
immune response to bacterial infection, and microorganism survival, adhesion or 
invasion. Finally, the use of these cells to evaluate the effect of several food com-
pounds and mucin secretion is summarized. 
 Keywords  HT29 •  Cell differentiation •  Transport studies •  Intestinal cell 
11.1  Origin 
 The human colon adenocarcinoma cell line HT29 was isolated from a primary tumor 
of a 44 years old Caucasian female in 1964 by Fogh and Trempe ( 1975 ). Since then, 
many cell lines have been derived from human colon cancers. Initially, this cell line 
was used to study different aspects of the biology of human cancers. However, these 
cells have attracted attention due to the fact they were able to express characteristics 
of mature intestinal cells, such as enterocytes or mucus producing cells. 
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11.2  Features and Mechanisms 
 These cells have shown a high rate of glucose consumption and therefore, they 
require high glucose concentration in the medium. Under these standard growth 
conditions, i.e., in the presence of 25 mM glucose and 10 % serum, these cells 
display an undifferentiated phenotype; they grow as a multilayer of unpolarised 
undifferentiated cells, and functionally they do not express any typical characteris-
tics of intestinal epithelial cells, and they express low amounts of hydrolases. Since 
the discovery that the replacement of glucose by galactose in the culture medium 
induced a reversible enterocytic differentiation (Pinto et al.  1982 ), HT29 cells have 
become a unique model for studying the molecular mechanisms of intestinal cell 
differentiation. When these cells are grown under appropriate culture conditions or 
after treatment with different inducers, like butyrate (Augeron and Laboisse  1984 ) 
or acid (Fitzgerald et al.  1997 ), they can be modulated to express different pathways 
of enterocyte differentiation. For this reason, HT29 is considered a pluripotent 
intestinal cell line which can be used for the study of the structural and molecular 
events involved in cell differentiation. 
 The polarised phenotype is characterised morphologically, physiologically and by 
biochemical markers. The differentiation is growth-related, starting after confl uence 
(after 15 days of growth), and the cells form a monolayer with tight junctions between 
cells and a typical apical brush border. The brush border of these differentiated cells 
contains proteins which are normally present in the intestinal microvilli, such as villin. 
In addition, these differentiated cells express brush border-associated hydrolases typi-
cal for the small intestine, have brush border microvilli although the enzyme activities 
is much lower than that of the normal intestine, and do not express lactase. The maxi-
mum enzyme activities, such as sucrose-isomaltase, aminopeptidase N, dipeptidyl-
peptidase-IV and alkaline phosphatase, are reached after 30 days in culture. Under 
these conditions, p.e. growth in glucose-free medium, cell differentiation is very 
similar to that observed in Caco-2 cells but in HT29 the time course of the differentia-
tion process is longer (30 days vs. 15–20 days in Caco-2); the levels of enzymatic 
activities are lower than in Caco-2; lactase is absent; and only 40–50 % of HT29 cells 
express sucrose-isomaltase (Zweibaum  1986 ; Zweibaum et al.  2011 ). However, one 
of the main differences between this cell line and Caco-2 is that HT29 cells can 
produce mucin at a relatively high level (Huet et al.  1987 ; Maoret et al.  1989 ). Stepwise 
adaptation of exponentially growing HT29 cells to increasing concentrations of meth-
otrexate (MTX) (up to 10 −5 mol) resulted in their transformation into mucus-secreting 
differentiated cells (Lesuffl eur et al.  1990 ). As occurs under other metabolic stress 
conditions like glucose- deprivation, after a high rate of mortality, the resistance to 
MTX is associated with the cells possessing this stable differentiated mucus-secreting 
phenotype. Interestingly, cells adapted to low-dose MTX consist of a double popula-
tion of columnar absorptive and mucus-secreting cells and, at a higher dose, cells are 
almost exclusively of mucus-secreting phenotype. This mucus-secreting phenotype 
has been used in the transport studies of different compounds, to study the mucus- 
inducing properties of different food compounds or in studies regarding microorganisms 
adhesion and survival (see Sect.  11.6 ). 
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 The factors secreted from cells in culture medium include metabolites, cytokines, 
growth factors, etc., which are known to promote cell survival. Recently, the soluble 
factors secreted by HT29 and other tumor cells in basal conditions and after gamma 
radiation have been reported. HT29 secreted pro-infl ammatory cytokines, such as, 
tumor necrosis factor (TNF) α and interleukins (IL) 1β and IL 6; growth factors such 
as platelet-derived growth factor AA and transforming growth factors (TGF) α and 
β; chemokines such as fractalkine, IL-8, monocyte chemoattractant protein-1 and 
interferon-γ-induced protein 10; pro-angiogenic factors such as IL-15 and vascular 
endothelial growth factor; and immune-modulatory cytokines such as granulocyte 
colony-stimulating factor, granulocyte macrophage colony-stimulating factor and 
IL-3. It was suggested, based on previous reports on biopsy samples, that in vivo, 
a similar cytokine secretion profi le can be observed (Desai et al.  2013 ). 
11.3  Stability, Consistency and Reproducibility 
 Many tumor-derived cells have been reported to show lack of culture stability and 
reproducibility based on the existence of irregular growth and non-specifi c genetic 
alterations (Lipps et al.  2013 ). To minimize these handicaps, the establishment of 
large cell banks is recommended to allow disposing cells at early and similar 
 passages. On the contrary, the consistency of the assumed cell properties should be 
verifi ed for highly different passages. For instance, Chen et al. ( 1987 ) proved that 
karyotypes were comparable for HT29 cells along more than 100 passages, which 
represents valuable data in the assessment of the cell line evolution. Likewise, derived 
cells adapted by specifi c treatments must be evaluated under different culture condi-
tions as time and presence/absence of responsible agent(s). Lesuffl eur et al. ( 1990 ) 
tested the irreversibility of the differentiation of MTX adapted cells by the compari-
son of the growth curve for several passages. No signifi cant differences were observed 
for both 10 −7 and 10 −6 M MTX-derived cell lines between cells cultured with drug-
enriched media and drug-free media. The stability of other differentiation character-
istics was also confi rmed for MTX-free cells compared with equivalent MTX-treated 
cells as well as themselves along several passages before. 
11.4  Relevance to Human In Vivo Situation 
 As in other cancer-derived cell line models, signifi cant differences in the gene 
expression of transporters and metabolic enzymes from the normal human intestinal 
cells can affect the suitability of the model in refl ecting the in vivo permeability 
(Langerholc et al.  2011 ). Similar protein expression was found in HT29 cells and the 
corresponding intestinal scrapings, of which some appear to be characteristic to 
human intestinal epithelium in vivo (Lenaerts et al.  2007 ). Nevertheless, several pro-
teins, including transporters, were over- or underexpressed. Bourgine et al. ( 2012 ) 
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compared the expression of 377 genes in HT29 and other intestinal cell lines that 
are used as in vitro models of the epithelium with the corresponding tissue biopsy. 
The results showed that differentiated HT29 cells and human colonic tissues do not 
appear to be signifi cantly different. 
 The use of HT29 as in vitro model of intestinal cells has some advantages and 
limitations that have been summarized by Zweibaum et al. ( 2011 ). This cell line in 
its differentiated phenotype is similar to small intestine enterocytes with respect 
their structure, and the presence of brush border-associated hydrolases and the time 
course of the differentiation process which is also comparable to that found in the 
small intestine. In addition, the amount of villin expressed in differentiated HT29 
cells is close to the value observed for normal freshly prepared colonocytes. 
However, these cells also have some limitations, because (1) they are malignant 
cells with a high rate of glucose consumption and an impairment of the metabolism 
of glucose; (2) although they mimic some characteristics of small intestine entero-
cytes, they are colonic cells; (3) they cannot be compared with enterocytes from 
normal colon since they express brush border-associated hydrolases; (4) but they 
cannot be compared with absorptive enterocytes because not all hydrolases are pres-
ent (e.g. lactase and maltase-glucoamylase are absent) and the ion transport proper-
ties are different. It has been postulated that these cells are close to human fetal 
colonic cells because of the type of hydrolases present and the intracellular concen-
tration of glycogen accumulated (Hekmati et al.  1990 ). 
 Regarding the expression of cell surface receptors, it has been reported that dif-
ferentiated HT29 cells express several receptors for peptides, such as vasoactive 
intestinal peptide, or insulin but also for non-peptide substances. In general, the 
receptors found in this cell line have their equivalent in normal intestinal cells, 
except for the receptor to neurotensin, which has been characterised in HT29 cells 
(Kitabgi et al.  1980 ), but it is not detectable in normal human colonic epithelium. 
On the contrary, receptors for peptide YY or neuropeptide Y which are well charac-
terised in normal small intestine epithelial cells have not been reported in HT29. It 
has to be taken into account that these receptors are located at the small intestine and 
that HT29 are of colonic origin. It is also remarkable that when using cell cultures, 
the expression of a particular receptor may depend on the degree of cell differentia-
tion and the growing conditions. Recently, the presence of opioid, serotonin, mus-
carinic, PPARβ/δ receptors has been reported in this cell line (Zoghbi et al.  2006 ; 
Ataee et al.  2010 ; Belo et al.  2011 ; Foreman et al.  2011 ). Information on the studies 
on receptors carried out in this cell line can be found at Zweibaum et al. ( 2011 ). 
11.5  General Protocol for HT29-MTX Cells 
11.5.1  Cell Maintenance Protocol 
 HT29-MTX cells are cultured using DMEM medium with high glucose (25 mM), 
without sodium pyruvate, but with GlutaMAX ® (Gibco, Paisley, UK), 10 % of heat- 
inactivated fetal bovine serum and penicillin/streptomycin (100 units/mL of penicillin 
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and 100 μg/mL of streptomycin) in a humidifi ed incubator with 5 % CO 2 atmosphere 
at 37 °C. Culture medium is changed every 2 days from the second day after seed-
ing, and cells are harvested in the logarithmic phase of growth after reaching 
80–90 % confl uency by 0.05 % trypsin/EDTA. Cells are seeded at 2.4 × 10 4 cells 
per cm 2 in 75 cm 2 culture fl asks. In these conditions, cells would be confl uent at 
day 6–7 of culture. 
11.5.2  Experimental Protocol for Test Compounds 
11.5.2.1  Study of the Mucin-Stimulating Activity 
 Cells are seeded in 12-well plates at a density of 5 × 10 5 cells per well and experi-
ments are performed 21 days after confl uency to ensure that the proportion of cells 
differentiated that express mucus reaches their maximum (Lesuffl eur et al.  1993 ). 
Culture media is changed every 2 days until 24 h prior to the experiment, when 
culture media is replaced by serum- and antibiotic-free media (DMEM GlutaMAX ® ) 
to minimize any extraneous interference. On the day of the experiment, cells are 
rinsed twice with PBS and treated with tested compounds dissolved in serum- and 
antibiotic-free medium for different incubation times at 37 °C in a 5 % CO 2 humidi-
fi ed atmosphere. After treatment, cell supernatants are collected for the determina-
tion of mucins, and adhered cells are lysed to obtain the total RNA according to the 
RNA isolation kit instructions. Mucin secretion is determined in cell supernatants 
by applying an enzyme-linked lectin assay, based on the strong binding between 
wheat germ agglutinin and goblet cell mucins (Campo et al.  1988 ). Standard curves 
prepared with porcine mucin are employed, and mucin gene expression is evaluated 
after isolating and reverse-transcribing the RNA from cell lysates. A quantitative 
PCR assay is performed with specifi c primers for MUC5AC, the HT29-MTX major 
secreted mucin gene (Martínez-Maqueda et al.  2013a ). Cells are employed between 
passages 12 and 24 without remarkable basal differences. 
11.5.2.2  Evaluation of Transepithelial Absorption by Transwell ® Inserts 
 Transwell ® inserts provides a reliable model once the integrity of the cell monolayer 
is verifi ed. HT29-MTX cells are seeded in 12-well Transwell ® inserts at a density of 
5 × 10 5 cells per well and medium is changed every 2 days. Cells are cultured for at 
least 21 days to ensure a suitable cell differentiation. Prior to the experiment, the 
integrity of the cell monolayers is verifi ed by measuring the transepithelial electrical 
resistance (TEER) with a cell electrical resistance system. Only monolayers with 
initial TEER values above 200 Ω cm −2 must be used. On the day of the experiment, 
cells are rinsed with Hanks’ balanced salt solution (HBSS) and test compounds are 
dissolved in culture medium, which are added to the apical side of the cell layer 
(HBSS to the basolateral chamber). According to Foltz et al. ( 2008 ), cells are main-
tained at 37 °C in a 5 % CO 2 humidifi ed atmosphere. Transport assay is initiated by 
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adding 0.5 mL of transport medium, containing compounds of interest to the apical 
compartment. Samples (100 μL) are taken from the basolateral compartment and 
replaced by transport medium. After the end of the experiment, TEER measurement 
is repeated and permeability values are only calculated from experiments in which 
the second TEER value is at least 75 % of the initial TEER value. Fluorescein fl ux 
can be measured as a second parameter of monolayer integrity. Monolayers are 
deemed intact when TEER values were above 200 Ω cm −2 , and the permeability 
coeffi cients of the paracellular transport marker fl uorescein is less than 
1 × 10 −6 cm s −1 . Apical and basolateral solutions can be collected and analyzed by 
RP-HPLC–MS/MS to evaluate the permeability, including permeability coeffi -
cients as indicated by Quirós et al. ( 2008 ) and Contreras et al. ( 2012 ), and degradation 
of tested compounds. 
11.6  Experimental Read Out 
11.6.1  Functionality Studies 
 HT29 cells have been widely employed to assess the potential anticancer effect of 
different food compounds, and their gastrointestinal digests, on the basis of the 
carcinoma origin of this cell line. An illustrative example is found in the study of the 
antiproliferative activity of the in vitro gastrointestinal digest of sea cucumber wall 
(Pérez-Vega et al.  2013 ). Another representative study is found in the assessment of 
the cytotoxic activity of different extracts from “Racimo” tomato variety and simu-
lated digests against HT29 cell growth, including also the evaluation of the selectiv-
ity of the toxic effect against cancer cells (Guil-Guerrero et al.  2011 ). Other activities 
have been widely studied on HT29 cells or derived lines, such as immunomodula-
tory, antioxidant or barrier protective properties. For instance, milk and soy fer-
ments with different strains of lactic acid bacteria (LAB) were evaluated on human 
intestinal epithelial cells, including HT29 cells, to test their immunomodulatory 
activity (Wagar et al.  2009 ). The study was carried out on cells treated with TNF-α 
and the production of IL-8 was evaluated in the cell supernatant by a commercial 
enzyme-linked immunosorbent assay. Another investigation focused on the study of 
the immunomodulatory activity of cereal β-glucan preparations on both HT29 and 
Caco-2 cells (Rieder et al.  2011 ). In vitro data of antioxidative activity for food 
compounds is often presented together with genotoxic tests performed with HT29 
cells. Among others, the comet assay has become one of the standard methods for 
assessing DNA integrity (Collins  2004 ). Ferguson et al. ( 2005 ) demonstrated both 
in vitro antioxidant activity and antigenotoxic effect in HT29 cells by using a comet 
assay for two hydroxycinnamic acids with an important percentage in certain plant 
foods, as spinach or cereals. Interestingly, the protection of resveratrol and querce-
tin against exogenous pro-oxidative damage was determined in HT29 cells with 
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induced oxidative stress by addition of fatty acid hydroperoxides (Kaindl et al. 
 2008 ). HT29-derived cell lines constitute a valuable tool related to the strengthening 
of the intestinal mucus barrier to study the mucin-stimulating activity of food com-
pounds. The protocol described above has been recently applied to asses the mucin-
stimulating effect of certain milk protein hydrolysates and derived peptides 
(Martínez-Maqueda et al.  2012 ,  2013a ,  b ). HT29-MTX cells and an analogous 
experimental design was also implemented to evaluate the regulation of the mucin 
production by the β-casomorphin-7, a μ-opioid peptide derived from bovine milk 
(Zoghbi et al.  2006 ), or by a yoghurt peptide pool (Plaisancié et al.  2013 ). Other 
HT29 derived cell lines have been employed due to their capability to form a mucus-
layer, e.g. HT29/B6 cells differentiated in a glucose-free culture (Kreusel et al. 
 1991 ). Hering et al. ( 2011 ) evaluated the expression of tight junction proteins and 
the related intestinal barrier-protection in HT29/B6 cells, under the effect of TGF-β, 
a whey protein component. Likewise, monoterpene  d -limonene, naturally occurring 
in the rind of citrus fruit, showed a signifi cant increase on the transepithelial resis-
tance in HT29/B6 cells (D’Alessio et al.  2013 ). 
11.6.2  Transport Studies 
 The HT29 cell line is not a particularly suitable model for transport studies, but it 
has been used for comparison with other lines or as co-culture. Monolayers of 
HT29-MTX cells have been previously used as a permeability model, for example 
for studying the effect of mucus on the permeation of drugs. However, in most 
cases, transport studies and permeation enhancement studies are performed with 
co-cultures of Caco-2 and HT29-MTX as an accurate model to take into account the 
mucus layer (Yuan et al.  2013 ). 
 It has been reported that casein phosphopeptides (CPPs) form aggregated 
 complexes with calcium phosphate and induce Ca 2+ infl ux into HT29 cells that have 
been shown to be differentiated in culture. Taking into account that upon differentia-
tion HT29 cells elicit a transient rise in Ca 2+ , this model is being used to explore the 
molecular mechanism by which CPPs elicit their biological activity (Gravaghi et al. 
 2007 ). Similarly, the HT29 cell line is a useful model to study key players involved 
in intestinal iron absorption because it endogenously expresses a number of genes 
known to be involved in iron transport in the intestine. Using this model, it has been 
suggested that the hemochromatosis protein HFE can have multiple roles in main-
taining iron homeostasis depending on the availability of other proteins (Davies and 
Enns  2004 ). 
 HT29 cells have also been applied to the study of the receptor and internalization 
transporter of toxins. As for the  Clostridium botulinum C16S toxin, it was reported 
that the receptor on the HT29 cell surface targeted is an O-linked sugar chain of 
mucin-like glycoproteins (Nishikawa et al.  2004 ). 
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11.6.3  Microorganisms Survival, Adhesion or Invasion 
 The HT29 cells represent a well characterised model to study the intestinal epithelial 
response to bacterial infection. This cell line expresses the features of enterocytes 
and is useful for attachment and mechanistic studies. Mucin secretion by these cells 
is of importance because the mucus layer has been suggested to play a role in modu-
lating the adhesion of live organisms to the epithelial surface as well as bacterial 
components such as LPS (Otte and Podolsky  2004 ). 
 The mechanisms underlying enteropathogenesis are one of the most important 
applications of this cell model. Studies on attachment, adherence and/or internaliza-
tion of several pathogens such as  Entamoeba histolytica ,  Salmonella enteriditis , 
 Escherichia coli ,  Clostridium diffi cile ,  Campylobacter jejuni ,  Clostridium butyri-
cum or  Shigella disenteriae , in some cases with food components intended to limit 
their access to cells have been reported. For example, in the study of Nickerson and 
McDonald ( 2012 ) it was shown that exposure to maltodextrin induced type I pilus 
expression, which was required for enhanced biofi lm formation by  E. coli in Crohn’s 
disease patients. Comparison of the results with those found in the HT29 cell model 
was used to suggest a novel mechanism of epithelial cell adhesion that can contribute 
to disease susceptibility. 
 Studies intended to evaluate the benefi cial role of probiotics in the human host 
are another application of the cell model. For the study of probiotic adhesion, the 
HT29 cell line and some HT29-derived lines have been used to study the molecular 
mechanisms underpinning host-microbe interactions or the enteric adaptation fea-
tures of  Bifi dobacterium strains, sometimes in the presence of food components as 
milk oligosaccharides (Kavanaugh et al.  2013 ). Probiotic delivery systems by coat-
ing biopolymers are also evaluated by using colonic epithelial models that are 
intended to mimic the colonic mucosa. The intestinal mucus offers numerous eco-
logical advantages for both resident microbiotic bacteria and some pathogenic 
 bacteria present within the lumen and in the intestinal epithelium. It can provide 
nutrients for bacterial growth, thus promoting intestinal colonization by the adher-
ing bacteria which have the ability to survive and multiply in the outer regions of 
the mucus layer (Liévin-Le Moal and Servin  2006 ). 
 In response to enteropathogens infection, the intestinal epithelium releases the 
chemokine IL-8 and other pro-infl ammatory molecules that provoke an acute 
infl ammatory response. For the protection against enteropathogens infections, the 
possibility of using food supplements containing probiotic bacteria is increasingly 
considered. Selected strains have shown to be able to survive under gastrointestinal 
challenges, while they were shown to adhere to human epithelial intestinal cell 
monolayers (Caco-2 and HT29), thereby preventing the establishment of enteric 
pathogens as  E. coli and  Cronobacter sakazakii (Serafi ni et al.  2013 ). Furthermore, 
many probiotic strains have been assessed for their immunomodulatory activity on 
IL-8 production by HT29 cells, protecting them from an acute infl ammatory 
response (Candela et al.  2008 ). 
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11.7  Conclusions 
 Despite several limitations of the human colon carcinoma cell lines, they are valuable 
tools to study several aspects related with food digestion and bioavailability of food 
compounds. HT29 cell line and some derived cell lines thereof are of interest to 
study food component absorption, especially when used in co-culture with other 
epithelial cell lines. Although the quantitative results can be questioned in comparison 
with those obtained in vivo, these in vitro models allow to identify modifi cations 
that the food compound may suffer during absorption and these results will help to 
perform further in vivo studies in animal or humans. The use of these human cells 
also offers a valuable opportunity to perform studies when a variance in response 
between different species is observed. For instance, the mucus secreting phenotype 
of HT29 cell line has proved to be a valuable model to screen food compounds or 
bacteria which may infl uence mucus secreting properties in the gut. Finally, it has 
provided results about the mechanisms by which microbes adhere, invade and 
signal to the host, as well as, to examine the mammalian cell response. Altogether, 
they are a complementary tool to the in vivo and ex vivo strategies to study food 
digestion and the effect of food components on the gut. 
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 Chapter 12 
 The IPEC-J2 Cell Line 
 Hans  Vergauwen 
 Abstract  IPEC-J2 cells are intestinal porcine enterocytes isolated from the  jejunum 
of a neonatal unsuckled piglet. The IPEC-J2 cell line is unique as it is derived from 
the small intestine and is neither transformed nor tumorigenic in nature. IPEC-J2 
cells mimic the human physiology more closely than any other cell line of non-
human origin. Therefore, it is an ideal tool to study epithelial transport, interactions 
with enteric bacteria, effects of probiotic microorganisms and the effect of nutrients 
and other feedstuffs on a variety of widely used parameters (e.g. transepithelial 
electrical resistance (TEER), permeability, metabolic activity) refl ecting epithelial 
functionality. 
 IPEC-J2 cells undergo in culture a process of spontaneous differentiation that 
leads to the formation of a polarized monolayer with low or high TEER, depending 
on the type of serum added to the culture medium, within 1–2 weeks. Porcine serum 
gives rise to low resistance and normal active transport rates, enabling comparison 
with the in vivo situation. The high resistance caused by fetal bovine serum can be 
benefi cial to use when investigating compounds having a negative effect on the 
monolayer permeability or tight junction structures. 
 There are still many opportunities for exploring the use of these cells as the available 
research is limited. This chapter will cover the origin, characteristics and methods 
of the use of IPEC-J2 cells as an in vitro model for several research applications, as 
well as comparisons between IPEC-J2 cells and other epithelial cell lines. 
 Keywords  IPEC-J2 •  Cell line •  Small intestinal epithelium •  Porcine origin • 
 Transepithelial electrical resistance •  Non-transformed •  Continuous 
12.1  Origin 
 The intestinal porcine enterocyte cell line (IPEC-J2) is a non-transformed, permanent 
intestinal cell line (Fig.  12.1 ). These secondary cells were originally isolated from 
the jejunal epithelium of a neonatal unsuckled piglet in 1989 by Helen Berschneider 
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at the University of North Carolina (Berschneider  1989 ). Given the correct culture 
conditions, these cells will divide and grow for an infi nite number of passages 
in vitro. To date, they have been cultured continuously for up to 98 passages. IPEC-J2 
cells were fi rst used to investigate transepithelial ion transport and enterocyte dif-
ferentiation (Berschneider  1989 ). They have already been shown to be a valuable 
tool in the characterization of epithelial cell interactions with enteric bacteria and 
viruses providing insight into initial host-pathogen and non-pathogen (e.g. com-
mensal or probiotic) interactions (Brosnahan and Brown  2012 ). 
12.2  Special Features/Morphology/Receptors 
 The strength of the IPEC-J2 cell line as an in vitro model originates from its 
morphological and functional similarities with intestinal epithelial cells in vivo. 
IPEC-J2 cells have microvilli on their apical side and tight junctions sealing neigh-
boring cells together (Schierack et al.  2006 ). To date, no brush border enzyme 
 Fig. 12.1  Transmission electron microscopical image of an IPEC-J2 cell grown on a fi lter insert 
with fetal bovine serum supplemented to the medium.  M mucopolysaccharides,  MV microvilli, 




activity has been investigated in IPEC-J2 cells. IPEC-J2 cells form polarized 
monolayers when cultured on 0.4 μm pore-size fi lters, with or without a collagen 
basis. High transepithelial electrical resistance (TEER) values and low active trans-
port rates are obtained when culturing the IPEC-J2 cells in fetal bovine serum (FBS) 
(Geens and Niewold  2011 ). These atypically high TEER values can be benefi cial to 
use when investigating compounds having a negative effect on the monolayer per-
meability or tight junction structures (Vergauwen et al.  2015 ). Porcine serum (PS) 
resulted in signifi cantly lower TEER values and higher active transport rates com-
parable to the in vivo situation (Zakrzewski et al.  2013 ). When IPEC-J2 cells are 
grown in 10 % PS they will become taller and smaller in diameter, increasing the 
tight junction ultrastructure (Zakrzewski et al.  2013 ). 
 The protein expression of claudin-1, -3, -4, -5, -7, -8, -12, tricellulin, occludin, 
E-cadherin and zonula occludens-1 (ZO-1) by IPEC-J2 cells has been confi rmed by 
immunoblotting (Zakrzewski et al.  2013 ). On the other hand, IPEC-J2 cells do not 
express claudin-2 and -15 resulting in lower cation selectivity, augmenting the ion 
permeability of tight junctions compared to the porcine jejunum (Zakrzewski et al. 
 2013 ; Schierack et al.  2006 ). 
 IPEC-J2 cells express and produce cytokines, defensins, toll-like receptors and 
mucins. The presence of glycocalyx-bound mucins like Muc1 and Muc3 has been 
confi rmed in IPEC-J2 cells, respectively by RT-PCR and ELISA (Schierack et al. 
 2006 ). The expression of the Muc2, the major gel-forming mucin in the human small 
intestine, was not detectable by RT-PCR (Schierack et al.  2006 ). Thus, the mucus 
production by IPEC-J2 cells is not comparable to the in vivo situation. The mucus 
layer is only a very thin layer that is superimposed on the IPEC-J2 cells when cul-
tured with fetal bovine serum. However, PAS staining showed an increase in mucus 
production when IPEC-J2 cells were cultured with porcine serum (Zakrzewski 
et al.  2013 ). 
 IPEC-J2 cells express proteins such as MHC I and secrete cytokines like GM-CSF 
and TNF-α that can establish communication between enterocytes and the immune 
system. Furthermore, mRNA expression of TLR-1, -2, -3, -4, -5, -6, -8, -9, -10 and 
IL-1α, -1β, -6, -7, -8, -12A, -12B, -18 has been confi rmed in IPEC-J2 cells. TLR-2, 
-3, -5, -9 and IL-6, -8 proteins were also detected in these cells (Brosnahan and 
Brown  2012 ; Arce et al.  2010 ; Burkey et al.  2009 ). 
 IPEC-J2 cells express the F4 fi mbrial receptor but not the F18 fi mbrial receptor 
as this has been correlated to older pigs (3–23 weeks). These features make IPEC-J2 
cells an interesting in vitro model to investigate the pathogenesis of zoonotic enteric 
infections that also affect humans. 
12.3  Stability/Consistency/Reproducibility of the System 
 In current research IPEC-J2 cells have been used until passage 98. However, most 
studies do not mention the passage number. Interlaboratory result evaluation pre-
sented a consensus that a confl uent IPEC-J2 cell monolayer grown in 5 % fetal 
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bovine serum corresponds to a TEER value of 1,000 Ω × cm 2 . TEER experiments 
are usually started at 1,000–3,000 Ω × cm 2 . These values are reached after 4–9 days 
of culturing on an insert with a semi-permeable membrane (0.4 μm pore size) with 
or without collagen coating. However, when IPEC-J2 cells are incubated with 10 % 
PS instead of 5 % FBS TEER values of 400–500 Ω × cm 2 are obtained. These TEER 
values are comparable to those found in Caco-2 cell cultures and in vivo. 
 The amount of cells seeded on the insert depends on the insert size and brand. It 
has been demonstrated that seeding density can infl uence TEER values over time, 
as well as proliferation capacity and functionality. When a 12-well plate insert is 
seeded with 1–10 × 10 5 cells/insert, minimal cell division is needed. 
 Results obtained from microbial investigations using IPEC-J2 cells show strong 
correlation with mucosal explants and in vivo. However, various EHEC mutants 
adhere differently to IPEC-J2 cells and porcine ileal loops. This indicates that 
different model systems may behave differently (Yin et al.  2009 ). Nonetheless, the 
ability of some EHEC mutants to adhere to IPEC-J2 cells and ileal loops was highly 
correlated. 
12.4  Relevance to Human In Vivo Situation 
 IPEC-J2, IPEC-1 and IPI-2I are three widely used porcine small intestinal cell lines 
(Arce et al.  2010 ). IPI-2I cells have been transformed with an SV40 plasmid, whereas 
IPEC-J2 and IPEC-1 are non-transformed cell lines. IPI-2I cells were isolated from the 
ileum, IPEC-J2 cells from the jejunum and IPEC-1 cells were isolated from a mixture 
of ileal and jejunal tissue. IPEC-1 and IPEC-J2 cells were both isolated from one day 
old piglets, whereas IPI-2I cells were isolated from an adult boar (Berschneider 
 1989 ). Furthermore, IPEC-J2 cells, unlike IPI-2I cells, form a polarized monolayer, 
promoting  S. typhimurium invasion and replication (Boyen et al.  2009 ). 
 Several normal and transformed cell lines are used in food science (Cencic and 
Langerholc  2010 ). Caco-2, T84, HT-29, HUTU-80 and SW620 are the most widely 
used human intestinal cell lines. The majority of human intestinal cell lines is iso-
lated from the colon, and most are tumorigenic. The HUTU-80 cell line is the only 
widely available small intestinal human cell line. It was derived from the duode-
num, but is also cancerous (Brosnahan and Brown  2012 ). 
 A drug transport permeability study showed that IPEC-J2 cells form a tighter 
monolayer compared to Caco-2 cells (Pisal et al.  2008 ). On the other hand, Caco-2 
and T84 cells produce a more pronounced mucus layer compared to IPEC-J2 cells 
(Navabi et al.  2013 ). HT29, T84, Caco-2, and SW620 are all negative for IL-2, IL-4, 
and IFN-γ, while mRNA for IL-1α, IL-8, and TNF-α is variable amongst the human 
cell lines, but is present in IPEC-J2 cells (Eckmann et al.  1993 ). Existing cancer- 
derived cell lines can have limitations such as an altered glycosylation pattern 
and an aberrant protein expression that defi ne the epithelial character as well as 
unresponsiveness to hormones or cytokines (Peracaula et al.  2008 ). 
 Two major advantages favor IPEC-J2 cells as a model of normal intestinal epithe-
lial cells compared to transformed cell lines: (1) as a permanent cell line they maintain 
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their differentiated characteristics and exhibit strong similarities to primary intestinal 
epithelial cells, and (2) IPEC-J2 cells have the advantage of being directly compa-
rable to the experimental animal that is used as an in vivo model for humans. Of all 
non-primates, the gastrointestinal (GI) tract of pigs is the most appropriate in vivo 
model as it is similar in size, weight, anatomy and physiology as the human GI 
system (Deglaire and Moughan  2012 ). 
 Due to the close similarity between swine and human intestinal function, studies 
with IPEC-J2 cells provide valuable insights into the pathogenesis of zoonotic enteric 
infections that also affect humans (Skjolaas et al.  2006 ). Extrapolating information 
can be diffi cult as in vitro, ex vivo and in vivo cells or tissue can respond differently 
to environmental stimuli (e.g. diet). Indeed, diet-induced gene expression patterns 
 differ between IPEC-J2 cells and intestinal tissue from preterm and newborn piglets, 
making interpretation rather diffi cult (Støy et al.  2013 ). However, an in vitro model is 
still a valuable tool to investigate a limited number of factors in a standardized, 
 regulated setting. A comparison of normal diploid IPEC-J2 cells with other trans-
formed or tumorigenic cell lines can give more insight when investigating gene 
expression and to greater extent the effects of bioactives on intestinal health. 
12.5  General Protocol 
12.5.1  Culture Conditions 
 The IPEC-J2 cells are cultured in DMEM/F-12 mix (Dulbecco’s Modifi ed Eagle 
Medium, Ham’s F-12 mixture) and supplemented with HEPES, fetal bovine serum 
(FBS) or porcine serum (PS), insulin/transferrin/selenium (ITS), penicillin/streptomycin 
and cultivated in a humid environment at 37 °C with 5 % CO 2 . The IPEC-J2 cells 
are usually grown for 1–2 weeks before initiating an experiment. When studying 
TEER and permeability, IPEC-J2 cells are commonly seeded (1 × 10 5 cells/well) at 
confl uence in a ‘Boyden chamber’ insert (upper chamber, apical) on a polyethylene 
terephthalate (PET) membrane (1.12 cm 2 , pore size 0.4 μm) in a 12-well plate 
(lower chamber, basolateral). Cells are seeded (1 × 10 5 /well) in a 12-well plate 
(fl at bottom) to investigate the intracellular oxidative stress and wound healing 
capacity. Cells are seeded (0.5 × 10 4 cells/well) in a 96-well plate (fl at bottom) to 
assess viability. The IPEC-J2 cell line is an easy to use and robust cell line, exhibiting 
structural and functional differentiation pattern characteristics of mature enterocytes 
(Geens and Niewold  2011 ). 
12.5.2  Experimental Readout 
 An increasing number of studies use IPEC-J2 cells to investigate interactions of 
various animal and human pathogens, including  Salmonella enterica and pathogenic 
 Escherichia coli (Boyen et al.  2009 ; Veldhuizen et al.  2009 ). Pathogenic permeation 
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(e.g.  E. coli ) is usually presented as colony forming units (CFU). IPEC-J2 cells 
have also been employed as an initial screening tool for adhesiveness and anti-
infl ammatory properties of potential probiotic microorganisms. IPEC-J2 cells were 
also used to investigate the effect of prebiotics on the adhesion of probiotic bacterial 
strains to these cells. Addition of 200 mM calcium has been shown to increase adhe-
sion (Marcinakova et al.  2010 ), while magnesium and zinc ions had no infl uence 
(Larsen et al.  2007 ). Innate immune responses (e.g. increase in porcine β-defensin 
1 and 2 gene expression) in relation to environmental stimuli (e.g. diet or infection) 
are investigated with relevance for human and porcine intestinal diseases, specifi cally 
in newborns (Schierack et al.  2006 ; Burkey et al.  2009 ; Veldhuizen et al.  2009 ). 
Numerous studies used IPEC-J2 cells to investigate feedstuffs and antioxidants in 
relation to infl ammation, intestinal permeability and wound healing capacity 
(Hermes et al.  2011 ; Ma et al.  2012 ; Pan et al.  2013 ; Vergauwen et al.  2015 ). 
 Permeability is expressed using TEER, either presented as absolute values or as 
percentages of control or time point (TEERtx/TEERt0). The net value of the TEER 
(Ω × cm 2 ) needs to be corrected for background resistance by subtracting the contri-
bution of the cell-free fi lter and the medium (80–150 Ω × cm 2 ). Alternatively fl uo-
rescein isothiocyanate (FITC)-dextran of 4 kDa (FD-4) permeability can be used to 
indicate monolayer integrity. FD-4 permeability results are presented as a percent-
age of control or as absolute quantities or concentrations (e.g. picomoles). 
 Viability and cytotoxicity are most commonly analyzed using the neutral red 
method, lactate dehydrogenase release or the MTT reduction assay and presented as 
percentages of control or absorbance values  (Table  12.1 ).
12.5.3  Sample Preparation 
 It is important only to incubate sterile fi ltered samples on the IPEC-J2 cells. 
Otherwise, interpretation of the results will be ambiguous as the effect cannot be 
contributed to an impurity, a pathogen or the agent of interest. 
 Samples that are not readily dissolved in water can be dissolved in ethanol or 
DMSO. The effect of different concentrations of ethanol or DMSO for either 1 or 
18 h on the viability of IPEC-J2 cells was investigated (Fig.  12.2 ). Results show that 
short and long term incubation do not favor DMSO or ethanol at concentrations 
below 1 %. DMSO is favored for long-term incubation at concentrations above 1 %. 
However, concentrations exceeding 1 % are not recommended. Furthermore, it is 
always important to minimize the concentration of DMSO or ethanol when solubi-
lizing a compound. 
12.6  Conclusion 
 In summary, the IPEC-J2 cell model provides a perfect tool to investigate intestinal 
epithelial function. This porcine cell line is closely related to the human in vivo 
situation and is not cancerous compared to other human (small) intestinal cell lines. 
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The tumorigenic nature of the human intestinal cell lines can infl uence gene expression, 
and transformed cell lines are usually more resistant to stress or cytotoxic insults. 
This will result in ambiguous information and an underestimation of cytotoxic 
compounds. Furthermore, IPEC-J2 cell monolayers are ready for experimentation 
after 1–2 weeks which is a lot faster compared to the 21-day culturing time of 
Caco-2 cells. In conclusion, IPEC-J2 cells are an ideal small intestinal enterocyte 
model to study effects of food bioactives in the gut prior to in vivo evaluation. 
 Open Access This chapter is distributed under the terms of the Creative Commons Attribution 
Noncommercial License, which permits any noncommercial use, distribution, and reproduction in 
any medium, provided the original author(s) and source are credited. 
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 Chapter 13 
 Co-cultivation of Caco-2 and HT-29MTX 
 Charlotte  R.  Kleiveland 
 Abstract  The intestinal epithelium is one of the body’s largest mucosal surfaces 
and it generates a physical barrier against the external environment. The majority of 
cells lining the epithelium are absorptive enterocytes with mainly metabolic and 
digestive functions. Hence, the diversity of functions the intestinal epithelium carries 
out depends on the presence of additional specialized intestinal epithelial cells 
(IEC). Secretory IEC, goblet cells, enteroendocrine cells and Paneth cells are 
specialized cells that participate in maintaining the digestive and barrier functions 
of the epithelium. Goblet cells release mucins, which give rise to a mucus layer on 
the epithelial surface that functions as physical and biochemical barrier for luminal 
content. The presence of the different epithelial cell types in an in vitro model will 
affect how well the model refl ects the properties of the intestinal epithelium. We here 
describe a co-cultivation system of enterocytes and goblet cells, which are the two 
major epithelial cell types. 
 Keywords  Co-culture •  Enterocytes •  Goblet cells •  Transport •  Absorption • 
 Transepithelial electrical resistance (TEER) 
13.1  Origin, Features and Mechanisms 
 The models described in this section include the cell lines Caco-2 and HT-29. 
Description of the origin, features and mechanisms of these cells are included in 
previous sections, and further information is found in  Chap.  10 for Caco-2, Chap.  11 
for HT-29. 
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13.2  Stability/Consistency and Reproducibility 
 The stability and reproducibility of the co-culture model of Caco-2 and 
HT-29MTX is very similar to the monocultures. The cells are cultivated together 
during the whole polarization period of 21 days. The co-cultures should be used 
for experiments between day 21 and 25. See Chap.  10 for Caco-2 cells and for 
HT29MTX Chap.  11 . 
13.3  Relevance to the Human In Vivo Situation 
 The intestinal epithelium is the main barrier preventing molecules from the lumen 
(e.g. food and toxins) reaching the systemic circulation. The epithelium is com-
posed of several cell types: enterocytes, goblet cells, Paneth cells, enteroendocrine 
cells and stem cells. However, absorptive and goblet cells constitute the two major 
cell types of the intestine. The cell lines Caco-2 and HT-29MTX are derived from 
intestinal absorptive and goblet cell types, respectively. The human intestinal cell 
line Caco-2 differentiates into enterocytes (Shah et al.  2006 ), and is extensively 
used as an in vitro model of the small intestine, particularly to determine the perme-
ability of the intestinal barrier to drug and food components (Sambuy et al.  2005 ). 
Caco-2 is of human colonic origin; however, when grown in culture, the cells exhibit 
many properties of the small intestinal epithelium. They form a well-differentiated 
polarized monolayer of columnar absorptive cells that express brush border with 
typical small intestinal enzymes and transporters on their apical surface (Artursson 
 1991 ; Hilgendorf et al.  2000 ). A disadvantages of the Caco-2 model and other 
monocultures of epithelial cells are that they do not closely simulate the composition 
of the normal epithelial layer with several types of cells (Hidalgo  1996 ). The epithe-
lial cell layer is separated from the luminal content by a mucus layer. The mucus 
layer acts as physical and chemical defence against food particles, chemicals, 
enzymes and host-secreted products such as bile acids, microbiota and microbial 
products (Johansson et al.  2008 ). Only goblet cells are mucus-secreting cells, hence 
a mucus layer will be lacking in the Caco-2 model. However, the HT-29MTX cells 
produce both the membrane bound MUC1 and the gel-forming MUC5 (for more 
information on HT-29 cells see Chap.  11 ). A co-cultivation of the two cell lines will 
therefore provide a model constituting the two cell types that are most represented 
in normal epithelium, enterocytes and goblet cells. In addition the mucin secretion 
from HT-29 will form a layer on top of the epithelial cells. Presence of mucus in the 
model system is important for estimation of intestinal permeability as the mucus 
acts as a barrier against the absorption of certain compounds, particularly those that 
are lipophilic (Behrens et al.  2001 ). The lack of mucus allows highly diffusible 
small molecules easy access to the cells, which often results in an overestimation of 
permeability of such compounds. 
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 Even though the Caco-2 cells have been widely employed to measure drug and 
nutrient transport, this model has been criticized because the permeability of the 
Caco-2 monolayer to hydrophilic compounds, generally transported by paracellular 
mechanisms, are poor because of the relatively tight junction that are characteristic 
of these cells (Artursson et al.  2001 ). A pure Caco-2 cell model also has a overex-
pression of P-glycoprotein which may lead to higher secretion rates and consequently 
lower permeability in the absorptive direction (Anderle et al.  1998 ). The HT-29MTX 
cell line has less expression of tight junctions. The ability of mannitol to penetrate 
tight junctions in HT-29 monolayer is 50-fold higher than that of Caco-2 monolayers 
(Wikman et al.  1993 ). The permeability of a cell layer resulting from co-cultivation 
between Caco-2 and HT-29 are more in resemblance with that of the normal intestine. 
The permeability of the Caco-2/HT-29 co-culture model was correlated with fractions 
absorbed in humans for selected drugs, and it was found relatively good correla-
tions (Walter et al.  1996 ). 
13.4  General Protocol 
 Maintain Caco-2 and HT-29MTX cells as described in Chaps.  10 and  11 
respectively. 
 The Caco-2 and HT-29MTX cells are grown separately. The two cell lines are 
mixed prior to seeding. The most physiological relevant ratios are between 90:10 and 
75:25 (Caco-2/HT-29MTX). In this range, the best compromise between model 
response and the presence of mucus layer will be obtained. Co-cultures of Caco-2 and 
HT-29MTX cells are seeded onto cell inserts with 0.4 μm pores at a density of 
3 × 10 5 cells per 0.9 cm 2 . The co-culture is maintained in Dulbeco’s Modifi ed Eagle 
Medium (DMEM) with 10 % heat inactivated fetal bovine serum, 2 mM  L - glutamine , 
1 % non-essential amino acids and 100 U/ml penicillin and 100 μg/ml streptomycin, 
at 37 °C in 5 % CO 2 . The culture medium is changed every 2–3 days (both in apical 
and basolateral compartment) for 21 days. 
 When investigating intestinal transport and absorption using undigested or 
digested food compounds it is important to adjust pH (7.4) and osmolality 
(310 mOsm/kg before addition to the cell culture.  Evaluation of transepithelial 
absorption is described in chapter 2, section 2.2.2 and calculation of the apparent 
permeability coeffi cient (P app ) is described in Chap.  10 . 
13.5  Assess Viability 
 The integrity of the cell layers should always be checked by measurement of TEER 
values, and fi lters with a TEER value below 200 Ω cm 2 should not be used for 
further experiments. A reference compound that is know to be transported over the 
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epithelium (LY, labetalol, propranolol, ranitidine, or colchicine) should always be 
measured concurrently in each permeability assay to ensure validity of the assay. 
 Evaluation of transepithelial absorption is described in chapter 2, section 2.2.2 and 
calculation of the apparent permeability coeffi cient (P app ) is described in Chap.  10 . 
13.6  Experimental Readout 
 The Caco-2/HT-29MTX co-culture model is widely used to study intestinal 
transport and absorption. An in vitro study of intestinal transport of inorganic and 
methylated arsenic species from in vitro digested rice, garlic and seaweed has 
compared the Caco-2 monolayer with various proportions of the Caco-2/
HT-29MTX co- culture model (Calatayud et al.  2012 ). They concluded that arse-
nic absorption increased with increased proportion of HT-29MTX. Another report 
studying transport of methylmercury and inorganic mercury in various Caco-2 
and HT-29MTX models showed that incorporation of HT-29MTX reduced the 
permeability for mercury (Vazquez et al.  2013 ). In this case, the layer of mucus 
secreted by HT-29MTX retained mercury. Iron bioavailability of in vitro digested 
food (white, red and soy beans, beef and fi sh) were investigated by the Caco-2/
HT-29MTX model (Mahler et al.  2009 ). They report that addition of HT-29MTX 
signifi cantly lowered the cell ferritin formation in the presence of high bioavail-
ability iron digests. 
 The use of Caco-2/HT-29 co-culture to evaluate transport and bioavailability of 
glutathione-enriched baker’s yeast also revealed an increase in transport rates when 
HT-29MTX was incorporated in the monolayer compared to only using Caco-2 
cells (Musatti et al.  2013 ). 
 Bacterial adhesion and invasion of  Salmonella enterica spp. has been studied 
using the Caco-2/HT-29 co-culture model (Dostal et al.  2014 ). Bacterial adhesion 
and invasion was determined by plating of serial dilutions of the disrupted cell 
suspension after an extensive washing procedure, on agar plates. In the case of inva-
sion, the extracellular bacteria were killed by incubation with gentamicin for 45 min 
before disrupting the cells. TEER was measured for evaluation of tight junction 
disruption during bacterial invasion. 
13.7  Advantages, Disadvantages and Limitations 
 The use of cell lines will give good reproducibility of the model system and there are 
several reports establishing good correlations between this model and human in vivo 
studies. The two cell lines are easily available and easy to cultivate. The model is 
quite easy to use and is effi cient for screening purposes. The disadvantages of this 
model is that some of the transporters/carriers found in normal human intestinal epi-
thelium are not expressed by the two cell lines, therefore in the case of transport 
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studies the expression of the necessary molecules should be checked. The ratio 
between the two cell types will be crucial for the formation of homogeneous mucin 
layer, which is of great importance for the relevance to the in vivo situation. 
13.8  Conclusions 
 The co-culture of Caco-2 and HT-29MTX is a model that is useful for the investiga-
tion of transport over intestinal epithelium and for bacterial adhesion and invasion. 
For such applications the mucin layer and the permeability of the cell layer is crucial 
and co-culture will give results that are more in compliance with the in vivo situation 
than monocultures.
Open Access This chapter is distributed under the terms of the Creative Commons Attribution 
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 As an organ specialized in food digestion and nutrient absorption, the intestinal 
mucosa presents a huge surface area (almost 300 m 2 in comparison with 2 m 2 in skin) 
to the outside milieu and is continually exposed to foreign antigens derived from 
dietary constituents and the large number of microbes that reside within the intestinal 
lumen. In order to maintain the intestinal integrity, it is crucial to possess a fully 
functional associated immune system able to respond appropriately to such antigens 
and also to generate protective immunity to potential pathogens that employ the 
intestine as a primary site of entry and infection. Inappropriate responses to such 
antigens, apart from infections, are thought to underlie several intestinal pathologies 
including infl ammatory bowel disease as well as food allergies (Bekiaris et al.  2014 ). 
 Cells from both the innate and adaptive immune system can be found throughout 
the intestinal mucosa working together cooperatively with other cells and molecules 
in order to maintain intestinal functionality. Innate immunity provides effective ini-
tial defense mechanisms that take place even before infection and are poised to 
respond rapidly to microbes. These mechanisms react only to microbes and prod-
ucts of injured cells, and they are specifi c for structures that are common to a group 
of related microbes, not being able to distinguish fi ne differences between foreign 
substances. On the contrary, adaptive immune responses comprise responses that 
are stimulated by exposure to antigens of both microbial and non microbial origin 
and that increase in magnitude and defensive capabilities with each successive 
exposure. The main characteristics of adaptive immunity are a very high specifi city 
for distinct molecules and the ability to “remember” and respond more vigorously 
to repeated exposures to the same antigen (Abbas et al.  2007 ). 
 When the immune response is triggered, a wide variety of cells from both 
the immune system and other tissues participate. These include epithelial and 
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endothelial cells, neutrophils, monocytes, macrophages, dendritic cells, mast 
cells, natural killer cells, basophils, eosinophils, B and T cells. All of them have 
the ability to secrete a wide array of mediators responsible in part for their infl am-
matory effects (Si-Tahar et al.  2009 ). Based on the number of publications dealing 
with the immunomodulant/anti-infl ammatory properties of food-derived compounds 
with bioactive properties, only monocytes, macrophages, dendritic cells, PBMCs 
and T cells will be covered in this part. 
 Monocytes and Macrophages 
 Monocytes and macrophages are essential for the development of infl ammation 
and together with neutrophils are the phagocytic cells involved in the clearance of 
inert particles and microbial agents. Monocytes are bone marrow-derived cells that 
are continuously released into the blood. When these cells are recruited by chemo-
tactic molecules, and leave circulation, they become activated and differentiate 
into macrophages under the stimulus of mediators such as TGF-β or M-CSF, 
between others (Gordon and Martínez  2009 ). Macrophages have a number of 
important functions in body defenses such as (1) capture by phagocytosis and 
intracellular killing of microorganisms; (2) scavenging of debris potentially harm-
ful to tissues; (3) processing and presentation of antigens for recognition by T 
cells, and (4) releasing cytokines and chemokines with a major role in immune 
responses (Davies et al.  2013 ). The major cytokines produced by macrophages are 
TNF-α, IL-1β, IL-6, IL-8 and IL-33, all of which are involved in local and systemic 
responses. Macrophages demonstrate great developmental plasticity and may dif-
ferentiate into cells with different phenotypes depending on the stimuli received as 
well as the tissue location. IFN-γ induces classically activated M1 macrophages 
(CAM), whereas IL-4, IL-13 and IL-10 induce alternatively activated 
M2-macrophages (AAM) (Mosser and Edwards  2008 ). In the intestinal mucosa 
M2-macrophages are more abundant, participating in the resolution of parasite 
infections, tissue remodeling, immune regulation, allergy development and tumor 
progression by stimulating a Th2-driven immune response (Takeuchi and Akira 
 2011 ). Chapter  14 describes in detail the main characteristics and differentiation 
protocols for THP-1 and U937, two human monocytic cells lines commonly 
employed in the study of the anti-infl ammatory properties of food bioactives. The 
main food components tested, together with the methods employed to evaluate 
their potential anti-infl ammatory activity are also explained. 
 Dendritic Cells 
 Dendritic cells (DC) are a widely distributed group of cells specialized in antigen 
sampling. In fact, they also constitute the most effi cient antigen presenting cells for 
T cell activation, hence being the linking bridge between innate and adaptive 
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immune responses. DCs are strategically positioned at body barriers and also organ 
entry ports, such as the splenic marginal zone, where they remain in an immature 
form until they encounter an antigen (Mildner and Jung  2014 ). Once the antigen 
has been sampled, DCs become activated and travel towards T-cell zones, either 
within their respective lymphoid organ of residence or towards draining lymph 
nodes to ensure the activation, proliferation and differentiation of naïve T cells into 
their corresponding effector cells. This migration depends on the expression of the 
chemokine receptor CCR7 (Foster et al.  1999 ). During migration, the mature den-
dritic cells express high surface levels of class II major histocompatibility complex 
(MHC) molecules with bound antigenic peptides as well as costimulatory mole-
cules. By the time DCs reach secondary lymphoid organs, they are able to present 
antigens to populations of naïve and memory T cells. Chapter  17 provides a com-
plete overview of the different DC subsets focusing on the DCs present in the 
intestinal mucosa as they are among the fi rst immune cells to come into contact 
with food compounds in the gastrointestinal tract and thus are instrumental in 
shaping the immune system’s response to such exposures. In the same chapter the 
main DC isolation techniques as well as in vitro/ex vivo culture settings that can 
be applied for in vitro testing of food compounds with bioactive properties are 
discussed. Special attention will be paid to the potential of food-derived bioactives 
in inhibiting DC activation due to the relevance of DCs in initiating the infl amma-
tory processes. 
 Human Peripheral Blood Mononuclear Cells 
 Human peripheral blood mononuclear cells (PBMCs) include a mixture of cells 
composed of lymphocytes (T cells, B cells, and NK cells), monocytes, and dendritic 
cells obtained from human blood or buffy coats. In humans, the frequencies of these 
populations vary across individuals, but lymphocytes are the most abundant, consti-
tuting in the range of 70–90 %. PBMCs are typically employed in studies where 
immune-regulatory effects of food bioactives are to be scrutinized. Main read-out 
systems include proliferation measurements, evaluation of surface activation mark-
ers by fl ow cytometry and quantifi cation of the cytokine profi le produced after add-
ing the food bioactive to the cell culture. Chapter  15 fully explains the principal 
features and isolation procedures of PBMCs from human blood. Moreover, protocols 
to perform proliferation assays and evaluation of the anti-infl ammatory properties 
with compounds from food origin are also described. 
 T Lymphocytes or T-Cells 
 As mentioned earlier, PBMCs are an important source of lymphocytes. Of special 
interest are T lymphocytes or T-cells (45–70 % of PBMCs in human peripheral 
blood), which are produced by stem cells in the bone marrow as progenitors and 
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then migrate to the thymus where they mature into T cells. After completing their 
maturation, T-cells enter the bloodstream and recirculate between blood and sec-
ondary lymphoid organs until they encounter their cognate antigen. After antigen 
presentation by DCs, along with other appropriate stimuli, the cells may proliferate 
and differentiate into different subsets of effector cells (Santana and Esquivel-
Guadarrama  2006 ). Originally, two main types of effector T cells, called T-helper 1 
( Th1 ) and 2 ( Th2 ) cells, were distinguished by their cytokine secretion patterns. 
Th1 cells secrete mainly IL-2, IFNγ and TNFα, and Th2 cells secrete IL-4, IL-13 
and IL-5 (Romagnani  2000 ). Recently, a new lineage of T cells characterized by 
their ability to secrete a proinfl ammatory cytokine, IL-17, and thus designated Th17 
cells has been discovered. This new T cell type has been related to autoimmune 
diseases (Jing and Dong  2013 ). Another subset, named regulatory T cells ( Treg ), 
acts by inhibiting, between others T cell responses by the production of cytokines, 
such as IL-10 and TGF-β and/or via cell–cell interactions (Jutel and Akdis  2011 ). 
T cell cultures are a valuable tool in food research, especially to perform studies 
within the food allergy fi eld. To study effects of food bioactives on T cells, it is 
necessary to activate the T cells by a polyclonal activator, either a mitogen like 
phytohaemagglutinin or monoclonal antibodies against CD3 and CD28. In food 
allergy, their main applications include analysis of immunological responses 
towards food protein antigens to gain further insights into the mechanisms respon-
sible for the development of oral tolerance or for the triggering of food allergies. 
Chapter  16 describes the main applications in food allergy research, isolation tech-
niques, and culture conditions for PBMC-derived T cells. Furthermore, critical 
parameters of the model, together with the experimental read outs are discussed. 
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 Chapter 14 
 THP-1 and U937 Cells 
 Wasaporn  Chanput ,  Vera  Peters , and  Harry  Wichers 
 Abstract  Monocytes are circulatory precursor cells from myeloid origin that can 
develop into macrophages or dendritic cells upon migration from the blood stream 
to tissues. Both macrophages and dendritic cells are professional antigen- presenting 
cells. Monocytes and their macrophage and dendritic-cell progeny serve three 
main functions in the immune system. These are phagocytosis, antigen presenta-
tion, and cytokine production. THP-1 and U937 are (pro-) monocytic cell lines that 
can, also in vitro, be differentiated into either various types of macrophages or into 
dendritic cells. 
 This chapter describes how to grow THP-1, resp. U937 cells, how to differentiate 
these into more specialised phenotypes such as various macrophage types or 
 dendritic cells, how to read-out their responses to stimuli and it gives examples of 
how such cell lines have been used into studying the effects of food compounds. 
 Keywords  THP-1 •  U937 •  Cell line •  Monocyte •  Macrophage 
14.1  Origin and Some Features of THP-1 and U937 Cells 
 The THP-1 cell line is a human monocytic leukaemia cell line which was established 
in 1980 by Tsuchiya et al. ( 1980 ). It was derived from the blood of a patient with 
acute monocytic leukaemia. THP-1 cells resemble primary monocytes and macro-
phages in morphology and differentiation properties. THP-1 cells show a large, 
round single-cell morphology and express distinct monocytic markers. Nearly all 
THP-1 cells start to adhere to culture plates and differentiate into macrophages after 
exposure to phorbol-12-myristate-13-acetate (PMA, also known as TPA,12-O- 
tetradecanoylphorbol-13-acetate; see below for details). 
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 THP-1 cells have some technical advantages over human primary monocytes 
or macrophages. For instance, their genetic background is homogeneous which 
minimizes the degree of variability in the cell phenotype. Another technical advantage 
is that genetic modifi cation of THP-1 cells by small interfering RNAs (siRNAs), 
in order to down regulate the expression of specifi c proteins, is relatively simple 
(Chanput et al.  2014 ). Furthermore, monocyte-derived macrophages can be polar-
ized into M1, M2a, M2b, and M2c cells. Spencer et al. ( 2010 ) published a protocol 
for THP-1 cell differentiation, showing that THP-1 cells represent a simplifi ed 
model to study monocyte-macrophage polarization (Qin  2012 ). 
 U937 is a pro-monocytic, human myeloid leukaemia cell line and was isolated 
from the histiocytic lymphoma of a 37 year old male (Sundstrom and Nilsson  1976 ). 
This cell line exhibits many characteristics of monocytes and is easy to use. A virtually 
unlimited number of cells can be prepared and they are relatively uniform. This cell 
line has been an important tool in the investigation of the mechanisms involved in 
monocyte-endothelium attachment (Liu et al.  2004 ). These leukaemia cells have 
been used as the experimental model to elucidate mechanisms of monocyte and 
macrophage differentiation. A genetic analysis by Strefford et al. ( 2001 ) showed 
that U937 bears the t(10;11)(p13;q14) translocation. This results in a fusion 
between the MLLT10 (myeloid/lymphoid or mixed-lineage leukaemia) gene and 
the Ap-3- like clathrin assembly protein PICALM (Clathrin assembly lymphoid 
myeloid leukaemia), which is likely important for the tumorous nature of the cell 
line (Strefford et al.  2001 ). 
14.2  Stability, Consistency and Reproducibility 
of the System 
 THP-1 is an immortalized cell line that can be cultured in vitro up to passage 25 
(approx. 3 months) without changes of cell sensitivity and activity. As far as our 
information reaches, U937 is used also at higher passage numbers (see e.g. Strefford 
et al.  2001 ). THP-1 as well as U937 cells can be stored for a number of years and, 
provided an appropriate protocol is followed, the cell lines can be recovered without 
any obvious effects on monocyte-macrophage features and cell viability (Chanput 
et al.  2014 and references therein). 
14.3  Relevance to Human In Vivo Situation 
 Cell lines always have a malignant background, which presents a signifi cant risk of 
experimental bias. The cultivation of cells under controlled conditions and outside 
their natural environment possibly results in different sensitivity and responses com-
pared to normal somatic cells in their natural environment (Schildberger et al.  2013 ). 
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Also, possibly relevant interactions between the target cells and surrounding cells, 
as in natural tissues, cannot be easily mimicked. In vitro co-cultivation of THP-1 or 
U937 cells with neighbouring cells might be an option to make this drawback less 
pronounced (Chanput et al.  2014 ). 
14.4  Other Models with the Same Applicability 
 Next to THP-1 and U937 cells, ML-2, HL-60 and Mono Mac 6 cells are used in 
biomedical research. U937 cells are the most frequently used. The basic difference 
between U937 and THP-1 cells is the origin and maturation stage. U937 cells are 
of tissue origin, thus at more mature stage, whereas THP-1 cells originate from a 
blood leukaemia origin at less mature stage (Chanput et al.  2014 ). Because Mono 
Mac 6 is able to phagocytose antibody-coated erythrocytes (Ziegler-Heitbrock 
et al.  1988 ) and mycobacteria (Friedland et al.  1993 ; Shattock et al.  1994 ) it is 
thought more suitable for the study of phenotypic and functional features of in vivo 
mature monocytes. Also, it expresses mature monocyte markers that cannot be 
found on the THP-1 and U937 cell lines, such as M42, LeuM3, 63D3, Mo2 and 
UCHMI. As THP-1 and U937 are very frequently used, we focus here on these two 
cell lines. 
14.5  General Protocol of Culturing THP-1 Cells 
 Roswell Park Memorial Institute (RPMI) 1640 medium is a commonly used medium 
for THP-1 as well as for U937 cells. Alternatively, DMEM (Dulbecco’s Modifi ed 
Eagle’s Medium; Morton  1970 ), also supplemented with 10 % FBS, is used to grow 
U937 cells. RPMI 1640 medium was originally developed by Moore et al. ( 1967 ), 
at Roswell Park Memorial Institute to culture human leukemic cells in suspension 
and as a monolayer. The formulation is based on RPMI-1630 medium and uses a 
bicarbonate buffering system and has alterations in the amounts of amino acids and 
vitamins. When RPMI is properly supplemented, it has a wide applicability for sup-
porting growth of many types of cell cultures including HeLa, Jurkat, MCF-7, 
PC12, PBMC, astrocytes and carcinomas. 
 In most of the studies, the RPMI medium is supplemented with a combination 
of foetal bovine serum (FBS) and antibiotics. FBS is also known as foetal calf 
serum (FCS) and is obtained from whole blood by removing blood cells, platelets 
and fi brinogen. Serum includes all proteins not involved in blood clotting and all 
electrolytes, antibodies, antigens, hormones and exogenous substances. Foetal 
bovine serum is obtained via collection at a slaughterhouse. In some studies, foetal 
bovine serum is heat-inactivated in order to destroy heat-labile complement proteins 
(Biowest). 
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 In many studies, the antibiotics penicillin and streptomycin are used to supplement 
the medium in order to prevent bacterial contamination of cell cultures due to their 
effective combined action against gram-positive and gram-negative bacteria. 
Penicillin, originally purifi ed from the fungus  Penicillium , acts directly and indirectly 
by interfering with the turnover of the bacterial cell wall and by triggering the 
release of enzymes that further alter the cell wall respectively. Streptomycin was 
originally purifi ed from  Streptomyces griseus and acts by binding to the 30S subunit 
of the bacterial ribosome, which leads to inhibition of protein synthesis and death in 
susceptible bacteria (Waksman  1953 ). 
 In some studies, cells were also supplemented with HEPES (4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid). HEPES is a zwitterionic organic chemical buffer 
and is widely used in many biochemical reactions and as a buffering agent in some 
cell culture media. These buffers have p K a values between 6.0 and 8.0, high solubility, 
limited effect on biochemical reactions, membrane permeability, are chemically and 
enzymatically stable and easy to prepare. 
14.6  Differentiation of THP-1 and U937 Monocytes 
into Macrophages 
 As already mentioned before, nearly all THP-1 cells start to adhere to culture 
plates and differentiate into macrophages after exposure to PMA. Also U937 
pro- monocytes differentiate into mature monocytes or into macrophages upon 
PMA- treatment. Typical exposure to PMA is for 48 h (Zhang et al.  2010 ; Gillies 
et al.  2012 ; Moreno-Navarrete et al.  2009 ; Cam and de Mejia  2012 ). The tem-
perature and atmosphere, if described, was the same for each study, namely 37 °C 
and 5 % CO 2 respectively. Different stimuli were used, depending on the aim of 
the study. 
 Subsequently, macrophages can be further differentiated into subsets. Typical 
markers for M1-type macrophages are transcription or production of TNF-α, IL-1β, 
IL12-p40, IL-6, IL-8 and LOX-1, and for M2-type macrophages MRC-1, dectin-1, 
and DC-SIGN (Chanput et al.  2010 ). 
 Based on literature and on our experience, 0.5 × 10 6 THP-1 monocytes fully dif-
ferentiate into macrophages after 48 h incubation at a minimal concentration of 
100 ng/ml PMA (162 nM), followed by washing twice with culture media without 
PMA and a resting period of 24 h (Chanput et al.  2014 ), resulting in macrophages 
with a high phagocytic capacity for latex beads and expressing cytokine profi les that 
resembled PBMC monocyte-derived macrophages after exposure to TLR ligands 
(Chanput et al.  2014 ). 
 Human promonocytic leukaemia U937 cells differentiate into monocytes and 
macrophages by use of various agents such as retinoic acids, 1,25- dihydroxyvitamin 
D3 (VD3; at 100 nM, i.e. 42 ng/ml, Rots et al.  1999 ), and 12-O-tetradecanoylphorbol- 
13-acetate (TPA; at 20 ng/ml, ca. 32 nM) (Chun et al.  2001 ). 
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14.7  Differentiation of THP-1 and U937 Monocytes 
into Dendritic Cells 
 THP-1 monocytes are described to differentiate into mature dendritic cells by trans-
ferring them to serum-free medium, and subsequently treating them with a mixture 
of IL-4, GM-CSF, TNF-α and ionomycin. These hematopoietic cell line-derived 
DCs are highly pure and monotypic, and display the morphologic, phenotypic, 
molecular, and functional properties of DCs generated from human donor-derived 
monocytes or CD34+ hematopoietic progenitor cells (see also Chap.  17 ). During 
differentiation into mature DCs, the cells exhibit de novo cell-surface expression of 
CD83, CD80, CD86, CD40, CD206, CD209, CD120a, CD120b, and intracellular 
synthesis of IL-10, increase their endocytotic capacity, and acquire the characteris-
tic stellate morphology (Berges et al.  2005 ). In the THP-1 monocytes, mRNAs of 
tight junction molecules, occludin, tricellulin, JAM-A, ZO-1, ZO-2 and claudin-4, 
-7, -8, and -9 were detected by RT-PCR. In mature DCs that had elongated den-
drites, mRNA and protein of JAM-A were signifi cantly increased compared to the 
monocytes (Ogasawara et al.  2009 ). 
 Exposure of U937 to a self-peptide from apolipoprotein E, Ep1.B, induces 
DC-like morphology and surface marker expression in U937 (Stephens et al.  2008 ). 
14.8  Controls to Test Viability and Performance 
of the Model 
 The by far most commonly used and imperative control test for analyses that are 
based on any kind of THP-1 or U937 derived cell is the possibility of cytotoxic 
effects of the test samples. For such checks, various methods and kits are in common 
use in various laboratories. Examples are assessment of functional mitochondrial 
reductase, with tetrazolium salts such as MTT, XTT and lamar blue. Alternatively, 
cell membrane integrity, degree of cell lysis via measurement of lactate dehydrogenase 
and apoptosis kits are used. 
14.9  Critical Notes 
 Regularly, solvents such as ethanol or DMSO are used to facilitate dissolution of test 
compounds. Also, sometimes a mimic of digestion is applied to the samples prior to 
analysis. It is highly recommended to determine the toxicity of such solvents or diges-
tion reagents, as well as their effect on the read-out parameters to be used for the cell 
assay, in a titration that at the least covers the eventual concentration to be used in the 
assays, and also for a relevant range of higher and lower concentrations (at least a 
factor 10 lower and higher than eventually applied conditions). Similar recommenda-
tions are valid for the use of buffers, salt concentrations and pH-ranges etc. 
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14.10  Read-Out of the System 
 Most commonly used read-out systems for responses of THP-1 or U937 cells are 
transcription or production of relevant cytokines. Which cytokines are relevant 
depends on specifi c experimental design. Gene expression of IL-1β, IL-6, IL-8, 
IL-10, TNF-α, iNOS, COX-2 and NF-κB is measured in many studies. This is done 
by RT-PCR, Western blot and ELISA. Examples that have been used to read out the 
effects of various food compounds on resp. THP-1 and U937 cells are presented in 
Tables  14.1 and  14.2 .
 Transcription can be measured by various PCR-methods, mostly and preferably 
quantitative PCR such as qPCR or RT-qPCR. Advantages of using PCR are its ease, 
speed and sensitivity, and possibly its low cost. A clear disadvantage is that not 
mRNAs are physiologically relevant, but the eventual gene product i.e. the 
cytokine. 
 Cytokines are most commonly measured by ELISA-methods or by FACS, for 
which a variety of commercial kits are available. An important advantage is rele-
vance as protein products are quantifi ed, and the standardized kits that are on the 
market that facilitate comparison of read-outs between various laboratories. An 
important drawback associated to such commercial kits is their cost. 
 THP-1 cells can also be used to study expression and activation of nuclear recep-
tors. Gillies et al. ( 2012 ) studied the effect of omega-3-PUFAs, eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA) and found that EPA-rich oil activated 
human peroxisome proliferator-activated receptor α (PPAR α) and PPAR β/α with 
minimal effects on PPARγ, liver X receptor, retinoid X receptor, farnesoid X recep-
tor, and retinoid acid receptor γ (RARγ). 
 Notably, several studies looked at the intracellular production of reactive oxygen 
species (ROS) by THP-1 cells. During infl ammation, ROS production is induced by 
infl ammatory cells in order to kill pathogens. However, ROS also act on infl amma-
tory cells themselves, thereby altering the intracellular redox balance and function-
ing as signalling molecules involved in the regulation of infl ammatory and 
immunomodulatory genes. ROS plays a key role in the control of transcription factors, 
like NF-κB and activator protein-1 (AP-1), which are involved in the gene expres-
sion of both infl ammatory and immune mediators. ROS can either activate or 
inactivate these transcription factors by chemically modifying critical amino acid 
residues within these proteins or on residues of accessory proteins of the respective 
signalling pathways (Jabaut and Ckless  2012 ). 
 ROS production can be measured by the intracellular ROS assay. In the study of 
Wu et al. ( 2011 ), 2′,7′-dichlorofl uorescein (DCF) is used to measure ROS produc-
tion. The cell-permeant 2′,7′-dichlorodihydrofl uorescein diacetate (H 2 DCFDA) 
(also known as dichlorofl uorescein diacetate) is a chemically reduced form of fl uo-
rescein used as an indicator for ROS in cells. Upon cleavage of the acetate groups 
by intracellular esterases and oxidation, the non-fl uorescent H 2 DCFDA is converted 
to the highly fl uorescent 2′,7′-dichlorofl uorescein (DCF). The chemically reduced 
and acetylated form of 2′,7′-dichlorofl uorescein (DCF) is non-fl uorescent until the 
acetate groups are removed. The fl uorescence can be measured by a fl ow cytometry, 
fl uorimeter, microplate reader, or fl uorescence microscope. 
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 Many studies using U937 have been used to analyse properties of poly-phenolic 
compounds. Responses like infl ammatory gene expression and NF-κB activity are 
commonly measured. The effect of quercetin on the phosphorylation of JNK and 
c-Jun and the degradation of IκBα was measured by Overman et al. ( 2010 ). The 
c-Jun N-terminal kinases (JNKs) are members of a group of serine/threonine 
(Ser/Thr) protein kinases from the mitogen-activated protein kinase (MAPK) family. 
The JNKs act within a protein kinase cascade and are activated by dual phosphoryla-
tion by MAPK kinases, but can also be activated by pro-infl ammatory cytokines 
including TNF-α and IL-1β. Moreover, the JNK pathway is activated in the innate 
immune response following the activation of various members of the Toll-like recep-
tor family by invading pathogens. The JNK pathways appears to act as a critical 
intermediate in signalling in the immune system. There is increasing evidence that 
JNK is activated following sensing of internal stress events, such as protein misfold-
ing. Studies also showed that bacterial, fungal, prion, parasitic, or viral infections 
activate JNK which may infl uence important cellular consequences such as altera-
tions in gene expression, cell death, viral replication, persistent infection or progeny 
release, or altered cellular proliferation. The exact mechanism of JNK activation 
under each of these circumstances remains not fully clear, but there may be involve-
ment of Toll-like receptors, direct pathway modulation through interaction with 
upstream protein regulators or the activation following an ER stress response 
(Bogoyevitch and Kobe  2006 ). 
 Overman et al. ( 2011 ) found that quercetin attenuated the phosphorylation of JNK 
and c-Jun, which means a decrease in JNK activation. They also observed attenuation 
in degradation of IκBα. Overman et al. ( 2010 ) showed the same results for grape 
powder extract. Degradation of IκB is a seminal step in activation of NF-κB. The IκB 
kinases (IKKs) lie downstream of the NF-κB-inducing kinase (NIK) and activate 
NF-κB by phosphorylation of IκBα. This leads to IκBα degradation and release of 
NF-κB. NF-κB is a key regulator of the pro-infl ammatory cytokine release, so an 
infl ammatory response is induced. In U937 monocytic cells, IL-1β and TNF-α induced 
IκB-dependent transcription equally (Nasuhara et al.  1999 ). These results are contra-
dicting with the results from studies with quercetin on THP-1 cells, in which quercetin 
showed anti-infl ammatory effects. It is possible that these cell lines respond differ-
ently to quercetin, simply because the cell lines are not the same. 
 Open Access This chapter is distributed under the terms of the Creative Commons Attribution 
Noncommercial License, which permits any noncommercial use, distribution, and reproduction in 
any medium, provided the original author(s) and source are credited. 
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 Chapter 15 
 Peripheral Blood Mononuclear Cells 
 Charlotte  R.  Kleiveland 
 Abstract  Numerous cell types are involved in maintenance of the intestinal tissue. 
However, the main players are cells of the epithelial lining and the immune system. 
Human peripheral blood mononuclear cells (PBMCs) are used to investigate the 
effect of food bioactives on various immune cells. These cells are easily isolated 
from blood of healthy donors or buffy coats (leukocyte concentrates, a by-product 
from hospital Blood Banks in the manufacturing of red blood cell and thrombocyte 
concentrates from anti-coagulated whole blood). PBMCs have a different composi-
tion, phenotype and activation status than cells found in intestinal tissue. However, 
this is a useful test system for investigation of immune modulatory effects of food 
bioactive compounds. Methods for the isolation of PBMCs and how they are used 
to investigate effects of bioactive components are discussed in this chapter. 
 Keywords  Peripheral blood mononuclear cells (PBMCs) •  Mitogenic lectins • 
 T cells •  Cytokines •  Surface markers 
15.1  Origin 
 Human peripheral blood mononuclear cells (PBMCs) are isolated from peripheral 
blood and identifi ed as any blood cell with a round nucleus (i.e. lymphocytes, 
monocytes, natural killer cells (NK cells) or dendritic cells). The cell fraction cor-
responding to red blood cells and granulocytes (neutrophils, basophils and eosino-
phils) is removed from whole blood by density gradient centrifugation. A gradient 
medium with a density of 1.077 g/ml separates whole blood into two fractions; 
PBMCs makes up the population of cells that remain in the low density fraction 
(upper fraction), whilst red blood cells and PMNs have a higher density and are 
found in the lower fraction (Fig.  15.1 ). 
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 PBMCs include lymphocytes (T cells, B cells, and NK cells), monocytes, and 
dendritic cells. In humans, the frequencies of these populations vary across indi-
viduals, but typically, lymphocytes are in the range of 70–90 %, monocytes from 10 
to 20 %, while dendritic cells are rare, accounting for only 1–2 %. The frequencies 
of cell types within the lymphocyte population include 70–85 % CD3 + T cells, 
5–10 % B cells, and 5–20 % NK cells. The CD3 + lymphocytes are composed of 
CD4 + and CD8 + T cells, roughly in a 2:1 ratio. After activation the CD4 + T cell 
subset may develop into diverse effector cell subsets, including Th1, Th2, Th17, 
Th9, Th22, follicular helper (Tfh) cells and different types of regulatory cells (Akdis 
et al.  2012 ; Crotty  2011 ; Tan and Gery  2012 ; Sakaguchi et al.  2008 ). The CD4 + 
helper T cells are essential mediators of immune homeostasis and infl ammation 
(Hirahara et al.  2013 ). 
15.2  Features and Mechanisms 
 Most of the PBMCs are naïve or resting cells without effector functions. In the 
absence of an ongoing immune response T cells, the largest fraction of the isolated 
PBMCs, are mainly present as naïve or memory T cells. The naïve T-cells have 
never encountered their cognate antigen before and are commonly characterized by 
the absence of activation markers like CD25, CD44 or CD69 and the absence of the 
memory marker CD45RO isoform. Antigen recognition by a naïve T cell may result 
in activation of the cell (described in detail in  Chap.  18 ), which will then enter a 
differentiation program and develop effector functions. Activated T cells may 
 Fig. 15.1  Schematic illustration of how to prepare the density gradient for isolation of PBMCs 
from blood ( a ,  b ) and where in the gradient the PBMCs ( grey layer ) are found after centrifugation 




further differentiate into memory T cells that are able to mount a faster and stronger 
immune response the second time the antigen is encountered. B cells are also 
present in blood as naïve cells with a surface-anchored antigen receptor. Upon 
encountering antigen, the B cell may become activated and differentiate into 
antibody-producing plasma cells. 
 In peripheral blood the frequency of lymphocytes with specifi city for a single 
antigen are low. Polyclonal activators are therefore used for in vitro stimulation as 
these will activate a large proportion of the lymphocytes, independently of their 
antigen specifi city. The most common activators are mitogenic lectins, carbohydrate- 
binding proteins that bind to a number of glycoproteins expressed on the plasma 
membrane of lymphocytes (Ashraf and Khan  2003 ). Also, polyclonal activation of 
T cells can be obtained by antibodies that specifi cally bind to CD3, alone or in 
combination with CD28. The most commonly used mitogenic lectins are phytohae-
magglutinin (PHA) and concanavalin A (con A) that mainly induce T cell prolifera-
tion, pokeweed mitogen (PWM) that induce T and B cell proliferation and 
lipopolysaccharide (LPS) which induce B cell proliferation and activation of mono-
cytes. Effects on the immune function of PBMCs are usually investigated by 
measuring changes in lymphocyte proliferation, characterization of cytokine 
secretion profi les or changes in gene expression. 
15.3  Stability, Consistency and Reproducibility 
 It is well known that multiple physiological factors such as nutritional status, 
hormone levels and infections/infl ammation will infl uence the reactivity of immune 
cells; hence, the composition of PBMCs will depend on donor and the donor’s 
physiological status. Compared to the use of cell lines, this can lead to increased 
inter- experimental variation when different donors are used. Although the use of 
different donors leads to increased variance, the strength of reproducing results with 
cells from several donors will support the generality of the results. 
15.4  Relevance to Human In Vivo Situation 
 PBMCs isolated from whole blood will be different from immune cells isolated 
from intestinal tissue or lymph nodes draining the intestine. Intraepithelial lympho-
cytes are predominantly CD8 + (90 %) cells whilst lymphocytes within the lamina 
propria are mainly CD4 + cells expressing a CD44 hi CD62L − effector memory phe-
notype which indicate that these are antigen-experienced cells (Shale et al.  2013 ). 
In addition, several populations of immune cells present in the intestinal mucosa is 
not present in blood i.e. B1 B cells, natural killer T cells (NKT cells) and innate 
lymphoid cells (ILCs). Upon infl ammatory signals, monocytes from blood will 
move into the site of infection and differentiate to myeloid antigen-presenting cells 
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which is a heterogeneous population of macrophages and dendritic cells (DCs) 
(Swiatczak and Rescigno  2012 ). Because of these differences in the phenotype of 
cells present in blood and in lamina propria of the gastrointestinal tract it can be 
expected that mononuclear cells isolated from blood will respond differently from 
lamina propria mononuclear cells. Care should therefore be taken in drawing con-
clusions about the mucosal immune response in the intestine from in vitro studies 
with PBMCs. 
15.5  General Protocol 
 Isolation of PBMCs is done from peripheral blood or buffy coats supplemented with 
anticoagulants (heparin, EDTA, citrate, ACD-A or citrate phosphate dextrose 
(CPD)). Blood is diluted with 2–4 volumes phosphate-buffered saline (PBS) pH-7.2. 
The more diluted blood samples the better purity of the mononuclear cells. Add 
35 ml of diluted blood to a 50 ml tube (Fig.  15.1a ). Place 10 ml of a density gradient 
medium with ρ = 1.077 g/ml (e.g. Ficoll-Paque PLUS) at the bottom of the tube with 
a 15 G hypodermic needle (or similar) (Fig.  15.1b ) before centrifugation at 400× g 
for 25 min at 20 °C in a swinging bucket rotor without brake. Using a brake during 
centrifugation will disturb the separation of the upper and lower fractions. Aspirate 
most of the upper layer leaving the mononuclear cells at the interphase (Fig.  15.1c ). 
Carefully transfer the mononuclear cells to a new 50 ml tube, fi ll the tube with PBS, 
mix and centrifuge at 300× g for 10 min at 20 °C (Fig.  15.1d ). Remove the superna-
tant completely and resuspend the cells in a small volume of PBS before diluting the 
cell suspension with 50 ml PBS and centrifuge at 200× g for 15 min at 20 °C. This 
step will remove platelets, and it should be repeated at least once. When most of the 
platelets are removed, resuspend the cells in complete RPMI 1640 with 10 % heat 
inactivated fetal calf serum (FCS), and count them. Cells can be used immediately 
or preserved and stored in liquid nitrogen. 
15.5.1  Study of Proliferative/Cytotoxic Activity 
 Dilute the test compounds in RPMI 1640 with additions as described above. Seed 
the PBMCs at a density of 1 × 10 5 cells/well in a 96 well plate. Incubate the PBMCs 
with serial dilutions of the test compound in triplicates at 37 °C in an atmosphere of 
5 % CO 2 and 100 % humidity. Measurement of effects on proliferative/cytotoxic 
responses must be done in the presence and absence of the mitogenic stimuli. An 
array of methods and kit-based assay systems are available for this purpose, for 
example incorporation of  3 H-thymidine or measurement of mitochondrial reductase 
with tetrazolium salts (MTT). The optimal concentrations of the polyclonal activa-
tors can be established by cultivating PBMCs in the presence of twofold dilutions of 
the activators. Effect of the test compound on proliferation/cytotoxicity should be 
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studied in combination with both optimal and suboptimal concentrations of the 
mitogenic stimuli. The vehicle control (solvent of the test compound stock) should 
be included too. As background control, RPMI 1640 with the test compound and 
activators can be used. As negative control, PBMCs in RPMI 1640 without both test 
compounds and activators should be used. 
15.5.2  Study of Infl ammatory Responses 
 Upon stimulation with polyclonal activators PBMCs will produce cytokines and 
up-regulate activation markers. Characterization of the cytokine profi le and changes 
in activation marker expression, especially on T cells, may provide information 
whether the response is in the direction of Th1, Th2, Th17 or regulatory T cells. 
Investigations of the cytokine profi le is most easily carried out by ELISA analysis 
of secreted cytokines in the culture supernatant. Alternatively, the number of cells 
producing the different cytokines can be studied after intracellular staining and 
analysis by fl ow cytometry. Also, changes in gene expression levels by qPCR can be 
informative. Test compounds should be diluted in RPMI 1640. Plate the PBMCs at 
a density of 1–2 × 10 6 cells/well in a 24 well plate. Incubate the PBMCs with a serial 
dilution of the test compound in the presence and absence of LPS (100 ng/ml), anti-
 CD3/CD28 or the above mentioned mitogenic lectins at 37 °C in an atmosphere of 
5 % CO 2 . Cytokines will be detectable in the culture supernatant after only a few 
hours. However, cytokines will be secreted with different kinetics, it will therefore 
be necessary to study the cytokine profi le at different time points. 
15.6  Assess Viability 
 In the case of the study of infl ammatory responses, the cytotoxicity of the test 
compound at varying concentrations should be tested for instance by using LDH 
or MTT. 
15.7  Experimental Read Out 
 PBMCs have been widely employed to assess several aspects of immune regulation. 
The physiological relevance of in vitro studies with PBMCs is debatable, but several 
reports have shown that these studies can be predictive for the in vivo situation. de 
Kivit et al. ( 2012 ) reported that increased galectin-9 expression in intestinal epithe-
lial cells and serum induced by dietary symbiotics in mice correlated with reduced 
acute allergic skin reactions and mast cell degranulation. Parallel studies with stim-
ulation of PBMCs with recombinant galectin-9, showed induction of development 
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of Th1 and Treg cells. CD3/CD28-activated PBMCs were incubated with either 
medium or increasing concentrations of recombinant galectin-9 for 24 h. The effect 
on T cell activation was assessed by analysis of surface markers by fl ow cytometry. 
Th1 cells were identifi ed as CD4 + , CD69 + and CXCR3 + and Treg cells as CD4 + , 
CD25 + and Foxp3 + . Further characterization of the cytokine profi le was used to sup-
port the results. Increased secretion of IFNγ and Il-10 suggest increased levels of 
Th1 and Treg cells, whilst a decrease in IL-17 supports suppression of Th17 cells. 
 Cytokine secretion is one of the most used outcomes for evaluating infl uence on 
immune responses and has been studied with a variety of different types of com-
pounds. For example, Schroecksnadel et al. reported immune modulatory effects of 
a vitamin K antagonist (Schroecksnadel et al.  2013 ). PBMCs were pre-incubated 
with the vitamin K antagonist for 30 min before the cells were stimulated with PHA 
for 48 h. The cytokines secreted into the supernatants were analyzed by ELISA. Also, 
in a recent report cytokine secretion and activation of mitogen-activated protein 
kinases (MAPK) in response to polysaccharides isolated from  Alchornea cordifolia 
(Kouakou et al.  2013 ) was studied. Evaluation of the effects of polysaccharides on 
the activation status of an array of different MAPKs was done using a phospho- 
MAPK kit. PBMCs were incubated with the test compound for 60 min before lysis 
of the cells. An array of methods and kit based assays are available for evaluation of 
the activation status of MAPK and other intracellular protein kinases. 
 Effect of polyphenolic extracts from  Carpobrotus rossii on cytokine release from 
PBMCs has been reported (Geraghty et al.  2011 ). The cytokine release induced by 
the polyphenolic extract was investigated in the presence and absence of stimulation 
with PHA and LPS. In this study, a multiplex cytokine profi ling kit (Luminex ® ) was 
used to determine cytokine concentrations in culture supernatants. 
 Several reports have used PBMCs to study the immunomodulatory effects of 
probiotic bacteria.  Lactobacillus plantarum genes involved in immune modulation 
were identified in a study with PBMCs (van Hemert et al.  2010 ). A total of 42 
 L. plantarum strains were evaluated for their capacity to stimulate cytokine produc-
tion in PBMCs. Comparison of strain-specifi c cytokine responses by PBMCs 
resulted in identifi cation of six candidate genetic loci with immune modulatory 
capacities. Ashraf et al. have recently reported effects of cell-surface extracts and 
metabolites from a probiotic organism on both cytokine production and induction of 
CD25 expression on PBMCs (Ashraf et al.  2014 ). 
15.8  Advantages, Disadvantages and Limitations 
of the System 
 The advantage of PBMCs is that it is an easy accessible source of human immune 
cells, as the cells are isolated form full blood or buffy coats. 
 Disadvantages and limitations of this model system is the phenotypic differences 
between peripheral mononuclear cells and immune cells of the intestinal mucosa. 
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15.9  Conclusions 
 Although PBMCs is an easy accessible source of human immune cells, there are 
two major points that are important to keep in mind. (1) These cells are blood 
mononuclear cells that will differ from immune cells found i.e. in intestinal tissues. 
(2) When using PBMC in in vitro experiments the cells will lack the environmental 
stimuli they would have been exposed to under normal in vivo conditions. Both of 
these points are of great importance for how immune cells responds to different 
stimuli and should be taken in to account when interpreting the results. 
 Open Access This chapter is distributed under the terms of the Creative Commons Attribution 
Noncommercial License, which permits any noncommercial use, distribution, and reproduction in 
any medium, provided the original author(s) and source are credited. 
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 Chapter 16 
 PBMC-Derived T Cells 
 Daniel  Lozano-Ojalvo ,  Rosina  López-Fandiño , and  Iván  López-Expósito 
 Abstract  T cell cultures are a valuable tool in food research to perform studies 
within the food allergy fi eld. Their main applications aim to analyze immunological 
responses towards food protein antigens to gain further insights into the mecha-
nisms responsible for the development of oral tolerance or for the triggering of food 
allergies. This chapter describes the main applications, isolation techniques, and 
culture conditions for PBMC-derived T cells. Furthermore, critical parameters of 
the model, together with the experimental read outs will be discussed. 
 Keywords  T cells cultures •  Food allergy •  Immunomagnetic cell isolation • 
 PBMCs  •  CD4 +  T cells 
16.1  Introduction and Origin 
 T lymphocytes or T cells are small (<10 μm) resting cells, which are generated in 
the bone marrow and migrate to the thymus where they become mature. Once 
matured, they enter the bloodstream and circulate to the secondary lymphoid organs, 
the sites of lymphocyte activation by the antigens. Actually, T cells are constantly 
recirculating between these organs until they encounter their specifi c antigen. Naïve 
T cells (T cells that have not yet met their specifi c antigen) bear antigen receptors 
specifi c for a single chemical structure, however lymphocytes in the body collec-
tively carry millions of different receptor specifi cities. Only those that meet an 
antigen to which their receptors bind will be activated to proliferate and differentiate 
into effector cells (Janeway et al.  2005 ). 
 This chapter deals with T lymphocytes derived from peripheral blood 
 mononuclear cells (PBMCs). T cells comprise, approximately, 45–70 % of PBMCs 
in human peripheral blood, with a count in healthy subjects in the range of 1 million 
cells/mL. For many years there was no function ascribed to these cells, until the 
1960s, when it gradually became apparent that T lymphocytes were the key mediators 
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of adaptive immunity. T cell cultures are a valuable tool in food research to perform 
studies within the food allergy fi eld. Their main applications aim to analyze 
immunological responses towards food protein antigens to gain further insights into 
the mechanisms responsible for the development of oral tolerance or for the trigger-
ing of food allergies (Martino et al.  2012 ). 
16.2  Features and Mechanisms 
 T cells express surface antigen receptors called T cell receptors (TCRs), which are 
inserted in the T cell surface and never secreted. The most common form is made up 
of α and β chains and it is found on about 95 % of circulating T cells. The TCR is a 
clonally distributed receptor, meaning that clones of T cells with different specifi cities 
express different TCRs. In the functional TCR, the α and β heterodimers are associ-
ated with a complex of four other invariant signaling chains, collectively called 
CD3, which are required for the cell-surface expression of the antigen binding 
chains and for signaling (Fig.  16.1 ) (Farber  2011 ). 
 There are two major types of T lymphocytes, classifi ed according to the 
expression of the cell surface co-receptors CD4 and CD8, which are proteins non- 
covalently associated with the TCR. Their function is to signal to the T cell that the 
TCR complex has bound the proper antigen. CD4 + T cells are generally referred as 
helper T cells or Th cells, because they secrete a multitude of cytokines that help or 
coordinate cellular and humoral immunity. CD8 + T cells are generally referred as 
cytotoxic T lymphocytes or Tc cells. Cytotoxic T cells recognize as antigens 
fragments of viral proteins on the surface of virus-infected cells, which they kill by 
the activation of a cascade of caspases. In humans, circulating CD4 + T cells out-
number CD8 + T cells by approximately 2:1 (Abbas et al.  2007 ). This chapter will 
deal with the CD4 + T lymphocytes, as they are the type of T lymphocytes that 
become activated during the allergic response. 
 T cell responses are initiated when a mature CD4 + T cell encounters a properly 
activated antigen presenting cell (APC), such as a dendritic cell, in a secondary 
 Fig. 16.1  TCR structural components (adapted from Farber  2011 ) 
 
D. Lozano-Ojalvo et al.
171
lymphoid organ. If the APC displays the appropriate peptide ligand through the 
major histocompatibility complex (MHC) class II molecule, it is recognized by the 
TCR. This is essential for activating a naïve T cell, but even if the co-receptor CD4 
is also ligated, for the T cell to proliferate and differentiate, two other stimulatory 
signals delivered by the APC are required. These signals are, on the one hand, the 
binding of two different ligands on the APC surface, designated as CD80 and CD86, 
to a surface molecule on the T cell, called CD28, and on the other, those involved in 
directing T cell differentiation into different subsets of effector T cells, the latter 
being mainly, but not exclusively, driven by cytokines, such as IL-6, IL-12 and 
TGF-β (Fig.  16.2 ). The CD28-dependent co-stimulation of activated T cells leads to 
production of IL-2 by the activated T cell themselves. Following expression of IL-2, 
there is also an upregulation of the third component (called α-chain) of the IL-2 
receptor, also known as CD25, in addition to other regulatory molecules such as 
ICOS and CD40L (Farber  2011 ). Binding of IL-2 to its high affi nity receptor pro-
motes cell growth, whilst APCs, mainly dendritic cells generate various cytokines 
or express surface proteins that induce the differentiation of CD4 + T lymphocytes 
into cytokine producing effector cells, depending on environmental conditions. 
 Originally, two main types of effector CD4 + T cells, called T-helper 1 ( Th1 ) and 
2 ( Th2 ) cells, were distinguished by the pattern of their cytokine secretion. Th1 cells 
secrete mainly IL-2, IFNγ and TNFα, and Th2 cells secrete IL-4, IL-13 and IL-5 
(Romagnani  2000 ). Recently, this view has been challenged by the discovery of a 
new lineage of T cells characterized by their ability to secrete a proinfl ammatory 
cytokine, IL-17, and thus designated Th17 cells. This new T cell type has been 
related with autoimmune diseases (Jing and Dong  2013 ). Another subset of antigen- 
driven CD4 + T cells, named regulatory T cells ( Treg ), acts by inhibiting T cell 
 Fig. 16.2  Signals involved in the activation of naïve T cells by APC 
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responses by the production of cytokines, such as IL10 and TGF-β and/or via 
cell–cell interactions (Jutel and Akdis  2011 ). Treg are CD4 + cells that also express 
the α-chain of the IL-2 receptor (CD25 + ) and the transcription factor FoxP3. 
 The immune response leading to food allergy is driven by two main groups of 
signals. The fi rst signal favors the differentiation of naïve T cells into a Th2 pheno-
type, and the second comprises the Th2 induced activation of B cells (mediated by 
cytokines such as IL-4 and IL-13 and co-stimulatory signals) to generate allergen- 
specifi c IgE antibodies (Mayorga et al.  2013 ). 
16.3  Applications of T Cell Cultures 
 The main application for T cell cultures is the  characterization of CD4  +   T cell 
epitopes from food allergens . The mapping of CD4 + T cell epitopes contributes to a 
better understanding of the pathophysiology of food allergy by enabling the identi-
fi cation of the major peptides that target allergen-specifi c T cells (Prickett et al. 
 2011 ,  2013 ). This requires the comparison of the epitope recognition patterns of a 
diverse and representative sample of allergic individuals, since a given T cell 
epitope elicits a signifi cant response only in subjects expressing MHC-class II 
molecules able to recognize and bind that particular epitope. In addition, the knowl-
edge of the sequence of T cell epitopes that stimulate CD4 + T lymphocyte responses 
allows the development of new forms of immunotherapy, which are safer and more 
effective than those using whole allergens. In this respect, peptide-based vaccines 
corresponding to T cell epitopes of the allergen of interest retain immunogenicity, 
but they are of insuffi cient length to cross-link allergen specifi c IgE on the surface 
of effector cells and elicit an allergic response (Worm et al.  2011 ). 
 Another important application related with the use of T cell cultures is the  study 
of the allergen - specifi c T cell responses during or after immunotherapy . In this 
context, evidence has accumulated that immunotherapy treatments shift a patient’s 
immune reaction to a specifi c allergen from a predominately allergic Th2 response 
to a Th1 response, while inducing Treg that downregulate Th2 and Th1-cells activity. 
The characterization of the frequency and phenotype of allergen-specifi c T cells is 
useful to understand the immunological changes subjacent to therapeutical inter-
ventions in allergic diseases (DeLong et al.  2011 ; Foster et al.  2011 ). In this context, 
the role of Treg producing IL-10 in allergen specifi c T cell tolerance and immune 
deviation has been studied by comparing the response of PBMCs and PBMCs 
depleted of CD25 + in patients undergoing immunotherapy, as well as in tolerant and 
allergic patients, allowing the identifi cation of potential markers that might be 
indicators of a favorable prognosis (Shreffl er et al.  2009 ; Bohle et al.  2007 ). 
Similarly, allergen-specifi c signaling can be assessed in activated and purifi ed CD4 + 
T cells to test whether there is a differential expression in the neonates who subse-
quently develop allergic diseases (Martino et al.  2012 ). 
 In the fi eld of food allergy, T cell gene and protein expression assays are very 
important for the understanding of the functional characteristics of allergen 
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reactive T cells. The use of PBMCs as a source of circulating T cells, that mimic 
effects occurring in remote target tissues of antigen exposure, presents the advantage 
that they can easily obtained by blood extraction and allow the study of parameters 
that otherwise would require more invasive methods, such a biopsy (de Mello et al. 
 2012 ). However, certain applications based on the exclusive employment of PBMC- 
derived T cells are limited because of the lack of APCs that are keys to the regula-
tion of the complicated set of mechanisms that determine the immune responses, as 
well as of other environmental infl uences that play an important role in shaping the 
APC functions. To overcome this limitation, there are other options, such as the use 
of co-cultures with APCs (Frischmeyer-Guerrerio et al.  2011 ; Hofmann et al.  2012 ) 
or complex culture systems with other cell types, such as APCs and intestinal epi-
thelial cells (Mileti et al.  2009 ). Another alternative are cell cultures from tissues of 
animal models of food allergy (spleen, lymph nodes, Peyer’s patches) (López- 
Expósito et al.  2011 ). In any case, and because of extension limits, this chapter will 
only deal with T cells that do not require APCs in the culture (more information 
available in Chap.  17 ). 
 Because of the low frequency of allergen-specifi c CD4 + T cells, several studies 
use allergen-specifi c CD4 + T cell lines or clones (Prickett et al.  2011 ,  2013 ), while 
others use primary CD4 + T cells, without addition of cytokines or repeated stimula-
tion (Frischmeyer-Guerrerio et al.  2011 ; Hofmann et al.  2012 ). Although T cell lines 
overcome the frequency limitation, previous in vitro expansion can alter cell pheno-
types or bias the results through the selection of the rapidly proliferating clones 
(Pascal et al.  2013 ). 
16.4  General Protocol 
16.4.1  T Cell Isolation Protocols 
 Because of the ease of access to peripheral blood, PBMCs, which contain T and B 
lymphocytes and monocytes, are the major source of human T cells used in most 
studies. There is a variety of available techniques for isolation and enrichment of T 
cells, including those based on their unique ability to bind and form rosettes with 
sheep red blood cells, as well as those based on differential adherence properties T 
cells to nylon wool. Despite their widespread use, the resulting T cell population is 
not very pure compared to the level of purity achieved with other procedures, and 
several reports suggest alterations in T cell functionality when these techniques are 
used (Wohler and Barnum  2009 ). 
 Human T cells can also be purifi ed on the basis of their cell-surface display if 
specifi c antigens can be recognized by monoclonal antibodies. This is currently 
carried out by two main methods: fl uorescence-activated cell sorting (FACS) and 
immunomagnetic cell separation (Martino et al.  2012 ; Prickett et al.  2013 ). FACS 
requires sophisticated technology, highly trained personnel; it is time consuming, 
expensive and may result in a signifi cant cell loss. Conversely, immunomagnetic 
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separation methods are faster, relatively inexpensive and do not require state of the 
art technology (Lancioni et al.  2009 ). 
 Immunomagnetic separation methods are based on the attachment of small 
magnetizable particles to cells via antibodies. The physical basis for such separation 
procedures involve the coupling of antibodies to magnetic beads, which subse-
quently allows the rapid capture of the cells specifi cally recognized by these anti-
bodies among a mixed population of cells placed in a magnetic fi eld. There are two 
types of magnetic cell isolation technologies, column and tube-based. Both work on 
the same principle, but the strength of the magnetic fi eld required is different 
because they use beads of different sizes. In particular, the  column - based technol-
ogy uses beads consisting of iron oxide and polysaccharide of, approximately 50 nm 
in diameter, which require a very strong magnetic fi eld. The main disadvantages of 
this system (exemplifi ed by MACS produced by Milteny Biotech) lay in its high 
initial and running costs, although it provides cells with high purity and optimal 
viability and functionality (Li et al.  2012 ). 
 The immunomagnetic  tube - based separation system utilizes micro-sized beads 
that can be selected using a magnet applied to a tube. The most commonly used 
beads, produced by Dynal, are 4.5 μm, uniform, spherical beads, which do not have 
any residual magnetism outside a magnetic fi eld. They consist of an iron-containing 
core surrounded by a thin polymer shell to which biomolecules may be adsorbed. 
These beads can be attached to cells via a coating of primary or secondary antibodies. 
The cells, surrounded by a “rosette” of beads, may then be separated from the unla-
beled population in a magnetic fi eld using a relatively small, but powerful magnet 
(Neurauter et al.  2006 ). 
 There are two main strategies for cell isolation using micro-sized beads:  positive 
and  negative selection . Positive selection can be performed using either direct or 
indirect approaches (Neurauter et al.  2006 ). Following  direct positive isolation , the 
appropriate antibody-coated beads are mixed with the sample and the target cells 
bound to the coated beads are subsequently collected with the aid of a magnet. For 
 indirect positive isolation , a cell population is exposed to saturating amounts of a 
primary antibody which binds to the target cells and, once the unbound antibodies 
are washed away, secondary-antibody coated beads bind to the primary antibodies 
on the surface of the target cells. For further functional applications, and in order to 
avoid modifi cations of the phenotype, the cells bound to antibody-coated beads 
should be detached by exposure to a soluble antiserum against Fab fragments (e.g., 
DETEACHaBEAD). However, surface bound antibodies may elicit the transmission 
of signals across the cell membrane. This can be avoided by negative isolation, 
which does not require attachment of antibodies to the cells of interest at any time 
(Neurauter et al.  2007 ). By  negative isolation , the cells are selected by removing all 
other cell types from the sample. Generally, a cocktail of monoclonal antibodies is 
incubated with the sample, followed by depletion of the undesirable cells using 
secondary antibody-coated beads (Biddison  1998 ; Mayer et al.  2013 ). Positive and 
negative separation strategies can be combined in the sequential sorting of T cell 
subsets, such as CD25 + FoxP3 + regulatory T cells, where depletion of unwanted cells 
is followed by positive selection of CD25 + T cell population (Mayer et al.  2013 ). 
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 The procedure described in this chapter is based on the indirect  positive isolation 
of a subset of human T cells relevant to food allergy, such as CD4 + T cells, by anti-
 CD4 and anti-IgG-coated beads (Biddison  1998 ; Neurauter et al.  2006 ). This 
methodology is very effi cient in removing target cells due to its fast cell capture 
kinetics, whereas the use of secondary-antibody coated beads makes it a fl exible 
protocol to isolate any cell of interest (Neurauter et al.  2007 ). 
16.4.2  Indirect Positive Isolation of Human CD4 + T 
16.4.2.1  Preparation of Cells and Antibodies 
 PBMCs could be obtained from whole blood by density gradient of Ficoll-Hypaque 
(Martino et al.  2012 ). It is convenient to determine the approximate number of CD4 + 
T cells in the starting population of PBMCs by fl ow cytometry using anti-CD4 
antibody. It is also helpful to establish the saturating concentration of anti-CD4 
mouse- IgG monoclonal antibody to be used by fl ow cytometry. Generally, 1 μg/mL 
per 1 × 10 6 cells works well as a saturating concentration. However, pretitration may 
allow the use of down to a tenfold lower concentration. 
16.4.2.2  Coating of PBMCs with CD4 Antibody 
 PBMCs (≤200 × 10 6 cells) are suspended in PBS/BSA and anti-CD4 mouse IgG 
antibody is added (10×). After incubation during 45 min at 4 °C with gentle tilting 
and rotation, cells are centrifuged 10 min at 600× g at room temperature. The super-
natant is discarded and the pellet resuspended in pre-cooled PBS/BSA. This step is 
repeated twice. Finally, washed cells are resuspended in 10 mL of pre-cooled PBS/
BSA and kept on ice for 15 min. 
16.4.2.3  Magnetic Beads Washing Procedure 
 On the basis of the number of CD4 + cells estimated by fl ow cytometry, the number 
of required goat anti-mouse IgG-coated magnetic beads is calculated. Five to ten 
magnetic beads are needed for each specifi c lymphocyte. Taking into account the 
concentration supplied by the manufacturer, the coated beads are resuspended in 
PBS and the desired volume of beads are transferred to a tube. PBS is added to the 
bead suspension and the tube is placed on a magnetic separation device for 2 min. 
The supernatant is then discarded by leaving the beads clinging to one side of the 
tube. The tube is removed from the magnet and the beads are washed following the 
previous step. Finally, the washed beads are resuspended in pre-cooled PBS/BSA 
and held on ice for 15 min. 
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16.4.2.4  Separation of T Cells 
 Anti-CD4-coated PBMCs are mixed with washed anti-IgG-coated beads and incu-
bated for 45 min at 2–8 °C with gentle tilting and rotation. Afterwards, the tubes are 
placed on a vertical magnet for 2 min and the supernatant is carefully discarded. 
It is important not to disturb the beads that are clinging to one side of the tube. Once 
the tube is removed from the magnet, the beads are gently resuspended in 5 mL of 
Lymphocyte Culture Medium (LCM), which contains RPMI-1640 medium, 2 mM 
 L -glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin and 5 % (v/v) fetal 
bovine serum (FBS) (heat-inactivated during 1 h at 56 °C) (Prickett et al.  2013 ). 
Then, the tube is placed on the magnet for another 2 min and the non-collected cells 
aspirated, as in the previous step. The same procedure is repeated adding 5 mL of 
LCM to the tube. Finally, 2.5 mL of supernatant are carefully removed and the tube 
gently tapped to resuspend the T cells-coated-bead suspension. 
16.4.2.5  Detachment of T Cells from Beads 
 Polyclonal anti-mouse Fab antiserum (200 μL) is added. Approximately 10 μL of 
Fab antiserum are needed per 10 7 beads, although a smaller amount of Fab antise-
rum solution may be used when starting with smaller numbers of lymphocytes (see 
manufacturer’s instruction). This is mixed gently by tilting and rotation during an 
incubation period of 45–60 min at room temperature (incubation at 4 °C reduces the 
number of detached cells, while 37 °C does not increase detachment effi ciency). 
Due to the relatively small sample volume, care should be taken that the cells remain 
on the bottom of the tube during agitation. 5 mL of PBS/BSA are added to the tube 
to resuspend the beads. Tubes are placed on a vertical magnet for 2 min. The super-
natant containing the detached cells is then aspirated and left aside, while the beads 
remain attached to the wall of the tube by the magnet. It is important not to disturb 
the beads clinging to the side of the tube. This step is repeated four times to improve 
the isolation yield, saving and combining detached cell-containing supernatants 
from each separation in the same tube. Then, the tube with the detached T cells is 
centrifuged 10 min at 600× g at room temperature. The supernatant is discarded and 
the cells resuspended in LCM. Finally, T cells are counted and the number of viable 
cells determined by trypan blue exclusion. It is convenient to determine the purity 
of the CD4 + T cell population by fl ow cytometry using anti-CD4 antibody. 
16.5  Assess Viability 
 Once PBMC-derived T cells have been isolated and detached from the magnetic 
beads, they are usually resuspended in LCM (Prickett et al.  2013 ). Alternatively, 
Iscove’s modifi ed Dulbecco’s medium (IMDM), containing 100 U/mL penicillin, 
100 μg/mL streptomycin, 5 μg/mL gentamicin and 5 % of heat-inactivated FBS, 
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could also be used (Frischmeyer-Guerrerio et al.  2011 ). In the above proposed T cell 
culture media, FBS could be replaced by 5 % of heat-inactivated human serum or 
10 % heparinized human plasma. While most protocols use serum to provide opti-
mal conditions for T cell viability, reactivity and expansion, a number of serum-free 
media have been developed (e.g., AIM-V, Invitrogen Corporation; or X-VIVO, 
Lonza) (Shreffl er et al.  2009 ). These media are specifi cally formulated to support 
the culture of T cells and incorporate defi ned quantities of purifi ed growth factors, 
lipoproteins, and other proteins, which are usually provided by the serum. 
 Commonly, T cells are seeded at a fi nal concentration of 1–2.5 × 10 6 cells/mL in 
24 or 48-well cell culture plates (Pascal et al.  2013 ). Although, in T cell proliferation 
([H 3 ]-thymidine) and viability (MTT or XTT) assays, 96-well plates are used and 
only 100 μL of the cell solution are added, resulting in 1–2.5 × 10 5 cells per well (Martino 
et al.  2012 ). T cell culture assays are usually carried out in sample (three different 
wells) and biological triplicates (three different plates) (Prickett et al.  2011 ). 
 All incubations of T cell cultures must be performed at 37 °C in a humidifi ed 5 % 
CO 2 incubator. The incubation period for T cell assays varies depending on the ini-
tial cell population, percentage of damaged cells and stimuli used. Proliferation 
following mitogen-induced activation generally peaks after 2–6 days of culture 
(Bohle et al.  2007 ). An incubation period of 72 h is also used when proliferative 
responses to food proteins (such as OVA or peanut extracts) are studied (Prickett 
et al.  2011 ; Martino et al.  2012 ). However, for gene expression and cytokine 
detection assays, the response may not peak until after 5–10 days. Thus, the effect 
of Ara h 2 peptides has been analyzed after 4 days of incubation (Pascal et al.  2013 ), 
milk allergenic proteins after 5 days (Shreffl er et al.  2009 ) and Ara h 1 peptides after 
7 days (Prickett et al.  2013 ). To ensure that treatments do not affect cell health, a 
viability test should be performed. An array of methods and kit-based assays are 
available for cell viability, such as the measurement of mitochondrial reductase with 
tetrazolium salts (e.g. MTT, XTT and Alamar blue). 
16.6  Samples 
 Hydrophilic samples, such as polar food proteins, are usually added to the cells 
diluted in PBS or directly in the culture medium at different fi nal concentrations, 
which range from 10 to 200 μg/mL of culture (Pascal et al.  2013 ; Wing et al.  2003 ). 
When samples contain polyphenols or alcohols, they need to be resuspended in PBS 
or culture media containing 10 % of the aprotic and highly polar solvent 
DMSO. Potent T cell activators, such as mitogens (lectins like PHA or Concanavalin 
A), antigens (tetanus toxoid) or antibodies (anti-CD3/CD28) should be included as 
positive controls in the assays to test both cell viability and functionality (Bohle 
et al.  2007 ; Pascal et al.  2013 ). 
 A critical parameter in the evaluation of the response to proteins of T cells is 
sample quality. This is crucial for recombinant proteins which are produced in 
bacterial systems. These can carry over contaminants from the host cells to the fi nal 
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recombinant preparation, including irrelevant proteins and lipopolysaccharide 
(LPS). LPS, synthesized by gram-negative bacteria, has profound effects on T cell 
responses. LPS drives the development of Th1 subsets and it is also associated with 
toxicity (McAleer and Vella  2008 ). Because of these reasons, the purity of the 
proteins, and particularly the LPS concentration, should be determined by available 
commercial kits before application to T cell assays (Hofmann et al.  2012 ). 
16.7  Experimental Readouts 
 In vitro T cell functional measures to stimuli may be monitored by assays that detect 
proliferation, cytokine secretion and the expression of genes of interest, or charac-
terizing proliferating cells to identify phenotype and frequency. Measurement of the 
proliferative responses of T cells is fundamental for the assessment of their biologi-
cal reaction to various stimuli, such as food allergens or hypoallergenic prepara-
tions. T cell proliferation is commonly determined by estimating incorporation of 
[H 3 ]-thymidine into the DNA, a process which is closely related to underlying 
changes in cell number. [H 3 ]-thymidine methodology has been widely utilized in 
allergen-specifi c T cell proliferation studies (Prickett et al.  2011 ; Shreffl er et al. 
 2009 ). Alternatively, carboxyfl uorescein diacetate succinimidyl ester (CFSE) 
labeling prior to T cell culture enables direct measurement of cell division and it 
may be used in combination with cell surface markers to identify the target cells by 
fl ow cytometry (Foster et al.  2011 ; Prickett et al.  2013 ). 
 Cytokine secretion in response to a stimulus may be detected by measuring either 
cytokine production (by ELISA) or enumerating individual cytokine producing T 
cells (by ELISPOT). ELISA has been used to evaluate T cell behavior towards food 
allergens in several studies (Glaspole et al.  2011 ; Hofmann et al.  2012 ). In contrast 
to ELISA, ELISPOT allows the visualization of the secretory products of individual 
activated or responding T cells. Thus, it provides both qualitative (kind of cytokine) 
and quantitative (number of antigen-specifi c T cells) information (Prickett et al. 
 2011 ; Faresjö  2012 ). Flow cytometry has been also used for the measurement of T 
cell cytokine production by fl uorescent bead arrays (e.g., Cytometric Bead 
Array™—CBA, BD Biosciences) (Kücüksezer et al.  2013 ; Pascal et al.  2013 ). Flow 
cytometry can also be used for phenotypic analysis of T cell subsets, frequency 
determination (Shreffl er et al.  2009 ; Hofmann et al.  2012 ) and detection of intracel-
lular cytokines (DeLong et al.  2011 ). Finally, Real-Time quantitative PCR 
(RT-qPCR) has been largely used for the study the expression of cytokine genes 
(Kücüksezer et al.  2013 ). Gene expression has also been assessed in purifi ed CD4 + 
T cells by DNA microarrays to characterize T cell signaling pathways of allergic 
and non allergic children (Martino et al.  2012 ). 
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 Chapter 17 
 Dendritic Cells 
 Maud  Plantinga ,  Colin  de  Haar , and  Stefan  Nierkens 
 Abstract  Dendritic cells (DCs) are the sentinels of the immune system and play a 
critical role in stimulating immune responses against pathogens and maintaining 
immune homeostasis to harmless antigens. They can be found in all lymphoid and 
most non-lymphoid tissues, including mucosal surfaces, like the lung and the gut, 
where intricate networks of DCs are situated to sense potential harmful exposures. 
As such, DCs are among the fi rst cells to come into contact with food bioactives in 
the gastrointestinal tract and thus are instrumental in shaping the immune system’s 
response to such exposures. Here we provide an overview of DC characteristics, 
with the emphasis on DCs in the mucosal immune system, and discuss in vitro/ex 
vivo DC culture settings that can be applied for in vitro testing of (food) 
compounds. 
 Keywords  Dendritic cells •  DC subsets •  Culture •  Mucosa 
17.1  Origin 
 Paul Langerhans was the fi rst to describe DCs in the nineteenth century, when he 
visualised dendritically shaped cells in the skin (Langerhans  1868 ). Ralph 
M. Steinman and Zanvil A. Cohn identifi ed “dendritic cells” as a specifi c group of 
white blood cells (Steinman and Cohn  1973 ), and it was not until 1998 that the 
central role of DCs as professional antigen presenting cells for the induction of 
adaptive immunity was defi ned (Banchereau and Steinman  1998 ). Over the last few 
decades the DC-fi eld has developed extensively with enhanced knowledge on DC 
progenitors, distinctive subsets, and their specifi c functions depending on the tissues 
where they reside. 
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17.2  Features and Mechanisms 
 DCs continuously sample antigens from their environment by phagocytosis, 
receptor- mediated endocytosis, and pinocytosis. After uptake of antigens, DCs 
migrate to the draining lymph node. During migration they may mature and upregu-
late co-stimulatory molecules like CD40 and CD86, depending on the maturation 
signals they have encountered. DCs are equipped with unique pattern recognition 
receptors (PRRs) for which the ligands may activate or inhibit DC maturation and 
facilitate antigen recognition, uptake and processing. The extensive sets of PRRs 
(e.g. Toll-like receptors (TLRs), C-type lectins (CLRs), Nod-like receptors (NLRs) 
and Retinoic acid induced gene-based (RIG)-I like receptors (RLRs)) are expressed 
on the cell surface or in intracellular compartments, like endosomes or in the cyto-
plasm to enable recognition of intra- and extracellular exposures. 
 Dendritic cells are instrumental for the activation of naïve T cells or reactivation 
of T cells from the memory pool (McLellan et al.  1996 ). T cell activation requires 
antigen presentation in MHC class I (for CD8 + T cell) or II (for CD4 + T cells) 
molecules (signal 1), in combination with expression of co-stimulatory molecules 
(signal 2). Cytokines provide a third signal and induce T cell differentiation and 
effector functions. Depending on the cytokine environment provided by DCs, CD4 + 
T cells differentiate into Thelper1 (Th1) via IL-12, Th2 via IL-4, or Th17 cells via 
IL-6 (Kapsenberg  2003 ; Bettelli et al.  2008 ). In addition, Th cells can also differen-
tiate into regulatory phenotypes (Tregs, Th3 and Tr1) that dampen immune responses 
(Sakaguchi et al.  2006 ). On the other hand, DCs instruct CD8 + T cells, which rec-
ognize MHC class I (cross)presented antigens, to develop into cytotoxic lympho-
cytes (CTLs) (Bhardwaj et al.  1994 ). 
 The responsiveness of DCs in terms of expression of co-stimulatory/regulatory 
molecules and cytokine profi les may thus provide insight into the immune modulat-
ing properties of food bioactives. Here, we provide an overview of the different DC 
subsets in blood, and more specifi cally in the gastrointestinal tract (Fig.  17.1 ). Then 
we will provide information on the in vitro and ex vivo possibilities to study effects 
of food bioactives on DCs. 
17.2.1  DC Subsets 
 To study immune modulatory effect of bioactives on DCs, different models systems 
may be considered, e.g. DC cell lines, in vitro-generated DCs, or directly isolated 
primary DCs, each with their own advantages and disadvantages. It is important to 
realize that different subsets of DCs exist in peripheral blood and (non)lymphoid 
tissues and that the differentiation and function of each of these subsets is highly 
dependent on the interacting cells and mediators in the local microenvironment. 
So, while this chapter provides experimental settings to study the direct effects of 
food bioactives on DCs, one should always consider the possible indirect effect via 
stimulation of the bioactives on for instance epithelial cells, and that different DC 
subsets may respond differently to the same exposure. 
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17.2.1.1  Blood DCs 
 DCs can be divided in conventional DCs (cDCs) and plasmacytoid DCs (pDCs). 
In human blood, both cDCs and pDCs can be phenotypically characterized by the 
lack of lineage marker expression (CD3, CD14, CD19, CD56) and a high expres-
sion of HLA-DR. The circulating cDCs are CD11c + and are divided by the expres-
sion of CD1c (BDCA1) or CD141 (BDCA3). Human pDCs lack expression of 
CD11c and are discriminated by the expression of BDCA2, BDCA4 and/or CD123. 
CD16 + MHC class II + cells cluster as a distinct population in the blood (Lindstedt 
et al.  2005 ) and have previously been associated with DC origins by some. However, 
CD16 + cells were recently assigned to the monocyte lineage (Robbins et al.  2008 ; 
Ziegler-Heitbrock et al.  2010 ), confi rmed by transcript profi ling comparing CD16 + 
cells with BDCA1 + DCs (Frankenberger et al.  2012 ). 
17.2.1.2  Mucosal DCs 
 The mucosal immune system is highly specialized: it has to be able to avoid inva-
sion of (commensal) bacteria, and tolerate their presence in the intestine. It should 
also induce tolerance to non-harmful food antigens and protect against potentially 
harmful pathogens, toxins and xenobiotics. All of this takes place over a single layer 
of highly specialized epithelial cells (Chapter  2 ). 





 The formulation of antigens determines the main site for antigen uptake in the 
intestinal tract. Considerable evidence suggests that the gut associated lymphoid 
tissues (GALT), such as Peyers Patches (PP) and isolated lymphoid follicles, are 
critical for handling of particulate antigens. The microfold cells (M cells), present 
in the GALT epithelium, are involved in actively transferring the particulate anti-
gens from the gut lumen into the lymphoid areas. The role for GALT in the induc-
tion of oral tolerance to soluble antigens is not entirely clear. Normal oral tolerance 
could be induced in mice lacking PP. It was therefore suggested that the main func-
tion of the GALT is to control immune responses to commensal bacteria. Antigen 
uptake by DCs underlying the villus epithelium of the lamina propria (LP) in the 
small intestine has been shown to be crucial for induction of oral tolerance to solu-
ble antigens. How the DCs are provided with the antigens over the epithelial barrier 
will strongly depend on the compound and is beyond the scope of this chapter. 
Since both the intestinal tract and its draining lymph nodes contain specifi c DC 
subsets we will briefl y discuss them before providing detailed information of pos-
sible DC systems that could be used to mimic these DCs. 
 Intestinal DCs : Thorough comparative transcriptional and functional profi ling in 
DCs isolated from a human and murine small intestine LP and peripheral blood 
showed three DC subsets within the CD45 + lin − MHCII + LP population based on the 
expression of CD103 and Sirpα (Watchmaker et al.  2014 ). The CD103 + Sirpα − DCs 
(SP) were related to human blood BDCA3 + DCs, whereas CD103 + Sirpα + (DP) DCs 
expressed CD11b, CD207 (Langerin), CD209 and high levels of RALDH (coincid-
ing with human blood CD1c + DCs) and supported the induction of (FoxP3 + ) regula-
tory T cells. The CD103 − Sirpa + expressed CX3CR1, but lacked CD64 expression, 
and clustered with human monocytes indicating that they may have developed from 
monocytes recruited in response to gut infl ammation. Most of these cells are located 
deeper into the LP when compared to the network of phagocytic cells that is located 
right beneath the epithelial cells. These phagocytic cells express CD45, HLA-DR, 
CD14, CD64 and high levels of CX3CR1, and since these cells also do not migrate 
to the lymph nodes, they have been depicted as intestinal macrophages (Rivollier 
et al.  2012 ; Bain et al.  2012 ; Tamoutounour et al.  2012 ; Mann et al.  2013 ). 
 Mesenteric lymph node DCs : Soluble food bioactives may also be directly available 
for internalization by DCs in the draining lymph nodes via the conduit system 
(Gretz et al.  1997 ; Anderson and Shaw  2005 ; Sixt et al.  2005 ; Roozendaal et al. 
 2009 ). The mesenteric lymph node DCs are a mixture of cells found in peripheral 
blood as well as the LP. As such, peripheral blood DCs and their CD34-derived 
counterparts could represent these lymph node DCs. 
17.2.1.3  Monocyte-Derived DCs 
 Monocyte-derived (mo)DCs are rare under steady-state conditions in both blood and 
peripheral tissues. They can be found in increased numbers in vivo under infl amma-
tory conditions. The ability to culture moDCs from monocytes boosted their 
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popularity as a model to study human DC biology (Sallusto and Lanzavecchia 
 1994 ). The gene profi le of in vitro-generated MoDCs is enriched for genes also 
found in in vivo occurring moDC (Segura et al.  2013 ) and also emphasizes the 
monocyte origin (not DC origin) with acquired DC features. 
17.3  General Protocols 
 Primary DCs can be isolated from blood, and lymphoid or peripheral tissues, but the 
presence of DCs in blood is scarce and they are diffi cult to obtain in suffi cient numbers 
from tissues. In addition, one may encounter large donor variations. The use of cell 
lines would overcome these challenges, but may hold insuffi cient similarity with pri-
mary DCs with respect to their response to environmental stimuli, ability to capture 
antigens, mature, migrate, produce cytokines, present antigens and activate T cells. 
Here we summarize a series of commonly used functional DC assays below and 
discuss the performance of cell lines and primary cells (summarized in Table  17.2 ). 
17.3.1  DC Cell Lines 
 Most DC cell lines were differentiated from leukemia-derived cells, originating from 
myelogenous or monocytic lineage: the cytokine independent cell lines THP- 1, U937, 
KG-1, HL-60 and the cytokine dependent cell line Mutz-3 are the most commonly 
used (Table  17.1 ) (Berges et al.  2005 ; van Helden et al.  2008 ; Santegoets et al.  2008 ). 
The use of these lines has the advantage of the availability of large numbers of synchro-
nized cells with a long life span, but the association with selective DC subsets in 
peripheral blood and mucosal surfaces is largely unclear. All of these cells are leuke-
mic, representing DC precursor stages and may often need the addition of specifi c 
growth and differentiation factors to induce at least some characteristics of differenti-
ated DCs. MUTZ-3 is suggested to have the highest DC differentiation capacity 
(Santegoets et al.  2008 ) and may therefore be most representative for in vivo DCs.
 Table 17.1  DC cell lines 
 Cell line  Derived from 
 DC 
differentiation 
 T cell 
activation 
capacity  References 
 THP-1  Monoblastic leukemia cell line  Low  Yes  Tsuchiya et al. 
( 1980 ) Chap.  14 
 U937  Monocytic leukemia cells  Moderate  Yes  Chapter  15 
 KG-1  CD34 myelomonocytic cell line  Incomplete  Yes  Koeffl er et al. ( 1981 ) 
 HL-60  Acute pro-myelocytic leukemia 
cell line 
 Moderate  Yes  Koski et al. ( 1999 ) 
 MUTZ-3  Myeloid leukemia cell line  Relatively high  ?  Hu et al. ( 1996 ) 
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17.3.2  Isolating Primary DCs from Blood 
 DCs can be directly isolated from PB using their unique surface markers (Fig.  17.1 ) 
and utilizing either magnetic bead separation or fl ow cytometric cell sorting (Vremec 
and Shortman  1997 ; Dzionek et al.  2000 ; Shortman and Liu  2002 ). Since the per-
centage of DCs in PB is generally low (cDC: 0.6 % and pDC 0.2 % of all PBMC), 
DC-enrichment (by depletion of cells expressing lineage markers CD3, CD14, 
CD16, CD19, CD20, and CD56) is often used. For magnetic bead sorting, separa-
tion/isolation kits are commercially available from companies such as Miltenyi 
Biotec and StemCell Technologies. Preferably, freshly isolated PBMCs obtained by 
a density gradient of Ficoll-Hypaque, are suspended in cell isolation buffer as per 
manufacturer’s instructions. To optimize survival of primary DCs after isolation it 
may be helpful to add survival factors to the culture medium: 800 U/ml GM-CSF 
for cDCs, like CD1c or CD141 DCs, or 10 ng/ml IL-3 for pDCs. 
 Culturing peripheral blood-derived CD1c (BDCA1) DCs for 2 days with 
GM-CSF, vitamin D and Retinoic Acid (RA) induced high expression of RALDH 
as well as the ability to induce gut-homing receptors resembling the gut-resident 
CD103 + Sirpα + (DP) DCs to some extent (Sato et al.  2013 ). 
 Although using primary DCs directly isolated from the blood is feasible for most 
academic research labs and will probably resemble the in vivo DC biology most 
closely, the limited amount of primary DCs in PB is an obvious obstacle when many 
conditions and functional effects need to be assessed. 
17.3.3  CD34 + -Derived DCs 
 Another alternative is to generate DCs from myeloid precursors. CD34 is a marker 
expressed on haematopoietic stem cells and early myeloid progenitors that contain 
high proliferative potential. The CD34 + cells can therefore fi rst be expanded followed 
by a differentiation towards DCs. CD34 + cells can be isolated from bone marrow 
(BM), peripheral blood (PB) or from umbilical cord blood (CB) using magnetic 
labelling (Kato and Radbruch  1993 ). 
 Firstly, CD34 + cells can be expanded using different combinations of cytokines 
and growth factors. Flt-3L, TPO, SCF, IL-3, and IL-6 are early-acting cytokines that 
support the proliferation of DC precursors from CD34 + HPC. Two different cock-
tails, Flt3-L, TPO, SCF and Flt3-L, SCF, IL-3, IL-6 (FS36), were compared for their 
capacity to induce proliferation of CD34 + HPC (Bontkes  2002 ). FS36 showed the 
greatest ability to expand the CD34 + HPCs. Expanded CD34 + cells can be differen-
tiated towards different DC subtypes i.e. BDCA3 + DCs up to only 3 % (Poulin et al. 
 2010 ), or pDCs up to 5 % (Demoulin et al.  2012 ). Addition of TGF-beta during 
differentiation enhances the formation of langerin + LC (Soulas et al.  2006 ; Caux et al. 
 1992 ; Szabolcs et al.  1995 ). 
 Established protocols to culture LCs, dermal DCs, BDCA3 + DCs and pDCs can 
be found in literature and are summarized below (Fig.  17.2 ). 
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17.3.4  Monocyte-Derived DCs 
 Monocytes can be selected via adherence or CD14 + isolation with magnetic beads. 
For adherence, PBMCs are resuspended in culture medium and placed in a humidifi ed 
incubator maintained at 37 °C and 5 % CO 2 , to allow the monocyte precursors to 
adhere. After 1 h, non-adherent cells are simply removed by fi rmly tapping the fl ask 
and isolating non-adherent cells. For bead selection, PBMCs are resuspended in cell 
isolation buffer as per manufacturer’s instructions, followed by isolation using a 
 commercially available kit. The isolated monocytes can be frozen for later use. 
 Once the monocytes are selected, they can be differentiated towards DCs with 
culture-medium (e.g. X-vivo) supplemented with 800–1,000 U/ml GM-CSF and 
300–500 U/ml IL-4 (37 °C and 5 % CO 2 ) for 7 days. After the 6/7-day culture 
period, the immature DCs can be used for testing the immune modulatory effects of 
food bioactives. 
 To generate mucosal CD103 + Sirpα + (DP) resembling moDCs, RA, the even more 
potent RARalpha agonist AM580 or TGFbeta, can be added to the culture (Hartog 
et al.  2013 ; Martin et al.  2014 ). RA-induced moDCs express CD103 and can induce 
increased percentages of FoxP3 + in allogeneic CD4 + cells. RA-induced moDC also 
express high levels of IL-22BP which is comparable to the CD11b + CD103 + DCs 
found in mouse LP and MLN (Martin et al.  2014 ). 




17.4  Asses Viability 
 To validate the generation of DCs in these cultures, the purity of DCs can be assessed 
by fl ow cytometric analysis of the surface markers CD11c and HLA-DR. This stain-
ing can be expanded with markers, depending on the specifi c protocol used (for 
instance CD14 expression on MoDC or CD1c on CD34-derived DC.) Viability can 
be checked by adding a viability dye (e.g. 7AAD) to the FACS panel, or count the 
amount of cells with Tryphan blue with a microscope (Table  17.2 ).
17.5  Experimental Readout 
 Although bioactive food components have been shown to interact with many 
 different types of cells, it remains a legitimate question whether DCs exposed to 
food bioactives may in turn affect features of the innate or adaptive immune system, 
in particular T cells. Some food bioactives may be associated with the development 
of allergic or autoimmune-like clinical symptoms in susceptible individuals. 
The clinical manifestation, ranging from mild to severe and life-threatening, vary 
considerably for different compounds and for the same compound in different sub-
jects and may be idiosyncratic in nature. They comprise pseudo-allergic reactions 
(interference with immunological effector mechanisms and cells, such as mast 
cells), compound- allergic reactions (activation of compound-specifi c T and B cells), 
 Table 17.2  Summary of (dis)advantages of using differentially generated DCs 
 Type of DCs  Advantages  Disadvantages 
 Cell lines 
( THP - 1 ,  U937 , 
 KG - 1 ,  HL - 60 ) 
 Large number of cells. 
 Relatively long life span. 
 Association to primary DCs unclear 
(different stages of differentiation, 
discrepancies in DC-functions) 
 Primary DCs 
 CD1c  Largely comparable to in vivo 
counterpart. 
 CD1c can be treated to 
differentiate into gut-like DCs. 
 Low cell numbers. 
 Isolation procedures might affect 
phenotype and function. 
 BDCA3 
 pDCs 
 CD34 - derived DCs 
 Dermal DCs/
LCs 
 CD34 + cells can be expanded to 
increase cell number. 
 Resemble primary DCs very well. 
 Acquisition requires specialized centres. 
 % of pDC and BDCA3 DC are still low 
in these cultures, thus requiring large 
numbers of cells for selection. 
 pDCs 
 BDCA3 
 Monocyte - derived DCs 
 Large number of cells. 
 Relatively easy to obtain and 
culture. 
 Very well studied: extensive set of 
data available. 
 Represent infl ammatory monocytes 
with DC-features, which may hamper 
translation for primary DCs. 
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and compound-induced autoimmune reactions. Although the induction of allergic 
or autoimmune responses requires DC activation, food bioactives may also inhibit 
DC activation. This may represent an advantageous effect of food bioactives in 
reducing (chronic) infl ammatory response like asthma, infl ammatory bowel dis-
ease, etcetera, by reducing the DC activity and possibly inducing regulatory T cells. 
 Different assays can be performed to test the DC’s responsiveness to bioactives 
for the prediction of the subsequent immune modulatory effect of that specifi c com-
pound. These assays include the monitoring of phenotypic markers expressed on the 
surface of DCs indicating their differentiation, activation and their potentially stim-
ulating effect on T cells. Nevertheless, even with a clear outcome of these assays, it 
remains to be seen whether indeed antigen-specifi c T cells with the potential to 
induce adverse effects in vivo will be induced. In this regards it is important to con-
sider whether the food bioactive contains potential antigens, are able to form neo- 
antigens or merely function as adjuvants for responses against other components in 
the food or play a role in sensitization to auto-antigens. 
17.5.1  Co-stimulation 
 DCs may undergo a number of phenotypical changes, following maturation by the 
uptake and processing of an antigen. The process of DC maturation, in general, 
involves an increase in the surface expression of co-stimulatory molecules, like CD40, 
CD80, CD83, and CD86, which can be measured by fl ow cytometry. As a negative 
control unloaded DCs can be taken along, as well as a DC positively stimulated with 
a known maturation cocktail, like IL-1beta, IL-6, TNF and PGE-2 or TLR ligands. 
17.5.2  Cytokine Production 
 Besides up-regulation of co-stimulatory molecules, DCs produce a large variety of 
cytokines that could be either pro/anti-infl ammatory or skew the phenotype of T cells. 
Therefore, a quite simple procedure to test the activity of the DCs towards the food 
bioactives is the measurement of cytokine levels. A wide variety of cytokines may 
be expressed by mature DCs including IL-1 alpha, IL-1 beta, IL-4, IL-6, IL-8, IL-10, 
IL-12, IL-15, IL-16, IL-17, IL-18, IFN-alpha, IFN-beta, IFN-gamma, and TNF. These 
cytokines can be measured by ELISA, or multiplex assays. 
17.5.3  Other DC Readouts 
 Co-stimulation and cytokine production are effect parameters used in the vast 
majority of studies on effects of food bioactives on DCs (see Table  17.3 for an 
overview). Studying the induction of specifi c T cells is complicated due to the low 
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frequency of T cell precursors with the corresponding TCR and requires extensive 
culture conditions and broad read-out tools as the TCR specifi city in these condi-
tions is unknown. With regard to the T cell stimulatory  potential of DCs the mixed 
lymphocyte reaction (MLR), in which DCs are used to stimulate alloreactive (naïve) 
T cells, can be considered. Proliferation in combination with cytokine production 
can be used as a read-out for T cell skewing.
17.6  In Vitro Studies on Food Bioactives Using DCs 
(Table  17.3 ) 
 The immunomodulatory effects of food bioactives can be broadly divided in ‘activa-
tion’, ‘suppression’ or ‘no detectable effect’. Table  17.3 shows that with regard to 
food proteins immune activation is generally the anticipated endpoint. It should 
however be considered that other food constituents instead of the protein itself, may 
stimulate DCs to internalize and present food proteins, and therefore may be 
involved in the risk for hypersensitivity. Immune suppression in DCs assays is 
mostly studied in combination with a trigger known to activate the DCs (TLR 
ligands i.e. LPS, CT or CD40 ligation). Inhibition of DC activation has been studied 
using probiotics, vitamins, polyphenols (Del Cornò et al.  2014a ), isofl avones and 
curcuminoids. Inhibition of DC activation may be relevant for people suffering from 
chronic infl ammation not only by reducing infl ammation directly but also by pre-
venting the risk for developing cancer, which is associated with chronic infl amma-
tion. Potential harmful effects of non-specifi c immune suppression include an 
increased risk of infection and also here the development of cancer. When there is 
no direct effect of the food bioactives on the DCs with the assays mentioned above, 
this does not mean that exposure to the compound is without risk. Indirect effects of 
the bioactives through their effects on other cells or the effects of their metabolites 
must be taken into consideration. 
17.7  Critical Notes 
 Extensive comparative studies using different DC assays with proven immune 
active compounds and food bioactive compound are lacking. 
 With regard to some of the DC parameters used to study immune modulatory 
effects of food bioactives, the expression of co-inhibitory molecules (e.g. PDL1 
and PDL2) has not been intensively studied. This family of molecules has however 
a large impact on the immune response and may therefore also be considered in 
future testing. 
 As mentioned before, the DCs are the sentinels of the immune system that gather 
not only by taking up or sensing the food bioactives only, but continuously receive 
input from cells and factors in their microenvironment. Potential responses should 
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therefore be evaluated in the light of the local environment. For instance, the choice 
for a particular DC model/subset may be dependent on the availability of certain 
compounds/entry site, which may relate to the size, solubility and formulation of 
the compound of interest. 
 In conclusion, studying the effects of food bioactives on DC (subsets) is an 
important step in addressing the immune modulating potential of these compounds 
in vivo, but should be part of a more extended monitoring program involving studies 
on the compound’s availability, factors of the microenvironment, and effects of 
metabolites/neo-epitopes. 
 Open Access This chapter is distributed under the terms of the Creative Commons Attribution 
Noncommercial License, which permits any noncommercial use, distribution, and reproduction in 
any medium, provided the original author(s) and source are credited. 
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 Chapter 18 
 Co-culture Caco-2/Immune Cells 
 Charlotte  R.  Kleiveland 
 Abstract  Numerous cell types are involved in maintenance of the intestinal tissue. 
However, the main players are cells of the epithelial lining and from the immune 
system. All these cells are communicating with each other and are strongly infl u-
enced by interactions with neighboring cells. Mono-cultivation of cells may provide 
valuable information as to understanding basic biology, but co- cultivation of more 
than one type of cells gives an opportunity to investigate effects of intercellular 
communication. Examples of systems for co-cultivation of epithelial cells and 
immune cells for the investigation of both direct cell–cell contact and communica-
tion with soluble factors will be discussed in this chapter. In addition, co-cultivation 
systems for differentiation to more specialized epithelial cells as microfold cells 
(M-cells) will be described. 
 Keywords  Epithelial cells •  Immune cells •  M-cells •  Co-culture •  Intercellular 
communication 
18.1  Origin, Features and Mechanisms 
 The models described in this section include the cell lines Caco-2 and THP-1 in 
addition to peripheral mononuclear cells (PBMCs) and dendritic cells (DCs). 
 Description of the origin, features and mechanisms of these cells are included in 
previous sections, and further information can be found in Chap.  10 for Caco-2, 
Chap.  14 for THP-1, Chap.  15 for PBMCs and Chap.  17 for DCs. 
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18.2  Relevance to Human In Vivo Situation 
18.2.1  Co-culture Caco-2 and Dendritic Cells 
 Precise regulation of the intestinal barrier function is important for the maintenance 
of mucosal homeostasis and prevents the onset of uncontrolled infl ammation 
(Pastorelli et al.  2013 ). A balanced and fi ne-tuned cross-talk between intestinal epi-
thelial cells (IECs), immune cells and the intestinal microbiota is necessary to main-
tain the intestinal homeostasis (Artis  2008 ). Different immune cells communicate 
with each other as well as with epithelial cells by an impressive network of regula-
tory signals. The complexity of the mucosal immune system is diffi cult to mimic 
in vitro, but a co-culture system makes it possible to elaborate mechanisms involved in 
communication between epithelial cells and cells of the immune system. It is possible 
to study effects of soluble molecules as well as contact dependent mechanisms. DCs 
are professional antigen-presenting cells central to the regulation of both innate 
and adaptive immune responses at mucosal surfaces (Coombes and Powrie  2008 ). 
The intestinal epithelium is not only a barrier to microorganisms entering via the 
oral route, but epithelial cells are directly infl uencing the activating properties of 
mucosal DCs (Rimoldi et al.  2004 ). Communication between immune cells and 
epithelial cells can be studied by co-cultivation of Caco-2 cells with CD14 + mono-
cyte-derived dendritic cells (mDC), PBMCs or THP-1 cells, a human monocytic 
cell line (described in Chap.  14 ). CD14 + monocytes isolated from blood are differ-
entiated into DCs by stimulation with GM-CSF and IL-4. The phenotype of these 
in vitro differentiated DC resembles that of infl ammatory DCs (Segura et al.  2013 ). 
Infl ammatory DCs differentiate from monocytes recruited to infl amed tissue from 
blood during an infl ammation. Therefore the CD14 + monocytes are phenotypically 
distinct from the bone marrow-derived DC precursors which give rise to tissue 
resident DCs (Steinman and Idoyaga  2010 ; Miller et al.  2012 ) (see Chap.  17 for 
further information on DCs). 
18.2.2  Co-culture Caco-2 and B-cells (Raji) 
 The follicle-associated epithelium (FAE) overlying the organized lymphoid follicles 
of the gut-associated lymphoid tissues (GALT) including Peyer’s patches, are 
 specialized for sampling luminal content. Approximately 10 % of the cells within 
the FAE are microfold (M) cells. M cells have unique morphological features that 
include a reduction in both glycocalyx and microvilli compared to other parts of the 
epithelial lining. They are highly specialized for phagocytosis and transcytosis of gut 
luminal content across the epithelium. Beneath the M-cell’s basolateral membrane 
there is an intraepithelial pocket where the luminal content samples are released 
after transcytosis. This dome structure contains various populations of lympho-
cytes, macrophages and dendritic cells. M-cells therefore provide an effi cient 
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delivery of gut luminal microorganisms and antigens to the underlying mucosal 
tissue and are therefore essential for mucosal immune responses (Gullberg et al. 
 2000 ; Kerneis et al.  1997 ). Cells with a M cell-similar phenotype can be obtained 
by co-cultivation of Caco-2 cells with Raji B cells (Gullberg et al.  2000 ). 
18.3  Stability, Consistency and Reproducibility 
 Co-culture systems of epithelial cells and immune cells have not been much in use 
for investigation of food bioactive components, despite several methodological 
reports on such systems. This might indicate that the system gives inconsistent data 
or has a low level of reproducibility. Some of the co-culture systems described here 
combine the use of cell lines and primary cells. The cells lines will represent a stable 
and reproducible system with low variability from experiment to experiment. 
However, the response of PBMCs and monocyte derived DCs will depend on the 
donor and can lead to increased variability between experiments. 
 The Caco-2/Raji B cell model is a simplifi ed model that induces cells with M 
cell-like morphology. A gene expression study comparing the Caco-2/Raji model 
with human FAE suggest that the Caco-2 differentiation model is associated with 
some functional features of M cells. However the genes induced refl ect the acquisi-
tion of a more general FAE phenotype (Lo et al.  2004 ). However, this is an easy 
accessible in vitro model system to study M cell-mediated translocation. 
18.4  General Protocol 
18.4.1  Co-culture of Caco-2/Human Monocyte Derived DCs 
(Include Contact Dependent Events) 
 In this co-cultivation system, the cells will be able to make direct cell–cell contacts 
between the immune cells and the basolateral side of the epithelial cells. Co-cultivation 
of the cells in this way makes it possible to investigate effects of both direct interac-
tions between DCs and epithelial cells and communication by soluble factors. 
 Caco-2 cells are seeded on the backside of fi lter inserts with 3 μm pores. 3 × 10 5 
Caco-2 cells in 100 μL RPMI 1640 with 10 % FCS, are placed on the bottom side 
of the inserts placed in an inverted orientation. After overnight incubation, to allow 
attachment of the Caco-2 cells, the inserts are transferred to their normal orientation 
in a 24 well plate. The Caco-2 cells now face the lower chamber and are cultured as 
this for the next 14 days. Every other day the medium has to be exchanged with 
fresh RPMI 1640 with 10 % FCS. At day 14 add 1 × 10 6 CD14 + human monocytes 
in 500 μL RPMI 1640 with 10 % FCS, 25 ng/mL IL-4 and 50 ng/mL GM-CSF. 
At day 4 of co-cultivation remove the medium in the upper chamber and replace it 
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with 500 μL RPMI 1640 with 25 ng/mL IL-4 and 50 ng/mL GM-CSF. The RPMI 
1640 in the lower chamber should be exchanged every other day. Maintain the 
 co-culture for 6 days before the experiments are conducted. Depending on the test 
compound, it could be added to either compartment. The lower chamber will refl ect 
the apical side and the upper chamber the basolateral side of the intestinal epithe-
lium. Incubation time for the test compound will depend on the type of compound 
and the read out system to be used and will have to be decided for each compound. 
18.4.2  Caco-2/Human Monocyte Derived DCs 
(Soluble Factors) 
 In comparison with the above mentioned system co-cultivation of cells in this way 
will only make it possible to study effect of communication caused by soluble factors. 
The epithelial cells and the DCs will not be able to be in direct contact with each 
other and communication can therefore only happen by soluble factors diffusing 
through the fi lter. 
 300 μL of a 1 × 10 6 /mL Caco-2 cells suspended in RPMI 1640 with 10 % FCS, 
are seeded on fi lter inserts with 0.4 μm pores. The cells are maintained at 37 °C in 
5 % CO 2 atmosphere for 14 days. The medium in both compartments should be 
exchanged with fresh RPMI 1640 with 10 % FCS, every other day. At day 14, 
1 × 10 6 CD14 + human monocytes in RPMI-1640 with 10 % FCS, 25 ng/mL IL-4 and 
50 ng/mL GM-CSF are added to the lower chamber, facing the basolateral side of 
the epithelial monolayer. The medium in the lower chamber is exchanged with fresh 
RPMI 1640 with 10 % FCS, 25 ng/mL IL-4 and 50 ng/mL GM-CSF at day 4 of the 
co-cultivation. Maintain the co-culture for 6 days before experiments are conducted. 
Continue to exchange the medium in the upper chamber with fresh RPMI 1640 with 
10 % FCS every second day. 
 The upper chamber will refl ect the apical side and the lower chamber the 
basolateral side of the intestinal epithelium. Incubation time for the test compound 
will depend on type of compound and the read out system to be used and will have 
to be decided for each compound. 
18.4.3  Caco-2/THP-1 (Soluble Factors) 
 300 μL of a 1 × 10 6 /mL Caco-2 cells suspended in RPMI 1640 with 10 % FCS, are 
seeded on fi lter inserts with 0.4 μm pores. The cells are maintained at 37 °C in 5 % 
CO 2 atmosphere for 21 days, exchanging the medium with fresh RPMI 1640 con-
taining 10 % FSC every other day. At day 18 the THP-1 cells are plated at a density 
of 2 × 10 5 cells/mL in RPMI 1640 with 10 % FCS, 200 ng/mL IL-4, 100 ng/mL 
GM-CSF, 20 ng/mL TNF-α and 200 ng/mL ionomycin in a 24 well plate for 3 days. 
At day 21 the medium of the THP-1 cells is exchanged with RPMI 1640 with 10 % 
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FCS and the fi lter inserts with polarized Caco-2 monolayers are placed into the 
wells together with the differentiated THP-1 cells. 
 The upper chamber will refl ect the apical side and the lower chamber the baso-
lateral side of the intestinal epithelium. Incubation time for the test compound will 
depend on type of compound and the read out system to be used and will have to be 
decided for each compound. 
18.4.4  Caco-2/PBMCs (Soluble Factors) 
 300 μL of a 1 × 10 6 /mL Caco-2 cells suspended in RPMI-1640 with 10 % FCS are 
seeded on fi lter inserts with 0.4 μm pores. The cells are maintained at 37 °C in 5 % 
CO 2 atmosphere for 21 days with exchanges of the medium with fresh RPMI 1640 
with 10 % FSC every other day. At day 20, PBMCs are plated in the basolateral 
compartment at a density of 1–2 × 10 6 cells/mL RPMI-1640 with 10 % FCS. PBMCs 
can be activated by anti-CD3/CD28, mitogenic lectins or LPS (see Chap.  15 
PBMCs). 
 The upper chamber will refl ect the apical side and the lower chamber the baso-
lateral side of the intestinal epithelium. Incubation time for the test compound will 
depend on type of compound and the read out system to be used and will have to be 
decided for each compound. 
18.4.5  Caco-2/B Cells 
 300 μL of a 1 × 10 6 /mL Caco-2 cells suspended in RPMI-1640 with 10 % FCS are 
seeded on fi lter inserts with 3.0 μm pores. The inserts are placed in a 24 well plate 
with 1 mL of RPMI 1640 with 10 % FCS. The cells are maintained at 37 °C in 5 % 
CO 2 atmosphere for 14 days with exchanges of the medium with fresh RPMI 1640 
with 10 % FSC, every other day. At day 14, 1 × 10 6 Raji cells in RPMI 1640 with 
10 % FCS are added to the lower chamber, facing the basolateral side of the epithe-
lial monolayer. Maintain the co-culture for 6 days. Continue to exchange the 
medium in the upper chamber with fresh RPMI 1640 with 10 % FCS every 
second day. 
 The upper chamber will refl ect the apical side and the lower chamber the baso-
lateral side of the intestinal epithelium. To investigate uptake through M-cells the 
test compound should be added to the apical side. The incubation time for the test 
compound must be investigated different compounds, but are usually in the range of 
minutes to a few hours. 
 In all of the above-mentioned systems, the effects of test compounds on co- cultures 
should be compared with effects on matched fi lters with Caco-2  monocultures. 
This will make it possible to identify whether the effects of the test compounds are 
related to cell–cell communication in the co-culture systems. 
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18.5  Assess Viability 
 The integrity of the Caco-2 monolayers should always be checked by measurement 
of TEER values, and fi lters with a TEER value below 300 Ω cm 2 should not be used 
for further experiments. 
 The paracellular transport marker Lucifer Yellow (LY) is used to measure changes 
in the integrity of the Caco-2 cell layer. LY is added to the apical compartment at a 
concentration of 100 μM, in control wells and wells treated with test compound. 
The fl uorescence of the LY transported to the basolateral side is then measured with a 
fl uorescence microplate reader (Calatayud et al.  2012 , and Chap.  10 ). 
 In comparison with polarized Caco-2 cells M-cells will lack microvilli on their 
apical surface which can be inspected by transmission electron microscope (TEM) or 
scanning electron microscope (SEM). Staining of the Caco-2 monolayer with fl uoro-
chrome-labeled Wheat Germ Agglutinin (WGA) or phalloidin (actin label) will give 
a continuous staining in a monoculture of Caco-2, however after co- cultivation of 
Caco-2 cells with Raji, M-cells are identifi ed as a discontinuations in the staining 
pattern. This is due to the absence of microvilli. Corresponding monocultures of 
Caco-2 cells on matched fi lter inserts should be used as controls. 
 Lactate dehydrogenase (LDH) is also a marker of cytotoxicity and its release can 
be determined in the supernatant of the cell cultures (Decker and Lohmann-Matthes 
 1988 ). There are several commercial kits for determination of LDH concentration in 
culture supernatants. 
18.6  Experimental Readout 
 Several methodological reports are describing co-culture conditions between Caco-2 
and CD14 + monocyte derived DCs, THP-1 or PBMCs (Araujo and Sarmento  2013 ; 
Leonard et al.  2010 ; Schimpel et al.  2014 ; Antunes et al.  2013 ; Kerneis et al.  2000 ; 
Parlesak et al.  2004 ). However, there are still few reports where these co- culture 
systems have been used to scrutinize communication between epithelial cells and 
immune cells. 
 Apical TLR ligation on intestinal epithelial cells and its effect on PBMCs have 
been studied by co-cultivation of HT-29 and PBMCs (de Kivit et al.  2011 ). The TLR 
ligands are added to the apical side of the epithelial monolayer, whilst the PBMCs 
are stimulated with anti-CD3/CD28 antibodies and LPS. The release of cytokines to 
the culture supernatants, both in the basolateral and apical compartments, were 
investigated by ELISA. There is also a report on the effect of the anti-infl ammatory 
drugs ibuprofen and prednisolone in a co-culture system of Caco-2 monolayers in 
co-culture with whole blood (Schmohl et al.  2012 ). 
 There is one report using a co-culture model of Caco-2 monolayers and THP-1 
cells to study the function of the immediate-early response gene 1 (IEX-1) (Ishimoto 
et al.  2011 ). Overexpression or knock down of the IEX-1 gene in Caco-2 cells were 
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induced by Lentivirus infection. Caco-2 cells were differentiated for 14 days on 
semi-permeable fi lter inserts. The THP-1 cells were differentiated for 4 days and 
then the fi lter inserts with Caco-2 were placed in the well with differentiated THP-1 
cells. After co-cultivation, mRNA was extracted from both Caco-2 cells and THP-1. 
Changes in expression of genes coding for cytokines were investigated by qPCR. 
 The Caco-2/B cell model is widely used to study translocation of bacteria over 
M-cells. Translocation of fl uorescence-labelled carboxylated latex or dextran particles 
was used to confi rm in vitro induction of the M-cell like phenotype. Translocation of 
bacteria was measured by serial dilutions of basolateral culture medium on agar plates 
2 h after addition of bacteria to the apical compartment (Finn et al.  2014 ). How dietary 
components affect translocation of bacteria over M-cells have also been investigated 
(Roberts et al.  2013 ). The test compound was added to the apical compartment for 
30 min before infection with bacteria. After 2–4 h, the basolateral medium was har-
vested and bacteria enumerated following serial dilution on agar plates. 
18.7  Advantages, Disadvantages and Limitations 
 These co-culture systems give the opportunity to study cell–cell communication, 
and most cell laboratories will have the possibility to establish at least some of these 
co-cultivation systems. The use of monocyte-derived DCs or PBMCs have the 
advantage of responding well with the production of cytokines, whilst THP-1 on the 
other side produce a limited number of cytokines. These protocols are time- 
consuming and therefore not suitable for high throughput screening. As for other 
in vitro culturing systems the data should be interpreted with care as they do not 
represent the complexity found in the in vivo situation. 
18.8  Conclusions 
 The co-cultivation systems described here needs to be carefully validated in order to 
be able to harvest reliable experimental data related to communication between 
immune cells and epithelial cells. They can be used for screening purposes, how-
ever, due to time consumption they are generally unsuitable for high throughput 
screening. Co-culture of Caco-2 and Raji cells generates cells with a M-cell like 
phenotype. Such cells can give useful information regarding transport of test com-
pounds through M-cells, however such studies will eventually have to be confi rmed 
in an in vivo system. 
 Open Access  This chapter is distributed under the terms of the Creative Commons Attribution 
Noncommercial License, which permits any noncommercial use, distribution, and reproduction in 
any medium, provided the original author(s) and source are credited. 
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 Part IV 
 Enteroendocrine Cell Models: 
General Introduction 
 During and after a meal, ingested nutrients modulate the release of a variety of 
 hormones, many of which serve roles to enhance nutrient digestion. A number of 
these gut hormones, most notably cholecystokinin (CCK), glucagon-like peptide-1 
(GLP-1) and peptide YY (PYY), are key players in infl uencing eating behaviour and 
food intake, largely through induction of satiety (Begg and Woods  2013 ). Some of 
these hormones (glucose-dependent insulinotropic peptide (GIP) and GLP-1)) are 
also incretins, enhancing glucose-dependent insulin secretion. Identifying food com-
ponents that alter the gastrointestinal hormonal milieu may aid in our ‘battle of the 
bulge’ as well as in the treatment of related metabolic diseases (Bruen et al.  2012 ). 
 Mammalian enteroendocrine cell lines provide the starting framework to  measure 
gut hormonal responses to food. In vitro models of enteroendocrine cell lines have 
proven diffi cult to develop, primarily because enteroendocrine cells are sparsely 
dispersed throughout the gastro-intestinal tract and are co-localized with abundant 
enterocytes. However, several groups have successfully established enteroendocrine 
cell models that are available for in vitro screening bioassays (Table  1 ).
 The NCI-H716 cell line is the only human enteroendocrine cell line available and it 
provides a unique L-cell model to screen food components for their ability to modulate 
secretion of the incretin hormone, GLP-1. This cell line was originally derived from 
cells present in the ascites fl uid of a male 33 year old patient with a poorly differenti-
ated adenocarcinoma of the cecum (Park et al.  1987 ). When propagated in vitro, these 
cells have been described to exhibit endocrine differentiation including the expression 
of secretory granules and chromogranin A (de Bruine et al.  1993 ). However, they do 
require attachment matrices (de Bruine et al.  1993 ; Anini and Brubaker  2003 ) which 
could limit their ease of use in high throughput assays. The NCI-H716 cells express 
both GLP-1 and PYY but not CCK (Reimer et al.  2001 ; Jang et al.  2007 ). GLP-1 
expression in these cells is mostly homogenous but PYY expression is much less 
uniform, with only ~30 % of cells containing PYY immunoreactivity (Jang et al. 
 2007 ). The NCI- H716 cell line is discussed in more detail in Chap.  20 . 
208





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 )  
Part IV Enteroendocrine Cell Models: General Introduction 
209
 To study GLP-1 secretion, researchers also routinely use the alternative, albeit 
non-human, cell lines; STC-1 and GLUTag, which were developed from murine 
genetically-induced proximal and distal intestinal tumours, respectively. The STC-1 
(secretin tumour cell) cell line is a heterogeneous enteroendocrine cell line which 
expresses several satiety and incretin hormones, including CCK, GIP, PYY, pancre-
atic polypeptide, neurotensin and the proglucagon-derived peptides: GLP-1, 
glucagon- like peptide-2 (GLP-2) and oxyntomodulin (Rindi et al.  1990 ). The pluri-
hormonal nature of these cells appears to be consistent with recent fi ndings on the 
primary murine duodenal L-cell (Habib et al.  2012 ,  2013 ). Molecular mechanisms 
underlying stimulus-hormone secretion coupling have been well defi ned in the 
STC-1 cell line. Primarily because of its ability to secrete several satiety hormones, 
it remains a popular choice for primary screening platforms, as detailed in the 
accompanying chapter. 
 In contrast to STC-1 cells, the GLUTag (proglucagon SV40-large T antigen) 
cell line appears quite differentiated and demonstrates a stable pattern of  proglucagon 
gene expression over a 4–8 week period (Drucker et al.  1994 ). However, unlike the 
NCI-H716 and STC-1 cells, the GLUTag cells express GLP-1 and CCK, but not 
PYY (Drucker et al.  1994 ). The absence of PYY is somewhat surprising given the 
colonic origin of the GLUTag cell line and the fact that most colonic L-cells express 
this hormone in vivo (Habib et al.  2013 ). Notwithstanding, GLUTag cells recapitu-
late the responsiveness of both of the other cell lines as well as of primary murine 
L-cells and fetal rat intestinal cultures, secreting multiple fully-processed glucagon- 
like peptides in response to known physiological and pharmacological secreta-
gogues (Lim et al.  2009 ). For use in high throughput assays, it is worth noting that 
GLUTag cells require a matrix for proper attachment to multi-well plates. Further 
details regarding the GLUTag cell line can be found in the accompanying chapter. 
 It is important to note that species-specifi c differences in nutrient sensitivity 
in vivo do exist and non-human cell lines may therefore not be appropriate beyond 
primary screens (Brubaker  1991 ; Brubaker et al.  1998 ; Habib et al.  2013 ). For 
example, while GIP is an effective stimulator of GLP-1 release in canine and rodent 
L-cells (Brubaker  1991 ; Brubaker et al.  1998 ) it has little effect on GLP-1 secretion 
in human L-cells in vivo (Kreymann et al.  1987 ). Moreover, it has been demon-
strated that the transcription factors and promoter regions important for human 
 proglucagon gene expression are distinct from those utilised by the rat  proglucagon 
gene (Nian et al.  1999 ). Findings made in any cell line may not completely recapitu-
late those made in vivo, due to the extremely high likelihood that the L-cell con-
stantly integrates multiple signals, from luminal, endocrine and neural inputs. It is 
thus imperative that all fi ndings made in vitro ultimately be confi rmed in the in vivo 
setting. With these limitations in mind, the enteroendocrine cell models still provide 
a set of powerful tools that enable a detailed examination of hormonal responses to 
food bioactives.
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 Chapter 19 
 STC-1 Cells 
 Triona  McCarthy ,  Brian  D.  Green ,  Danielle  Calderwood ,  Anna  Gillespie , 
 John  F.  Cryan , and  Linda  Giblin 
 Abstract  Gastrointestinal hormones such as cholecystokinin (CCK), glucagon like 
peptide 1 (GLP-1), and peptide YY (PYY) play an important role in suppressing 
hunger and controlling food intake. These satiety hormones are secreted from 
enteroendocrine cells present throughout the intestinal tract. The intestinal secretin 
tumor cell line (STC-1) possesses many features of native intestinal enteroendo-
crine cells. As such, STC-1 cells are routinely used in screening platforms to 
identify foods or compounds that modulate secretion of gastrointestinal hormones 
in vitro. This chapter describes this intestinal cell model focussing on it’s applica-
tions, advantages and limitations. A general protocol is provided for challenging 
STC-1 cells with test compounds. 
 Keywords  Enteroendocrine cells •  Secretin tumor cell line (STC-1) •  Satiety 
 hormones •  GLP-1 •  CCK •  PYY •  Food components •  G protein coupled receptors 
•  Nutrient sensing 
19.1  Origin 
 STC-1 was originally established from cells present in murine enteroendocrine 
tumours. These tumours arose in the duodenum of double transgenic mice express-
ing the rat insulin promoter linked to the simian virus 40 large T antigen and to the 
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polyomavirus small T antigen (Rindi et al.  1990 ). STC-1 is a relatively slow growing 
cell line, with a doubling time of 54 h in standard growth media. They are not easily 
amenable to transfection with several studies reporting low transfection effi ciencies 
(stable and transient). Under culturing conditions, this cell line is heterogenous. 
However most subpopulations demonstrate immunoreactivity to the gut hormone, 
cholecystokinin (CCK) (Rindi et al.  1990 ). As such, STC-1 cells were originally 
used as a model of native CCK-producing I-cells. Over the past two decades, the 
uses of the STC-1 cell line has been expanded to investigate (a) the cellular signal-
ing mechanisms involved in secretion and gene transcription of other gut hormones 
(Cordier-Bussat et al. 1998; Geraedts et al.  2009 ), (b) enteroendocrine cell differen-
tiation (Ratineau et al.  1997 ), (c) tumor cell growth (Bollard et al.  2013 ) and (d) 
intestinal immune responses (Palazzo et al.  2007 ). 
19.2  Features and Mechanisms 
 In addition to CCK, STC-1 cells express and secrete a wide range of gut hormones 
known for their roles in metabolism, feeding and satiety, including glucose depen-
dent insulinotropic polypeptide (GIP), peptide YY (PYY), pancreatic polypeptide, 
neurotensin and the proglucagon derived peptides [glucogon-like peptide-1 (GLP-1), 
glucogon-like peptide-2 (GLP-2) and oxyntomodulin] (Rindi et al.  1990 ; Hand 
et al.  2013 ). STC-1 cells secrete these hormones in response to a range of physio-
logical stimuli, although levels may differ to native enteroendocrine cells (Reimann 
et al.  2008 ). This ability to secrete a variety of gut hormones ensures that the STC-1 
cell line remains a popular ‘look-see’ choice with food researchers. 
 Monosaccharides (Mangel et al.  1994 ), fatty acids (Hand et al.  2010 ), aromatic 
amino acids (Cordier-Bussat 1998; Wang et al.  2011 ), peptidomimetic compounds 
(Geraedts et al.  2011 ) and bitter tastants (Miyata et al.  2014 ) have all been demon-
strated to dose dependently elicit CCK and GLP-1 secretion from STC-1 cells. 
Several studies have also reported that sucralose and other sweeteners increase 
CCK and GLP-1 secretion in STC-1 cells (Geraedts et al.  2012 ). Interestingly, these 
substances do not appear to be GLP-1 stimulants in primary cultures of murine 
intestinal epithelium (Reimann et al.  2008 ). Although PYY secretion has been less 
widely investigated, STC-1 cells reliably produce and secrete PYY in response to a 
variety of fatty acids including valeric acid, linoleic acid and conjugated linoleic 
acid 9,11 (Hand et al.  2013 ). GIP expression and production by STC-1 cells is poor. 
Nevertheless as there are few in vitro alternatives, GIP subclones of STC-1 cells 
with increased  GIP expression have been generated (Kieffer et al.  1995 ). 
 Several neural and hormonal stimuli which play an important role in coordinat-
ing early responses to food ingestion in vivo also induce gut peptide release from 
STC-1 cells. These include the neurotransmitters gamma-aminobutyric acid 
(GABA), acetylcholine, orexin, bombesin, apelin, gastrin releasing peptide as well 
as bile acids and leptin. 
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 Hormone secretion from this cell line appears to be dependent on a rise in 
 cytoplasmic cAMP and Ca 2+ which ultimately leads to alteration in hormone gene 
transcription levels or hormone peptide release. Increased Ca 2+ levels can occur as a 
result of (a) an infl ux of Ca 2+ across the plasma membrane through activation of 
voltage- gated calcium channels or (b) inositol 1,4,5-triphosphate (IP3) triggered 
Ca 2+ release from intracellular stores. In native enteroendocrine cells, intracellular 
levels of Ca 2+ and cAMP are also altered by the activity of a number of G-protein 
coupled receptors (GPCR’s) and nutrient transporters. STC-1 cells have been found 
to intrinsically express many of these important GPCRs including GPR40 and 
GPR120 (Tanaka et al.  2008 ). Hormone secretion is dependent on GPR40 in native 
murine I-cells, as linolenic acid induced CCK secretion was absent in cells lacking 
this receptor (Liou et al.  2011b ). In contrast, GPR40 knockdown had little effect on 
the ability of STC-1 cells to sense fatty acids. Rather, it is GPR120 that appears to 
play a more important role in fatty acid sensing in STC-1 cells. Fatty acid-induced 
hormone release is impaired in  GPR120 siRNA silencing experiments (Tanaka et al. 
 2008 ). Wang  et al . demonstrated that phenylalanine induced Ca 2+ mobilization and 
hormone secretion occurs via the calcium-sensing receptor which is highly 
expressed in native murine enteroendocrine cells (Wang et al.  2011 ). This receptor 
is however poorly expressed in STC-1 cells, although it is functional. Several taste 
signalling elements such as alpha-gustducin, phospholipase C-β2, transient receptor 
potential channel M5 and the taste receptor T1R/T2R subunits are present and func-
tional in STC-1 cells similar to native enteroendocrine cells (Dyer et al.  2005 ). 
 Recent evidence suggests that ATP-sensitive K + channels and transporters [e.g. 
sodium-coupled glucose transporters (SGLTs) and peptide transporters (PEPTs)] 
contribute to hormone secretion in enteroendocrine cells (Tolhurst et al.  2009 ). 
However STC-1 cells express low levels of the K ATP channel subunits, Kir6.2 and 
SUR1. Endogenous expression of PEPTs is also poor in STC-1 cells (Liou et al. 
 2011a ). 
 In addition to stimulating gut hormone release, common luminal nutrients added 
to the growth media are also capable of modulating gene expression in STC-1 cells. 
As such this cell line has been widely used to investigate the regulation of  CCK 
gene expression. However, for the  proglucagon gene, aberrant posttranslational 
 processing has been documented (Blache et al.  1994 ). In vivo, the synthesis of 
proglucagon- derived peptides is tissue specifi c due to the action of various prohor-
mone convertase enzymes (e.g. PC1/3). In pancreatic α cells, posttranslational pro-
cessing of proglucagon liberates glucagon, glicentin-related pancreatic peptide, and 
the major proglucagon fragment, which contains the sequences for both GLP-1 and 
GLP-2. In contrast, processing of proglucagon in the intestinal enteroendocrine 
L-cell generates GLP-1 and GLP-2, as well as the glucagon-containing peptides, 
glicentin and oxyntomodulin. Blache  et al . reported that proglucagon processing in 
STC-1 cells results in the production of signifi cant quantities of glucagon in addition 
to glicentin and oxyntomodulin (Blache et al.  1994 ). Thus STC-1 cells appear to 
process the proglucagon fragment in a manner which is intermediate between 
intestinal L-cells and pancreatic α cells. 
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19.3  Stability, Consistency and Reproducibility 
 When used appropriately, STC-1 cell line has been shown to be a reliable and repro-
ducible enteroendocrine cell model. However, considerable variances in hormone 
secretion levels have been reported by different laboratories for the same substance 
(Geraedts et al.  2009 ; Hand et al.  2013 ). For example, Cordier-Bussat  et al . showed 
that addition of protein hydrolysates from meat, casein and soybean to STC-1 cells 
increased CCK and GLP-1 release compared to undigested proteins (Cordier-Bussat 
et al.  1997 ). In contrast, other studies have demonstrated that intact protein is a 
much stronger stimulant for CCK and GLP-1 release in STC-1 cells than hydroly-
sates or specifi c peptides (Geraedts et al.  2011 ). In addition to differences between 
different laboratories, signifi cant inter-experimental variability in the amount of 
CCK secreted has also been reported within study groups. Differences in culture 
protocols such as seeding density, cell feeding routine, washing steps, test buffer 
and passage number may account in part for this variability. However, inter- 
experimental variability is most likely a direct result of the heterogenous non-stable 
nature of the cell line. Cultured STC-1 cells demonstrate 95 % immunoreactivity to 
CCK, while only 7 % stain positively for GIP (Rindi et al.  1990 ). Glassmeier  et al . 
reported that the sensitivity of STC-1 cells to the neurotransmitter GABA varied 
considerably from cell to cell, due to the heterogeneous density and expression of 
GABA A receptors in this cell line (Glassmeier et al.  1998 ). STC-1 cells may switch 
to multiple differentiated states during proliferation (Rindi et al.  1990 ). Consequently 
levels of hormone secretion may signifi cantly differ from one test to another. 
To improve the homogeneity and the stability of STC-1 cells, several studies have 
attempted to isolate and characterize clonal cell lines from parental STC-1 cells. 
However even these cells do not express a stable phenotype. For example, while 
attempting to clone a pure GIP-expressing cell, Kieffer  et al . observed that only 
30 % of the expanded clone still expressed GIP immunoreactivity due to dediffer-
entiation of the cells (Kieffer et al.  1995 ). These observations highlight the impor-
tance of including adequate controls and replicates for each independent experiment. 
As early passage number STC-1 cells have greater heterogeneity, cells that have 
been passaged more than 10 times are recommended. It also underlines the impor-
tance of verifying results with experiments independent of STC-1 cells. 
19.4  Relevance to Human In Vivo Situation 
 A major requirement of any in vitro model is that it should demonstrate a strong 
predictive power, yielding data that support interpretation of results for the in vivo 
situation. Although STC-1 cells do respond to a range of physiological stimuli 
shown to elicit gut hormone secretion in vivo, some inconsistencies have been 
observed. Hall  et al . demonstrated that while whey consumption in humans resulted 
in a greater increase in GLP-1, GIP, and CCK plasma levels compared to other pro-
tein sources (Hall et al.  2003 ), whey protein hydrolysate are ineffective stimulants 
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of CCK release in STC-1 cells (Foltz et al.  2008 ). STC-1 and the native state also 
differ in PYY secretion to fatty acids (Hand et al.  2013 ). 
 In vivo gut hormone release occurs through direct sensing of luminal nutrients 
but also indirectly by vagal and humoral stimulation (Gribble  2012 ). Evidence 
shows that the release of bile acids, gastric acid secretions, mechanical stimula-
tion by peristaltic contractions, gastric emptying and hormonal stimulation all 
result in gut hormone modulation. While STC-1 cells harbour many features of 
native intestinal hormone secreting cells, they are cultivated as monolayers on 
plastic surfaces and lack a normal cellular environment. They therefore cannot 
reproduce the integrative physiological interplay present in vivo. Thus many 
components which stimulate gut hormone secretion through indirect mechanisms 
will not be detected by this model. A typical example of this limitation is that 
potato protease inhibitors fail to elevate CCK expression or release in STC-1 cells 
(Komarnytsky et al.  2011 ). However in vivo potato protease inhibitors reduce 
food intake, and increase plasma and duodenal mucosal mRNA levels of  CCK in 
rats indirectly by inhibiting trypsin mediated deactivation of endogenously pro-
duced CCK releasing factors (Komarnytsky et al.  2011 ). 
 It is also worth noting that compounds which elicit gut hormone secretion from 
STC-1 cells and in vivo, do not always effect food intake or the perception of the 
feeling of fullness. For example, Korean pine nut oil effectively increases CCK 
secretion from STC-1 cells and in plasma levels of humans. This increase in satiety 
hormone levels however did not correspond to a change in subjective appetite sensa-
tions as assessed by visual analogue scales (Pasman et al.  2008 ). This lack of rela-
tionship between increased plasma concentrations of gut hormones and appetite 
ratings has been observed in other studies (Veldhorst et al.  2009 ). 
19.5  General Protocol 
19.5.1  Cell Maintenance Protocol 
 STC-1 cells should be cultured in supplemented DMEM media (DMEM containing 
4.5 g/l  D -glucose, without sodium pyruvate) (GlutaMAX, GIBCO, Paisley, UK) 
with 17.5 % foetal bovine serum (FBS), 100 U/ml penicillin, 100 mg/l streptomycin 
and incubated in a 5 % CO 2 humidifi ed atmosphere at 37 °C. Cells should be pas-
saged at 80–90 % confl uence. Passage number should be between 15 and 40. 
19.5.2  Experimental Protocol for Test Compounds 
 Test compounds should be prepared in pre-warmed buffer. Buffer should be tested 
to ensure compatibility with the particular immunoassay. 
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 Figure  19.1 indicates that dramatically different results can be obtained depending 
on the buffer system used. Use of buffer solutions which are highly stimulatory 
(e.g. DMEM media which contains amino acids and vitamins), should be avoided 
because hormone levels for vehicle controls will be greatly elevated and can distort 
results. In previous experiments, we have favoured KREBS buffer. The test solution 
pH should be adjusted to 7.0–7.4 and fi lter sterilised (0.45 μm fi lter). If solubility of 
test compounds is an issue (e.g. in the case of lipids or fatty acids) careful monitor-
ing is needed to ensure test compounds remain in solution for the duration of experi-
ments. To measure acute hormone secretion, STC-1 cells should be seeded into 6 well 
plates at 1.5 × 10 6 cells in supplemented DMEM media. After 18 h at 37 °C in 5 % 
CO 2, media should be aspirated and cell monolayers washed 1–2 times with selected 
buffer. The cells should be acclimatised in buffer for 1 h. Culture media and wash 
buffers can be kept to ensure that cells have reached basal levels of hormone secre-
tion (Fig.  19.1 ). After 1 h, the buffer is aspirated and 1 ml test solution added to 
wells. Cells are then incubated for 1–4 h at 37 °C, 5 % CO 2 (in our experience a 
period of 3–4 h is optimal for hormone secretion, Fig.  19.2 ). Positive controls 
known to stimulate gut hormone secretion and negative controls (buffer alone) 
 Fig. 19.1  Effect of various incubation buffers on levels of Total GLP-1 secreted from STC-1 cells. 
STC-1 cells (2 × 10 6 ) were challenged with mixed nutrients [glutamine + valine + lysine + gly-
cine + glucose + fructose (all at 40 mM)] for 3 h. Samples were prepared in PBS or HANKS or 
KREBS or HEPES buffers or DMEM media (GlutaMAX, GIBCO, Paisley, UK). The composition 
of the buffers are as follows; PBS (136.9 mM NaCl, 2.7 mM KCl, 10.1 mM Na 2 HPO 4 , 1.8 mM 
KH 2 PO 4 ), HANKS (136.9 mM NaCl, 5.4 mM KCl, 1.3 mM CaCl 2 , 1 mM MgSO 4 , 0.2 mM 
NaHPO 4 , 0.4 mM KH 2 PO 4 , 4.2 mM NaHCO 3 , 5.6 mM glucose), KREBS (118 mM NaCl, 4.7 mM 
KCl, 25 mM NaHCO 3 , 1.25 mM CaCl 2 , 1.2 mM MgSO 4 , 1.2 mM KH 2 PO 4 , 11 mM glucose) and 
HEPES (140 mM NaCl, 4.5 mM KCl, 1.2 mM CaCl 2 , 1.2 mM MgCl 2 , 20 mM HEPES). Total 
GLP-1 was measured by a specifi c GLP-1 radioimmunoassay. Statistical comparisons (unpaired 
Student’s t-test) were only performed on 3 h incubations with or without nutrient challenge for 
each selected buffer. Signifi cant differences are indicated on the graph (*P < 0.05) 
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should always be included in each experimental unit. Post-incubation, we recom-
mend the addition of 10 μl 10X Halt Protease and Phosphatase Inhibitor (Thermo 
Fisher Scientifi c, USA) to protect against gut hormone degradation. Cellular super-
natants are collected and store at −80 °C prior to further analysis. It is best practice 
to immediately transfer solutions to tubes placed on ice and to centrifugate (900× g 
for 5 min) to remove cellular debris. At least three biological replicates should be 
performed. 
19.6  Assess Viability 
 Prior to hormone studies, viability or integrity of STC-1 cells challenged with test 
compounds at various concentrations should be tested. Where test compounds are 
digested, viability tests should be performed with the inactivated and pH adjusted 
(7.0–7.4) digestion matrix. An array of methods and kit-based assays are available 
for cell viability (e.g. measurement of mitochondrial reductase with tetrazolium 
salts, measurement of cell membrane integrity or signs of cytolysis and/or detection 
of increased apoptosis). Due the ability of healthy STC-1 cells to change morphol-
ogy and grow extensions, systems based on electrical impedance may be unsuitable 













































































































 Fig. 19.2  Determining the optimal incubation time to measure levels of Total GLP-1 secreted 
from STC-1 cells. STC-1 cells (2 × 10 6 ) were exposed for various incubation times with stimula-
tory amino acid solution (40 mM glutamine, 40 mM valine, 40 mM lysine and 40 mM glycine) and 
monosaccharide solution (40 mM glucose and 40 mM fructose) which were prepared in HEPES 
buffer. Data were statistically compared using the unpaired Student’s t-test and signifi cant differ-




19.7  Experimental Read out 
 Intracellular levels of the secondary messengers (cAMP, IP3 and Ca 2+ ) are often used 
as rapid indirect indicators of gut hormone secretion. Several types of assays are cur-
rently available to measure cAMP including radioimmunoassay approaches, time-
resolved FRET-bioluminescence resonance energy transfer based assays, enzyme 
fragmentation complementation and cyclic nucleotide gated ion channel coupled 
assays. Intracellular Ca 2+ concentrations can be determined directly using membrane 
permanent calcium-sensitive dyes (e.g. Fluo-3, Fluo-4 or Fura-2) that fl uoresce upon 
exposure to free Ca 2+ . IP1, a downstream metabolite of IP3, can be used as a surro-
gate for direct determination of Ca 2+ as it has a longer half-life. A competitive immu-
noassay is commercially available that uses terium cryptate- labeled anti-IP1 and D2 
labeled IP1 (Cisbso Bioassays, France). IP1 levels only refl ect release of Ca 2+ from 
intracellular stores and do not account for increased Ca 2+ levels resulting from infl ux 
across the cellular membrane. 
 Specifi c assays for individual hormones include qRT-PCR assays and immuno-
assays (ELISA and RIA). For qRT-PCR, standard methods apply. Result interpreta-
tion is important as increases in mRNA levels and intracellular peptide levels may 
not result in corresponding increases in secretion levels of gut peptides (Hand et al. 
 2010 ). A number of sensitive and accurate commercial immunoassays (ELISA and 
RIA) are available for the detection of CCK, PYY and GLP-1, although multiplex-
ing these analytes has proved diffi cult. Antibodies may not discriminate between 
bioactive and inactive forms of gut peptides. Moreover, a large cross-reactivity with 
gastrin has been observed for many commercially available assays. To overcome 
these limitations Foltz  et al . developed an assay based on the ability of dietary com-
ponents to induce CCK release from STC-1 cells and in turn activate the CCK 
receptor overexpressed in the chinese hamster ovary cell line (Foltz et al.  2008 ). 
Upon activation of the CCK receptor, Ca 2+ levels increase, which can be visualized 
with a fl uorescent dye. Thus this assay rapidly and directly determines the effect of 
a nutritional intervention on activation of CCK receptor yielding results which are 
more physiological relevant. 
19.8  Conclusions 
 The murine STC-1 cell line is regarded as ‘best in class’ to evaluate secretion of 
several satiety hormones in response to food components in vitro. The gut hormones 
CCK, GLP-1, GIP, PYY, pancreatic polypeptide, neurotensin, GLP-2 and oxynto-
modulin are all secreted by STC-1 cells. However the heterogeneous nature of STC-1 
cells can introduce discrepancies from experiment to experiment. In addition, it’s 
response to stimulants can vary from the native enteroendocrine cell which underlines 
the importance of substantiating results in vivo. 
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 Chapter 20 
 NCI-H716 Cells 
 Jeffrey  Gagnon and  Patricia  L.  Brubaker 
 Abstract  The endocrine response to nutrient ingestion is vital to the maintenance 
of energy homeostasis in the body. Glucagon like peptide-1 (GLP-1) is one such 
hormone that is released from L-cells of the distal small intestine and colon in 
response to meal ingestion. GLP-1 acts on various systems in the body to enhance 
glucose-stimulated insulin secretion, delay gastric emptying and promote satiety. 
As such, elevating the levels of active GLP-1 in the circulation, as well as enhanc-
ing GLP-1 bioactivity, is the basis of several recent anti-diabetic medications. 
Gaining an understanding of how GLP-1 secretion is regulated at the cellular level 
requires in vitro L-cell models. NCI-H716 is a cell line derived from ascites fl uid of 
a colorectal adenocarcinoma from a 33 year old Caucasian male. This cell line is 
 currently the only human model available for the in vitro study of GLP-1 regulation 
and is the topic of the following chapter. This chapter will cover the origin, charac-
teristics and methods for using this model. Comparisons are then made between 
other available in vitro GLP-1 models. 
 Keywords  GLP-1 •  Endocrine hormone •  Nutrient •  Neurotransmitter •  Receptor • 
 Cell line •  Cell culture •  L-cell •  Secretion •  Enteroendocrine •  Human 
20.1  Introduction 
 Glucagon like peptide 1 (GLP-1) is a key hormone in the regulation of nutrient 
metabolism. Its release from intestinal enteroendocrine L-cells is stimulated by the 
ingestion of nutrients (both directly, through luminal nutrient sensing, and indirectly, 
via parasympathetic innervation). The L-cells are distributed primarily in the distal 
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small intestine and colon. Once released into the circulation, GLP-1 acts to promote 
satiety as well as the storage of ingested nutrients. A well-established and pharma-
cologically-targeted aspect of GLP-1 action is its role in potentiating glucose- 
stimulated insulin secretion from the β cells of the pancreas. This action creates a 
larger insulin response to ingested glucose as compared to isoglycemic levels of 
glucose delivered intravenously, and is known as the incretin effect. The GLP-1 
responses to various dietary nutrients and their respective intracellular mechanisms 
of action on the L-cell have been, and continue to be, intensively studied using 
in vitro GLP-1-secreting cell models. One such model is the human colonic cell 
line, NCI-H716. This review will describe the origin, utility and associated methods 
of use of this cell line in the study of GLP-1 biology. 
20.2  Origin 
 NCI-H716 cells were one of several colorectal cancer cell lines originally described 
in 1987 (Park et al.  1987 ). This particular cell line was developed from cells har-
vested in ascites fl uid of a 33-year old Caucasian male with colorectal cancer. 
Interestingly, of the 14 cell lines described in this study, NCI-H716 was the only line 
that contained dense-core granules, which are characteristic of endocrine cells. 
While it was unclear as to the contents in these granules at the time of discovery, 
later work in several laboratories elucidated the hormones produced by these cells. 
Early studies with these cells demonstrated the expression of both the secretory 
granule marker, chromogranin A, and mucin, as well as receptors for gastrin, soma-
tostatin and serotonin (de Bruine et al.  1992 ). This not only confi rmed that these 
cells had an endocrine phenotype but suggested that they were also sensitive to 
other gastrointestinal hormones. After several years of being used as model of 
tumour/endocrine differentiation, Reimer et al. demonstrated both expression and 
regulated secretion of glucagon-like peptide-1 (GLP-1) by these cells (Reimer et al. 
 2001 ). In that study, NCI-H716 cells were found to secrete high levels of active 
GLP-1 in amounts that could be easily measured by collecting cell culture medium 
and cell lysates. They also showed that nutrients, including fatty acids and protein 
hydrolysate, dose-dependently stimulated GLP-1 secretion by these cells (Reimer 
et al.  2001 ). Following this, work by our group elucidated roles for several hor-
mones (Anini and Brubaker  2003b ; Lim et al.  2009 ), neurotransmitters (Anini and 
Brubaker  2003a ), fatty acids (Lauffer et al.  2009 ) and anti-diabetic medications 
(Mulherin et al.  2011 ) in the regulation of GLP-1 secretion. To date, the NCI-H716 
cells remain the only characterized model of the human intestinal L-cell. 
20.3  Features and Mechanisms 
 NCI-H716 cells are considered pseudo-diploid with an average chromosome count 
of 61 (Park et al.  1987 ). Electron micrographs shown in this initial study clearly 
demonstrate many dense-core granules. In culture, these cells appear spherical and 
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undifferentiated, and they grow in suspension, occasionally forming clumps. 
Plating the cells on a basement membrane-coated surface allows the cells to attach 
and grow horizontally. Although this plating strategy was initially reported to allow 
the cells to become differentiated towards an endocrine lineage (Reimer et al. 
 2001 ), studies by our laboratory and other groups have indicated that plating does 
not change the levels of GLP-1 in these cells (Anini and Brubaker  2003a ; Cao et al. 
 2003 ). 
 Anini and Brubaker demonstrated expression of the leptin receptor in NCI-H716 
cells by western blot and fl uorescent immunocytochemistry (Anini and Brubaker 
 2003b ). This study further showed that leptin stimulates GLP-1 secretion by these 
cells, and that the hyperleptinemia that occurs during obesity leads to leptin resis-
tance and impaired GLP-1 secretion in this condition. In that same year, Anini and 
Brubaker also demonstrated expression of the M1, M2 and M3 muscarinic receptors 
in the NCI-H716 cells by western blot and fl uorescent immunocytochemistry (Anini 
and Brubaker  2003a ). Herein, they also established a role for M1 muscarinic regula-
tion of GLP-1 secretion. Shortly after, Lim et al. showed that NCI-H716 cells express 
the insulin receptor, by semi-quantitative reverse transcriptase PCR and fl uorescent 
immunocytochemistry (Lim et al.  2009 ). They further demonstrated that, while insulin 
was able to stimulate GLP-1 secretion acutely, extended pre- incubation with insulin 
led to a loss in the ability of these cells to respond to other GLP-1 secretagogues. 
Hence, the hyperinsulinemia that occurs in patients with type 2 diabetes mellitus 
(T2DM) may also result in impaired GLP-1 secretion. 
 The ability of the L-cell to respond to luminal nutrients is a vital component of 
the incretin system. GLP-1 regulation by ingested nutrients through specifi c recep-
tors has been demonstrated using the NCI-H716 cell line. In the initial NCI-H716 
and GLP-1 secretion study, the authors showed that meat hydrolysate stimulated 
GLP-1 release (Reimer et al.  2001 ). Several years later, they also demonstrated 
mRNA expression of several amino acid transporters by these cells, including 
Y + LAT2, ASCT2, and ATA-2 (Reimer  2006 ). 
 Luminal glucose sensing by the L-cells has also been demonstrated through the 
sweet taste receptor system. NCI-H716 cells express several of the type 1 taste 
receptors and α-gustducin, which is a key component of the taste transduction 
pathway (Jang et al.  2007 ). In this study, knockdown of α-gustducin prevented the 
glucose- stimulated GLP-1 response by NCI-H716 cells. While this study and others 
(Zhang et al.  2012 ) have demonstrated that glucose can stimulate GLP-1 secretion 
from NCI-H716 cells, the presence of a glucose transporter has yet to be 
demonstrated. 
 Lipid sensing by the NCI-H716 cell line has been demonstrated by several 
groups (Chen et al.  2012 ; Lauffer et al.  2009 ). Expression of the monoacylglycerol- 
sensing G-protein coupled receptor, GPR119, by RT-PCR in NCI-H716 cells was 
shown by Lauffer et al. ( 2009 ). While examining the effects of milk products on 
GLP-1 secretion, Chen et al. also demonstrated expression of fatty acid transport 
protein 4 in the NCI-H716 cells by quantitative RT-PCR (Chen and Reimer  2009 ). 
 The above studies clearly indicate that NCI-H716 cells possess many of the 
receptors and intracellular machinery required to sense hormones, neurotransmitters 
and nutrients, and to release GLP-1 in response to these agents. 
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20.4  Stability/Consistency/Reproducibility 
 The increasing use of the NCI-H716 cells as a model of the human intestinal L-cell 
necessitates an examination of the consistency of fi ndings between different research 
groups using these cells. In terms of GLP-1 secretion, many groups now present 
secretion data relative to an untreated control, making interpretation of actual percent 
secretion diffi cult. However, early studies with the NCI-H716 cells demonstrated 
percent secretion to be in the range of 1–15 % of the total well/plate content of 
GLP-1 over a 2 h incubation period (Reimer et al.  2001 ; Anini and Brubaker  2003a ; 
Lim et al.  2009 ; Lauffer et al.  2009 ). Regarding the error in replicates of GLP-1 
secretion, these studies report standard error to be ~10 % (of the mean). 
 Some groups have examined the effect of similar treatments on GLP-1 secretion. 
Anini et al. found that the protein kinase C activator, phorbol 12-myristate 13- acetate 
(PMA) caused a 2.5-fold stimulation in GLP-1 secretion (Anini and Brubaker 
 2003a ), whereas Reimer et al. saw a 4.3-fold stimulation with the same dose and 
duration of incubation (Reimer et al.  2001 ). While both studies showed a robust 
stimulation of GLP-1 secretion, the difference in magnitude may be due to differ-
ences in media/buffers used during the secretion experiment or in sample preparation 
(both subjects of further discussion below). 
20.5  Relevance to the Human L-Cell In Vivo 
 Since NCI-H716 cells were derived from a human sample, they are of particular sig-
nifi cance to the study of human GLP-1 secretion. However, while these cells do secrete 
GLP-1 in response to nutrients, as found in vivo, it must be recognized that they are 
derived from a tumour cell which was likely to have been relatively undifferentiated 
initially. Furthermore, one study examined the ability of NCI-H716 cells to regulate 
expression of reporter plasmids encoding human and rat  proglucagon (i.e. the GLP-1 
prohormone gene). Surprisingly, no basal promoter activity was observed even in the 
presence of several positive regulators of rodent  proglucagon gene expression (Cao 
et al.  2003 ). In addition, compounds that are known to enhance  proglucagon gene 
expression in rodent models failed to stimulate the endogenous human  proglucagon 
gene in NCI-H716 cells. These fi ndings suggest that either the NCI-H716 cells do not 
regulate  proglucagon gene expression normally or that there are marked species-
specifi c differences in the regulation of  proglucagon expression. 
20.6  General Protocol 
20.6.1  Cell Maintenance Protocol 
 NCI-H716 cells are normally grown in suspension culture. Our group uses Roswell 
Park Memorial Institute (RPMI) media containing  L -glutamine and Phenol Red. 
This media is further supplemented to contain 10 % fetal bovine serum (FBS) and 
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100 units/ml each of penicillin and streptomycin (‘complete RPMI’). Cells can be 
grown in suspension in cell culture fl asks and should be kept at a density of ~500,000 
cells/ml to ensure a rapid growth rate; lower densities may cause stalled growth. 
Under these conditions, cells double every ~3 days and should be passaged once a 
week. To passage, cells do not require any enzymatic digestion; any small clumps 
of cells are simply dissociated using repeated serological pipetting. 
20.6.2  Experimental Protocol for Test Compounds 
 As NCI-H716 cells require a basement membrane matrix coating to attach to cell 
culture plates, preparation must occur before seeding cells for an experiment. Matrigel 
(BD Biosciences) is provided as a concentrate with lot-dependent concentration. It is 
stored frozen and gels at 15 °C. Matrigel is therefore thawed on ice (stock aliquots of 
the concentrate can be thawed overnight on ice in a 4 °C fridge, as per manufacturer’s 
directions). Plates or wells are then coated with 0.5 g/ml Matrigel diluted in ice-cold 
sterile Hanks Buffered Saline Solution (HBSS), with the area of the surface being 
coated dictating how much diluted Matrigel is required (generally ≥200 μl/well in a 
24-well plate, ≥ 800 μl/well in a 6-well plate, etc.). After allowing the Matrigel to gel 
for 1 h at room temperature, the plates/wells are then rinsed with HBSS and allowed 
to dry for 30 min; the surface is then ready for seeding of the cells. Cells should be 
reconstituted in complete RPMI to ~200,000 cells/ml (1 ml for each well in a 24-well 
plate, 2 ml for each in a 12-well plate, etc.). This density is optimized to allow ~2 days 
of growth before experimental treatments. On the day of treatment, cells are rinsed 
with low-serum RPMI media (i.e. 0.5 % FBS) then incubated with treatments in 
low-serum RPMI. For GLP-1 secretion studies, 2-h of incubation time is ideal as any 
possible effects on de novo GLP-1 synthesis are unlikely to be observed in this rela-
tively short time-frame. Over a 2-h incubation period, a 24-well plate treated with 
vehicle (control) will have ~300 pg of GLP-1 (total) per well in the collected media, 
with ~7,000 pg of GLP-1 in the cell lysate. Based on these values, the percent 
secretion (i.e. pg in media/(pg in media + cells) × 100) is 4.1 %. 
 Similar plating densities can be used for RNA and protein extraction experi-
ments. A larger surface area can be used for such studies (i.e. 6-well, 10-cm), 
depending on expression levels for the mRNA transcript or protein of interest. From 
a 6-well plate containing ~800,000 cell/well, ~20 μg of RNA and ~60 μg of protein 
can be collected. 
20.7  Assess Viability 
 To ensure treatments do not affect cell health or viability, standard tests should 
be employed. These tests include the 3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium (MTT) assay and neutral red uptake assay. Both of these tests 
can be done within a few hours of an experimental treatment, and should include a 
positive control, such as hydrogen peroxide, to ensure that the assay is reliable. 
20 NCI-H716 Cells
226
20.8  Experimental Readout 
 Sample processing from NCI-H716 cells is dependent on the nature of the experiment 
being conducted. Samples collected for GLP-1 secretion assay, as described in the 
experimental protocol above, are processed as follows. 
 Immediately after the 2-h incubation with treatments is complete, media is col-
lected and centrifuged for 5 min at 1,000× g and 4 °C to remove any fl oating cells. 
This media is then decanted into a new tube containing 1 % trifl uoroacetic acid 
(TFA) to make a fi nal TFA concentration of 0.1 %. This acidic environment pre-
vents protease activity and prepares the sample for the subsequent peptide purifi ca-
tion step. The culture plate with the cells is simultaneously placed on ice and then 
1 ml of ice-cold acidic cell lysis solution (i.e. 1 % TFA, 1 N hydrochloric acid, 5 % 
formic acid, and 1 % NaCl) is added. The cells are scraped and wells are rinsed with 
an additional volume of lysis buffer. These cell lysates are then sonicated, pelleted 
by centrifugation, and the supernatants collected on ice. However, of note, media 
and cells may be collected in a variety of different buffers, as indicated by the 
desired assay protocol, as long as proteolysis is prevented. 
 Depending on the method of hormone assay, samples may require additional 
purifi cation. Using a total GLP-1 radio-immuno assay (RIA; i.e. Millipore), we 
have found that additional purifi cation by C18 solid phase peptide extraction 
removes salts and proteases that may interfere with the assay. Peptides are thus 
 purifi ed using Sep Pak C18 Classic columns (Waters Associates) with 0.1 % TFA 
water (Solution A) and 0.1 % TFA/80 % isopropyl alcohol (Solution B), as follows: 
(1) 4 ml Solution B (wetting/clearing); (2) 4 ml Solution A (equilibrating); (3) sample 
loading; (4) 4 ml Solution A (washing); and (5) 4 ml Solution B (sample elution). 
A portion of the total 4 ml peptide eluate is then dried under vacuum in preparation 
for the RIA. Once samples have been purifi ed using this method, they can be sealed 
and stored at −20 °C for later analysis. 
 Media and cell GLP-1 content determined from the assay can be used to calculate 
percent GLP-1 secretion, as described above. These percent secretion values may differ 
slightly from 1 week to the next due to inter-assay variability. To control for differences 
in percent secretion, treatment groups are often normalized to a vehicle- treated control; 
as such, data often appears “relative to control” in papers examining GLP-1 secretion, 
although absolute values should always be included in the publication to facilitate 
comparison between studies. The use of an appropriate control in each experiment is 
critical. The control treatment group must thus contain the solvent in which the treat-
ment group is dissolved at an identical fi nal concentration. This may include dimethyl 
sulfoxide, ethanol or a buffer solution. In addition, experiments should also be designed 
to include a positive control for GLP-1 secretion. Strong activators of cAMP signaling, 
such as forskolin, have thus been used by several groups to demonstrate cell respon-
siveness to a known secretagogue in parallel with experimental treatment groups. 
 In GLP-1 secretion experiments with NCI-H716 cells, at least three biological 
replicates should be produced for each treatment and control group. Additionally, 
any given experiment should be repeated at least twice to ensure statistical power 
for subsequent analysis, thereby constituting a minimum of six replicates. 
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 For RNA and protein extraction, standard methods apply. For RT-PCR and 
 qRT-PCR studies, the target gene of interest should be determined relative to an 
internal control, such as 18S ribosomal RNA. However, quantifi cation of appropri-
ate reference genes for a particular treatment must also be done to ensure that the 
internal control does not change in response to the experimental treatment. Similarly, 
protein expression analysis by immunoblot should also include a suitable validated 
control, such as actin, for protein loading. 
20.9  Conclusions 
 The ability of the L-cell to respond to nutrient, hormonal and neurotransmitter cues 
is vital in the regulation of GLP-1 secretion and, ultimately, glucose homeostasis. 
Strategies targeting the GLP-1 system in humans have garnered great interest and 
application in the treatment of T2DM (Drucker  2011 ). Cell systems that enable a 
direct mechanistic examination of GLP-1 regulation have been and continue to be 
essential tools in developing novel GLP-1 therapies. The NCI-H716 cell line is the 
only human cell line currently available to study GLP-1. This places it in an impor-
tant position to relate the effects of various treatments to human biology, although 
experimental effects should always be cross-examined through the use of additional 
in vitro and in vivo models to strengthen the hypothesis. The NCI-H716 cells are 
thus a useful tool to study the control of GLP-1 release and the underlying cell 
signaling pathways as well as, potentially,  proglucagon gene expression. Overall, 
they are an excellent model to investigate the regulation of human GLP-1. 
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 Chapter 21 
 Murine GLUTag Cells 
 Manuel  Gil-Lozano and  Patricia  L.  Brubaker 
 Abstract  The incretin hormone, glucagon-like peptide-1 (GLP-1) serves as a link 
between ingested nutrients and insulin secretion. Because of the anti-diabetic prop-
erties exerted by GLP-1, several derivative drugs are currently in the market for the 
treatment of patients with type 2 diabetes. Over the past few years, several cell lines 
have been established as useful models for the study of the GLP-1- secreting entero-
endocrine L-cells. This review focuses on the murine GLUTag cell line, derived 
from colonic tumours of transgenic mice expressing large T antigen under the control 
of the  proglucagon promoter. These cells are widely used to examine the effects of 
food components on GLP-1 secretion, as well as the signaling pathways underlying 
nutrient-induced GLP-1 release. The effects of different food components, as well 
as of nutrient-related signals, on GLP-1 secretion, and the protocols for the mainte-
nance and use of the murine GLUTag L-cell line will be discussed. 
 Keywords  Cell line •  Cell culture •  Endocrine hormone •  Enteroendocrine •  Food 
components •  GLP-1 •  L-cell •  Murine •  Nutrient •  Neurotransmitter •  Receptor • 
 Secretion 
21.1  Introduction 
 The potent insulinotrophic activity of the intestinal hormone, glucagon-like 
peptide-1 (GLP-1), in the perfused rat pancreas was fi rst described almost 30 years 
ago. This fi nding was rapidly followed by the demonstration that physiological lev-
els of the peptide also stimulate insulin secretion in a glucose-dependent manner in 
humans. Since then, our knowledge of the physiological effects of GLP-1 has vastly 
increased and several anti-diabetic properties such as suppression of glucagon 
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secretion, induction of satiety, reduction of gastric activity and potentiation of pan-
creatic β-cell mass have also been attributed to the peptide. Overall, these effects made 
GLP-1 a promising novel therapeutic tool for the treatment of type 2 diabetes mel-
litus, and GLP-1 derivative drugs have been successfully used to reduce glycemia 
in patients with type 2 diabetes since 2005. These anti-diabetic agents include ago-
nists of the GLP-1 receptor long-lasting analogues of the native peptide and inhibi-
tors of the enzyme responsible for the rapid degradation of the active forms of 
GLP-1 (Dong and Brubaker  2012 ). Interestingly, potentiation of the endogenous 
secretion of the peptide is another possible therapeutic approach which has gained 
much attention lately; however, a better understanding of the processes regulating 
GLP-1 secretion by the intestinal L-cell (an enteroendocrine type of cell which is 
the major source of circulating GLP-1 in the body) is still required. 
 Over the past few years, the establishment of different enteroendocrine cell lines 
has markedly improved our understanding of the different signals that modulate 
GLP-1 expression and secretion, as well as the intracellular pathways activated by 
these signals. The use of cell lines has also helped to troubleshoot the inherent diffi cul-
ties derived from the use of intestinal primary cell cultures, such as low L-cell density 
and a high risk of bacterial contamination. Among all cell line models for the study of 
GLP-1 secretion, the murine GLUTag cells are the most widely used as well as the 
most specifi c. Thus, GLUTag cells not only have been demonstrated to appropriately 
respond to the same stimuli that trigger GLP-1 secretion in vivo, but they also have 
been shown to closely, although not fully, mirror the profi le of genes and proteins 
expressed in non-immortalized L-cells. The present chapter will cover the modulation 
of GLP-1 secretion by the GLUTag cells, primarily focusing on the effect of food 
components, as well as the methodology for the use of this cell line. 
21.2  Origin 
 GLUTag cells derive from a colonic tumour of a transgenic mouse expressing SV40 
large T antigen under the control of approximately 2,300-base pairs of the promoter 
for  proglucagon , the gene that encodes GLP-1 amongst other bioactive peptides. 
The mice developed endocrine carcinoma of the large bowel, the cells of which 
were positive for immunoreactive GLP-1 and cholecystokinin but were negative for 
other hormones, including adrenocorticotrophin, β-endorphin, calcitonin, cortico-
trophin-releasing hormone, gastrin, growth hormone-releasing hormone, insulin, 
pancreatic polypeptide, serotonin, somatostatin and vasoactive intestinal peptide, 
suggesting an L-cell lineage for these tumour cells. Fragments of the colonic 
tumours were subcutaneously propagated in nude mice, and individual cells from 
one of these tumours were isolated and single-cell cloned (Drucker et al.  1994 ). 
The cultured cells displayed pleomorphic nuclei with prominent nucleoli, and well-
developed cytoplasmic organelles along with abundant secretory granules. GLUTag 
cells were found to express both  proglucagon and cholecystokinin transcripts. The 
cells secrete GLP-1 in response to incubation with protein kinase A and protein 
kinase C activators, whereas  proglucagon expression was only induced by 
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activators of protein kinase A, confi rming previous studies in primary cells (Drucker 
et al.  1994 ). As described for the normal intestinal L-cell, the predominant GLP-1 
form produced by the GLUTag cells is GLP-1(7-36)-amide (Drucker et al.  1994 ). 
Importantly, similar profi les in the expression of genes that encode mediators of 
nutrient-induced GLP-1 secretion, including glucokinase, sodium-glucose linked 
transporter 1 (SGLT1) and G protein-coupled receptors such as GPR40, GPR41, 
GPR119, GPR120 and GPR131 (TGR5), have been found in GLUTag and non-
immortalized L-cells (Reimann et al.  2008 ; Tolhurst et al.  2012 ). The GLUTag cells 
are thus widely considered as the best in vitro model of the murine L-cell. 
21.3  Features and Mechanisms 
21.3.1  Regulation of GLUTag Cell Secretory 
Activity by Nutrients 
 Nutrient ingestion is the most powerful mechanism for triggering GLP-1 secretion 
by the intestinal L-cell (Dong and Brubaker  2012 ). Since the L-cells are open-type 
enteroendocrine cells residing in the intestinal epithelium, with their apical surfaces 
and associated microvilli open into the gut lumen, they can directly sense and 
respond to luminal nutrients. The effects of the major groups of food components 
on GLUTag cell physiology are discussed below. 
 Carbohydrates  GLUTag cells are highly sensitive to glucose, such that cells that 
are propagated at 5 mmol/L concentration of glucose become quiescent and hyper-
polarized when this monosaccharide is removed from the medium. Accordingly, 
when glucose is added back to the bath solution, the membrane conductance 
decreases, and the frequency of action potentials in the cells, as well as the secretion of 
GLP-1 are strongly enhanced, even at very low glucose concentrations (Reimann 
and Gribble  2002 ). Initial studies demonstrated that glucose metabolism was associ-
ated with the closure of K + channels sensitive to ATP (K ATP ), resulting in increases in 
membrane conductance and enhanced GLP-1 release (Reimann and Gribble  2002 ). 
However, recent studies have indicated a more important role for a metabolism- 
independent glucose-sensing pathway in GLUTag cells (Parker et al.  2012a ). Hence, 
GLUTag cells express two sodium-glucose co-transporters, SGLT1 and SGLT3a, 
which have been found to increase glucose uptake inducing an inward current of Na+ 
ions that results in cell depolarization and stimulation of GLP-1 secretion. These 
effects are appropriately diminished by SGLT inhibitors (Parker et al.  2012a ). SGLTs 
also appear to be involved in the effects of non-metabolisable sugars, such as methyl-
α- glucopyranoside, on GLP-1 secretion by the GLUTag cell line, but not in the 
effects of dietary sugars such as fructose that are not substrates for these transporters. 
Expression of SGLT1 in the intestinal epithelium is enhanced by dietary carbohy-
drates, a process believed to be mediated by type 1 taste receptors and gustducin 
(Margolskee et al.  2007 ). Interestingly, these receptors are also expressed by the 
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GLUTag cells and they seem to mediate the effects of artifi cial sweeteners in this cell 
line, although they may not be relevant in vivo (Fujita et al.  2009 ). The facilitative 
glucose transporters, GLUT, are also involved in the stimulatory effects of glucose 
on GLP-1 secretion in the GLUTag cell line, while SGLT1 appears to be the most 
important glucose-sensing mechanism for the L-cells in vivo. The different glucose-
sensing mechanisms exhibited by GLUTag and non-immortalized L-cells may explain 
why GLUTag cells respond to small changes in glucose levels when they are incubated 
at very low concentrations of glucose (<1 mmol/L) but they are not sensitive to addi-
tional increments in glucose concentration (5–25 mmol/L; Reimann and Gribble  2002 ), 
as opposed to the dose-dependent effect of glucose in primary L-cells (Reimann et al. 
 2008 ). 
 Lipids  Free fatty acids are potent stimulators of GLUTag cell activity, the magnitude 
of the effects being proportional to their chain length (Iakoubov et al.  2007 ). 
Furthermore, GLP-1 secretion is stimulated by long-chain monounsaturated fatty 
acids, such as oleic acid, but not by similar length saturated fatty acids such as palmitic 
acid, in agreement with previous observations in primary L-cell cultures. The effects of 
oleic acid on GLP-1 secretion are known to be mediated by the atypical isozyme 
protein kinase C ζ in GLUTag cells, as also found in vivo (Iakoubov et al.  2007 ; Dong 
and Brubaker  2012 ), while a role for fatty acid transport protein 4 in the uptake of oleic 
acid by GLUTag cells has also been demonstrated (Poreba et al.  2012 ). 
 The activation of the Gq-coupled receptors, GPR40 and GPR120, by long-chain 
unsaturated fatty acids has also been associated with enhanced GLP-1 release 
in vivo (Edfalk et al.  2008 ; Hirasawa et al.  2005 ). However, although GLUTag cells 
have also been reported to express these receptors (Lauffer et al.  2009 ), their role in 
the physiology of this cell line has not been extensively studied to date. In contrast, 
the Gs-coupled receptor, GPR119, has been shown to mediate the stimulatory 
effects on GLP-1 secretion of oleoylethanolamide, an endogenously-occurring oleic 
acid derivate (Lauffer et al.  2009 ). Furthermore, synthetic GPR119 agonists have 
been found to stimulate GLP-1 secretion both in vivo and in GLUTag cells (Chu 
et al.  2008 ). Another G-protein-coupled receptor, TGR5, has also been recently 
demonstrated to play a role in the stimulatory effects of bile acids on GLP-1 secre-
tion in GLUTag cells, as previously also found in vivo (Parker et al.  2012b ; Dong 
and Brubaker  2012 ). 
 Finally, short-chain fatty acids (SCFAs), including acetate, butyrate, and propio-
nate, are generated by the gut microbiota through the digestion of complex carbohy-
drates, such as dietary fi bers. It has been recently reported that SCFAs stimulate GLP-1 
secretion via the G-protein-coupled receptor GPR43 (Tolhurst et al.  2012 ), establishing 
a novel and exciting link between gut microfl ora and gastrointestinal hormones. 
Unfortunately, the GLUTag cell line appears to be an inappropriate model to study the 
effects of SCFAs, since they express barely detectable levels of GPR43 and do not 
release GLP-1 in response to 1 or 10 mmol/L SCFAs (Tolhurst et al.  2012 ). 
 Proteins  Protein hydrolysates stimulate GLP-1 secretion and production from a 
variety of cell lines, including GLUTag cells (Hira et al.  2009 ). When the effects 
of individual amino acids were examined, several were found to stimulate GLP-1 
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secretion, with a particularly robust effect promoted by glutamine. Two major 
mechanisms have been invoked in the stimulatory effects of glutamine on GLUTag 
cells: electrogenic sodium-coupled amino acid uptake which leads to membrane 
 depolarization and voltage-gated calcium entry, and an elevation of intracellular 
cAMP levels (Tolhurst et al.  2011 ). The synergy of these two mechanisms appears 
to be a particularly strong stimulus for GLP-1 release in vitro. Other amino acids, 
such as alanine and glycine, have been found to trigger GLP-1 release from 
GLUTag cells via a pathway involving ionotrophic glycine receptors (Gameiro 
et al.  2005 ), whereas the G protein-coupled receptor family C group 6 subtype A 
receptor has been implicated in the effects on GLP-1 secretion elicited by 
 L - ornithine (Oya et al.  2013 ). 
21.3.2  Regulation of GLUTag Cell Secretory Activity 
by Other Signals 
 Despite the predominant role of nutrients in the regulation of GLP-1 release, a number 
of other signals have been identifi ed that exert stimulatory effects on the primary 
L-cell as well as on GLUTag cells. As many of these signaling mediators are induced 
by nutrient ingestion, this constitutes an indirect pathway that links food compo-
nents to the release of GLP-1. Such indirect actions are particularly important to 
GLP-1 release, since L-cells are mainly concentrated in the distal ileum and colon 
(Dong and Brubaker  2012 ), and nutrients have not reached this area of the gastroin-
testinal tract when the initial phase of prandial GLP-1 secretion is triggered. Initially, 
a neurohormonal mechanism, involving the vagus nerve, was shown to mediate the 
very rapid rise in GLP-1 levels after nutrient ingestion (Dong and Brubaker  2012 ). 
Consistent with this hypothesis, a stimulatory effect of two muscarinic agonists, 
bethanechol and carbachol, has been found in GLUTag cells (Brubaker et al.  1998 ), 
although expression of muscarinic receptors by this cell line has not been reported 
to date. Notwithstanding, direct activation of downstream protein kinase C signal-
ing does stimulate GLP-1 release from the GLUTag cells (Brubaker et al.  1998 ). 
Similarly, the incretin hormone, glucose-dependent insulinotrophic peptide (GIP), 
secreted by the enteroendocrine K cells in response to carbohydrates and fats, has 
been reported to trigger GLP-1 secretion at a concentration range of 30–100 nM 
(Brubaker et al.  1998 ). The effects of GIP on GLUTag cells are mediated through 
activation of the protein kinase A signaling pathway (Simpson et al.  2007 ). Other 
agents capable of raising the intracellular levels of cAMP, such as forskolin plus the 
cAMP phosphodiesterase inhibitor, 3-isobutyl-1-methylxanthine, have also been 
found to stimulate both GLP-1 secretion and production in GLUTag cells (Drucker 
et al.  1994 ) and are commonly used as positive controls when the secretory activity 
of this cell line is examined. Supporting the prominent role of intracellular cAMP 
levels in GLP-1 secretion, it has been reported that phosphodiesterase inhibition 
enhances the GLP-1 response to physiological secretagogues such as GIP (Simpson 
et al.  2007 ). Finally, other nutrient-dependent bioactive peptides, including leptin and 
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insulin, have also been shown to stimulate GLP-1 secretion from GLUTag cells. 
The effects of leptin are believed to be produced via activation of the Janus-activated 
kinase/signal transducers and activators of transcription signaling pathway (Anini 
and Brubaker  2003 ), whereas the effects of insulin are mediated through the activa-
tion of the extracellular signal-regulated kinases and are dependent upon the presence 
of glucose (Lim et al.  2009 ). 
21.4  Relevance to the Human Situation (L-Cell In Vivo) 
 Despite the rodent origin of GLUTag cells, they are the most extensively used in vitro 
model for the study of GLP-1 release. They have been demonstrated to respond to the 
same stimuli that trigger GLP-1 secretion in humans and they have been used to test 
potential therapeutic agents (i.e. GPR119 agonists). The diffi culties in obtaining pri-
mary L-cell cultures from humans, as well as the homogeneity of the GLUTag 
cells (i.e. single-cell clone) as compared to other L-cell models, have made GLUTag 
cells an invaluable tool for the characterization of the intra- cellular pathways that 
govern GLP-1 secretion. 
21.5  General Protocol 
21.5.1  Maintenance of the GLUTag Cell Line 
 GLUTag cells are routinely grown in Dulbecco’s Modifi ed Eagle’s Medium (DMEM) 
supplemented with 10 % fetal bovine serum (FBS), whereas supplementation with 
antibiotics, normally penicillin and streptomycin, is optional but not required. 
Cells must be trypsinized and passaged every 3–4 days when they reach 60–80 % 
confl uence. The presence of fl oating cells may be indicative of contamination or 
overgrowth. There is no standard glucose concentration to grow the cells but a fi nal 
concentration within the range 5–25 mmol/L is commonly used. It has recently been 
reported that cells grown with 25 mmol/L of glucose show increased reactive oxygen 
species production, upregulated  proglucagon , prohormone convertase 1/3 and gluco-
kinase content, and elevated basal secretion of GLP-1 as compared to cells main-
tained under 5 mmol/L conditions, suggesting enhanced metabolic activity. However, 
no difference in cell viability was found between the two conditions, and the cells 
grown with 25 mmol/L glucose were more resistant to a further metabolic insult 
(Puddu et al.  2014 ). Moreover, cells grown at either a low (5 mmol/L) or high 
(25 mmol/L) concentration of glucose have been demonstrated to respond to stim-
uli in a similar way, and no differences in GLP-1 secretion or production were 
found in cells exposed to low or high glucose for 2 h (Reimann and Gribble  2002 ), 
which is the standard incubation period to examine the GLUTag cells secretory 
response to stimuli. 
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21.5.2  Performance of Secretion and Expression Assays 
 To study the effects of different treatments on GLP-1 release (secretion assays), 
cells can be cultured in 6- or 24-well plates coated with either poly- D -lysine or 
Matrigel ® to avoid detachment of cells during the washes. A 2-day period between 
plating and the secretion assay is recommended in order to allow the cells to recover 
from trypsin and to reach the proper size and confl uence. When the cells are too 
confl uent (over 80 %), they tend to grow on top of each other, forming clumps. This 
should be avoided since it is associated with higher basal levels of secretion (per-
sonal observations). During the test period of 2 h, GLUTag cells should be main-
tained in either FBS-free DMEM or DMEM with a very low concentration of FBS 
(0.5 %), containing the treatments tested at different doses; buffers such as Krebs–
Ringer are also acceptable. To study the effects of treatments on gene expression or 
protein content, larger surface areas, such as 10 cm culture plates, may be required 
and longer incubation periods are recommended. 
 A recent study has shown that GLUTag cells possess an endogenous metabolic 
clock and that the activity of the cells can be synchronized after overnight incuba-
tion with a low concentration of FBS (0.5 %) followed by a 1-h shock with 10 % 
FBS and 10 μmol/L forskolin (Gil-Lozano et al.  2014 ). Synchronized GLUTag cells 
show a rhythm in clock genes expression as well as in their GLP-1 response to 
secretagogues, with higher responses at 4 h after synchronization and lack of effect 
at 16 h. This protocol may be adopted to obtain maximum secretory responses to a 
particular treatment. 
21.6  Assess Viability 
 Some treatments can affect viability in GLUTag cells, inducing abnormally high levels 
of GLP-1 secretion that can lead to misinterpretation of the results. Both the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and the neutral 
red uptake assays have been routinely performed in our laboratory to test the effects of 
new treatments on cell viability. Both are colorimetric assays and a reduction in absor-
bance corresponds with loss of cell viability. These tests are not quantitative and the 
addition as a reference of a positive control, such as hydrogen peroxide, is required. 
21.7  Experimental Readout of the System 
 In secretion assays, GLP-1 content in medium and cells should be determined inde-
pendently. Both medium and cell lysate should be collected and acidifi ed to ensure 
preservation of peptides and facilitate the subsequent purifi cation step. Our laboratory 
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routinely extracts peptides from the medium and cell lysate by reversed-phase 
adsorption to C18 silica columns after acidifi cation with trifl uoroacetic acid. GLP-1 
levels can then be determined by radioimmunoassay, ELISA or alternative quantifi -
cation methods. GLP-1 secretion must be calculated as the total GLP-1 content of 
the medium divided by the total GLP-1 content of medium plus cells. A ratio of 
secretion is then obtained, which can be normalized to the percentage of secretion 
of the control group. A two- to fourfold increment in secretion can be found for the 
most potent secretagogues, such as the combination of forskolin and 3-isobutyl- 1-
methylxanthine, which are often included in the study as positive controls. 
 In expression assays, medium is discarded and cells are scraped in a solution 
containing lysis buffer and β-mercaptoethanol to inactivate RNAses. Our labora-
tory has found that extraction of RNA using RNeasy Plus Mini Kit with 
QIAshredder (Qiagen, MD) permits collection of high quality RNA with a 
260/280 nm ratio over 2 and 30–100 μg of RNA per 10 cm plate. In real-time PCR 
analysis involving cDNA derived from GLUTag cells,  H3f3a amplicon (H3 his-
tone gene) is strongly recommended as an internal control, since it shows much 
better consistency than other primers commonly used as housekeeping genes, 
such as  18S amplicons (personal observations). For protein extraction, medium is 
discarded and cells are scraped in a lysis buffer such as RIPA (radioimmunopre-
cipitation assay) and then sonicated. As much as 100 μg of protein per well can be 
collected from a 12-well plate. 
21.8  Conclusions 
 Since the original generation of the GLUTag cell line in 1994 by Drucker, 
Brubaker and colleagues, these cells have been instrumental in the studies address-
ing the role of nutrients in L-cell physiology, and particularly in GLP-1 secretion. The 
easy maintenance of the cells, their close similarity in phenotype with non-immortal-
ized L-cells and the ability to apply advanced techniques such as patch-clamp record-
ing and gene silencing are clear advantages for the use of this cell line. Yet, as is 
common for many tumoural cell lines, some phenotypic differences are found between 
GLUTag cells and the normal L-cell, notably, the former presenting a higher diversity 
of glucose-sensing mechanisms and, apparently, insensitivity to SCFAs. Nevertheless, 
the use of GLUTag cells has been crucial to develop potential novel therapies for 
diabetes, such as GPR119 agonists. It is highly likely that GLUTag cells will continue 
to be intensively used as a model of the enteroendocrine L-cell until the isolation of 
primary L-cells becomes an easier and more standardized procedure. 
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 Part V 
 In Vitro Intestinal Tissue Models: 
General Introduction 
 A reliable prediction and thorough understanding of the food-intestine interactions 
and oral bioavailability in humans is crucial for the food industry. For this purpose 
different in silico methods, in vitro cell lines, ex vivo intestinal tissue and/or in vivo 
animal studies can be used. However, their predictive value for the human situation 
is often limited. In vitro intestinal models are used to study many different biological 
processes and are used to minimize the use of animals. The optimal conditions and 
the choice of in vitro model depends on the research questions. For example, for 
mechanistic studies aiming to elucidate cellular processes, a simple cell-line model 
may be accurate. However when crosstalk and possible feedback mechanisms have 
to be studied, these single cell type culture models are not satisfactory and either 
co-cultures of multiple cell types and/or intact tissue models or functional organs 
are needed. In that case, often ex vivo experiments are used which include proce-
dures with viable functional tissues or organs isolated from an organism and incu-
bated outside the organism in an artifi cial environment under highly controlled 
conditions. 
 The simplest in vitro model is one containing a monolayer of intestinal epithelial 
cells from either human or animal origin, which can be exposed to bacteria, food or 
drug compounds. However, a major drawback of these cell models are, that they are 
composed of a single cell type (e.g. absorptive or secretive cells), whereas the intesti-
nal epithelium is a conglomerate of absorptive enterocytes and other cells such as 
goblet cells, endocrine cells, and Paneth cells (Madara and Trier  1994 ). For this rea-
son, more complicated models using intestinal tissue are preferable to study the effect 
of food and food compounds. In the following section, the most common in vitro 
intestinal tissue models are described and an overview of the major characteristics of 
these models are presented in Table  1 .
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 Intestinal Rings and Intestinal Segments 
 The use of intestinal rings as an in vitro intestinal model is fi rst described in 1954 
by Agar et al. ( 1954 ) and is mainly used to measure the accumulation of compounds 
into the enterocytes rather than transport through the enterocytes (Hillgren et al. 
 1995 ). In the intestinal ring model, a part of the intestine is isolated and after thor-
ough washing everted (inside out) over a glass rod and cut into small rings. The 
rings are then submerged in high oxygenated buffer containing the compound of 
interest. The intestinal rings are generally viable for 30–60 min, probably due to bad 
oxygenation caused by the presence of the muscle layers. 
 In case of intestinal segments, the outer muscle layers are removed and segments 
are punched out the intestinal tissue. The intestinal segments are viable for approx. 
2 h. Like the intestinal rings, the segments are also submerged in high oxygenated 
buffer. Both systems are easy to use and many samples can be obtained from one 
animal. The main disadvantage of these models is that the serosal as well as the 
mucosal layer are exposed to the buffer containing the compound of interest. The 
use of radiolabelled compounds is preferable, since this simplifi es the analysis of 
absorbed compound in the tissue. 
 Everted Sac 
 The everted gut sac system was fi rst reported for the study of the transport of glucose 
and amino acids across rat and hamster intestinal barrier (Wilson and Wiseman 
 1954 ). In the everted sac method, the intestinal section is everted and both ends are 
tied after fi lling the sac with buffer. The ‘sausage’ is incubated into buffer with the 
compound of interest (Mariappan and Singh  2004 ). The technique can be used to 
study the absorptive properties of food compounds by measuring the amount ending 
up on the serosal side and in the epithelial cells, provided that the used analytical 
method is sensitive enough. The use of radiolabelled compounds is highly recom-
mended. A downside of this type of experiment is that in everted sac experiments, 
the speed of absorption might be unrealistically slow as, in contrast to the in vivo 
situation, since the compound has to cross the muscle layers and the fl uid is stagnant. 
Under optimal conditions the tissue is viable for up to 2 h, and the system is predomi-
nantly used for studying drug absorption mechanisms, intestinal metabolism of 
drugs, roles of transporter in drug absorption, and for investigating the role of intes-
tinal enzymes during drug transport through the intestine (Acra and Ghishan  1991 ). 
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 Ussing Chamber 
 Ussing chambers were initially developed to measure the transport of ions, nutrients, 
and drugs across various epithelial tissues (Ussing and Zerhan  1951 , see Chap.  23 ). 
With the Ussing chamber technique, the intestinal segment is mounted in an Ussing 
chamber where one side will be exposed to buffer with the compound of interest 
(apical or lumen side) and the other side to buffer without the compound of interest 
(basolateral or mucosal side). The major advantage of this system is that different 
parts of the intestine (from duodenum to colon) can be used (Smith et al.  1992 ). 
However the method is laborious and has a relatively low-throughput, and short-
term survival in culture. Recently, TNO described a more high throughput system, 
InTESTine™ which allow up to 96 incubations simultaneously (Roeselers et al. 
 2013 , see Chap.  24 ). 
 Isolated and Perfused Intestinal Segments 
 Isolated and perfused intestinal segments were fi rst described by Baker et al. ( 1968 ) 
who prepared these segments from dog ileum. During the last decade, a wide range 
of isolated organ systems, either from whole organs or resected intestinal tissue, 
have been developed for biomedical and pharmaceutical research. For this system a 
part of the intestine including the vascular bed is isolated and both ends of the intes-
tine is sealed before the tissue is mounted in to the perfusion system, where the 
artery is perfused with a well-defi ned buffer. The compound of interest can be 
administered as a bolus injection into the gut lumen and samples can be withdrawn 
at several times points form the recirculating perfusate (Wei et al.  2009 ). A major 
advantage of the system is that the model displays a normal morphology, histology 
and physiology. However, the diffi culty of obtaining suffi cient quality and quantity 
of organs and the limited duration of experiments are a major drawback. 
 3-D Culture Systems 
 The development of 3D cell culture models have been increased in the past few 
years (Salerno-Goncalves et al.  2011 ; Yu et al.  2012 ). 3-D culture systems are pre-
pared from cell lines, primary cells and/or organ cultures using various methods, 
including spontaneous aggregation in a suspension culture, implantation onto 3D 
scaffolds (e.g. collagen or synthetic materials) and culture in Transwell ® systems 
or in rotating culture bioreactors (Schmeichel and Bissell  2003 ). These systems 
range in complexity and carry distinct advantages and disadvantages including 
experimental costs, level of expertise, optimization, reproducibility and validation. 
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The power of 3-D culture systems is that they permit cells to change shape and form 
cell–cell connections that are prohibited on rigid conventional culture substrates. 
The models can be applied for instance to study cell attachment, migration and 
proliferation. One example of a 3-D intestinal system is the gut organoid. Organoids 
are cultured from adult intestinal stem cells and have self-renewing capacity. 
Their structure and hierarchy highly resemble the in vivo intestinal epithelium. The 
major advantage of the gut organoid system over other GI models is the long-term 
culturing, next to the broad range host species and GIT compartments (stomach, 
ileum, colon) and gene manipulation possibilities (Koo et al.  2012 ). So far, devel-
opment and application of the intestinal organoid system focused mainly towards 
the use of organoids for regenerative medicine purposes. However, further expan-
sion of this system will lead to broader application range and expansion of the read 
out possibilities. 
 Most ex vivo intestinal tissue models make use of tissue obtained from different 
animal species (e.g. rabbit, piglets or rats), since the availability of healthy human 
intestinal tissue is limited. The disadvantage of using animal tissue, is the inter- 
species differences in anatomy, physiology, metabolism, diet and micro-biota, 
which complicates the extrapolation of data to humans (Nejdfors et al.  2000 ; 
Deferme et al.  2008 ). Pigs share more physiological and immunological similarities 
to humans than rodents, and the use of (mini)pigs is becoming increasingly common 
in nutritional research (Patterson et al.  2008 , see Chap.  24 ). 
 The majority of the in vitro intestinal tissue models are used for absorption studies 
using drug or food compounds. Since intestinal tissue consist of multiple cell types 
(e.g. immune cells, enteroendocrine cells) it can be envisioned that these models 
could also be applicable to study innate immune responses or satiety. Unfortunately 
hardly any evidence was found to use these models to study the effect of food on 
innate immune response, this is most likely due to viability issues. Intestinal tissue is 
viable for approx. 2 h due to intestinal oedema and disruption of the villi (Plumb 
et al.  1987 ). Two hours is too short to measure the production of excreted compounds 
like cytokines or chemokines. Efforts to elongate viability of tissue incubations 
are on-going and promising (Tsilingiri et al.  2012 ). However measurements of these 
compounds on mRNA level should be possible. Recently, intestinal segments were 
used to study the effect of sugars, proteins and fatty acids on the release of satiety 
hormones (Voortman et al. 2012, see Chap.  23 ). The advantage of this model is that 
the hormone release can be studied in different parts of the intestine. This is very 
important, since it has been shown that the secretion of satiety hormones is site 
 specifi c. A novel method to study effects of foods and drug compounds on intestinal 
tissue is the organoid model (see Chap.  22 ). This is a promising model, since the 
lifetime of this, from stem cells derived tissue, is much longer than excised intestinal 
tissue. However the model is still being in its infancy and the wide applicability still 
has to be proven. 
 In the following chapters we will focus more in depth on the applicability of 
three intestinal models namely, Ussing chamber, intestinal segments and 
organoids. 
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 Chapter 22 
 Intestinal Crypt Organoids as Experimental 
Models 
 Sabina  Lukovac and  Guus  Roeselers 
 Abstract  When it comes to studying the effect of food bioactives on gut health, one 
of the essential steps that needs to be assessed is characterizing specifi c effects of 
the bioactives on the physical barrier of the lumen, the gastrointestinal tissue. In 
addition to studying the effects on transport function (e.g. by using Ussing cham-
bers or cell culture systems), it is of great interest to evaluate the effects on mor-
phology, cell biology, gene expression, and relevant functions of different cell types 
that are resident in the gastrointestinal (GI) tract. An ideal near- physiological model 
should contain a mixture of different GI epithelial cells (e.g. Paneth cells, goblet 
cells, absorptive and hormone secretive epithelial cells), which can be cultured 
indefi nitely. Recently, the culture and applications of long-term primary multi-cel-
lular cluster structures gastrointestinal organoids (or enteroids) have been demon-
strated, and within the last 5 years the number of researchers that commonly use this 
tissue culture model has increased rapidly. This multi-cellular system may be a 
promising addition for existing ex vivo and alternative for animal models for testing 
effects of food bioactives on the intestinal tissue, and could provide a model for pre-
screening of compounds prior to moving to the large scale testing systems. Moreover, 
intestinal organoids can be cultured from different species (e.g. human, pig and 
mouse). In this chapter we will focus on organoids cultured from mouse and pig 
crypt cells. We will give a short overview on how to isolate, culture, incubate, and 
apply them in different research fi elds. 
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22.1  Gastrointestinal Organoids 
 Several attempts have been made to isolate the proliferative regions of the intestinal 
epithelium from different species (e.g. mouse, porcine, human) (Pageot et al.  2000 ; 
Agopian et al.  2009 ). Proliferative regions of the intestinal epithelium consist of the 
transit amplifying cells, which are undifferentiated progenitor cells that can differ-
entiate into all different epithelial cells of the intestinal epithelium. Initially cultured 
intestinal tissue contained crypt and villus domains, resembling the intestinal epi-
thelial architecture present in vivo. However, these cultured intestinal tissue pieces 
from the intestinal epithelial could be maintained in culture for up to several days at 
maximum, and thus were not self-renewing . 
 The need for a self-sustaining, long-term GI model remained. The big break-
through came when Dr. Hans Clevers and colleagues, for the fi rst time, identifi ed the 
intestinal stem cells by thorough lineage tracing experiments (Barker et al.  2007 ). 
These experiments were performed over a period of 60 days in mice, and confi rmed 
the presence of Lgr5 (marker for adult stem cells)-positive stem cells in small intes-
tinal and colonic crypts. These stem cells are able to differentiate in to all intestinal 
epithelial cells (enterocytes, Paneth cells, Goblet cells, enteroendocrine cells, but 
also stem and progenitor cells), as shown in vivo and in culture where these Lgr5-
positive cells formed so-called ‘mini-guts’ or ‘organoids’ (Sato et al.  2009 ) (Fig.  22.1 ). 
 Fig. 22.1  Schematic image of an intestinal organoid. All epithelial cell types normally present 
in vivo are also present in the cultured intestinal organoids, as indicated by different colored cells. 
Figure adapted from Roeselers et al. ( 2013 ) 
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Secretion of mucins into the luminal space and lysozyme production by Panneth 
cells illustrate the functionality of this epithelium (McCracken et al.  2011 ). 
 The discovery of these stem cells opened a new world of the possibilities for GI 
culture methods, by manipulation of these cells. The great potential of these now 
self-sustaining ‘mini-guts’ in the fi eld of transplantation and regenerative medicine 
was immediately evident, and soon engraftment of intestinal organoids in mice was 
successfully performed (Yui et al.  2012 ; Shaker and Rubin  2012 ). So far, the human 
organoid transplantation has not been performed in humans yet, although human 
intestinal organoids can be cultured and maintained in culture for some time now 
(Sato et al.  2011a ). 
 Recently human organoids cultured from induced pluripotent stem cells (iPSCs) 
have been transplanted into mice (in vivo), where intestinal adaptive capacity as well 
as epithelial function (peptide uptake and permeability) have been demonstrated in 
the transplants (Watson et al.  2014 ). In addition, Clevers and colleagues (University 
Medical Center Utrecht, the Netherlands), proposed treatment for children suffering 
from a rare gastrointestinal disease (microvillus inclusion disease) by transplantation 
of stem-cell derived organoids (Wiegerinck et al.  2014 ), but the outcomes of these 
studies have not been published yet. Intestinal organoids have been applied to study 
cystic fi brosis by using primary organoids from cystic fi brosis patients. This model 
facilitates diagnosis, functional studies, drug development and personalized medicine 
approaches in cystic fi brosis (Dekkers et al.  2012 ). 
 Recently, we have demonstrated that intestinal organoids provide a powerful 
model for host–microbiome interaction studies (Lukovac et al.  2014 ). In this study 
we observed that specifi c gut bacteria and their metabolites differentially modulate 
epithelial transcription in mouse organoids (Lukovac et al.  2014 ). 
22.2  General Protocol 
 Isolation of mouse intestinal crypts and organoid culture, adapted from (Sato and 
Clevers  2013 ) is schematically represented in Fig.  22.2 . A detailed protocol of the 
culture protocol is described below. 
22.2.1  Small Intestinal Crypt Isolation 
 Thaw aliquots of Matrigel™ Basement Membrane Matrix (BD Biosciences) on ice 
before isolation and pre-incubate a 24-well plate in a CO 2 -incubator (5 % CO 2 , 
37 °C). Matrigel™ is a solubilized gelatinous protein mixture and is derived from 
the Engelbreth–Holm–Swarm (EHS) mouse sarcoma cells. The extract resembles 
the complex extracellular environment found in many tissues and is commonly used 
as a substrate for culturing cells. At room temperature, Matrigel™ polymerizes into 
a three dimensional structure that is useful for both cell culture and studying cellular 
processes in three dimensions, including cell migration. 
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 Isolate a piece of mouse small intestine (at least 5 cm) and open longitudinally. 
Wash the intestine with ice cold PBS until most of the luminal contents are cleared 
and scrape off the villi using a coverslip. After another washing with ice-cold PBS, 
cut the intestine into 2–4 mm pieces with scissors and transfer them to a 50-mL 
tube. Add 30 mL ice-cold PBS and wash the fragments by gently pipetting the 
fragments up and down with a 10 mL pipette and discard supernatant after settling 
down. Repeat this step 5–10 times until the supernatant is almost clear. Next, add 
30 mL of ice-cold crypt isolation buffer (5 mM EDTA in PBS; one can also use 
higher EDTA concentration, up to 10 mM if yields are low) and gently rock the tube 
at 4 °C for 30 min. Keep pipetting up and down the tissue in solution every 10 min 
in order to release as much epithelium as possible. After settling down the frag-
ments, the supernatant can be removed and 20 mL of ice-cold PBS can be added to 
wash the fragments using a pipet. Repeat this procedure when the fragments are 
settled down, in order to release most of the crypts, that will also settle down after 
some time. Villous fractions present in the supernatant are discarded and crypts 
fractions are passed through a 70-mm cell strainer and collected into 50 mL tube(s), 
after adding 5 % FBS to a crypt solution. Spin down the crypt fractions at 300× g 
5 min and resuspend the pellets in 10 mL of ice-cold basal culture medium (advanced 
Dulbecco’s modifi ed Eagle medium/F12 supplemented with penicillin/streptomycin, 
10 mmol/L HEPES, Glutamax, 1 × N2, 1 × B27, and 1 mmol/L  N -acetylcysteine). 
The suspension is transferred to a 15 mL Falcon tube and centrifuged at 150–200× g 
for 2 min, to remove single cells (mostly lymphocytes), which end up in the supernatant. 
 Fig. 22.2  Schematic summary of intestinal epithelial crypt isolation and subsequent organoid 
cultures 
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This washing step should be repeated 2–3 times until most single cells are cleared. 
After the washing steps, the number of crypts can be calculated (take 10 μL of the 
crypts suspension and count numbers of crypts using a heamocytometer by inverted 
microscopy; the total number of crypts = the number of crypts counted × 1,000). 
It should be noted that at this point it is diffi cult to distinguish true crypts from other 
epithelial debris, hence the count is only a rough estimate. 
22.2.2  Small Intestinal Organoid Culture 
 Centrifuge small intestinal crypts, and remove supernatant as much as possible to 
avoid dilution of Matrigel™ in the next step. Keep the tube at 4 °C and resuspend 
the crypts pellet in Matrigel™ (200–500 crypts/50 μL matrigel). Pipet 50 μL of the 
crypt-Matrigel™ suspension into the pre-warmed 24-well plate. The suspension 
should be applied on the center of the well so a hemispherical droplet can be formed. 
Transfer the plate back into the CO 2 incubator (5 % CO 2 , 37 °C) as soon as possible 
after the seeding. Allow the Matrigel™ to solidify for 5–10 min and add 500 μL 
complete organoid culture medium per well. For preparation of the organoid culture 
medium (e.g. amount of growth factors) check Table  22.1 . Place the 24-wells plate 
in a CO 2 -incubator and refresh the culture medium every 4–6 days.
22.2.3  Small Intestinal Organoid Passage 
 Crypt organoids can be passaged 7–14 days after seeding. Place the plate with 
organoids on ice to allow the matrigel to dissolve. Remove the culture medium and 
gently break up the Matrigel™ by pipetting with a 100–1,000 μL-pipette. Resuspend 
the organoids in 1–2 mL basal culture medium and transfer them to a 15 mL-tube. 
Gently disrupt the organoids using a fi re-polished Pasteur pipette to remove released 
dead cells and single cells. Pellet everything by centrifuging at 300× g for 5 min, and 
wash the organoids afterwards with 10 mL basal culture medium. Pellet again at the 
same speed and add the correct amount of Matrigel™, namely 50 μL per well that 
you would like to plate. Count the “crypts/immature organoids” as described before 
(by hemocytometer) and pipet the Matrigel™  suspension with crypts (50 μL per 
well) into a new 24 culture plate and place the plate back in CO 2 incubator (5 % 
CO 2 , 37 °C) to culture the organoids. 
22.3  Monitoring Viability 
 Organoid culture and development across time after isolation, and post-passage can 
be verifi ed using microscopy. Mainly, the dead cells of the organoid tissue will be 
visible in the central part of the organoid, corresponding to the intestinal lumen 
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in vivo (these aggregates of dead cells can be visualized by microscopy as shown in 
Fig.  22.3 at day 5–7). Figure  22.3 shows a very simplifi ed summary of a mouse 
intestinal crypt development into a mature organoid structure. Additional conforma-
tion of the viability of the organoids can be performed upon by the use of the LDH 
toxicity assay or the immunofl uorescent staining procedures for viability markers 
(e.g. apoptotic caspase 3 staining), but the organoids have to be sampled destruc-
tively in order to perform this assay, thus this step can be only applied at the fi nal 
stages of specifi c experiments. It should be noted that once growth, normal cell 
proliferation and differentiation stops, and organoids start to die, that this will 
immediately become visible, thus it is essential to monitor the organoid growth and 
proliferation on a daily basis. 
 Culture and maintenance of intestinal organoids, relies on the presence and activity 
of mature (intestinal) stem cells. Even though intestinal organoids can be isolated 
 Table 22.1  Concentrations of growth factors and other compounds added to the basal culture 
medium used for mouse and pig organoid culture 
 Reagent (supplier)  Mouse a  Pig 
 Advanced DMEM/F12 (ADF) (Invitrogen, Cat 
#11320-082) 
 1×  1× 
 HEPES buffer (Sigma-Aldrich, Cat #83264-100ML-F)  10 mM  10 mM 
 GlutaMax (Invitrogen, Cat #35050-061)  2 mM  2 mM 
 Penicillin/Streptomycin (Invitrogen, Cat #15070-063)  0.5 U/mL 
(100×) 
 0.5 U/mL (100×) 
 N2 Supplement (Invitrogen, Cat #17502-048)  1× (stock: 100×)  1× (stock: 100×) 
 B-27 Supplement Minus Vitamin A (Invitrogen, Cat 
#12587-010) 
 1× (stock: 50×)  1× (stock: 50×) 
 Mouse Recombinant EGF (Invitrogen, Cat #PMG8041)  50 ng/mL  50 ng/mL 
 Mouse Recombinant Noggin (Peprotech, Cat #250-38)  100 ng/mL  100 ng/mL 
 Human Recombinant RSPO1 (R&D Systems, Cat 
#4645-RS-025) b 
 500 ng/mL  500 ng/mL 
 Wnt3a (Cell Guidance Systems, Cat # GFM77)  –  100 ng/mL 
 Gastrin (Sigma-Aldrich, Cat # SCP0152)  –  15 nM 
 Nicotinamide (Sigma-Aldrich, Cat # N0636)  –  10 mM 
 P38 Mapk inhibitor SB202190 (Sigma-Aldrich, Cat # 
S7067) 
 –  10 μM 
 TGFb tyoe Itrecepror inhibitor A83-01 (Tocris, Cat # 
2939) 
 –  600 nM 
 N -Acetylcysteine (Sigma-Aldrich, Cat # A9165-5G)  –  12.5 mM 
 Primocin (Invitrogen, Cat # ant-pm-1)  –  100 μg/mL 
 For the protocol used for the isolation and cultivation of human intestinal organoids we refer to 
Sato et al. ( 2011a ,  b ) 
 a The mouse organoid culture protocol was adapted from Sato et al. ( 2009 ) 
 b Instead of using the commercially available RSPO1, one can culture transfected HEK293 cells, 
which carry a plasmid encoding mRSPO1-Fc (construct developed by Dr. Calvin Kuo at Stanford 
University, La Jolla, CA). For the protocol for HEK293 RSPO1 production, we refer to Carmon 
et al. ( 2011 ) and the ATCC website:  http://www.lgcstandards-atcc.org/en.aspx 
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and cultured from human induced pluripotent stem cells (iPPS), as described by 
McCracken et al. ( 2011 ), most studies culture organoids from mature stem cells 
from the intestinal crypt regions. The reason for this is that this method described is 
relatively elaborative and it takes much longer to mature the intestinal organoids in 
culture compared to the other method based on the organoid culture from adult 
intestinal cells. For a detailed protocol of iPPS-based culture of the intestinal tissue 
we refer to McCracken et al. ( 2011 ). As mentioned previously, lineage studies con-
fi rmed the stem cell hierarchy in intestinal organoids, either by fast cycling Lgr5+- 
or slowly cycling Bmi1+-stem cell activity (Sangiorgi and Capecchi  2008 ; Sato 
et al.  2009 ). Stem cell-based organoid cultures are an attractive model due to the 
presence of the self-renewing capacity; they can be passaged every 5–7 days. In 
addition, the structure and hierarchy of the mature organoids (after 5–7 days of 
culturing), highly resembles the in vivo intestinal epithelium (Fig.  22.1 ). Similar to 
the intestinal epithelium, stem cells and highly proliferative transit amplifying cells 
reside in the crypt-like domain of the organoids (Fig.  22.1 ). Differentiated cell types 
reside in the villus-region of the organoids and include enterocytes, goblet cells, 
Paneth cells, and enteroendocrine cells. These cells can be identifi ed using immu-
nohistochemistry with intestinal epithelial cell-specifi c markers. 
22.4  General Advantages and Limitations of Intestinal 
Organoid Systems 
 Despite the described signifi cant advances in culturing organoids, this system has 
some limitations. A major advantage of intestinal models in which an apical to 
basolateral polarity is preserved is the possibility to characterize epithelial transport 
mechanisms and barrier integrity upon exposure to microorganisms and microbial 
components. Indeed intestinal organoids consist of polarised, columnar epithelia. 
However, the inwards orientation of the epithelia (i.e. villi protrude into the lumen 
 Fig. 22.3  Phase contrast images of a developing mouse intestinal crypt into a organoid in 
culture. ( a ) immature organoid in culture 0.5–1 day after crypt isolation; ( b ) mature organoid 
in culture 3–5 days after crypt isolation; ( c ) mature organoid in culture 5–14 days after crypt 
isolation, ready to be passaged (note the accumulated debris of dead cells in the lumen of the 
organoid). This morphology is representative for other species as well [image adapted from 
Lukovac et al. ( 2014 )] 
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of the organoids) makes the apical side relatively inaccessible for direct experimen-
tal stimulation (Fig.  22.1 ). 
 Also, the organoids lack several essential components of the living digestive 
tract, such as the enteric nervous system, the vascular system, lymphatic systems 
and functional adaptive and innate immune systems. Additionally, the 3D architec-
ture is not as regular as seen in vivo, and the crypt-villus structures are variable in 
size and shape from one organoid to another. 
 Regardless of these drawbacks, this model offers great experimental utility for 
understanding and modeling human intestinal development, physiology, and host–
microbe interactions. Indeed, this model has several other advantages, such as a 
long-term culturing, broad range host species and GI tract compartments (stomach, 
ileum, colon) and gene manipulation possibilities (Koo et al.  2011 ). Moreover, this 
system provides a viable starting point for the development of screening platforms 
for pharmaceutical and food compounds. 
 Further expansion of this system will lead to broader application range and 
expansion of the read out possibilities. One example is transition of the existing 
system towards a structure with the apical/luminal compartment exposed on the 
outer site of the organoids, which will make the apical site of the organoids experi-
mentally more accessible. Furthermore, this system might be a promising tool in 
studies on epithelial interactions with food bioactive in individual subjects, as it has 
been demonstrated that organoids can be cultured from human intestinal biopsy 
samples (Sato et al.  2011b ). 
 Open Access  This chapter is distributed under the terms of the Creative Commons Attribution 
Noncommercial License, which permits any noncommercial use, distribution, and reproduction in 
any medium, provided the original author(s) and source are credited. 
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 Chapter 23 
 Porcine Ex Vivo Intestinal Segment Model 
 D.  Ripken and  H. F. J.  Hendriks 
 Abstract  This chapter describes the use of the porcine ex vivo intestinal segment 
model. This includes the advantages and disadvantages of the segment model and a 
detailed description of the isolation and culture as well as the applications of the 
porcine ex vivo intestinal segment model in practice. Compared to the Ussing 
chamber (Chap.  24 ) the porcine ex vivo small intestinal segment model is a rela-
tively simple to use intestinal tissue model. The main difference being that the tissue 
segment is not mounted in a chamber, but is freely fl oating in a solution. Therefore 
the ex vivo intestinal segment model does not distinguish between the apical and 
basolateral side of the tissue. The intestinal segments can be obtained from various 
anatomical regions of the small intestine (e.g. duodenum, jejunum, ileum or even 
the colon) and the segments consist of various cell types (e.g. epithelial cells, paneth 
cells, goblet cells, enterochromaffi n cells and enteroendocrine cells). The intestinal 
segment model has been shown to be a suitable tool to study compound and location 
specifi c effects on the release of gastrointestinal hormones and gastrointestinal 
metabolism of endocannabinoids and related compounds. 
 Keywords  Ex vivo •  Porcine ex vivo intestinal segment model •  Gastro-intestinal 
hormone release 
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23.1  The Porcine Ex Vivo Intestinal Segment Model 
 Although it is possible to obtain human intestinal material for example by taking 
biopsies using endoscopic techniques, the availability of human tissue is often a bot-
tleneck. Despite human biopsies from the duodenum can be obtained, biopsies from 
the more distal parts of the small intestine, such as the ileum, are diffi cult to obtain. 
This makes it diffi cult to study region specifi c effects. The use of tissue segments 
from other species (e.g. rat, mice, dogs and pigs) can provide a solution for these 
limitations. It is possible to obtain intestinal tissue segments from various regions of 
the intestine e.g. duodenum, jejunum, ileum or even the colon. Since the pig intestine 
shows a high degree of macroscopic and microscopic resemblance with that of 
humans the best alternative for human tissue is pig (Clouard et al.  2012 ; Miller and 
Ullrey  1987 ; Patterson et al.  2008 ). Despite the difference in dietary quantity between 
the two species, pigs and humans have the same dietary habits. Furthermore they 
have comparable organ sizes, and especially of importance are the similarities in the 
anatomy, morphology and physiology of the gastrointestinal tract (Clouard et al. 
 2012 ; Miller and Ullrey  1987 ; Patterson et al.  2008 ). The model was therefore opti-
mized using pig tissue. The porcine ex vivo intestinal segment model will be further 
referred to as intestinal segment model. 
 The development of the intestinal segment model was necessary to obtain a more 
high throughput screening system compared to in vivo studies and the Ussing cham-
ber technique. Moreover a model resembling the human in vivo situation more than 
single cell cultures was needed to study processes in the gastrointestinal tract, such 
as nutrient transport and/or hormone release. Currently different cell lines are used 
for this purpose; Caco-2 and HT-29 cell lines for nutrient uptake and enteroendocrine 
cells such as murine STC-1 cells (Abello et al.  1994 ; Geraedts et al.  2009 ; McLaughlin 
et al.  1998 ), GLUTag cells (Reimer et al.  2001 ) and the human NCI-H716 cell 
line (Brubaker et al.  1998 ) to study satiety hormone release. These cell lines are 
already discussed extensively in the previous chapters. Since intestinal segments 
consist of many different cell types (e.g. epithelial cells, paneth cells, goblet cells, 
enterochromaffi n cells and enteroendocrine cells), it can be envisioned that this 
model can be used to study many different biological processes (e.g. nutrient uptake, 
immune response, hormone release). However up till now only a few applications 
were found and the model has to compete with a more established model, the Ussing 
chamber. The main difference of this model compared to the Ussing chamber is that 
the tissue segment is not mounted in a chamber and thus not distinguishes between 
the apical and basolateral side of the tissue. 
 Up till now the model has been used predominantly to study gastrointestinal 
hormone release due to its short viability (150 min). In this chapter we will therefore 
focus on gastrointestinal hormone release following interaction with nutrients or 
related compounds. The presence of nutrients and other molecules in the small 
intestine could be sensed and consequently stimulate the release of hormones such 
as Glucagon Like Peptide-1 (GLP-1), Cholecystokinin (CCK) and Peptide YY 
(PYY). These hormones are released following interaction of nutrients and other 
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compounds with G-protein coupled receptors and solute carrier transporters located 
on enteroendocrine cells. CCK, GLP-1 and PYY are involved in generating satiety 
and satiation (Gribble  2012 ; Tolhurst et al.  2012 ). Enteroendocrine cells are scat-
tered throughout the epithelial layer of the gastrointestinal tract (Tolhurst et al. 
 2012 ). Enteroendocrine I-cells mainly release CCK and are relatively abundant in 
the duodenum, whereas GLP-1 and PYY are released by L-cells mainly present in 
the distal jejunum, ileum and colon (Holst  2007 ; Iwasaki and Yada  2012 ). Satiety 
hormone responses depend on the type of nutrient and anatomical region of the 
small intestine. Nutrient type and anatomical region can both be varied when the 
intestinal segment model is being used. 
23.2  General Protocol 
 Small intestinal tissue can be obtained from sacrifi ced pigs. The reproducibility of 
the results will improve when intestine is used from pigs with comparable health 
status, age and diet. This is certainly true for satiety studies, however the exact effect 
of varying health status, age and diet on the physiology of the intestinal segment 
system is never studied. Furthermore, it is important to collect the intestine as quick 
as possible; within 5 min after sacrifi cing the animal. During the procedure the 
tissue has to be kept on ice. Various anatomical regions of the small intestine can 
be collected, including duodenum (starting 10 cm distal of the pylorus, total 
length ± 0.5 m), proximal, mid and distal jejunum (1.5, 5 and 10 m distal of the 
pylorus, respectively), proximal, mid and distal ileum (1.5, 1 and 0.5 m proximal 
from the ileal cecal valve), and colon. The intestine is stored in ice cold Krebs- 
Ringer Bicarbonate (KRB) buffer, which is bubbled with a O 2 /CO 2 (95 %/5 %) gas 
mixture to prevent ischemia, and transported as quickly as possible to the labora-
tory. Upon arrival the intestinal tissue is carefully fl ushed and rinsed with ice cold 
KRB buffer, to remove luminal debris and put in a beaker with KRB on ice. The 
intestine is cut open in a longitudinal direction and the outer muscle layers are care-
fully stripped off with the basolateral side upwards. The mucosal tissue has to be 
placed on gauze (pores = 250 μm, Sefar Nitex 03-250/50, Sefar Heiden Switzerland) 
with the apical side upward, then circles of tissue (tissue segments) can be punched 
out (payers patches are excluded) using a biopsy punch with a diameter of 8 mm 
(Miltex, York, USA) (Fig.  23.1b ). Tissue segment size may be varied depending on 
research question and amount of tissue required for analysis. After collecting all 
segments in the 24-wells plate fi lled with 500 μl ice cold KRB buffer/well (Fig.  23.1c, d ), 
the tissue is brought to room temperature in 30 min, followed by a pre- incubation at 
37 °C for 1 h in a humidifi ed incubator at 5 % v/v CO 2 . To study the effects of 
nutrients on intestinal hormone release, incubations can be initiated by replacing the 
KRB buffer with 500 μl pre-warmed solution without  D -glucose (0 mM) containing 
the test compounds and incubate for 1 h at 37 °C at 5 % v/v CO 2 . Add phenylmeth-
anesulfonyl fl uoride (PMSF) (fi nal concentration 100 μM) to the collected media to 
inactivate serine protease activity and to avoid cleavage of active GLP-1 (7-36 and 
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7-37) by dipeptidyl peptidase IV (DPP-IV). The collected media as well as the 
tissue can be stored at 4 °C, or −80 °C until further analysis. For lactate dehydrogenase 
(LDH) analysis, store media samples at 4 °C for maximal 48 h, for GLP-1, PYY and 
CCK at −80 °C. Tissue sample has to be snap frozen immediately after the incuba-
tion and stored at 80 °C until further analysis (e.g. mRNA, or fatty acid and metabo-
lites thereof (endocannabinoids (ECs),  n -acyl ethanolamines (NAEs) or  n -acyl 
serotonins (NAs)). 
23.3  Sample Analysis 
 Satiety hormones can be analyzed using commercially available ELISA kits accord-
ing to the manufacturer’s instructions. Porcine GLP-1 can be measured using the 
human GLP-1 kit from Millipore (EGLP-35K, Billerica, MA, USA), since the 
GLP-1 hormone gene sequence is highly preserved. GLP-2 can be determined using 
a competitive human GLP-2 (1-34) ELISA kit from Phoenix Pharmaceuticals Inc. 
(Belmont, CA, USA) according to the manufacturer’s instructions. There is a 92 % 
homology of GLP-2 protein between humans and pigs. The cross reactivity of this 
kit with GLP-1 is 6 %. 
 PYY release can be measured with a commercial available ELISA kit for total 
PYY (Bachem, Peninsula Laboratories, San Carlos, CA, USA). This kit measures 
porcine PYY, which is identical to human PYY (Adrian et al.  1987 , 11). 
 CCK concentrations can be determined using a human EURIA-CCK radioim-
munoassay (RIA) kit (Euro-diagnostica, Malmö, Sweden) according to the manu-
facturer’s instructions. An identical sequence of CCK-8 has been found form most 
mammals, among them pigs and human. The kit measures CCK-8 sulfate (CCK 
26-33). Tissue concentrations of ECs (AEA and 2-AG) and NAEs (DHEA, EPEA, 
DLE, OEA, PEA and SEA) can be analyzed according to a method described previ-
ously (Balvers et al.  2012 ). For this analysis 50–100 mg freeze-dried tissue is 
 Fig. 23.1  Porcine ex vivo intestinal segment model 
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required to be within the detection limit of LC–MS method. Although the paper 
describes the extraction of ileal mouse tissue, this method can also be used for por-
cine pig tissue (unpublished data). Tissue concentrations of NAEs can be analyzed 
according to the method described previously (Verhoeckx et al.  2011 ). For this 
method 50–300 mg intestinal tissue is required. 
23.4  Monitoring Viability 
 The viability of the tissue segments is important to analyze, especially when secre-
tagogue effects are studied. It has to be avoided that the release of satiety hormones 
is secondary to cell lysis or other nonspecifi c toxic effects. To analyze tissue viabil-
ity macroscopic and microscopic tissue checks could be done after staining with 
markers for proliferation and apoptosis (e.g. hematoxylin–eosin staining). Another 
method to check the viability is measuring leakage of intracellular lactate dehydro-
genase (LDH). LDH is stable enzyme common in all cells which can be readily 
detected when cell membranes are no longer intact for instance due to active prote-
ases or mechanical forces during the preparation of the biopsies. The enzyme activity 
is determined with respect to the total intracellular lactate dehydrogenase. The total 
LDH activity of the tissue can be determined by homogenize the tissue in ice cold 
KRB buffer, using a Potter Elvehjem-type tefl on pestle tissue grinder (Braun, 
Melsungen Germany) for 5 min at 200 rpm. It is also possible to use Triton-x as a 
positive control. Triton-x dissolves membranes and makes the tissue leaky. Samples 
are excluded when the LDH leakage is more than 10 % of the total intracellular 
LDH. The incubation time of the segments should not exceed 1 h, since at longer 
incubation times, LDH leakage will be >10 % (Voortman et al.  2012 ). 
23.5  Incubation with Food Components and Digested Food 
Samples 
 The intestinal segment model can be used to study the effect of digested and 
 un- digested food components (e.g. sugars, fatty acids and proteins) as long as the 
components are dissolved and diluted with KRB buffer (Voortman et al.  2012 ). 
When diluting compounds in the KRB buffer, care should be taken that the levels of 
alcohol and DMSO are below 1 %. It has been shown that the use of undiluted 
digested food samples from the TIM model (including bile, pancreatic enzymes 
and/or food components) can be applied onto the apical side of the tissue segments 
if mounted in a chamber (Westerhout et al.  2014 ). However, the use of undiluted 
digested food samples is not yet tested for the intestinal segment system. In this 
system tissue is exposed on both the apical and the basolateral side and therefore the 
use of digestion fl uid has to be tested fi rst. 
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23.6  Readout of the Porcine Ex Vivo Intestinal 
Segment Model 
 The intestinal segment model is used to study the effects of fatty acids, carbohydrates 
and proteins on the release of gastrointestinal hormones, such as GLP-1, PYY and 
CCK (Table  23.1 ). Hormone concentrations can be expressed as both the relative 
release compared to basal release after the negative control set to 100 % (KRB buffer 
without  D -glucose), or as the absolute hormone release (pmol/l) per surface area 
(cm 2 ). The model is also used to study the tissue concentrations of both ECs and 
NAEs and NAs. The concentration can be expressed per gram tissue, or as relative 
concentration compared to the negative control set to 100 % (KRB buffer without 
 D -glucose).
 The model can also be used to study the uptake of food compounds after label-
ling these compounds radioactively. The radioactivity in the tissue and in the media 
can be analyzed using liquid scintillation counting. However since this model does 
not distinguish between the apical and basolateral side, it is not possible to study 
transport of molecules from the apical side to the basolateral side with this model. To 
study this transport, the Ussing technology, or Caco-2 cells might be better systems. 
23.7  General Advantages and Disadvantages of the Model 
 The advantages and disadvantages of the model are summarized in Table  23.2 . 
The advantage of the current intestinal segment model compared to cell cultures is 
that this intestinal segment model consist of multiple cell types (e.g. epithelial cells, 
enterochromaffi n cells, paneth cells, goblet cells and enteroendocrine cells) instead 
of one cell type only. This makes it possible to study effects which depend on 
cell–cell communication. Another advantage of this intestinal segment model is that 
it can be used to study region specifi c effects (duodenum, jejunum, ileum, etc.), 
since the anatomical region of the small intestine is an important parameter to study 
 Table 23.1  Different studies using the ex vivo porcine intestinal segment model 
 References  Compound tested  Analysis in tissue  Analysis in culture media 
 Voortman et al. 
( 2012 ) 
 Casein hydrolysate 
 Long chain fatty acids 








 Verhoeckx et al. 
( 2011 ) 
 Fatty acids 
 N -Acyl serotonins 
 Serotonin 
 N -Acyl serotonins  GLP-1 
 Ripken et al. 
( 2014 ) 
 Casein (intact protein) 
 Sucrose 
 Saffl ower oil 
 Rebaudioside A 
 Endocannabinoids  GLP-1 
 PYY 
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compound specifi c effects on satiety hormone release. Furthermore the intestinal 
segment model has a higher throughput since it is a simplifi ed version of the Ussing 
chamber model. Since it is not required to mount the tissue of the intestinal segment 
model in a Ussing chamber, the practical skills required for the intestinal segment 
model are relatively simple compared to the Ussing chamber technology.
 An important aspect which might be different from other systems such as organ-
oids and Caco-2 cells is the presence of microorganisms in the intestinal segment 
model (Roeselers et al.  2013 ). Although the presence of microorganisms in the intes-
tinal segment system was never tested, it is likely that the natural fl ora of the host is 
still present since the intestine is directly isolated from the animal. The infl uence of 
microorganisms on nutrient specifi c effects is still not known and has to be 
investigated. 
 One of the main disadvantages of this model is the biological variation in the 
release of satiety hormones per intestinal segment. The enteroendocrine cells are not 
homogenously distributed over the tissue and account for only 1 % of the total 
 epithelial cells. Therefore the number of enteroendocrine cells per surface area (cm 2 ) 
tissue may vary. For this reason the amount of replicates and the use of different pigs 
are important when using this model. The number of intestinal replicates can be 
determined using a power calculation, which depend on the variation of the mea-
sured parameter within the population. To study the effects of a specifi c compound 
the statistical method should test the effect within the animal (compared to the KRB 
buffer). The inter-tissue coeffi cient of variation (CV) for GLP-1 release is 33 ± 7 %, 
based on the average CV of incubations in triplicate from 10 pigs. The intra-animal 
CV for basal GLP-1 release is 78 % based on the basal GLP-1 release (after KRB 
buffer) from 10 pigs. For this reason the effects should be studied within the animal, 
and not between animals. 
 Another issue is the tissue source. It is recommended to use tissue from healthy 
animals who were kept on a controlled diet. The controlled diet is especially impor-
tant when the effects of nutrients or digested compounds have to be studied. 
However the effects of various diets, age, weight or health status on the release on 
satiety hormones using the intestinal segment model are never studied. 
 Open Access  This chapter is distributed under the terms of the Creative Commons Attribution 
Noncommercial License, which permits any noncommercial use, distribution, and reproduction in 
any medium, provided the original author(s) and source are credited. 
 Table 23.2  Advantages and disadvantages 
 Advantages  Disadvantages 
 Multi-cell system 
 All intestinal regions can be used 
 Less labor intensive than Ussing chamber technology 
 More incubations possible (from the same intestine), 
since the surface area is smaller compared to the 
Ussing chamber technology 
 Biological variations 
 No distinction between apical and 
basolateral side 
 Not studied whether the effect of 
undiluted digested food samples can be 
studied 
 Infl uence of microbiota not studied 
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Joost Westerhout, Heleen Wortelboer, and Kitty Verhoeckx
Abstract The Ussing chamber system is named after the Danish zoologist Hans 
Ussing, who invented the device in the 1950s to measure the short-circuit current as 
an indicator of net ion transport taking place across frog skin (Ussing and Zerahn, 
Acta Physiol Scand 23:110–127, 1951). Ussing chambers are increasingly being 
used to measure ion transport in native tissue, like gut mucosa, and in a monolayer 
of cells grown on permeable supports. However, the Ussing chamber system is, to 
date, not often applied for the investigation of the impact of food bioactives (pro-
teins, sugars, lipids) on health.
An Ussing system is generally comprised of a chamber and a perfusion system, 
and if needed, an amplifier and data acquisition system. The heart of the system lies 
in the chamber with the other components performing supporting roles. The classic 
chamber design is still in wide use today. However, several newer designs are now 
available that optimize for convenience and for diffusion- or electrophysiology- 
based measurements. A well designed Ussing chamber supports an epithelia mem-
brane or cell monolayer in such a way that each side of the membrane is isolated and 
faces a separate chamber-half. The chambers are then filled with a physiologically 
relevant solution, such as Ringer’s solution. This configuration allows the researcher 
to make unique chemical and electrical adjustments to either side of the membrane 
with complete control. The Ussing chamber technique has its strengths and limita-
tions, which will be explained in more detail in this chapter.
Keywords Ex vivo • Intestine • Intestinal barrier • Intestinal transport • Ussing
chamber
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24.1  The Ussing Chamber
A commercially available ‘classic’ Ussing chamber system (Fig. 24.1) is machined 
from solid acrylic into two halves and has vertical and horizontal ports in each half 
for connection to the circulation system and for making electrical connections. The 
face of one chamber-half is imbedded with sharp stainless-steel pins which mate 
with corresponding holes in the other chamber-half face. These pins allow punctur-
ing and positioning of an epithelium membrane within the chamber. Each chamber- 
half also has a separate air/gas inlet to drive the circulation system. Gas, commonly 
a 95 % O2/5 % CO2 mixture, is forced under low pressure into these inlets and 
allows contact with the buffer solution. The rising bubbles drive circulation and 
oxygenate the buffer. Each chamber-half also has an inlet or outlet port for access to 
the water jacket. Water at the desired temperature is pumped through the jacket and 
allowing thermoregulation of the perfusion solutions. Each chamber is supplied 
with 2 Ag-AgCl pellet electrodes (for voltage) and 2 Ag wire electrodes (for current). 
Electrodes are connected into the chamber by means of an agar salt bridge.
One of the major limitations of the classic Ussing chamber model is that it does 
not allow simultaneous preparation and analyses of a large set of segments of epi-
thelial tissues thereby having a relatively low throughput. The original Ussing 
chamber system incorporates the intestinal tissue segments in a vertical position, 
whereas other systems also allow horizontal placement (e.g. TNO’s InTESTine™
system or Warner Instruments’ NaviCyte™). This horizontal setup can be used for
transport or toxicology studies using cells or tissue exposed to liquids and semi- 
solid compounds, such as digested food samples, while the basolateral surface 
remains exposed to the medium.
Fig. 24.1 Schematic representation of a small piece of intestinal epithelial tissue mounted in the 
Ussing chamber
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Further development of the Ussing chamber system has led to various multichannel 
systems capable of supporting up to 24 independent chambers, all operating in 
parallel. TNO recently developed a medium throughput system (InTESTine™) in
which up to 96 ex vivo intestinal tissue segments can be used per system per day to 
investigate intestinal absorption (Westerhout et al. 2014).
Food compounds can be transported across the intestinal barrier by different 
transport mechanisms (Fig. 24.2). The transport route and velocity of absorption of 
these compounds are influenced by different factors that are related to physiological 
factors of the tissue (e.g. composition and thickness of the mucus layer, disease state 
or membrane permeability, intestinal pH, concentration bile acids, composition of 
pancreatic juice, surface area, enzyme activity, lipid and protein content of the 
enterocyte membrane and the amount of Peyer’s patches in the tissue), physico-
chemical factors of the compound (e.g. water solubility, molecular weight, aggrega-
tion state, charge, H-bonding capacity, and hydrophobicity) and formulation factors 
(e.g. food matrix) (Deferme et al. 2008).
In general compounds are transported via one of the following mechanisms:
 (1) Paracellular (e.g. small hydrophilic and polar compounds)
 (2) Transcellular
 – passive transport (lipophilic compounds)
 – endocytosis (e.g. proteins and small nucleotides)
 – carrier mediated transport (e.g. glucose and amino acids)
Fig. 24.2 Different transport routes across the intestinal wall (Reitsma et al. 2014, copyright 
Wiley-VCH Verlag GmbH & Co. KGaA. Reproduced with permission)
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 (3) Cell mediated transport
In contrast to single cell-culture models, such as the epithelial Caco-2 cell model,
intestinal epithelium consists of absorptive enterocytes and other cells such as gob-
let cells, endocrine cells, and M cells, with the mucus secreting goblet cells repre-
senting the second most frequent cell type, ranging from 10 % in the small intestine 
and 24 % in the distal colon (Madara and Trier 1987). The transport of food com-
pounds across the intestinal barrier can also be facilitated by the other cell types 
present in the lamina propria (Fig. 24.3), including M cells, Peyer’s patches, den-
dritic cells and macrophages.
As the Ussing chamber technique uses intestinal tissue segments, they still con-
tain the morphological and physiological features of the intestine, including inter-
play of many complex processes, such as interaction between the multicellular 
environment (Rozehnal et al. 2012). Using ex vivo intestinal tissue segments gives 
a better representation of the complex in vivo morphology (multicellular conglom-
eration, presence of the mucus layer) and thereby a better representation of the vari-
ous possible processes involved in the in vivo situation. Furthermore, ex vivo 
intestinal tissue segments from the different regions of the small and large intestine 
allow the investigation of regional absorption and immune responses, which is not 
possible when using single cell-culture models.
The major limitation of using ex vivo intestinal tissue segments is the limited 
availability of (healthy) human tissue. Therefore, animal tissue is often used. Porcine 
intestinal tissue could possibly be used as alternative based on its high similarity 
with that from humans (Patterson et al. 2008; Walters et al. 2011; Groenen et al. 
2012). When using human tissue, often a small segment of non-diseased biopsy is 
Fig. 24.3 The intestine at a cellular level (Reitsma et al. 2014, copyright Wiley-VCH Verlag
GmbH & Co. KGaA. Reproduced with permission)
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used, which could be more-or-less influenced by the adjacent diseased tissue. 
However, besides the effects of the possible side effects of diseased tissue and/or 
historic drug treatment, the inter-individual variability among humans or any other 
non in-bred animal model also in a healthy stage is high, making it difficult to 
directly compare results.
Another major limitation of using ex vivo intestinal tissue segments is the limited 
viability of the tissue. Previous studies by Haslam et al. (2011), Rozehnal et al. 
(2012) and Sjöberg et al. (2013) have shown that the intestinal tissue remains viable 
only for up to 150 min (on average 120 min), which is long enough to study absorp-
tion and/or secretion of satiety hormones. For the investigation of the impact of food 
bioactives on other health effects 2 h may be too short for any clear response, such 
as release of cytokines, reversible disruption of tight junctions, extensive metabo-
lism. However, changes in mRNA levels within 2 h should be measurable by using 
reverse transcription polymerase chain reactions (RT-PCR).
24.2  General Protocol
Human intestinal tissue segments are often obtained via biopsies or by surgical 
resection, whereas intestinal tissue segments from animals are often obtained from 
section of sacrificed animals. Collect the intestine, directly after opening the 
abdominal cavity, in a cold Krebs’ Ringer Bicarbonate buffer (pH 7.4), supple-
mented with 25 mM HEPES (KRB/HEPES), which is bubbled with a O2/CO2 
(95/5 %) gas mixture, prior to use to prevent ischemia (e.g. during transport). The 
intestine can be divided in different segments; duodenum can be found directly after 
the stomach and is approx. 20 cm long, followed by the jejunum (approx. 1.0 m), 
ileum (approx. 1.6 m) and after the cecum you will find the colon (approx. 1.1 m) 
(DeSesso et al. 2001).
Upon arrival in the laboratory, flush and rinse the intestinal tissue segments care-
fully with ice cold physiologically relevant buffer, such as KRB/HEPES buffer, to
remove luminal debris and put in a beaker with KRB/HEPES on ice. The tissue
segments are then opened longitudinally next to the juncture to the peritoneum and 
the serosa and muscle layers are removed (stripping) while the tissue is submerged 
in chilled and oxygenated KRB/HEPES buffer. Removal of muscle layers is either
performed using scissors keeping the feather scissor at an angle towards the mus-
cles, or using a pair of curved tweezers to gently strip off the muscle layers while 
holding the rim of the tissue segment with a Kocher. After the muscle layer is gen-
tly removed, the tissue is cut clean from fat, connective tissue and parts of the sub- 
mucosa to reach the blood vessel level. Depending on the system, intestinal tissue 
segments with a surface area of 0.1–1.8 cm2 are prepared using for instance a 
punch. Keep the tissue and segments in cold buffer during the whole procedure.
Stripped intestinal segment is then mounted in the Ussing chamber system 
(Fig. 24.4). Since epithelial tissue is polarized, it contains an apical (mucosal) and 
basolateral  (serosal) side, so pay attention on how to mount the tissue in the system. 
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Both chamber halves are then filled with ice cold physiologically relevant buffer,
such as KRB/Hepes buffer. The basolateral KRB/HEPES buffer is sometimes
supplemented with 0.1 % bovine serum albumin (BSA) to enhance intestinal trans-
port. The solution is then oxygenated (95 % O2:5 % CO2), circulated, and warmed 
to 37 °C. Once at 37 °C, carefully flush the mucus layer from the segments and 
replace the apical buffer by fresh, pre-warmed buffer containing the compound of 
interest, to investigate the permeability. In most cases compounds are labelled
radioactively (e.g. 14C) or with a fluorescent label. During the permeability studies 
small (100 μl) samples are taken over time from the basolateral and apical compart-
ment for up to 150 min. After 150 min, the viability of the tissue and the integrity of 
the intestinal barrier starts to decrease (Sjöberg et al. 2013). If desired, the basolat-
eral and apical buffer can be supplemented with fresh, pre-warmed, blank buffer, to 
complement for the samples taken. Usually, an apparent permeability value (Papp 







* ,0  
(24.1)
Here, dQ/dt (in disintegrations per minute (dpm)/s or mg/s) indicates the rate of 
transport of the compound from the apical side to the basolateral side over time 
when the rate of transport is linear (usually between T = 60 and T = 120 min), SA is 
the surface area of the exposure area (cm2) and CApi,0 is the initial donor concentra-
tion of the compound (concentration at apical side at T = 0 in dpm/ml or mg/ml).
To study the absorption of compounds, the presence of an unstirred water layer 
upon the enterocytes should be prevented by continuous moving of the incubation 
buffers, either by gassing of the media (Ussing system) or placement of the complete 
system on a rocker platform (InTESTine™ system, Westerhout et al. 2014). Care 
must also be taken to prevent nonspecific binding of the test compound,  evaporation 
of the media during incubation, cross-contamination of the test compound to other 
Fig. 24.4 (a) Photograph of obtaining a small segment from stripped porcine intestinal tissue by 
using a hollow punch. (b) The smaller segments are then mounted in the InTESTine™ system
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chambers (especially in case of gassing of the incubation media). The reusable 
Ussing system therefore requires thorough cleaning and fine adjustment of the 
gassing rate prior to performing experiments. The InTESTine™ system inserts
are generated from disposable glass material, which reduces nonspecific binding 
of the compound of interest and risk of contamination of the mounted device. 
Furthermore, the set-up and horizontal mounting enables the InTESTine™ system
to be incubated in a carbogenated, humidified incubator at 37 °C on a rocker plat-
form thereby reducing the unstirred water layer, evaporation and possible foaming 
(Westerhout et al. 2014).
24.3  Monitoring Viability
Previous studies by Haslam et al. (2011), Rozehnal et al. (2012) and Sjöberg et al. 
(2013) have used the potential difference (>4 mV), short-circuit current (>100 μA/cm2), 
trans epithelial electrical resistance (TEER; >20 Ω cm2) for continuous monitoring 
of the viability. Low resistance indicates tissue leakage. Due to the set-up of the 
Ussing chamber system, these measurements can be performed for each experiment. 
Other markers that can be studied in parallel to a typical transport study include the 
intestinal metabolism of testosterone and midazolam, by measuring the presence of 
metabolites apically, basolaterally and intracellularly by means of, for instance, 
High Pressure Liquid Chromatography (HPLC) (Sjöberg et al. 2013). Transport via 
the paracellular pathway can be assessed by measuring the permeability of Lucifer 
yellow (Papp value <6 × 10−6 cm/s) (Rozehnal et al. 2012) leakage of fluorescein 
isothiocyanate dextran to the basolateral side (FD4; <0.5 %) (Westerhout et al. 
2014), or the linearity of transport of atenolol (R2 > 0.995 with at least 3 datapoints) 
(Haslam et al. 2011). Values higher than the ones mentioned above, indicate leakage
of the intestinal tissue. Ideally, one would monitor multiple parameters to evaluate
the viability and integrity of the intestinal mucosa in parallel to the transport of the 
compound of interest, but in some cases the compound of interest has the same 
properties as the marker compounds (e.g. when using fluorescently labeled or radio-
labeled compounds).
24.4  Use of Digested Food Samples
While we have shown that undiluted digested food samples (including bile, pancre-
atic enzymes and/or food components), obtained by using TNO’s dynamic 
computer- controlled in vitro gastrointestinal model of the stomach and small intes-
tine (TIM-1, Minekus et al. 1995) can be applied directly onto intestinal tissue seg-
ments (Westerhout et al. 2014), it must be noted that the digested food samples can 
also be presented in a different formulation. Care should be taken that the levels of 
alcohol and DMSO are below 1 % and other conditions, such as bile salt concentra-
tion, osmolarity and pH, are in concordance to what has been presented by Bergström
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et al. (2014). In general, bile salt concentrations should be between 1.4 and 24 mM,
the osmolarity should be between 137 and 416 mOsm and the pH should be between 
5.4 and 7.8.
24.5  Readout of the Ussing Chamber System
Since the Ussing chamber system is not often applied for the investigation of the 
impact of food bioactives (proteins, sugars, lipids) on health it is difficult to identify 
typical readout parameters. To date, the Ussing chamber has been applied to inves-
tigate the general transport of proteins, sugars and lipids across intestinal tissue 
(Table 24.1). The readout for these types of studies is the percentage of the applied 
dose that can be detected in the basolateral compartment intact using for instance 
radiolabel counting (e.g. 3H, 125I, 14C), HPLC coupled to a mass spectrometer or UV
Table 24.1 Different absorption studies using intestinal tissue segments of different species 
mounted in the Ussing chamber system
References Species Protein Sugar Lipid
Food- 
related Analysis
Ducroc et al. 
(1983)
Rabbit HRP No Enzymatic activity, 
3H-radioactive 
labeling
Gabler (2009) Pig Glucose Yes Potential difference
Hardin et al. 
(1999)


















Pig HRP No Enzymatic activity
Larsen et al. 
(2001)












Rabbit Cholesterol Yes Merckotest




Glucose Yes 14C-radioactive 
labeling





labeling and HPLC 
gel filtration
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detector or enzymatic activity. While horseradish peroxidase (HRP) and BSA are
not food-related, at least it shows that the Ussing chamber technique can be applied 
to investigate the transport of proteins across intestinal tissue. At TNO we are cur-
rently investigating the possibility to use porcine intestinal tissue segments for 
studying the transport of different allergens across intestinal tissue. Furthermore, 
we also use porcine intestinal tissue segments to monitor cytokine release at mRNA 
levels, since cytokine release at protein level is limited due to viability issue’s men-
tioned before.
24.6  General Advantages, Disadvantages and Limitations 
of the Ussing Chamber System
The Ussing chamber system is, to date, not often applied for the investigation of the 
impact of food bioactives (proteins, sugars, lipids) on health. This indicates that still 
a lot of research can be done in this field. The general advantages and disadvantages 
of the Ussing chamber system are summarized in Table 24.2.
Open Access This chapter is distributed under the terms of the Creative Commons Attribution 
Noncommercial License, which permits any noncommercial use, distribution, and reproduction in 
any medium, provided the original author(s) and source are credited.
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 Part VI 
 In Vitro Fermentation Models: 
General Introduction 
 The human colonic microbiota is a dense and highly diverse microbial community 
that contributes in many ways to host health, including through the recovery of 
metabolic energy from non-digestible dietary components and the maintenance of 
intestinal homeostasis (Bäckhed et al.  2012 ; Hooper et al.  2012 ). The evaluation of 
gut microbial composition and diversity, and its impact on food digestion, by either 
culture dependent or culture independent (e.g. metagenomics) methodologies has 
focused primarily on fecal samples, which are considered to be representative of the 
distal large intestine. These studies, however, do not provide insights into dynamic 
microbial processes and functionality or digestion at their locations in the gut. 
In vitro fermentative models are considered excellent tools to allow the screening of 
a large number of substances, ranging from dietary ingredients to pathogens, drugs 
and toxic or radioactive compounds, to assess how they alter and are altered by 
gastrointestinal environments and microbial populations without ethical constraints. 
In vitro models vary from batch incubations using anaerobic conditions and dense 
fecal microbiota to more complex continuous models involving one or multiple 
connected, pH-controlled chemostats inoculated with fecal microbiota and repre-
senting different parts of the human colon (Venema and Van den Abbeele  2013 ). 
 The common purpose of in vitro gut fermentation models is to cultivate a com-
plex intestinal microbiota under controlled environmental conditions for carrying 
out microbial modulation and metabolism studies. Selection of the appropriate 
model depends on the study objectives and the advantages and limitations exhibited 
by each type of system (Payne et al.  2012 ). Part VI describes a number of these 
in vitro gut fermentation models. 
 Batch Fermentation Models 
 Batch-type simulators represent models ranging from closed bottles used to grow 
defi ned (single or mixed) bacterial strains to controlled reactors inoculated with 
fecal microbiota suspensions. These models usually operate under anaerobic 
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conditions and studies proceed over short-term periods. They are used to study the 
effects of substrates on the physiology and biodiversity of intestinal microorganisms, 
and vice versa. The impact on the microbiota is evaluated by molecular quantitative 
and qualitative techniques and the impact on metabolic activity is assessed by evalu-
ating the formation of short chain fatty acids (SCFA) or other metabolites. These 
models are appropriate to check for inter-individual variability in the response to a 
particular bioactive or agent or for comparison of the consequences of exposure to 
different sources or doses of compounds. In addition, as noted, they provide a fi rst 
assessment of the types of microbial metabolites formed and helps to elucidate the 
pathways involved (see Chap.  25 ). On the other hand, they are limited by substrate 
depletion and the accumulation of the end products of microbial metabolism that 
alter the conditions in the batch away from the microbial balanced starting point, 
thus affecting the in vivo relevance in longer simulations. 
 Dynamic Fermentation Models 
 Several dynamic fermentation models have been developed in recent years with the 
purpose to establish in vitro a relatively stable microbial ecosystem under physio-
logically relevant colon conditions. Continuous multistage and single-fermentation 
models are useful for longer-term experiments needed to evaluate the spatial and 
temporal adaptation of the colonic microbiota to dietary compounds and the micro-
bial metabolism of dietary ingredients. 
 Most of the dynamic multistage-fermentation models are based on the  Reading 
model fi rstly described by Gibson et al. ( 1988 ). The model consists of three vessels 
of increasing size, aligned in series such that a sequential feeding of growth medium 
occurs, mimicking the conditions of proximal, transverse and distal colon. The oper-
ating conditions included setting of pH for the three vessels at 5.5, 6.2, and 6.8, 
respectively; values which were calculated using measurements made on colonic 
contents taken from sudden death victims (Macfarlane et al.  1992 ). Thus, the fi rst 
vessel has a high availability of substrate, representing a rapid bacterial growth rate 
and is operated at an acidic pH, similar to events in the proximal colon. In contrast, 
the fi nal vessel resembles the neutral pH, slow bacterial proliferation rate and low 
substrate availability which is characteristic of more distal regions. The authors also 
developed a nutritious medium that has been extensively used in both batch and 
dynamic fermentation models. The medium consists of protein substrates (casein 
and peptone), complex carbohydrates (pectin, xylan, arabinogalactan and resistant 
starches) that are not digested by gastrointestinal enzymes, and a mixture of salts and 
vitamins (Gibson et al.  1988 ). The viability of the in vitro gut microbiota is depen-
dent on the continuous replenishment of nutrients and the control of physiological 
temperature and anaerobic conditions. The control of these factors allows the 
establishment of steady-state conditions, with respect to both microbial composition 
and metabolic activity, whereas the control of defi ned pH values, downstream nutri-
ent limitations and retention times in the different vessels allows a region- specifi c 
Part VI In Vitro Fermentation Models: General Introduction 
277
differentiation of the colonic microbiota in terms of metabolic activity and microbial 
communities. Anaerobic conditions are usually reached through continuous CO 2 or 
N 2 fl ushing of the headspace. Two representative three-stage fermentation models 
are described in Chaps.  27 (SHIME) and  28 (SIMGI). 
 Continuous single-stage fermentation models are often designed to simulate the 
proximal colon conditions and to reproduce its metabolic activity. The most sophis-
ticated dynamic model is represented by the multiple-component continuous system 
TIM-2 (Minekus et al.  1999 ). The model reproduces the peristaltic mixing of proxi-
mal colonic luminal content as well as the absorption of water and fermentation 
products (see Chap.  26 ). A comparison of the TIM-2 and the multistage- fermentation 
model SHIME (see Chap.  27 ) to study long-chain arabinoxylans as potential prebiot-
ics has demonstrated that both models similarly revealed a compound- specifi c mod-
ulation of prebiotics in terms of short chain fatty acid production and stimulation of 
specifi c  Bifi dobacterium species (Van den Abbeele et al.  2013 ). The simulation of the 
human distal gut environment by maintaining neutral pH conditions and a constant 
culture volume has been recently described by McDonald et al. ( 2013 ) using a twin-
vessel single-stage chemostat model. Moreover, recent developments are addressing 
the construction of single-stage models simulating the ileum microbiota (Venema 
and Van den Abbeele  2013 ). The ileum is the region harboring the highest bacterial 
population within the small intestine due to its slower peristalsis and lower concen-
trations of digestive enzymes and bile. This type of model can be of special utility to 
demonstrate bacterial competition against food-borne pathogens and toxin produc-
tion (Ceuppens et al.  2012 ). 
 Inoculation of Gut Fermentation Models 
 The inoculation and colonization of in vitro fermentation systems infl uences the 
reproducibility of the studies and constitute a challenge of the models (Payne et al. 
 2012 ). Fermenters are usually inoculated with a liquid fecal suspension from an indi-
vidual or pooling stools from several subjects. In the last case, the fecal samples are 
used to inoculate a fed-batch fermenter to produce a standardized inoculum that is 
stored frozen. Cinquin et al. ( 2004 ) developed an immobilization process for the 
entrapment of fecal microbiota in mixed xanthan–gellan gum gel beads to reach high 
cell densities and to maintain the microbial diversity over long time continuous 
colonic fermentations. The model has recently been updated into the model 
PolyFermS where it is possible to stably and reproducibly cultivate complex intesti-
nal communities in multiple reactors allowing studying in parallel the impact of dif-
ferent treatments compared to a control reactor (Zihler Berner et al.  2013 ). In order 
to facilitate the reproducibility of experiments, recent developments are addressing 
the inoculation of fermentation models with defi ned populations of human gut 
microorganisms represented by common saccharolytic and amino acid- fermenting 
populations in the large intestine (Newton et al.  2013 ). 
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 Host-Gut Microbiota Interaction 
 A major drawback of gut fermentation models is the limitations for simulating 
the host functionality. The combination of fermentation models and intestinal cell 
cultures represent a common approach to reproduce in vitro the host responses. 
These studies have been usually performed with colon epithelial cell cultures and/or 
immune cells to evaluate adherence, cytokine production and gene expression, 
among others (Venema and Van den Abbeele  2013 ). Additional tools that have 
improved modeling of the physiological colonic conditions are the incorporation in 
the reactors of a mucosal environment able to differentiate between the luminal 
microbiota and the microbial biofi lms adhering to the colonic epithelium (Macfarlane 
et al.  2005 ; Van den Abbeele et al.  2012 ). The Host-Microbiota Interaction (HMI) 
module is a recently developed device adapted to the SHIME model that allows 
 long-term studies of a complex microbial community colonizing a mucus layer, while 
being co-cultured microaerophilically (up to 48 h) in the presence of shear forces and 
a monolayer of enterocyte human cells (Marzorati et al.  2014 ). This combination of 
in vitro models represents an approximation to the conceptualized ideal experimental 
model for the study of host-gut microbiota interactions described by Fritz et al. ( 2013 ). 
These authors claim that the ideal model should include epithelial cells, complex gut 
microbiota, anaerobic/microaerophilic conditions, a mucus layer and physiological 
conditions of pH, fl uid retention times and dissolved O 2 concentrations. 
 The progress made in developing in vitro fermentation models able to closely 
mimic the gut microbial environment and the increasing knowledge regarding micro-
bial populations and host-gut microbiota interactions can offer remarkable insights 
into gut microbiota functions. Moreover, ongoing studies would allow the develop-
ment of well-defi ned mixtures of microorganisms that retain a high level of diversity 
and encompass key functions required for healthy intestinal homeostasis in an 
approach coined “microbial ecosystem therapeutics” by Petrof et al. ( 2013 ). 
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 Chapter 25 
 One Compartment Fermentation Model 
 Anna-Marja  Aura and  Johanna  Maukonen 
 Abstract  In vitro colon model was fi rst applied in an inter-laboratory dietary fi bre 
(DF) fermentation study and adapted at VTT for whole foods and beverages, iso-
lated dietary phenolic compounds and pharmaceuticals. The application of the 
 models includes strict anaerobiosis, which ensures active anaerobic microbial com-
munity. Pooling of faecal samples from several donors ensures reproducibility 
between the experiments. The correlation of in vitro data with in vivo data is quan-
titatively challenging, but is qualitatively highly relevant. In this chapter we explain 
the applicability of the one compartment fermentation model, including the general 
protocol as well as the advantages and disadvantages of the system. 
 Keywords  One compartment colon in vitro model •  Human faecal microbiota • 
 Anaerobic conditions •  Microbial metabolites •  Dietary fi bre •  SCFA 
25.1  Description of the VTT One Compartment 
Fermentation Model 
25.1.1  History of the Model 
 In 1995, VTT developed an enzymatic digestion model to simulate the digestion of 
DF in the upper intestine. The model was optimized for maximal starch digestion 
and to obtain non-digestible DF residue using physiological conditions (Aura et al. 
 1999 ). In the same year an inter-laboratory study of in vitro colon fermentation 
models was published by Barry et al. ( 1995 ). The physiological relevance of the 
model was ensured by a multidisciplinary approach involving specialists in nutri-
tion and gastroenterology. The fermentation was expressed as the difference 
between the faecal control (inoculum, no substrates) and substrates under investiga-
tion (e.g. plant foods or other DF ingredients). Later the model was adapted for pure 
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phenolic compounds (Aura  2005 ), fruit matrices and beverages (Bazzocco et al. 
 2008 ; Aura et al.  2013 ). The fermentation model from Barry et al. has been used in 
combination with the enzymatic digestion model from Aura et al. ( 1999 ) for cereal 
studies ( Nordlund et al.  2012 ,  2013 ). Most recently the model has been coupled to 
a platform with bioinformatics tools to obtain non-targeted metabolite profi ling of 
plant foods (Aura et al.  2013 ). 
25.1.2  Special Features 
 Venema and van den Abbeele ( 2013 ) have pointed out recently a non-physiological 
slow rate of conversion in “static cultures”. In reference to the unit operation the 
authors describe the “static” culture conditions (in contrast to the continuous 
“dynamic” culture conditions) (Venema and van den Abbeele  2013 ) often in context 
of one compartment cultures. When one compartment in vitro colon models are per-
formed in well-buffered non-nutrient media with strictly anaerobic microbiota, accu-
rately timed sampling and monitoring of pH changes, they appear to show also the 
distinctively higher rate of conversion. The time course studies under agitation bring 
out the dynamic processes, which occur from food components also in “batch” unit 
operations. Static, standing cultures without agitation cannot be used in conversions 
related to DF components or isolated phenolic compounds, because the suspension 
would sediment and enzyme–substrate interaction would be suppressed, especially 
in incubations with solid substrates such as DF components. 
 A distinctive characteristic of the VTT one compartment in vitro colon model is 
the use of a strong buffer with minerals as the main matrix of the medium (Barry 
et al.  1995 ) instead of nutritive medium with additional carbon sources (Hughes 
et al.  2008 ). The faecal material brings additional carbohydrates and a matrix to 
support the microbiota together with the buffer and mineral solution. It has been 
shown in previous studies (McBurney and Thompson  1989 ; Mortensen et al.  1991 ) 
that use of faeces from at least three donors secures the diversity of the microbiota 
and enables the reproducibility of the results. Therefore in the one compartment 
in vitro model applied at VTT a pooled human faecal suspension is prepared from 
samples from at least 3 but usually from 4 to 6 donors. 
 The faecal inoculum is dense (10–16.7 %, w/v), especially, when non-digestible 
carbohydrate fermentation is performed. The microbiota acts as a source of enzymes, 
which degrade and convert released components such as sugars to short-chain fatty 
acids (SCFA) or phenolic compounds to microbial phenolic acid or lactone 
metabolites. 
 One of the positive features of the VTT model is that the anaerobic conditions 
can be easily maintained as the system is closed and air-tight. This anaerobic envi-
ronment is needed to avoid damaging of the strictly anaerobic microbiota during the 
preparation of the inoculum (homogenization, dilution and fi ltration) and its 
 incubation with substrates. It also ensures that the microbial enzymes can perform 
degradation of DF constituents under the same conditions as in the human gastroin-
testinal tract. 
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 The quality of the anaerobic conditions in the VTT model was tested by cultivating 
samples from the fresh faecal suspension in aerobic and in anaerobic conditions and 
counting the microbial cells after the cultivation. The initial (0 h) anaerobic cell 
count (1.6 × 10 9 CFU/ml) exceeded that from the corresponding aerobic cell count 
(3.1 × 10 7 CFU/ml). After 4 h of anaerobic incubation at 37 °C, cell counts were 
changed to 3.2 × 10 9 CFU/ml and 2.3 × 10 7 CFU/ml, for the anaerobic and aerobic 
cell counts, respectively. The corresponding log 10-anaerobic-to-aerobic ratios 
were 1.2 and 1.3 for 0 h and 4 h, respectively, indicating that anaerobic conditions 
were not disturbed during the incubation. When frozen faeces were used as an inoc-
ulum in three experiments, the log 10-anaerobic-to-aerobic ratio was 1.5 ± 0.2, but 
cell counts were 10 % of the fresh inoculum. After 4 h in corresponding conditions 
both the cell counts showed fourfold increase, and the log 10-anaerobic-to-aerobic-
ratio was still 1.3 ± 0.04. Based on these results it was concluded that fresh inoculum 
was the most vital for DF fermentations and that the inoculum preparation condi-
tions need to be strict enough for maintaining the adequate difference between the 
anaerobic and aerobic microbiota (2–3 log difference). When the cultivated 
log 10-anaerobic-to-aerobic ratio is between 1.2 and 1.6, anaerobic microbiota 
dominates the population. If the ratio were 1, strictly anaerobic strains would 
be dead and only microaerophilic strains would stay alive. This would be non- 
physiological situation in terms of DF fermentations. 
 Faecal samples from each donor and the corresponding faecal suspension were 
obtained from the in vitro colon model and kept frozen at −70 °C before microbio-
logical analysis. Partial 16S rRNA gene was amplifi ed for the denaturing gradient 
gel electrophoresis (DGGE) analysis of predominant bacteria,  Eubacterium rectale –
 Blautia coccoides group (Erec-group,  Lachnospiraceae ),  Clostridium leptum group 
(Clept-group,  Ruminococcaceae ),  Bacteroides ,  Bifi dobacterium and  Lactobacillus 
as previously described (Maukonen et al.  2006 ,  2012 ). Above mentioned bacterial 
profi les of individual donors were compared to the bacterial profi les of the corre-
sponding faecal suspension. Even though the inter-individual similarity between the 
donors was low (Fig.  25.1 ), and partly different people were used as donors in dif-
ferent in vitro colon model experiments, the bacterial profi les of faecal suspensions 
were rather similar (Fig.  25.2 ). In predominant bacteria, Clept-group, lactobacilli 
and bifi dobacterial profi les clear differences between faecal suspensions were 
observed. However, the observed differences corresponded to intra-individual 
 temporal variation previously observed in healthy adults (Maukonen et al.  2012 ). 
Moreover, in the Erec-group (Fig.  25.2b ) and in  Bacteroides profi les there were no 
major differences between the different faecal suspensions. Erec-group bacterial 
populations have also previously been shown to be temporally rather stable 
(Maukonen et al.  2006 ). 
 In conclusion, the microbiological reproducibility of the in vitro model was 
good: the microbiological variation observed between the different in vitro colon 
model experiments was equivalent to intra-individual temporal variation. Since 
DNA-based methods were used, which target both living and dead bacteria, it can-
not be reliably stated that the active microbiota has been the same in each experi-
ment. The used DGGE methods target only the rDNA amplicons obtained from the 
population that exceeds 1 % of the species present in the analysed community 
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(Muyzer et al.  1993 ), therefore our results show that the most dominant bacteria 
within each bacterial group were similar. This study of microbiological reproduc-
ibility was a quality measure, which ensures that the metabolites are less dependent 
on the microbiota than from the substrates. Other microbial ecological studies are 
not recommended with the one compartment in vitro colon model, since the model 
is designed to study microbial metabolism of various substrates and for comparison 
of their metabolite dynamics. 
 Fig. 25.1  Bifi dobacterial 
profi les of samples used for 
in vitro fermentation 
(BM = bifi dobacterial marker; 
A–C = donors; 3 = faecal 
slurry) 
 Fig. 25.2  Predominant bacterial ( a ),  Eubacterium rectale – Blautia coccoides group ( b ),  Clostri-
dium leptum group ( c ) and  Bifi dobacterium ( d ) DGGE-profi les of faecal slurries used for fi ve (1–5) 
different in vitro fermentations.  Red arrows denote clear differences between samples 
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25.2  Validation of the System 
 The validation of the model was performed by comparing the variability of meta-
bolite concentrations in the faecal control (inoculum, no substrates) and in the sub-
strate incubation in experiments performed on different days. The faecal control 
measurement provided information on the variation of the background fermentation 
of the remaining fermentable carbohydrates or phenolic compounds from the diet of 
the faecal donors. Table  25.1 shows comparison of 4 or 5 experiments in respect to 
major microbial metabolites and pH in the faecal control at 0-h- and 24-h-time 
points. The smaller the response, the higher is the variation of the response. The 
variation is smallest (14–25 %) for total SCFA, acetic acid, propionic acid and 
3-phenylpropionic acid, whereas butyric acid varies 21–37 % between the experi-
ments. pH shows only 1–2 % variation, for the initial pH 5.5 of the buffer; and 
3-hydroxyphenylpropionic and -acetic acids show 65–114 % (0 h) and 23–27 % 
(24 h) variations. Furthermore, when the concentrations of the metabolites in the 
faecal control are compared between the experiments, the differences are dependent 
on the metabolite and its dynamics and particularly the diets of the donors of the 
faeces. The differences are balanced by pooling the inoculum from several donors. 
Therefore, the major phenolic metabolites in the in vitro model show similar variation 
between experiments (65–114 %) in phenolic microbial metabolites than corre-
sponding urinary excretion profi les shown between different human individuals 
(70–113 %) (Vetrani et al.  2014 ).
 The true validation requires the same reference substrate for all experiments 
under investigation. Usually the space in the experiment is limited and the reference 
substrate is chosen according to the hypotheses of the specifi c projects. Rye bran 
and fl axseed meal were used in several experiments, the responses were measured 
 Table 25.1  Variation of different microbial metabolites (mean ± standard deviation) measured 
from the faecal control between experiments (n: number of experiments) in the beginning (0 h) and 
in the end (24 h) of the incubation 
 Response  0 h  24 h  n  References 
 Total SCFA (mM)  11.7 ± 2.6  32.6 ± 5.7  5  1 
 Acetic acid (mM)  7.6 ± 1.5  20.5 ± 4.5  5  1 
 Propionic acid (mM)  1.7 ± 0.3  5.9 ± 1.1  5  1 
 Butyric acid (mM)  2.4 ± 0.9  6.2 ± 1.3  5  1 
 pH (initial 6.9) (range) 
 pH (initial 5.5) 
 6.99–7.07 
 6.07 ± 0.05 
 6.67– 6.68 




 3-Hydroxyphenylpropionic acid (μM)  7.7 ± 3.5  7.3 ± 2.4  3  2 
 3-Phenylpropionic acid (μM)  96 ± 15  235 ± 71  3  2 
 3-Hydroxyphenylacetic acid (μM)  5.4 ± 4.4  8.7 ± 1.7  3  2 
 1: Nordlund et al. ( 2012 ), Bazzocco et al. ( 2008 ), Aura et al. ( 2013 ) and Nordlund et al. ( 2013 ) 
 2: Aura et al. ( 2013 ) and Bazzocco et al. ( 2008 ) 
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as SCFA production and were summarized in Aura ( 2005 ). The total SCFA  formation 
at the end of the fermentation showed 10 % and 18 % variations for  enzymatically 
pre-digested rye bran (83.3 ± 8.5 mM, n = 4) and pre-digested fl axseed meal 
(95.3 ± 17.5 mM, n = 3), respectively. Taking into account the different inoculum 
concentrations (10 % or 16.7 %) used in these studies, the variation was surprisingly 
low for SCFA production. In contrast, the 97 % variation of the enterolactone for-
mation from predigested fl axseed meal (43 ± 42 nM, n = 3) was highly dependent on 
the inoculum concentration. This could be explained by the minor population 
of enterolactone-converting bacteria (Clavel et al.  2005 ) and therefore the extent of 
conversion was susceptible to the depletion by the low concentration of inoculum. 
Furthermore, the resilient structure of fl axseed meal and low nano-molar concentra-
tions may have contributed to the high variation (Aura  2005 ). 
25.3  Relevance to Human In Vivo Situation 
 The one compartment in vitro colon model measures only those conversions, which 
occur in anaerobic conditions by faecal microbiota. These reactions take place in cae-
cum prior to absorption. The model does not take into account the membrane func-
tions which occur in the colon epithelia, the intestinal epithelia and in the liver. The 
major metabolites from the DF intake are SCFA and phenolic microbial metabolites. 
The major SCFA formed in the colon is acetic acid, which does not have distinctive 
structural characteristics, which would be needed for follow-up of its route without a 
radiolabel. For example a correlation was sought for SCFA production between a fi bre 
blend and its components in vivo and in vitro (Koecher et al.  2014 ). In vitro experi-
ments showed SCFA formation and analysis of SCFA from faeces revealed an increase 
of SCFA content in faeces after consumption of the fi bre blend versus fi bre free 
diet, however, signifi cant differences between the ingredients of the blend were not 
observed in vivo (Koecher et al.  2014 ). The authors speculated about the balance 
between production and absorption rates of microbial metabolites and concluded that 
the in vivo interventions and in vitro studies may not be directly correlated, but in vitro 
models are additionally informative (Koecher et al.  2014 ). 
 Phenolic compounds and their microbial metabolites may be better biomarkers 
for plant food and dietary fi bre intake than SCFA. The metabolites in urine include 
also membrane-derived metabolites, such as glucuronidated and sulfated deriva-
tives of phenolic compounds. In addition to this urine contains the microbial metab-
olites derived from the diet (Aura  2008 ). The closest and most non-invasive measure 
is the analysis of 24-h-urine, which describes the excretion of metabolites from 
the food and beverage intakes (Vetrani et al.  2014 ). The fi rst challenge is that the 
urinary analysis describes the excretion of the metabolites from the whole diet from 
several precursors (Vetrani et al.  2014 ) which share the microbial metabolites (Aura 
 2008 ). If the diet is not controlled the background can be disturbed by the excretion 
of phenolic metabolites from the non-controlled components, and statistical differ-
ences are not obtained (Lappi et al.  2013 ). 
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 Another issue is that a single component does not change the excreted  metabolites 
in a signifi cant way (Lappi et al.  2013 ), whereas a fully controlled diet high or low 
in polyphenols can show signifi cant metabolite profi les typical for the polyphenols 
(Vetrani et al.  2014 ). Therefore, the metabolites cannot be connected to a single food 
or component, but refer to a whole diet. The third challenge is that the comparison 
of in vivo responses match qualitatively well with the microbial metabolites expected 
to be excreted from the food phenolic components (Aura  2008 ; Lappi et al.  2013 ; 
Vetrani et al.  2014 ). However, quantitative comparisons are problematic because of 
the high individual variation of microbial metabolites in vivo (Vetrani et al.  2014 ) 
and the diversity of hepatic metabolites, the quantifi cation of which requires unavail-
able authentic standards for most of them for signifi cant correlation. 
25.4  Quality in Relation to Other Models 
with the Same Applicability 
 When microbial metabolism of rutin (quercetin-rhamnoglucoside) and chlorogenic 
acid was studied in a one compartment fermentation model using four individual 
donors (Rechner et al.  2004 ), the patterns of the metabolite formations varied 
according to the subject. The formation of 3,4-dihydroxyphenylacetic or -propionic 
acid from rutin and chlorogenic acid, respectively, showed maxima at 8–10 h using 
10 % (w/v) suspension (Rechner et al.  2004 ). In contrast, using the diluted suspen-
sion (5 %, w/v) pooled and homogenized under strict anaerobic conditions, the 
corresponding value was shown in 2 h and complete dehydroxylation was observed 
in 8 h ( Aura et al.  2002 ). The inoculum in VTT one compartment system has to be 
diluted 1 % in order to observe the deglycosylation of quercetin derivatives or 
anthocyanins in different experiments (Aura  2005 ). It is likely that strict application 
of anaerobic conditions enables faster conversions, when vulnerable anaerobic 
microbial suspension is used as a source of activity. 
 When in vitro colon models using monogastric pig and human faeces as inocula 
were compared, human inoculum showed more effi cient fermentation for several 
sources of DF, whereas pig inoculum was more effi cient in cellulose digestion. The 
pig inoculum produced less SCFA and more gas compared with the human inocu-
lum. These differences were attributed to an adaptation of human microbiota to a 
more diverse diet compared to the pig feed and an adaptation of pig microbiota to 
a cellulose-rich diet (Jonathan et al.  2012 ). 
25.5  General Protocol 
 The latest description of the model is from Nordlund et al. ( 2012 ). In vitro colon 
model for measurement of SCFA and phenolic acids was started by weighing 
100 mg per 10 ml of incubation suspension (dry w/v) of plant foods or their 
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fractions to the bottles, and hydrating with 20 % of the volume of medium 1 day 
before inoculation. Human faeces were collected from at least 3 (usually from 4–6) 
healthy volunteers, who had not received antibiotics for at least 6 months and had 
given a written consent. Freshly passed faeces were immediately taken in an anaer-
obic chamber or closed in a container with an oxygen consuming pillow (Anaerocult 
Mini; Merck, Darmstadt, Germany) and a strip testing the anaerobiosis (Anaerotest; 
Merck, Darmstadt, Germany). Faecal suspension was prepared under strictly anaer-
obic conditions. Equal amounts of faecal samples were pooled and diluted to a 
12.5 % (w/v) or 20.8 % (w/v) suspension, depending on the application and 80 % of 
the volume of the incubation suspension was dosed to the fermentation bottles to 
obtain a 10 % or 16.7 % (w/v) fi nal faecal concentrations as described previously 
(Aura  2005 ). Lower concentrations can be used. For example 5 % suspension is 
suitable for isolated components, because the metabolite responses from faecal con-
trol are high in more dense inoculum and the substrate concentration should be 
below the saturation point of the substance to keep the substrate in the solution and 
not to suppress the activity of the microbiota. 
 The fermentation experiments were performed in triplicate and a time course of 
0, 2, 4, 6, 8 and 24 h is followed using the same inoculum for all the substrates. 
Incubation is performed at 37 °C in tightly closed bottles and in magnetic stirring 
(250 rpm). Faecal background is incubated without addition of the supplements 
(Aura  2005 ). Headspace is sampled for the measurement of gas pressure (Nordlund 
et al.  2012 ) and the liquid space is sampled for SCFA and phenolic acid metabolite 
analyses (Nordlund et al.  2012 ; Aura et al.  2013 ). 
25.6  Controls: Positive and Negative 
 Monitoring of metabolite background in the faecal control without substrate is 
 crucial. In addition to this it is recommendable to use inactive microbiota as a nega-
tive control (Aura  2005 ). Relevant reference compounds/ingredients should be 
used. For instance when fermentation rate is the focus of the study, reference sub-
strates such a “rapid” or “slow” standards can be used to make comparisons between 
different experiments. The controls should also be performed at least in three repli-
cates for adequate statistical evaluation. 
25.7  Read Out of the System 
 The read out of the in vitro colon model is caused by the interaction between micro-
bial enzymes and the precursors and expressed as time course of metabolite forma-
tion. The precursors can be carbohydrates and the products are then SCFA or gas 
formation (Nordlund et al.  2012 ). Other precursors can be fl avonoids, proanthocyani-
dins or plant-derived phenolic acids (ferulic acid, chlorogenic acid), which lead to 
the formation of benzoic acid derivatives or of hydroxylated phenylpropionic, -acetic 
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or -valeric acids (Aura  2008 ; Aura et al.  2013 ; Nordlund et al.  2012 ). Plant lignans 
are the precursors for enterodiol and enterolactone (the enterolignans) (Heinonen 
et al.  2001 ) and isofl avonoids for equol or O-desmethylangolensin  production 
(Heinonen et al.  2004 ; Possemiers et al.  2007 ). Furthermore ellagitannin conversion by 
intestinal microbiota results in formation of urolithins (Cerda et al.  2004 ). 
 The responses should be compared always within the experiment, using the ade-
quate number of intermediary time points, at least in triplicates and in respect to the 
inoculum, the responses of which is dependent on the diet of the donor. Moreover, 
the quantitative results should not be extrapolated between experiments and the 
responses should be related to the clearly indicated faecal control read out within 
the experiment. Thus the accepted microbial metabolite can only be one which 
shows at least two- to fi vefold higher responses than the background metabolites 
from the faecal control. Therefore the results show specifi c metabolite profi les from 
each substrate. These semi-quantitative results can be obtained from non-targeted 
metabolomics platform for identifi cation of new metabolites. Quan ti tative measures 
are achieved using the targeted approach, which limits the profi ling to those metab-
olites, which are available as authentic standards. A unit to be measured should be 
on molar basis, because structural transformations affect the molar masses and 
responses based on weight are not comparable. 
 The one compartment colon model can be applied to comparison of fermentation 
rates of different sources of DF or ingredients having different characteristics (Kaur 
et al.  2011 ; Koecher et al.  2014 ), whereas changes in microbial population requires 
a semi-continuous unit operation (Hughes et al.  2008 ). 
25.8  Summary of Advantages, Disadvantages 
and Limitations of the System and Contingency Plan 
 Table  25.2 summarizes the advantages, disadvantages and limitations of the one 
compartment in vitro colon model and is divided into characteristics of the opera-
tion of the model (unit operation, microbiota, anaerobiosis, pH monitoring and 
 control, timing and sampling, stirring) and into those of the outcome (data analysis, 
comparison of substrates, prediction of human metabolism, and absorption). It is 
important to judge the limitations in context of the hypotheses that are studied in the 
one compartment model.
 In conclusion, the one compartment fermentation model experiments perhaps do 
not mimic human pH changes or include absorption as the computer-controlled 
continuous models do, but the one compartment incubations are very suitable when 
the perspective is in the food matrix or its chemistry. In vitro colon models do not 
have membrane functions required for full mimicking of the xenobiotic metabo-
lism. However, in vitro one compartment digestion models explain the effects of 
food matrix on release of components or bioconversion of food components to their 
microbial metabolites and they can elucidate factors affecting these processing and 
predict in vivo bioavailability. This fi eld of food biochemistry is essential to eluci-
date phenomena, by which food chemistry turns into nutrition. 
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 Chapter 26 
 The TNO In Vitro Model of the Colon (TIM-2) 
 Koen  Venema 
 Abstract  This contribution describes the development and use of the TNO in vitro 
model of the colon (TIM-2). The unique features of this system are briefl y dis-
cussed, as well as how these contribute to the predictability of this validated in vitro 
model for clinical trials. Several examples are provided of data where experiments 
in TIM-2 yielded similar data as clinical trials. Other examples highlight the use of 
the system to screen dietary components for certain functionality (e.g., increase in 
butyrate production), or determine likely mechanisms of action of dietary substrates 
(e.g., the bifi dogenic nature of dietary carbohydrates). Moreover, examples are pro-
vided of metabolism of dietary compounds such as polyphenols of which the deter-
mination of in vivo metabolism is extremely diffi cult, due to the limited access we 
have to the colon. The system is inoculated with a microbiota originating from 
healthy volunteers (single donor or pooled microbiota) of different age, or from 
people with a disease (e.g., infl ammatory bowel disease). Also, differences between 
the microbiota from lean and obese individuals have been studied. Recent develop-
ments in building hypotheses on the role of the microbiota in health and disease 
have been generated using substrates that were labeled with a stable isotope (i.e.,  13 C), 
that allows tracing the label into microbial biomass and into metabolites produced 
by the gut microbiota. This has signifi cantly advanced our knowledge on the role of 
the activity of the gut microbiota in health and disease and the members of the 
microbiota that are involved in this. 
 Keywords  In vitro model •  Colon •  Microbiota •  SCFA •  Prebiotics 
26.1  Description of TIM-2 
 This contribution focuses on food-application of TIM-2. Although numerous 
examples are available for pharmaceutical applications as well, these will not be 
exemplifi ed here. 
 K.  Venema (*) 
 Benefi cial Microbes Consultancy ,  Wageningen ,  The Netherlands 
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26.1.1  History of the Model 
 The  T NO computer-controlled, dynamic in vitro gastro- I ntestinal  M odel of the 
colon (nick-named TIM-2; Fig.  26.1 ) was developed by TNO some 15 years ago 
(Minekus et al.  1999 ). It is based on the TIM-1 system (the TNO in vitro gastro- 
intestinal model of the stomach and small intestine) that is discussed elsewhere in 
this book. 
 Briefl y, the model consists of four interconnected glass compartments, with a 
fl exible membrane inside (Fig.  26.1a ). In between the glass jacket and the membrane 
there is water of body temperature (37 °C for humans, 39 °C for pigs, 41 °C for birds, 
etc.). The temperature is controlled by a temperature sensor (Fig.  26.1j ). By applying 
pressure on the water at regular intervals and in a certain sequence, the fl exible mem-
brane contracts and causes peristaltic waves which mixes the luminal contents and 
moves it through the system. This mixing is better than can be accomplished in a 
fermentor, where phase separation of fl uids and solids occur. The system is kept at a 
pH of 5.8, the pH occurring in the proximal colon, or above by continuous measure-
ment of the pH (Fig.  26.1b ) and secretion of 1M NaOH (Fig.  26.1c ) to neutralize the 
 Fig. 26.1  Schematic fi gure of the TNO in vitro model of the colon (TIM-2). (a) peristaltic com-
partments containing faecal matter; (b) pH electrode; (c) alkali pump; (d) dialysis liquid circuit 
with hollow fi bre membrane; (e) level sensor; (f) N 2 gas inlet; (g) sampling port; (h) gas outlet; (i) 




acids that are produced by the microbiota. To prevent accumulation of microbial 
metabolites, which would lead to the inhibition or death of the microbes in the model 
when they would accumulate, the system is equipped with a dialysate system, 
consisting of a bottle with dialysate, a dialysis membrane running through the model 
and a bottle collecting the spent dialysate (Fig.  26.1d ). This dialysis system is unique, 
and moreover, required to maintain an active microbiota for periods for up to 3 weeks. 
This was the longest the system has been tested. Normally experiments are per-
formed over a period of 1 week (see Sect.  26.2 ). 
 The dialysis system has been tuned to keep physiological concentrations of micro-
bial metabolites in the lumen of the model. For example, short-chain fatty acid (SCFA) 
concentrations are within the physiological range of 80–120 mM (Venema et al. 
 2000 ). The model is equipped with a level sensor to control the volume (Fig.  26.1e ). 
When the volume in the system rises due to addition of the feed or through dialysis, 
this sensor activates the dial-out pump and maintains the volume at a constant level of 
~120 mL. To keep the model anaerobic, it is fl ushed with gaseous nitrogen (Fig.  26.1f ). 
This, plus the activity of the microbiota in the system, keeps the redox-potential at a 
level of ~ −300 mV, which is the value that has been reported to occur in the large 
intestine. Samples can be taken from the lumen through the sampling-port (Fig.  26.1g ) 
or from the spent dialysate (Fig.  26.1d ). This allows for a complete mass-balance to 
be calculated. Gases produced by the microbiota can be sampled too, although nor-
mally this is not done and the gas just escapes from the model through a bubbling-vial 
(Fig.  26.1h ). Frequent sampling over time allows the study of the kinetics of produc-
tion of certain microbial metabolites (e.g., SCFA) on specifi c substrates. It is obvious 
that such sampling is not possible in vivo, and hence TIM-2 allows studying the mode 
of action of certain compounds (foods or drugs) which cannot be studied in detail in 
man, nor in animals. The microbiota in the system is fed through a food syringe 
(Fig.  26.1i ) which contains a simulated ileal effl ux medium (SIEM), which in compo-
sition mimics the components that reach the colon from the terminal ileum through 
the ileal-cecal valve. It consists of some complex carbohydrates, some protein (not all 
protein is digested in the small intestine [SI]), some residual bile (not all bile is 
resorbed in the SI), and some minerals and vitamins [for details see Minekus et al. 
 1999 ; van Nuenen et al.  2003 ; Venema et al.  2000 ]. 
26.1.2  Special Features of the Model 
 Several features in TIM-2 are unique over other models. First of all, the peristaltic 
movements of the fl exible membrane give a better mixing and movement of com-
ponents through the entire model than would be accomplished by stirring (in a 
fermentor) or shaking (on a rocking-platform or otherwise). In TIM-2 there is no 
phase-separation of solids and liquids, which does occur in other systems. Viscous 
‘meals’ or insoluble components can be used without problems in the system. 
Secondly, as eluded to above, the dialysis system is not only unique, but also required 
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to maintain a highly active microbiota with a similar density as that found in the 
human large intestine. In batch incubations or less sophisticated models the micro-
biota is usually inoculated at a much lower density (100-fold or more) and is allowed 
to slowly grow to physiological densities. However, the metabolites produced by 
the microbiota start to inhibit further fermentation at these high densities in these 
systems. Since these metabolites are also taken up by the epithelial cells of the colon 
(colonocytes) in vivo, TIM-2 mimics much better the physiological situation in the 
large intestine. In fact, since all metabolites are collected and can be measured, a(n 
almost) complete mass-balance can be made, which is not possible in vivo, not even 
in animals, although in scientifi c studies usually animal are sacrifi ced to sample as 
much as possible, including blood samples. However, even in animals a mass-
balance is not possible, as e.g., butyrate—one of the SCFA—is used by the colono-
cytes and does not reach the blood circulation. Therefore, TIM-2 allows studying 
(molecular) mechanisms. This is certainly the case if labeled substrates are used, as 
will be discussed in other sections of this chapter. 
 The model is incubated by using a fecal donation from volunteers. This fecal 
donation can be used in two ways: (a) a fecal donation from individual one can be 
introduced into one of the TIM-2 systems, the donation from individual 2 in a second 
unit, and so on. The composition and activity of the microbiota of the individuals can 
then be compared on say one and the same substrate. This has for instance been done 
for lactulose, with ten donors (Venema et al.  2003 ); or (b) the fecal donations of 
several donors are mixed to create a standardized microbiota that can subsequently 
be used for ~100 experiments. This allows comparison of multiple substrates or con-
ditions starting with the same microbiota composition. This pool of fecal donations 
to a certain extent mimics a (small) population. It has been argued by many that 
 mixing different fecal samples may disturb the microbial balance within a single 
fecal sample, but as far as we know, no direct comparison has been done to show this. 
Recently, we have set out to show that by mixing a number of different fecal 
 donations, the functionality of the microbiota is not infl uenced (Aguirre et al.  2014 ). 
That is, the individual microbiotas showed the same functionality as the pool and 
produced very similar amounts and ratios of microbial metabolites (amongst others 
SCFA), despite being different in microbial composition. This underscores our 
hypothesis that there is an enormous functional overlap between microbes in the 
large intestine. This is not entirely surprising, as there are only a limited number of 
biochemical routes (let’s say 5) from e.g., glucose to acetate. Since the microbiota is 
composed of approximately 200 species or more, there has to be enormous func-
tional overlap between these microorganisms. 
 Upon introduction of the microbiota in the system, an adaptation period of 
~16 h is applied, to allow the microbes to adapt to their new environment and the 
feed components. After that the experimental period starts, which normally takes 
72 h (see Sect.  26.2 ). Fecal donations can be obtained from healthy volunteers of 
different age-classes (baby, adults, elderly), people with a disease or disorder 




26.1.3  Stability and Reproducibility of the System 
 Since the model is computer-controlled it is highly reproducible. This has been 
shown e.g., by the clustering of the microbiota after the adaptation period referred 
to in the previous section (Fig.  26.2 ). In this example, the microbiotas originating 
from lean and obese individuals were compared. The fi gure shows that both micro-
biotas clustered separately, but that each t = 0 sample of the lean microbiota clus-
tered very closely together with the other lean samples, and similarly for the obese 
samples. It should be said that the microbiota in this adaptation period undergoes a 
change in composition, as it adapted to the model and feed (Rajilic-Stojanovic et al. 
 2010 ). This is not entirely surprising, as the conditions in the model are different to 
the colon, although we try to simulate them as good as possible. But, the system 
does not contain epithelial cells or immune cells that may infl uence the microbiota 
composition. This will be discussed in more detail later (see Sect.  26.5 ). 
 No matter whether the system is inoculated by a standardized microbiota or a 
microbiota from a single donor, it is highly reproducible. This has been shown in 
numerous studies (Kovatcheva-Datchary et al.  2009 ; Martinez et al.  2012 ; Rose 
et al.  2010 ). This is why experiments in TIM-2 are performed in duplicate. 
 In every project a control with the standard growth medium (SIEM) is performed. 
The other conditions applied in such projects are then compared to the effects 
obtained with the standard medium. This allows correcting for effects that occur 
simply through use of the in vitro model. 
 Fig. 26.2  Phylogentic tree ( left ) and heatmap ( right ) of samples from TIM-2 taken at t = 0 in an 
experiment where a lean and obese microbiota was compared. The lean and obese microbiotas 
cluster separately, although all t = 0 samples of each microbiota (lean or obese) cluster closely 
together 
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26.1.4  Relevance to Human In Vivo Situation 
 The model has been developed and optimized with the use of data from sudden- 
death individuals (Macfarlane et al.  1992 ). The data from these samples with respect 
to microbial metabolites and microbiota composition were used to develop TIM-2. 
 The effect of several food components that have been well-established in vivo 
have been confi rmed in TIM-2. These include the bifi dogenic nature of inulin (van 
Nuenen et al.  2003 ) and galacto-oligosaccharides (GOS) (Maathuis et al.  2012 ), or 
the high production of butyrate out of resistant starches (Rose et al.  2010 ). Due to 
this, the validated system is frequently used to test experimental substrates and is 
thought to be predictive for the in vivo situation. 
 Yet, in some situations the model is even capable of predicting results in the 
proximal colon that cannot be measured in a clinical trial. This has for instance been 
done in experiments using lactulose (Venema et al.  2003 ). Here, fecal donations 
were obtained from volunteers before they ingested lactulose for 10 days, and after. 
Both fecal donations were inoculated independently in TIM-2 and were fed lactu-
lose in the system. The production of the major microbial metabolites, the SCFA, 
was analyzed both in fecal samples as well as in TIM-2 samples. At fi rst surpris-
ingly, the in vivo fecal samples before and after lactulose did not differ in SCFA 
content and ratio, while the samples in TIM-2 showed a marked reduction in butyr-
ate production. However, since lactulose is a disaccharide, it is fermented very 
quickly by the gut microbiota (as also indicated by the accumulation of lactate), and 
this occurs in the proximal colon. We now hypothesize that the SCFA that were 
produced by the microbiota in vivo in the proximal colon were all taken up during 
transit to the distal colon, and that the SCFA present in the excreted fecal samples 
refl ect those produced locally in the distal colon, rather than refl ect the SCFA that 
were produced in the proximal colon. This is highly likely as it has been estimated 
that 95 % of the SCFA produced by the microbiota are absorbed. Therefore, TIM-2 
gave insight in the processes at the site where the fermentation of lactulose hap-
pened—the proximal colon. This is data that could not be inferred from fecal sam-
ples taken from these volunteers. 
26.1.5  Quality in Relation to Other Models 
with the Same Applicability 
 Compared to other in vitro models mimicking the colon, TIM-2 has a number of 
features that are unique (see Sect.  26.1.2 ) and that allow to predict what would 
 happen in a clinical trial. In the previous section the example of lactulose was given. 
To validate these results one would need to sample the proximal colon, which is 
only possible when using a long catheter that is inserted through the nose or throat 
and reaches the proximal colon (Venema  2011 ), or a tube that is stuck up the rectum 
to reach the proximal part of the large intestine. Although this has been done, it is 
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very invasive and it is diffi cult to get ethical approval for testing functionality of 
numerous food components. Nevertheless, it is our belief that the results that were 
found in TIM-2 predict what happens in vivo, even though this could not be con-
fi rmed because the analytes in fecal matter in this case were not representative for 
those produced in the proximal colon, as they had all been absorbed by the colonic 
tissue during transit from proximal to distal colon, which may take anything from 
24 to 72 h. 
 One of the reasons the system can predict what happens in real life so well is the 
presence of the dialysis system. As discussed above, this system prevents the accu-
mulation of microbial metabolites, which normally are also taken up by the gut 
epithelium. In other systems metabolites tend to accumulate. Apart from slowing 
down or stopping further microbial breakdown of the substrates under study 
(Ramasamy et al.  2014 ), both the kinetics and true production of e.g., SCFA are 
inaccurate in these incubations. Since the metabolites are not removed, this allows 
for them to be converted into one another. For example, two molecules of acetate 
can be coupled to form butyrate, while lactate can be converted to propionate or 
butyrate. While this normally occurs to a certain extent in the gut microbiota, and is 
called cross-feeding (Kovatcheva-Datchary et al.  2009 ), in batch incubations this 
happens to a degree that is no longer physiological. 
 Also, the accumulation of the SCFA (in particular) leads to the inhibition of cer-
tain members of the microbiota, certainly if this is accompanied by a drop in 
pH. Because of this, the composition of the microbiota may change and no longer 
refl ect that of the normal gut. It should be said that even in TIM-2 the microbiota 
will change after introduction of the inocula (Rajilic-Stojanovic et al.  2010 ). 
 Due to the fact that the system closely mimics physiological parameters, the 
experiments in TIM-2 usually take 1 week (see Sect.  26.2 ). In contrast, other models 
that mimic the large intestine usually take several weeks due to the need to reach 
steady state. Since multiple units of TIM-2 can be run at the same time (maximally 10), 
comparisons with a control can be made and steady state in TIM-2 is not strictly 
required. For a more extensive review of TIM-2 in comparison to other in vitro mod-
els mimicking the colon, please refer to Venema and van den Abbeele ( 2013 ). 
26.2  General Protocol 
 After introduction of the microbiota into TIM-2 (at ~11 % w/w; 120 mL), the 
microbiota is allowed to adapt to the new situation over a period of 16 h and is fed 
with the standard SIEM medium, composed of complex carbohydrates, protein, 
some ox-bile, Tween 80 and vitamins and minerals (Maathuis et al.  2012 ). A total 
of 60 mL/day of this medium is fed to the microbiota. The medium is provided at a 
speed of 2.5 mL/h, refl ecting the occasional opening and closing of the ileal-cecal 
valve in vivo. 
 After the 16 h adaptation period, there usually is a 2–4 h starvation period to 
allow the microbiota to ferment all the available carbohydrates in the system. 
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After this, the standard medium is replaced by the test carbohydrate. This test 
medium is fed for another 72 h. Just prior to the start of feeding the test medium, 
samples are taken from the lumen and dialysate at t = 0. Subsequently, every 24 h 
samples are taken from both the lumen and dialysate, and after analysis the cumulative 
production of microbial metabolites is calculated. Similarly, samples are taken 
every 24 h from the lumen to study changes in microbiota composition using micro-
array or, nowadays, next generation sequencing technology. 
 Although the above is considered to be a general protocol, every project may 
require the tailor-made adjustment of this protocol. Some experiments may not use 
a carbohydrate test substrate, but e.g. polyphenols (Gao et al.  2006 ; Bordonaro et al. 
 2014 ) or saponins (Kong et al.  2009 ), which requires addition of these compounds 
to the standard medium. 
 Over the past 5 years or so, we have also ran experiments in which we gave a 
single shot of 1 g of uniformly stable-isotope ( 13 C) labeled carbohydrates at t = 0 and 
then followed degradation of these substrates over time. Incorporation of label into 
microbial biomass using Stable Isotope Probing (SIP) (Maathuis et al.  2012 ) and 
into microbial metabolites using NMR and LC-MS (Binsl et al.  2010 ) were used to 
trace the fate of these labeled carbohydrates. 
 By choice no mucin is added to the system. The only commercial source of mucin 
is pig gastric mucin, which has a completely different composition than human colonic 
mucin, and therefore is not a good mimic for human colonic mucin. Therefore, the 
choice was made not to standardly add mucin to TIM-2 fermentations. In cases where 
addition of mucin would be essential, it could be added, although the above should be 
taken into consideration. Similarly, we do not add the insoluble and unfermentable 
cellulose. It is hardly fermentable to the human gut microbiota (Slavin et al.  1981 ), 
and microorganisms capable of using this substrate appear to only be present in fecal 
samples from methane-excretors while this community remained undetectable in 
non-methane-excretors (Robert and Bernalier- Donadille  2003 ). Sometimes however, 
it is used as a negative (non-fermentable) control. 
 Most of the times, the model simulates the proximal colon with a pH of 5.8, 
although sometimes the systems mimics the entire colon and the pH is programmed 
as a gradient over time from 5.8 in the proximal colon, to 6.4 in the transverse colon, 
to 7.0 in the distal colon. The lumen is then considered a plug which transits through 
the different parts of the large intestine. 
26.3  Controls to Test Stability and Performance of the Model 
 TIM-2 is completely computer-controlled. All data with respect to the secretion of 
fl uids (feed, NaOH, dialysate) as well as temperature and pH are monitored and 
stored. Moreover, these values are plotted on a computer-screen, such that the person 
operating the model is immediately aware of how the system is performing. 
Furthermore, the stability and performance of the system is monitored by studying 
these values after the experiment, in addition to monitoring the production of SCFA 
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under standardized conditions. The production of SCFA should essentially be equal 
under identical conditions even if the experiments are performed over a stretch of 
several months. Unfortunately, SCFA cannot be measured online (yet), but the secre-
tion of NaOH (to neutralize the drop in pH caused by the acids) is used as a proxy for 
SCFA production and this has worked very well to monitor the performance of the 
model. When a parameter is out of range, the run is terminated. Usually this happens 
because of a mechanical error in a pump or due to a leak in the system allowing 
 oxygen to diffuse in, which would preclude a complete anaerobic environment. 
 The pH may not drop below 5.8 (the set-point value), but is allowed to rise above 
this value if for instance protein fermentation is expected or occurs. Protein fermen-
tation leads to the production of putrefactive metabolites, amongst others ammonia, 
which raises the pH in the system. Under circumstances of excess protein it may in 
fact raise to a pH near neutrality. 
 The speed of dialysis is important to maintain physiological levels of microbial 
metabolites in the system. If dialysis does not occur (e.g., a pump broke down, or a 
tube got disconnected) this is immediately refl ected in the production of acids 
(with NaOH as the proxy for that) and eventually in the microbiota composition, 
although the latter is only established days to weeks after the experiments, when the 
molecular analyses have been done. 
 Usually the experiments are very reproducible. The standard deviation (or range) 
normally falls within 10 %. This is why it was decided in the early 2000s to only 
perform duplicate experiments, and only repeat an experiment if the duplicates were 
way off. 
26.4  Read-Out of the System and How This Information 
Can Be Used 
 Because of the health benefi t of SCFA (den Besten et al.  2013 ), in particular butyrate 
(Havenaar  2011 ), most of the experiments carried out in the past 15 years focused 
on carbohydrate fermentation and the consequent production of the individual 
SCFA and their ratio. Experiments could screen numerous substrates for optimal 
SCFA production or would advance pre-established hypotheses that certain com-
pounds would lead to the production of increased levels of certain SCFA, such as 
the case for butyrate when starch is fermented. 
 This requires the analysis and calculation for the cumulative production of these 
SCFA over time. Since all metabolites that are produced by the microbiota are 
 collected in the system (from dialysate and lumen) this assessment of total SCFA 
production can be made. 
 Coupled to analyses for SCFA the (change in) composition of the microbiota is 
usually measured, to establish the link between SCFA produced and the micro- 
organisms responsible for this. With the advent of the stable-isotope technology in 
gut microbiology this has become even easier, as there is a direct link between label 
incorporation into metabolites and into microbial biomass (Venema  2011 ). 
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 However, the system has been used for numerous other applications as well. 
For instance, the effect of probiotics upon antibiotic treatment to quickly re-establish 
the microbial balance (Rehman et al.  2012 ), fermentation of polyphenols from tea, 
citrus or chocolate into more simple phenolic compounds, each with their own func-
tionality (Bordonaro et al.  2014 ; Gao et al.  2006 ), or the metabolism of saponins 
from traditional Chinese medicines (Kong et al.  2009 ). No matter what the example, 
the aim has always been to increase the health of the host through the microbiota. 
Recently, the microbiota has also been shown to be involved in obesity (Venema 
 2010 ). This has led to the investigation in TIM-2 of the metabolism of microbiotas 
originating from lean and obese individuals (as yet unpublished). Numerous 
attempts are made to mine the microbiota for functional (healthy) activities 
(Roeselers et al.  2012 ). It is expected that TIM-2 may play a role in deciphering the 
benefi cial microbes and metabolites that play a role in health and disease. 
 Sometimes samples from TIM-2 are incubated with other in vitro models described 
in this book, such as Caco-2 cell cultures (Lamers et al.  2003 ), immune cells 
(van Nuenen et al.  2005 ), or ex vivo pig intestinal tissue. In these cases, the effects of 
the microbial metabolites on parameters studied in these cells are of importance, such 
as barrier function, DNA damage, or induction of satiety hormones (such as GLP-1 or 
PYY). We have recently shown that samples from TIM-2 induce PYY, which is 
involved in appetite regulation, in pig intestinal tissue (Bussolo et al.  2014 ). 
26.5  Advantages, Disadvantages and Limitations 
of the System 
 TNO has 10 units of TIM-2 available, allowing multiple parameters to be tested in 
parallel. In contrast to other multi-compartmental in vitro models, experiments 
are quick (usually three test days or less), yet still physiological and predictive. 
The advantages over other models are the presence of peristaltics and a dialysis 
system, the latter of which allows production of physiological concentrations of 
metabolites, and a highly active microbiota of normal density to be used. Another 
advantage is that a single parameter in the system can be changed, and the effect of 
that single parameter on microbiota activity can be studied. This has been done 
e.g., when studying the effect of different pH’s on fermentation of carbohydrates 
(unpublished). Naturally, in vitro models have their limitations. As with every other 
in vitro model that mimics the colon, TIM-2 does not have epithelial or immune 
cells. However, as discussed in Sect.  26.4 , samples can be incubated with these cells 
for even better predictability. Another limitation is that the model has been developed 
on the basis of literature data of mostly health individuals. Due to this, it is unclear 
exactly which parameters to simulate when simulating patient populations as dis-
cussed in van Nuenen et al. ( 2004 ). Another limitation is that (apart from volume 
and pH) there are no feed-back mechanisms in the system. Therefore, the experi-
ments in such in vitro models will always be at most an indication of what may occur 
in real life, and the results need to be interpreted with care. 
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 Chapter 27 
 The Simulator of the Human Intestinal 
Microbial Ecosystem (SHIME ® ) 
 Tom  Van de Wiele ,  Pieter  Van den  Abbeele ,  Wendy  Ossieur ,  Sam  Possemiers , 
and  Massimo  Marzorati 
 Abstract  This chapter provides a general explanation of the Simulator of the Human 
Intestinal Microbial Ecosystem (SHIME ® ). The SHIME is one of the few gut models 
that mimics the entire gastrointestinal tract incorporating stomach, small intestine 
and different colon regions. After a general description of the model’s development 
history and an overview of the specifi c features that distinguish SHIME from other 
gut models, we will give some insight in the general protocol of running SHIME 
experiments. However, with the SHIME being a highly fl exible experimental setup, 
we also dedicate some part of this chapter discussing the modifi cations that can be 
performed, especially with respect to simulation of the mucosal (micro-)environment 
and interaction with host cells. 
 Keywords  Multi-stage gut model •  Colon microbiome •  Mechanistic •  Microbial 
adaptation 
27.1  Description of SHIME ® 
 ‘SHIME’ is an acronym for the Simulator of the Human Intestinal Microbial 
Ecosystem and since 2010, the name has been jointly registered by ProDigest and 
Ghent University. This paragraph primarily describes the conventional experimental 
setup of the SHIME ® system. Yet, because of its modular setup, the SHIME is 
highly fl exible and it can be technically modifi ed to target digestive conditions of 
interest: this will be briefl y discussed further down this chapter. 
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27.1.1  History of the Model 
 The Simulator of the Human Intestinal Microbial Ecosystem (SHIME) is a multi- 
compartment dynamic simulator of the human gut developed in 1993 (Molly et al. 
 1993 ). The development of multi-compartment simulators of (parts of) the human gut 
originated from the awareness that fecal microbiota signifi cantly differ from the 
in vivo colon microbiota in terms of community composition and metabolic activity. 
While inoculation of fecal microbiota into single-stage chemostats was a fi rst attempt 
to mimic colon conditions, it was only useful for limited periods of time since envi-
ronmental parameters such as pH, redox potential, available nutrients and microbial 
population dynamics constantly change. In order to maintain the inoculated intestinal 
microbiota over a longer timeframe, semi-continuous fermenters were developed 
where the intermittent supplementation of nutritional medium and the removal of 
microbial suspension could be simulated (Miller and Wolin  1981 ). While the latter 
systems typically make use of one single fermenter, the colon is a very heterogeneous 
region with clear differences in substrate availability, fermentation activity, microbial 
composition and several environmental conditions. This makes it impossible to 
simulate a representative culture of colon microbiota in one compartment. Several 
multi-compartment reactors were therefore developed to simulate the different condi-
tions of the colon lumen (Macfarlane et al.  1989 ; Miller and Wolin  1981 ), from which 
the SHIME was one of the last in this generation of gut simulators. 
 Technically, the SHIME is an evolution of the simulator of the University of 
Reading introduced by Macfarlane et al. ( 1989 ) and mimics the conditions in the 
ascending, transverse and descending colon regions. The SHIME differentiates from 
the Reading model by incorporation of upper digestive tract conditions, leading to a 
succession of fi ve compartments simulating the upper (stomach, small intestine) and 
the lower (ascending, transverse and descending colon) digestive tract. 
 The entire SHIME reactor operates at 37 °C. It contains double-jacketed glass 
vessels that are connected through peristaltic pumps (Fig.  27.1 ). The fi rst two reactors 
 Fig. 27.1  Schematic representation of the SHIME ® 
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follow a fi ll-and-draw principle adding three times a day a defi ned nutritional medium 
to a gastric compartment, and pancreatic and bile liquid to a small intestine compart-
ment. The medium is composed of complex carbohydrate and protein sources with 
addition of mucins and a mineral and vitamin mix (Molly et al.  1993 ). Upon digestion 
in the gastric and intestine compartments, the slurry is pumped in the ascending colon 
vessel where colon digestion is initiated. The three colon compartments are continu-
ously stirred with constant volume and pH control. Retention times in the upper diges-
tive tract can be modulated by changing the fl ow rates from the gastric and intestine 
compartments, while retention times from the colon compartments are primarily 
modulated through a change in compartment volume. Depending on the human target 
group of interest the retention time may vary from 24 h to 72 h. 
 The pH of the gastric compartment used to work at a fi xed pH of 2.0, yet with the 
advent of a completely computer-controlled SHIME system, specifi c pH profi les 
during gastric and intestine digestion can be established as well. While the small 
intestine compartment typically operates at slightly acidic to neutral conditions, the 
pH of the colon compartments is controlled between 5.6 and 5.9 in the ascending, 
6.1–6.4 in the transverse and 6.6–6.9 in the descending colon. Mixing of the diges-
tive slurry in the respective compartments is obtained with magnetic stir bars. 
The entire SHIME system is kept anaerobic by daily fl ushing the headspace of the 
respective compartments with N 2 gas or a 90/10 % N 2 /CO 2 gas mixture. 
27.1.2  Special Features of the Model 
 The emphasis of the SHIME ® system is primarily put on the simulation of the colon 
microbial community. Because of the inaccessibility of the human colon region to 
take a representative microbial inoculum, the fecal microbiota is chosen as inoculum 
to the colon compartments of the SHIME reactor. The fecal microbiome is signifi -
cantly different from the in vivo colon microbiome, both in terms of composition as 
metabolic activity. Yet, the colon being considered as a plug-fl ow system, the fecal 
microbiome is nothing else than a colon microbiome that has undergone community 
and metabolic shifts during transit from the proximal colon to the rectum. The idea 
of the SHIME system—and other multi-stage colon compartment reactors such as 
the Reading model—is to allow a suitable adaptation period for the fecal microbi-
ome to adapt to the conditions that prevail in the respective colon compartments. 
From an engineering perspective a suitable adaptation time for starting up a reactor 
is around 5–10 times its residence time. Taking the example of a male individual 
with a gut residence time of 48 h and imposing that in the SHIME system, this 
would entail an adaptation time of 10–20 days upon inoculation with the fecal 
microbiota in the colon compartments. We will come back to this stabilization 
aspect in the next paragraph. 
 A second aspect is the choice of inoculum. The SHIME is typically inoculated 
with the fecal microbiome, derived from one individual. There has been or there still 
is a lot of debate on what is the most suitable inoculum for mimicking the human 
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gut microbiome in the most representative way. Some research groups specifi cally 
opt for pooling fecal microbiota from for example ten different individuals (Minekus 
et al.  1999 ), thereby (partly) accounting for the huge interindividual variability that 
exists in microbiome composition and to incorporate properties from different 
microbiomes in order to create an ‘average’ 11th microbiome. Given the enormous 
functional redundancy of the gut microbiome such pooled microbiome will indeed 
take on a normal fermentation profi le which generally not that different from the 
microbial fermentation profi le of a single individual. While such approach may work 
when investigating hydrolysis and fermentation of carbohydrates, it fails to accu-
rately mimic microbial processes that lack this functional redundancy. To exemplify, 
it has become clear that the microbial metabolic potency towards polyphenols such 
as daidzein, isoxanthohumol, catechins and others is highly dependent on an indi-
vidual’s microbiome (van Duynhoven et al.  2011 ). The existence of different 
‘metabotypes’ has therefore even been proposed to distinguish a bioactive metabolite 
producing phenotype from a non-producing phenotype (Bolca et al.  2013 ). The above 
element is the primary reason why a SHIME reactor is inoculated with the fecal 
microbiome from one individual and succeeds in maintaining the microbial meta-
bolic phenotype towards specifi c polyphenols during the in vivo/in vitro transition 
and several weeks after (Decroos et al.  2006 ; Possemiers et al.  2006 ). 
 The choice for individual inocula also appears to be a crucial aspect in recent 
studies where the SHIME was fundamentally optimized to enable colonization of 
the mucosal microbiome (Van den Abbeele et al.  2013 ). This concerns a third spe-
cial feature of the SHIME model. The mucosal microbiome is this part of the gut 
microbial ecosystem that is able to colonize the mucus overlying the gut epithelium. 
Due to its close proximity to host epithelial cells, the mucosal microbiome is thought 
to have an intrinsically higher potency to modulate gut health, and by extension, 
human health (Van den Abbeele et al.  2011 ). The mucosal microbiome was already 
known to fundamentally differ from the luminal microbiome in composition and 
interestingly, presence of important mucosal colonizers such as  Faecalibacterium 
prausnitzii seems to negatively correlate with occurrence (Willing et al.  2009 ) and 
postoperative recurrence of ileal Crohn’s disease (Sokol et al.  2008 ). Given the 
 diffi cult access to the mucosal environment, the development of gut simulators that 
accurately mimic mucosal microbial colonization is considered a strong asset to 
obtain a better understanding of the host-microbe interactome. It is in this philoso-
phy that Van den Abbeele et al. ( 2013 ) decided to optimize the SHIME for mimick-
ing mucosal microbial colonization by incorporation of mucin-covered microcosms. 
The major fi nding of this so-called M-SHIME, or mucosal SHIME, was that colo-
nization of the mucosal environment was characterized by a higher abundance of 
butyrate producing Clostridium clusters IV and XIVa. This phylogenetic group is 
considered crucial for delivering butyrate as primary energy source to colonocytes 
and improves gut barrier function by strengthening the tight junctions. Coming back 
to the importance of individual inocula and avoiding pooled samples, it was also 
demonstrated that the M-SHIME was able to maintain the unique features of an 
individual’s microbiome in terms of its mucosal composition (Van den Abbeele 
et al.  2013 ). 
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 The fourth feature is the fl exibility of the SHIME model and the ease with which 
reactor compartments can be added or left away. This modular setup is useful when 
a placebo-controlled study needs to be conducted, when different prebiotics need to 
be compared (Grootaert et al.  2009 ) or when a microbiome phenotype producing a 
bioactive metabolite is compared with a non-producing phenotype (Possemiers 
et al.  2006 ). Moreover, it is even possible to explore the interindividual variability 
in microbiome behavior upon specifi c treatments by having a common upper diges-
tive tract simulation in the gastric and intestine compartments and subsequently 
split up the system in several parallel colon compartments, each of which are inocu-
lated with the fecal microbiota from separate individuals. 
 A fi fth feature of the SHIME model refers to the possibility of simulating the 
microbiome from different human target groups such as adult vs. infant, healthy vs. 
diseased (e.g. ulcerative colitis patients: Vermeiren et al.  2012 ) as well as the simu-
lation of animal (pig, dog) microbiomes. In each of these specifi c cases, the micro-
bial inocula, residence times of the different gastric compartments, composition of 
the gastric juices, region specifi c pH’s, feed, feeding regimes and body temperatures 
are adapted in the SHIME set-up leading to an accurate and relevant simulation of 
the targeted human or animal host. Finally, other features of the SHIME include the 
gradual emptying of the gastric digest into the intestine compartment, the option of 
running a dynamic pH profi les in the gastric compartment and the possibility of put-
ting a dialysis unit behind the intestine compartment to enable running experiments 
with real food matrices or food constituents that need to undergo predigestion and 
removal of sugar monomers or amino acids and peptides before the digest is trans-
ferred to the colon compartment. 
27.1.3  Stability and Reproducibility of the System 
 As the SHIME ® reactor is inoculated with a fecal microbiome, the latter needs an 
appropriate amount of time to adapt to the prevailing environmental conditions in the 
respective colon compartments. This adaptation process was studied more in detail 
by Possemiers et al. ( 2004 ) who monitored the increasing colonization of microbial 
groups of interest upon inoculation, as well as their metabolic activity. Highly-
abundant groups such as  Bacteroides obtained stable concentrations more easily, at 
10 days, compared to less-abundant groups such as lactobacilli which needed 15 days 
of stabilization. To obtain a stable functionality in terms of short chain fatty acid 
production, an adaptation period of at least 15 days, even approaching 20 days, was 
needed. The length of stabilization obviously relates to the residence time that 
is imposed in the SHIME, but may also depend on the microbiome composition 
as such. 
 As the SHIME is a highly standardized system, and many digestive parameters 
are under control of the operator, it also leads to highly reproducible results. This 
is especially required when different products such as novel prebiotics, candidate 
drug components or new plant extracts, need to be compared with one another. 
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When it is not always possible to run different SHIMEs in parallel, for example 
because of the multitude of test compounds, SHIME experiments may need to be 
repeated. The scientist in charge needs to be cautious to conduct this experiment in 
exactly the same way and with the same inoculum to enable an adequate comparison 
between different compounds. Such reproducibility was previously tested for the 
conventional SHIME (without mucin-coated microcosms) and proven very effective 
in obtaining a reproducible microbial colonization process and accompanied meta-
bolic activity (Van den Abbeele et al.  2010 ). Noteworthy, the authors found a small 
preferential colonization of  Bacteroidetes and  Clostridium cluster IX in the colon 
compartments in comparison with the stool sample. While the overall colonization 
profi le was still representative of the in vivo colonization process, this slight bias has 
been a common observation for several dynamic models that work with luminal 
content only. Van den Abbeele et al. ( 2013 ) succeeded in removing this colonization 
selectivity by incorporating mucin-covered microcosms in the SHIME, thereby 
 creating the M-SHIME or mucosal SHIME. Butyrate producing  Clostridium clusters 
IV and XIVa were found to specifi cally colonize the mucosal environment thereby 
compensating for their lower abundance in the lumen. 
27.1.4  Relevance to Human In Vivo Situation 
 The fi rst validation paper of the conventional SHIME ® setup concerned a study 
from Molly et al. ( 1994 ) where several microbe-associated characteristics were 
defi ned. The authors focused on fermentation profi les of pectin, xylan, arabinoga-
lactan and starch and found these to be consistent with the results from incubations 
of the same products with fecal microbiota from human volunteers (Englyst et al. 
 1987 ). Similarly, an enzymatic profi le focusing on glycosyl hydrolases (galactosi-
dase, glucosidase, xylosidase) was recorded and no differences with the fecal incu-
bations were found. Apart from the comparison with fermentation activity the 
metabolic potency towards sulphasalazin, a prodrug for ulcerative colitis treatment, 
and its conversion to the active compound 5-aminosalicylic acid (5-ASA) was also 
evaluated. Consistent with in vivo literature, no 5-ASA was detected in the gastric 
compartment, while small amounts of 5-ASA were detected in the intestine com-
partment and full sulphasalazin conversion was observed in the colon compartments 
(Peppercorn and Goldman  1972 ). 
 A second validation study discusses the preservation of metabolic phenotypes 
when transferring fecal microbiota from an individual to the in vitro SHIME sys-
tem. Focusing on the microbial conversion of isoxanthohumol to 8- prenylnaringenin 
(8-PN), a metabolite with strong pseudo-estrogenic activity, Possemiers et al. ( 2006 ) 
demonstrated a one-on-one correlation between urinary 8-PN excretion by human 
individuals and their microbiome. Secondly, the microbiome from a 8-PN produc-
ing and non-producing individual could be stably transferred to the SHIME system 
and the metabolic phenotype was adequately preserved. 
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 A third validation study concerns the application of the M-SHIME where both the 
luminal as mucosal microbiome from an individual were simulated in the SHIME 
colon compartment (Van den Abbeele et al.  2013 ). Analyzing the microbiome from 
the luminal and mucosal regions with the HIT-Chip micro-array revealed the largest 
variability in the microbial dataset to originate from the in vivo/in vitro transition 
and difference between the luminal and mucosal environment. Yet, those species 
that account for the unique profi le of an individual’s microbiome were preserved in 
the M-SHIME as well and accounted for 25 % of the variability in the microbial 
dataset. 
27.1.5  Quality in Relation to Other Models 
with the Same Applicability 
 The SHIME ® model is the sole in vitro model that integrates the entire gastrointestinal 
transit into one system. This is interesting to study for example digestibility of 
prebiotic substrates and its subsequent fermentability in the colon or the survival of 
pathogens or probiotics in the upper digestive tract before they reach the colon envi-
ronment. Yet, one must consider that the conventional SHIME system operates 
without an absorption unit: this means that the nutritional medium for the SHIME 
must already be deprived of easily digestible carbohydrates or proteins that would 
normally be absorbed in the intestine. 
 The SHIME is the last of a generation of multi-compartment models that operate 
according to a semi-continuous stirred tank reactors setup. In comparison with the 
Reading model (Macfarlane et al.  1989 ) the SHIME connects the different 
 compartments through peristaltic pumps. In terms of studying the gut microbiome 
over a long timeframe, both models would however be applicable. 
 In general, it must be stressed that the SHIME model has a strong emphasis on 
the ecological aspects of the colon microbiome. This entails that incubation experi-
ments with the SHIME reactor are seldomly short and commonly take several 
weeks. This is put in place to look at the gradual adaptation of the microbiome to 
incoming substrates of interest (e.g. prebiotics or pharmaceuticals) or to evaluate 
the resilience of the microbial community against colonization by a (opportunistic) 
pathogen. Such research, which often necessitates an experimental period of more 
than a week to several weeks, strongly differs from the TIM-2 model, which moni-
tors the microbiome on a shorter timeframe. One could conclude that short term 
experiments are highly suitable for evaluating the immediate metabolic potency of 
a carbohydrate or colonization ability of a microorganism of interest, while long- 
term experiments are primarily suitable to look at the adaptation of the microbial 
ecosystem to changing environmental conditions or inputs. 
 A last strong asset of the SHIME is its extension to M-SHIME—incorporating the 
mucosal microbiota (Van den Abbeele et al.  2013 ). While previous attempts primarily 
focused on the immediate and aspecifi c adhesion potency of gut microorganisms to 
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mucin-covered glass slides, the integration of mucin-covered microcosms that can 
be replaced, to mimic desquamation, has been a breakthrough in the simulation of 
the mucosal microbiome and in the understanding of its dynamics. 
27.2  General Protocol 
 Inoculation of the SHIME ® colon compartments occurs with microbiota that has 
been isolated from fecal material of one individual. In contrast with other gut models, 
we deliberately choose not to work with the microbiome from pooled fecal samples 
from different human volunteers. The artifi cially high microbial diversity in pooled 
inocula creates disturbances in the cross-feeding processes between microorganisms 
that are adapted to one another in each of the separate microbiomes. We therefore 
advise to study interindividual variability through separate experiments. Upon inocu-
lation of the colon compartments with fecal microbiota, the microbiome is given 
time to adapt itself to the prevailing conditions in the ascending, transverse and 
descending colon compartments. 
 A typical SHIME experiment consists of four stages: a stabilization period 
(2 weeks) to allow adaptation of the microbial community to the environmental 
conditions in the respective colon regions; a basal period (2 weeks) in which the 
reactor is operated under nominal conditions and baseline parameters are measured; 
a treatment period (2–4 weeks) where the effect of a specifi c treatment on the gas-
trointestinal microbial community is tested; and a washout period (2 weeks) to 
determine how long the changes induced by the tested substance can still be mea-
sured in the absence of the substance itself. This approach has mainly been used to 
investigate the activity and stability of probiotics and prebiotics during 
 gastrointestinal transfer, the microbial conversion of bioactive food components 
(e.g. phytoestrogens), the metabolism of pharmaceutical components, the effi cacy 
of colonic targeted delivery systems and the conversion and biological (in)activation 
of food and/or ingested environmental contaminants. 
 Shorter-term SHIME experiments are also a possibility. Specifi cally in the 
context of monitoring the initial stages of microbial colonization on the mucosal 
surface, 1-week experiments can be conducted. Distinguishing the mucosal from 
the luminal microbiome, Van den Abbeele et al. ( 2013 ) evaluated the colonization 
process of the microbiome derived from fi ve human volunteers in M-SHIME sys-
tems over a timeframe of 5 days. The presence of mucins seems to play a specifi c 
role in the colonization process. In contrast with mucin surfaces, other contact 
surfaces, such as agar or plastic surfaces, did not result in a distinct colonization 
profi le. Despite the fact that the applied mucins are derived from the porcine 
gut—and hence do not have the exact same composition as human mucins—the 
presence of this fairly similar glycoprotein surface already is an important driver 
in the colonization process. 
 Finally, by choosing the inoculum, tweaking digestive parameters, incorporating 
surface carriers or working with parallel reactor compartments, a SHIME operator 
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is able to mimic the gastrointestinal conditions of a host target group or phenotype 
of interest, to incorporate internal control experiments or experimental replicates 
and to take into account the gastrointestinal colonization by mucosal microbiota. 
27.3  Controls to Test Stability and Performance of the Model 
 As the SHIME ® system can be operated over a longer timeframe, stability of the 
 system is a crucial aspect. Investigating the modulation of the intestinal microbiome 
through certain treatments, also requires proper knowledge of a baseline situation and 
assumption of a stable microbiome. The microbial community composition and 
fermentation activity in the respective colon compartments is therefore closely moni-
tored, especially during reactor startup, to evaluate the reactor’s capacity to create a 
stable microbiome that is still representative for the human in vivo situation. Using 
moving window correlation, Possemiers et al. ( 2004 ) previously introduced a stability 
criterion based on measurements with PCR-DGGE for different microbial groups, 
short chain fatty acids and ammonium. Calculating the correlation between two con-
secutive days along reactor startup, the authors considered a community to be stable 
once 80 % correlation was measured. The remaining 15–20 % variability typically 
originates from normal biological fl uctuations. Overall, community stability is 
reached after about 2 weeks, while functional stability is obtained after 3 weeks. 
This startup phase seems quite long for a conventional SHIME experiment, but it is 
desired when the microbiome from different colon regions is under study and when 
the research question concerns microbial adaptations to applied treatments. Yet, short-
term SHIME experiments can be conducted as well. The mucosal colonization pro-
cess in the M-SHIME occurs quite rapidly—within 5 days—when a clear distinction 
between luminal and mucosal microbiome composition is noted. The preferential 
colonization of butyrate producing clostridia in the mucosal environment is one of the 
characteristic features (Van den Abbeele et al.  2013 ). 
27.4  Read-Out of the System and How This Information 
Can Be Used 
 Assessing fermentation activity is one of the most important SHIME ® read-outs. 
During operation of the SHIME system, short chain fatty acid or ammonia production 
can be preliminary assessed by the amount of NaOH or HCl that is supplemented by 
the pH controllers to maintain proper pH values in the respective colon vessels. 
As the conventional setup of the SHIME system does not have an absorption unit, 
short chain fatty acids (SCFA) do accumulate throughout the distal colon compart-
ments. However, the SCFA concentrations in the SHIME do not lead to values above 
100 mM, which would eventually result in product inhibition of the fermentation 
process. As saccharolytic conditions are more abundant than proteolytic conditions 
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in the proximal colon and vice versa, the operator can still deduce the drop in 
 saccharolytic activity by subtracting the SCFA concentration in the proximal colon 
from the SCFA concentration in the distal colon and thereby obtain the net amount 
of SCFA that are produced in the distal colon. Such strategy has been used before to 
discern the colon regions where specifi c fi bers or oligosaccharides are broken down 
(Grootaert et al.  2009 ). 
 While adaptation of microbiome fermentation profi les to changing nutritional 
conditions is often monitored over several weeks (Grootaert et al.  2009 ), the 
immediate metabolic potency of the colon microbiome towards specifi c com-
pounds of interest can be evaluated within days, e.g. with the onset of isoxantho-
humol conversion into 8-prenylnaringenin (Possemiers et al.  2006 ), or even hours, 
e.g. with the microbial conversion of tea catechins and wine polyphenols (Gross 
et al.  2010 ). 
 Apart from the general fermentation activity and metabolic potency, the SHIME 
is evaluated for the microbiome composition in the respective colon vessels. 
The common approach typically includes establishment of DGGE profi les, either at 
Eubacteria or at group-specifi c level, as a quick screening for evaluating what treat-
ments or what sample times are interesting to study in more detail. This can then be 
complemented by a quantitative analysis with q-PCR or a high-throughput analysis 
at the phylogenetic level with next generation sequencing. One of the important 
read-outs with microbiome fi ngerprints and profi les is the determination of the 
 so- called ‘MRM-parameters’ (microbial resource management) (Marzorati et al. 
 2009 ). These typically contain calculation of richness, evenness and diversity indi-
ces and of microbiome dynamics throughout the study period. Especially evenness 
seems to be a strong indicator of microbiome resilience against invasion by exoge-
nous species (Wittebolle et al.  2009 ). 
 A fi nal read-out consists of an evaluation of host-microbe interactions. Colon 
suspension or the derived intestinal water (supernatant after centrifugation) can be 
brought in indirect or direct contact with host epithelial cells. This allows assessing 
to what extent changes in microbiome composition, microbial metabolites, signal-
ing molecules or antigens have differential effects at the level of the host. This can 
be performed both with epithelial cells (Grootaert et al.  2011 ) as with a combina-
tion of epithelial and immune cells (Possemiers et al.  2013 ). Interestingly, the 
SHIME has recently been coupled to the Host-Microbe Interaction Module (HMI), 
which is a bi-compartmental system containing mucosal microbiota one the one 
side and host cells on the other side of a semi-permeable membrane (Marzorati 
et al.  2014 ). 
27.5  Advantages, Disadvantages and Limitations 
of the System 
 The advantages, disadvantages and limitations of the system are summarized in 
Table  27.1 . 
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 Chapter 28 
 The Computer-Controlled 
Multicompartmental Dynamic Model 
of the Gastrointestinal System SIMGI 
 Elvira  Barroso ,  Carolina  Cueva ,  Carmen  Peláez ,  M.  Carmen 
 Martínez- Cuesta , and  Teresa  Requena 
 Abstract  The SIMGI (SIMulator Gastro-Intestinal) is an automated gastrointestinal 
in vitro model designed to dynamically simulate the physiological processes taking 
place during digestion in the stomach and small intestine, as well as to reproduce the 
colonic microbiota responsible for metabolic bioconversions in the large intestine. 
This computer-controlled system is a fl exible modulating system that combines a 
gastric compartment that operates with peristaltic mixing movements, a reactor 
simulating the small intestine and three-stage continuous reactors that reproduce the 
colon region-specifi c microbiota. The compartments designed for digestion (stomach 
and small intestine) and fermentation (colon) can be connected to operate jointly. 
Alternatively, the digestion and fermentation processes can proceed independently. 
This section describes the conditions needed to inoculate, stabilize and differentiate 
the fecal microbiota in the SIMGI system, as well as the steps to follow in order 
to test the stabilized colonic microbiota with different food ingredients and/or by 
modifying the caloric intake in the nutrition media. 
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28.1  Description of the Model 
28.1.1  History and Special Features of the Model 
 The SIMGI model is a fully automated gastrointestinal multichamber simulator that 
has been recently developed at the Institute of Food Science Research CIAL (CSIC-
UAM, Madrid, Spain). The SIMGI comprises fi ve interconnected compartments 
(units) that simulate the stomach, small intestine and three stages of the large intes-
tine (Fig.  28.1 ). The process of digestion is simulated in units Stomach and Small 
Intestine. Unit Stomach is comprised of two cylindrical transparent and rigid meth-
acrylate plastic modules covering a reservoir of fl exible silicone walls where the 
gastric content is mixed by peristaltic movements. The simulation of gastric peri-
stalsis is achieved by changing the pressure of the water that fl ows in the jacket 
between the plastic modules and the reservoir. The pumped thermostated water 
keeps the temperature of the gastric content at 37 °C. The stomach compartment has 
different ports for input of experimental food components, gastric juice, and HCl. 
The pH decrease is computer-controlled to follow the curve resulting from a linear 
fi t of data representing experimental in vivo conditions. The small intestine consists 
in a double jacket glass reactor vessel continuously stirred that receives the gastric 
content which is mixed with pancreatic juice and bile. The intestinal content is 
digested during 2 h at 37 °C and kept at pH 6.8. The stages of the large intestine are 
simulated in three double jacket glass reactors and the colon content is kept at 37 °C 
by pumping thermostated water into the space between the glass jackets. The pH in 
the colonic units (named ascending AC, transverse TC and descending DC colon) is 
controlled by addition of 0.5 M NaOH and 0.5 M HCl to keep values of 5.6 ± 0.2 in 
the AC, 6.3 ± 0.2 in the TC and 6.8 ± 0.2 in the DC compartments. When the digested 
content of the small intestine is transferred to the proximal colon compartment 
(AC), the transit of colonic content between the AC, TC and DC compartments is 
simultaneously initiated at the same fl ow rate. The intestinal and colonic vessels 
contain ports for transit of intestinal content, sampling, continuous fl ushing of nitro-
gen and pH and temperature control. 
 Fig. 28.1  Schematic diagram of the SIMulator Gastro-Intestinal SIMGI 
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 The SIMGI design is aimed to dynamically operate with the fi ve units simulating 
the whole gastrointestinal process. In addition, the SIMGI software allows the work 
of the stomach and the small intestine in a continuous way to study food digestion 
and at the same time running in parallel, direct feeding of the small intestine and the 
transit to the colonic vessels to study microbial community development and 
metabolism. In this way, the system is fl exible and adaptable to each need of experi-
mental approach. 
28.1.2  Stability and Reproducibility of the System 
 The SIMGI model has been recently developed and, therefore, it has a short history 
in evaluating digestion of food components and/or the effects of diet on modulating 
the gut microbiota and its metabolic activity. The fermentative module of the sys-
tem (AC, TC and DC compartments) follows the concept of multiple connected, 
anaerobic, pH-controlled vessels. Multi-compartment fermentation models are usually 
represented by three-stage culture reactors as initially designed by Gibson et al. 
( 1988 ). This feature allows these models to reproduce differences from proximal 
(characterized by acidic pH and carbohydrate-excess conditions) to distal colonic 
regions (showing a carbohydrate-depleted and non-acidic environment). The vali-
dation of three-stage culture fermentation models to simulate the ascending, trans-
verse and descending colon conditions have been earlier described by Macfarlane 
et al. ( 1998 ) and Molly et al. ( 1994 ). 
 The biological functioning of these fermentation models requires the develop-
ment of a colon region-specifi c microbial community that needs to be stabilized 
before starting any experimental approach. This initial stage allows the microbial 
evolution in the three reactors from a fecal inoculum to a colon region-specifi c 
microbiota ( Possemiers et al.  2004 ; Macfarlane et al.  1998 ). In addition, the stabili-
zation period is required to provide a steady-state environment where the composi-
tion and metabolism of the microbial community can be evaluated during long-term 
experimental dietary interventions. 
 The evolution of the gut microbiota in the AC, TC and DC compartments of the 
SIMGI model was followed during a 2-week stabilization period (Barroso et al. 
 2015 ). Results indicated that from day 8 onwards the microbial DGGE fi ngerprints 
of samples from the same compartment clustered together and that at 14 days the 
microbial communities reached the steady state. The counts of some representative 
microbial groups analyzed by quantitative PCR (qPCR) in the AC, TC and DC 
compartments are shown in Fig.  28.2 . Differences observed between the compart-
ments indicated that  Bacteroides were more representative in the AC and TC com-
partments than in the DC reactor, whereas the butyrate-producing groups  C. leptum 
and  Ruminoccocus were less represented in the proximal colon compartment (AC) 
than in the distal vessels (TC and DC). This specifi c microbiota composition during 
the stabilization period has also been observed in the three-stage culture model 
SHIME (Barroso et al.  2014 ; Van den Abbeele et al.  2010 ). 
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28.1.3  Relevance to Human In Vivo Situation 
 The suitability of the SIMGI fermentation model to reproduce human conditions 
associated to changes in dietary lifestyles has been evaluated by the simulation of 
an obesity-associated microbiota in this in vitro system (unpublished results). For 
this purpose, the three colonic reactors were inoculated with fecal microbiota from 
an overweight individual after which the system was feeding daily with a high 
energy nutritive medium for 2 weeks (microbial stabilization period). Increase of 
energy in the nutritive medium was achieved by increasing the content of simple 
sugars (fructose), simulating high consumption of sugar-sweetened beverages, and 
of carbohydrates from simple starches (maize and potato). After the stabilization 
period a dietary intervention during 7 days was performed by lowering energy of 
the nutritive medium in order to observe possible changes in microbial composition 
and metabolism induced by a sharp shift in the diet. This low energy diet was 
obtained by suppression of simple carbohydrates and reduction of the content of 
readily fermentable starches. The selection of components of the nutritive media 
was based on the rational design of media with different energy content described 
by Payne et al. ( 2012 ) to compare the impact of dietary energy on gut microbiota 
in a three-stage in vitro continuous fermentation model that uses fecal microbiota 
immobilized within a porous, non-biodegradable polysaccharide matrix (Cinquin 
et al.  2006 ). 
 Fig. 28.2  Mean ± SD of qPCR counts (log copy number/mL) for the microbial groups analyzed in 
the ascending (AC), transverse (TC) and descending colon (DC) compartments of the SIMGI after 
2 weeks of stabilization 
 
E. Barroso et al.
323
 The comparison of short chain fatty acids (SCFA) and ammonium formation 
under high energy  (microbiota stabilization period) and low energy (dietary inter-
vention) diets is shown in Fig.  28.3 . Shift to a low energy diet resulted in a twofold 
decrease in the average content of total SCFA of the three colon compartments 
compared to the high energy intake period. Additionally, the shift from high to low 
energy medium caused a twofold increase in the ammonium content of the distal 
colon compartments (TC and DC) and a remarkable sixfold increase in the proximal 
colon compartment (AC). The SFCA and ammonium results could be compared 
with in vivo data from obese subjects, where a signifi cant decrease of SCFA and 
increase of proteolytic products were observed when the individuals consumed 
diets high in protein and reduced in total carbohydrates (Russell et al.  2011 ). 
28.1.4  Quality in Relation to Other Models 
with the Same Applicability 
 The SIMGI is designed to simulate not only the fermentation process as described 
above, but also the process of digestion. This is a competitive advantage compared 
to other systems that simulate digestion and fermentation operating in separate 
modules (TIM-1 and TIM-2). The whole system is computer controlled through an 
operator panel and programmable logic controller. It can be set up to sequentially 
proceed (continuously or feeding the system from 1 to 6 times daily) from the oper-
ation of food intake into the stomach throughout the delivery of distal colon content 
to waste. The system differs from the SHIME model in that the stomach uses peri-
staltic movements for mixing the ingested food with gastric fl uids. Additionally, the 
computer software allows the defi nition of pH acidifi cation curves that can be set up 
according to results obtained from in vivo studies (Marteau et al.  1990 ). The stom-
ach emptying is programmable to follow the equation described by Elashoff et al. 
( 1982 ) that allows the modifi cation of the shape of the emptying curve depending 
 Fig. 28.3  Changes in concentration (mM) of SCFAs ( a ) and ammonium ( b ) in the ascending (AC; 
 circles ), transverse (TC;  squares ) and descending colon (DC;  triangles ) compartments of the SIMGI 
at different times after inoculation and feeding with high energy (HE) and low energy (LE) diets 
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on liquid, semisolid or solid foods. This process implies that the gastric content will 
be delivered to the small intestine at different pH values (up to pH 2). This is an 
important feature to take into account when evaluating probiotic survival growth 
under gastric and duodenal conditions (Fernández de Palencia et al.  2008 ) that 
would enable their eventual functionality when reaching the large intestine. Another 
distinctive characteristic of the SIMGI is that the small intestine and the three colon 
reactors are continuously fl ushed with nitrogen inducing anaerobic conditions for 
the oxygen-sensitive intestinal microbial communities, thus allowing a permanent 
anaerobic atmosphere. 
28.2  General Protocol 
 The operation of the SIMGI as a fermentation model mainly follows the protocols 
established for multi-compartment culture reactors. For most of dietary interven-
tions, the choice of the nutritive medium can be based on the medium developed by 
Macfarlane et al. ( 1998 ). Therefore, the three colonic vessels which will be inocu-
lated with fecal samples are fi lled and pre-conditioned with the nutritive medium 
that will be fed to the system during the microbial stabilization period in a volume 
of 250, 400 and 300 mL for the AC, TC and DC compartments, respectively. The 
volumes of the colonic reactors and the transit of colonic content between compart-
ments, three times daily at a fl ow rate of 5 mL/min, are intended to give an overall 
residence time of 76 h, adapting the conditions already standardized in the SHIME 
model (De Boever et al.  2000 ; Molly et al.  1993 ; Van den Abbeele et al.  2010 ). 
Further on, the AC, TC and DC vessels are inoculated with 20 mL of a fresh 20 % 
(w/v) human fecal slurry prepared in anaerobic conditions with sodium phosphate 
buffer (0.1 M, pH 7.0), containing 1 g/L sodium thioglycolate as reducing agent, as 
described by De Boever et al. ( 2000 ). The inoculated AC, TC and DC vessels are 
allowed to equilibrate overnight in batch conditions at 37 °C. The pH in the colonic 
compartments is controlled by addition of 0.5 M NaOH and 0.5 M HCl to keep 
values of 5.6 ± 0.2 in the AC, 6.3 ± 0.2 in the TC and 6.8 ± 0.2 in the DC. The tem-
perature is kept at 37 °C by pumping water into the space between the double glass 
jackets of the reactor vessels. The development and stabilization of the microbial 
community until steady-state conditions in the three colon vessels is approached by 
feeding the small intestine compartment with nutritive medium (75 mL, pH 2) 
mixed with pancreatic juice (40 mL of a solution of 12 g/L NaHCO 3 , 6 g/L oxgall 
dehydrate fresh bile and 0.9 g/L porcine pancreatine) three times a day during 
14 days (Van den Abbeele et al.  2010 ). The small intestine digestion is performed 
during 2 h at 37 °C and the whole content of the vessel is automatically transferred 
at a fl ow rate of 5 mL/min to the proximal colon compartment (AC). The transfer of 
intestinal content between the reactors is initiated to operate simultaneously in order 
to keep constant the AC, TC and DC reactor volumes. The process of stabilization 
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of the colon microbiota in the three-stage reactors of the SIMGI model is usually 
reached after 14 days of running the system under the described conditions. 
This 2-week stabilization period allows the development of the fecal microbiota to 
colon region-specifi c microbial communities. After this period, the system provides 
a steady-state microbial environment ready to be evaluated under different experi-
mental dietary interventions. 
28.3  Controls to Test Stability and Performance of the Model 
 The SIMGI model is entirely under computer control that is conducted through 
an operator panel and a programmable logic controller Unitronics’ Vision120™. 
The software offers several operating modes: (1) the whole gastrointestinal tract; 
(2) independent experiments in parallel with stomach and small intestine in one 
module and the three-stage colon reactors in the other; and (3) the same but with the 
small intestine working with the colon reactors. If needed, each compartment can 
operate individually one by one. Instructions for setting up the working pH values, 
temperature, peristaltic or rotation frequency, volume and fl ow rates of fl uids, etc., 
are all set before starting the experiments as well as the number of daily repetitions 
of the process. All the parameters are registered and errors (if any) are documented. 
For the fermentation process, the three reactors are equipped with pumps that sup-
ply NaOH and HCl to control the consigned pH values. The representation on line 
of pH curves and volumes of acid and base added to the compartments are indica-
tive of microbial development and metabolism. This information is crucial as con-
trol of the process since the analyses of metabolites and fermentation products are 
delayed and not measured online. Occasionally, general plate counts can be per-
formed as an additional control of microbial viability. The system, however, can be 
upgraded to analyze on line the formation of gas (ammonium, H 2 , CO 2 and CH 3 ). 
28.4  Read-Out of the System 
 The system displays sampling ports between compartments to remove aliquots of 
colon content without disrupting the anaerobic conditions. The primary information 
searched during the set-up of the system and the diet interventions is the general 
evolution of the gut microbial community and the quantifi cation of the targeted 
microbial groups and their metabolites. Analyses of colon microbiota is based 
on molecular biology tools (PCR-DGGE, qPCR, metagenomics, etc.), whereas gen-
eral plate counts are only occasionally performed as a control of microbial viability. 
The choice of non-culturable microbial methods is in accordance with the large num-
ber of gut bacterial groups that are non-culturable by conventional techniques due to 
their generally fastidious growth requirements (Allen-Vercoe  2013 ). 
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 The stabilization of the microbial community until steady-state conditions in the 
three colonic reactors and its further development during dietary interventions 
are evaluated by sampling and measuring the production of SCFA, branched chain 
fatty acids (BCFA) and  ammonium over time. These metabolites are considered 
representative of fermentative and proteolytic microbial metabolism. Depending on 
the conditions assayed (diet interventions, development of microbial communities 
representative of dysbiosis associated to intestinal pathologies, etc.), specialized 
analytical methodologies targeting the formation of specifi c intermediate and end 
products are currently being developed to be incorporated to the system (unpublished 
results). 
28.5  Advantages, Disadvantages and Limitations 
of the System 
 The advantage of the SIMGI model is associated to its fl exible-modulating charac-
teristics and the automated control of the working parameters that can be adjusted 
to simulate physiological conditions. The combination of peristaltic movements and 
controlled emptying of the gastric and small intestine compartments are advantages 
of the system in comparison to other multicompartmental models. The SIMGI 
model has not yet incorporated devices simulating the gut microbiota-host interac-
tions. Therefore, assays for evaluating this type of crucial interaction is currently 
approached by co-culturing colon-region specifi c microbiota suspensions from the 
AC, TC and/or DC vessels with epithelial or immune cells. The incubation of this 
SIMGI complex colonic microbiota with Caco-2 cells has shown not to disturb the 
epithelial barrier integrity (unpublished results). Moreover, the SIMGI microbiota 
has demonstrated to induce the phenotypical maturation of human monocyte-
derived dendritic cells (unpublished results). However, a limitation of the SIMGI 
model is the lack of devices to evaluate the formation of microbial biofi lms adher-
ing to the colonic epithelium. The simulation of intestinal absorption to remove end 
products of microbial metabolism is also a limitation of the system to prevent inhi-
bition of the colon microbiota. Both drawbacks of the system are on the way to be 
overcome by setting up microbial/mucosa interfaces in the SIMGI lumen and by 
including dialysis devices between compartments. 
 In summary, the fully automation of the SIMGI model allows precise control of 
the environmental parameters that simulate the gastrointestinal tract. This multi- 
stage dynamic model has demonstrated to reproduce complex and stable microbial 
communities and it can be used as a tool for studying the effects of diet or food 
components on modulating the gut microbiota and its metabolic activity. 
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